Potent and selective inhibitors of nav1.7

ABSTRACT

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na v 1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na v 1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

This application claims the benefit of U.S. Provisional Application No. 61/778,331, filed on Mar. 12, 2013, which is hereby incorporated by reference in its entirety.

Throughout this application various publications are referenced within parentheses or brackets. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the biochemical arts, in particular to therapeutic peptides and conjugates.

2. Discussion of the Related Art

Voltage-gated sodium channels (VGSC) are glycoprotein complexes responsible for initiation and propagation of action potentials in excitable cells such as central and peripheral neurons, cardiac and skeletal muscle myocytes, and neuroendocrine cells. Mammalian sodium channels are heterotrimers, composed of a central, pore-forming alpha (α) subunit and auxiliary beta (β) subunits. Mutations in alpha subunit genes have been linked to paroxysmal disorders such as epilepsy, long QT syndrome, and hyperkalemic periodic paralysis in humans, and motor endplate disease and cerebellar ataxia in mice. (Isom, Sodium channel beta subunits: anything but auxiliary, Neuroscientist 7(1):42-54 (2001)). The β-subunit modulates the localization, expression and functional properties of α-subunits in VGSCs.

Voltage gated sodium channels comprise a family consisting of 9 different subtypes (Na_(v)1.1-Na_(v)1.9). As shown in Table 1, these subtypes show tissue specific localization and functional differences (See, Goldin, A. L., Resurgence of sodium channel research, Annu Rev Physiol 63: 871-94 (2001); Wilson et al., Compositions useful as inhibitors of voltage-gated ion channels, US 2005/0187217 A1). Three members of the gene family (Na_(v)1.8, 1.9, 1.5) are resistant to block by the well-known sodium channel blocker tetrodotoxin (TTX), demonstrating subtype specificity within this gene family. Mutational analysis has identified glutamate 387 as a critical residue for TTX binding (See, Noda, M., H. Suzuki, et al., A single point mutation confers tetrodotoxin and saxitoxin insensitivity on the sodium channel II” FEBS Lett 259(1): 213-6 (1989)).

TABLE 1 VGSC family with rat TTX IC₅₀ values. Abbreviations: CNS = central nervous system, PNS = peripheral nervous system, DRG = dorsal root ganglion, TG = Trigeminal ganglion. (See, Wilson et al., Compositions useful as inhibitors of Voltage-gated ion channels, US 2005/0187217 A1; Goldin, Resurgence of Sodium Channel Research, Annu Rev Physiol 63: 871-94 (2001)). TTX VGSC IC₅₀ isoform Tissue (nM) Indication Na_(V)1.1 CNS, PNS 10 Pain, Epilepsy, soma of Neurodegeneration neurons Na_(V)1.2 CNS 10 Neurodegeneration, Epilepsy high in axons Na_(V)1.3 CNS, 2-15 Pain, Epilepsy embryonic, injured nerves Na_(V)1.4 Skeletal muscle 5 Myotonia Na_(V)1.5 heart 2000 Arrhythmia, long QT Na_(V)1.6 CNS 1 Pain, movement disorders widespread, most abundant Na_(V)1.7 PNS, DRG, 4 Pain, Neuroendocrine terminals disorders, prostate cancer neuroendocrine Na_(V)1.8 PNS, small neurons >50,000 Pain in DRG & TG Na_(V)1.9 PNS, small neurons 1000 Pain in DRG & TG

In general, voltage-gated sodium channels (Na_(v)s) are responsible for initiating the rapid upstroke of action potentials in excitable tissue in the nervous system, which transmit the electrical signals that compose and encode normal and aberrant pain sensations. Antagonists of Na_(v) channels can attenuate these pain signals and are useful for treating a variety of pain conditions, including but not limited to acute, chronic, inflammatory, and neuropathic pain. Known Na_(v) antagonists, such as TTX, lidocaine, bupivacaine, phenytoin, lamotrigine, and carbamazepine, have been shown to be useful for attenuating pain in humans and animal models. (See, Mao, J. and L. L. Chen, Systemic lidocaine for neuropathic pain relief, Pain 87(1): 7-17 (2000); Jensen, T. S., Anticonvulsants in neuropathic pain: rationale and clinical evidence, Eur J Pain 6 (Suppl A): 61-68 (2002); Rozen, T. D., Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia, Headache 41 Suppl 1: S25-32 (2001); Backonja, M. M., Use of anticonvulsants for treatment of neuropathic pain, Neurology 59(5 Suppl 2): S14-7 (2002)).

The α-subunits of TTX-sensitive, voltage-gated Na_(v)1.7 channels are encoded by the SCN9A gene. The Na_(v)1.7 channels are preferentially expressed in peripheral sensory neurons of the dorsal root ganglia, some of which are involved in the perception of pain. In humans, mutations in the SCN9A gene have shown a critical role for this gene in pain pathways. For instance, a role for the Na_(v)1.7 channel in pain perception was established by recent clinical gene-linkage analyses that revealed gain-of-function mutations in the SCN9A gene as the etiological basis of inherited pain syndromes such as primary erythermalgia (PE), inherited erythromelalgia (IEM), and paroxysmal extreme pain disorder (PEPD). (See, e.g., Yang et al., Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia, J. Med. Genet. 41:171-174 (2004); Harty et al., Na_(v)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons, J. Neurosci. 26(48):12566-75 (2006); Estacion et al., Na_(v)1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders, J. Neurosci. 28(43):11079-88 (2008)). In addition, overexpression of Na_(v)1.7 has been detected in strongly metastatic prostate cancer cell lines. (Diss et al., A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo, Prostate Cancer and Prostatic Diseases 8:266-73 (2005); Uysal-Onganer et al., Epidermal growth factor potentiates in vitro metastatic behavior human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel, Molec. Cancer 6:76 (2007)).

Loss-of-function mutations of the SCN9A gene result in a complete inability of an otherwise healthy individual to sense any form of pain. (e.g., Ahmad et al., A stop codon mutation in SCN9A causes lack of pain sensation, Hum. Mol. Genet. 16(17):2114-21 (2007)).

A cell-specific deletion of the SCN9A gene in conditional knockout mice reduces their ability to perceive mechanical, thermal or inflammatory pain. (Nassar et al., Nociceptor-specific gene deletion reveals a major role for Na_(v)1.7 (PN1) in acute and inflammatory pain, Proc. Natl. Acad. Sci, USA. 101(34): 12706-12711 (2004)).

Based on such evidence, decreasing Na_(v)1.7 channel activity or expression levels in peripheral sensory neurons of the dorsal root ganglia (DRG) has been proposed as an effective pain treatment, e.g. for chronic pain, neuropathic pain, and neuralgia. (E.g., Thakker et al., Suppression of SCN9A gene expression and/or function for the treatment of pain, WO 2009/033027 A2; Yeomans et al., Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Na_(v)1.7 sodium channels in primary afferents, Hum. Gene Ther. 16(2):271-7 (2005); Fraser et al., Potent and selective Na_(v)1.7 sodium channel blockers, WO 2007/109324 A2; Hoyt et al., Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain, Bioorg. Med. Chem. Lett. 17(16):4630-34 (2007); Hoyt et al., Benzazepinone Na_(v)1.7 blockers: Potential treatments for neuropathic pain, Bioorg. Med. Chem. Lett. 17(22):6172-77 (2007)).

The α-subunits of TTX-sensitive, voltage-gated Na_(v)1.3 channels are encoded by the SCN3A gene. Four splice variants of human Nav1.3 were reported to have different biophysical properties. (Thimmapaya et al., Distribution and functional characterization of human Na_(v)1.3 splice variants, Eur. J. Neurosci. 22:1-9 (2005)). Expression of Na_(v)1.3 has been shown to be upregulated within DRG neurons following nerve injury and in thalamic neurons following spinal cord injury. (Hains et al., Changes in electrophysiological properties and sodium channel Na_(v)1.3 expression in thalamic neurons after spinal cord injury, Brain 128:2359-71 (2005)). A gain-in-function mutation in Nav1.3 (K354Q) was reportedly linked to epilepsy. (Estacion et al., A sodium channel mutation linked to epilepsy increases ramp and persistent current of Na_(v)1.3 and induces hyperexcitability in hippocampal neurons, Experimental Neurology 224(2):362-368 (2010)).

Toxin peptides produced by a variety of organisms have evolved to target ion channels. Snakes, scorpions, spiders, bees, snails and sea anemones are a few examples of organisms that produce venom that can serve as a rich source of small bioactive toxin peptides or “toxins” that potently and selectively target ion channels and receptors. In most cases, these toxin peptides have evolved as potent antagonists or inhibitors of ion channels, by binding to the channel pore and physically blocking the ion conduction pathway. In some other cases, as with some of the tarantula toxin peptides, the peptide is found to antagonize channel function by binding to a region outside the pore (e.g., the voltage sensor domain).

Native toxin peptides are usually between about 20 and about 80 amino acids in length, contain 2-5 disulfide linkages and form a very compact structure. Toxin peptides (e.g., from the venom of scorpions, sea anemones and cone snails) have been isolated and characterized for their impact on ion channels. Such peptides appear to have evolved from a relatively small number of structural frameworks that are particularly well suited to addressing the critical issues of potency, stability, and selectivity. (See, e.g., Dauplais et al., On the convergent evolution of animal toxins: conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures, J. Biol. Chem. 272(7):4302-09 (1997); Alessandri-Haber et al., Mapping the functional anatomy of BgK on Kv1.1, Kv1.2, and Kv1.3, J. Biol. Chem. 274(50):35653-61 (1999)). The majority of scorpion and Conus toxin peptides, for example, contain 10-40 amino acids and up to five disulfide bonds, forming extremely compact and constrained structures (microproteins) often resistant to proteolysis. The conotoxin and scorpion toxin peptides can be divided into a number of superfamilies based on their disulfide connections and peptide folds. The solution structure of many of these has been determined by Nuclear Magnetic Resonance (NMR) spectroscopy, illustrating their compact structure and verifying conservation of their family folding patterns. (E.g., Tudor et al., Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin, Eur. J. Biochem. 251(1-2):133-41(1998); Pennington et al., Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin, Biochem. 38(44): 14549-58 (1999); Jaravine et al., Three-dimensional structure of toxin OSK1 from Orthochirus scrobiculosus scorpion venom, Biochem. 36(6):1223-32 (1997); del Rio-Portillo et al.; NMR solution structure of Cn12, a novel peptide from the Mexican scorpion Centruroides noxius with a typical beta-toxin sequence but with alpha-like physiological activity, Eur. J. Biochem. 271(12): 2504-16 (2004); Prochnicka-Chalufour et al., Solution structure of discrepin, a new K+-channel blocking peptide from the alpha-KTx15 subfamily, Biochem. 45(6):1795-1804 (2006)). Conserved disulfide structures can also reflect the individual pharmacological activity of the toxin family. (Nicke et al. (2004), Eur. J. Biochem. 271: 2305-19, Table 1; Adams (1999), Drug Develop. Res. 46: 219-34). For example, α-conotoxins have well-defined four cysteine/two disulfide loop structures (Loughnan, 2004) and inhibit nicotinic acetylcholine receptors. In contrast, ω-conotoxins have six cysteine/three disulfide loop consensus structures (Nielsen, 2000) and block calcium channels. Structural subsets of toxins have evolved to inhibit either voltage-gated or calcium-activated potassium channels.

Spider venoms contain many peptide toxins that target voltage-gated ion channels, including Kv, Cav, and Nav channels. A number of these peptides are gating modifiers that conform to the inhibitory cystine knot (ICK) structural motif. (See, Norton et al., The cystine knot structure of ion channel toxins and related polypeptides, Toxicon 36(11):1573-1583 (1998); Pallaghy et al., A common structural motif incorporating a cystine knot and a triple-stranded β-sheet in toxic and inhibitory polypeptides, Prot. Sci. 3(10):1833-6, (1994)). In contrast to some scorpion and sea anemone toxins, many spider toxins do not affect the rate of inactivation but inhibit channel activity by restricting the movement of the voltage sensor into the open channel conformation, shifting their voltage dependence of activation to a more positive potential. Many of these spider toxins are promiscuous within and across voltage-gated ion channel families.

A variety of toxin peptides that target VGSCs, in particular, have been reported. (See, Billen et al., Animal peptides targeting voltage-activated sodium channels, Cur. Pharm. Des. 14:2492-2502, (2008)). Three classes of peptide toxins have been described: 1) site 1 toxins, the μ-conotoxins, bind to the pore of the channel and physically occlude the conduction pathway; 2) site 3 toxins, including the α-scorpion toxins, some sea anemone toxins and δ-conotoxins, bind to the S3-S4 linker of domain IV and slow channel inactivation; and 3) site 4 toxins, including the β-scorpion toxins, bind to the S3-S4 linker in domain II and facilitate channel activation. Both site 3 and site 4 families of peptides alter the open probability of Na_(v) channels and affect gating transitions and are therefore called “gating modifiers.”

μ-Conotoxin KIIIA (SEQ ID NO:530), a site 1 toxin originally isolated from Conus kinoshitai, is a C-terminally amidated peptide 16 amino acids in length that contains 6 cysteine residues engaged in 3 intramolecular disulfide bonds. It was initially characterized as an inhibitor of tetrodotoxin (TTX)-resistant sodium channels in amphibian dorsal root ganglion (DRG) neurons. (See, Bulaj et al., Novel conotoxins from Conus striatus and Conus kinoshitai selectively block TTX-resistant sodium channels, Biochem. 44(19):7259-7265, (2005)). Later it was found to more effectively inhibit TTX-sensitive than TTX-resistant sodium current in mouse DRG neurons. (See, Zhang et al., Structure/function characterization of μ-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels, J. Biol. Chem. 282(42):30699-30706, (2007)) KIIIA has been found to block cloned mammalian (rodent) channels expressed in Xenopus laevis oocytes with the following rank order potency: Na_(v)1.2>Na_(v)1.4>Na_(v)1.6>Na_(v)1.7>Na_(v)1.3>Na_(v)1.5. Intraperitoneal injection of KIIIA has demonstrated analgesic activity in a formalin-induced pain assay in mice with an ED₅₀ of 1.6 nmol/mouse (0.1 mg/kg) without observed motor impairment; some motor impairment but not paralytic acitity was observed at a higher dose (10 nmol). (See, Zhang et al., 2007). Substitution of alanine for Lys7 and Arg10 modified maximal block, while substituion of His12 and Arg14 altered Nav isoform specificity. (See, McArthur et al., Interactions of key charged residues contributing to selective block of neuronal sodium channels by μ-conotoxin KIIIA, Mol. Pharm. 80(4): 573-584, (2011)). “Alanine scan” analogs of KIIIA have identified Lys7, Trp8, Arg10, Asp11, His12, and Arg14 as being important for activity against rNa_(v)1.4. (See Zhang et al., 2007). The NMR solution structure of KIIIA places these residues within or adjacent to an α-helix near the C-terminus of the molecule. (See, Khoo et al., Structure of the analgesic μ-conotoxin KIIIA and effects on the structure and function of disulfide deletion, Biochem. 48(6):1210-1219, (2009)). The disulfide bond between Cys1 and Cys9 may be removed by substitution of alanine (KIIIA[C1A,C9A]) without greatly reducing the activity of the compound. (See, Khoo et al., 2009; Han et al., Structurally minimized μ-conotoxin analogs as sodium channel blockers: implications for designing conopeptide-based therapeutics, ChemMedChem 4(3):406-414, (2009)). Replacing a second disulfide bond between Cys2 and Cys16 with a diselenide bond between selenocysteine residues has given rise to the disulfide-depleted selenoconopeptide analogs of KIIIA These compounds have retained the activity of KIIIA but are more synthetically accessible. (See, Han et al., Disulfide-depleted selenoconopeptides: simplified oxidative folding of cysteine-rich peptides, ACS Med. Chem. Lett. 1(4):140-144, (2010)). The native structure has been further minimized to a lactam-stabilized helical peptide scaffold with Nav inhibitory activity. (See, Khoo et al., Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA, J. Med. Chem. 54:7558-7566 (2011)) KIIIA binds to the neurotoxin receptor site 1 in the outer vestibule of the conducting pore of the VGSCs and blocks the channel in an all-or-none manner. Recent studies have shown that some analogs of KIIIA only partially inhibit the sodium current and may be able to bind simultaneously with TTX and saxitoxin (STX). (See, Zhang et al., Cooccupancy of the outer vestibule of voltage-gated sodium channels by μ-conotoxin KIIIA and saxitoxin or tetrodotoxin, J. Neurophys. 104(1):88-97, (2010); French et al., The tetrodotoxin receptor of voltage-gated sodium channels-perspectives from interactions with μ-conotoxins, Marine Drugs 8:2153-2161, (2010); Zhang et al., μ-Conotoxin KIIIA derivatives with divergent affinities versus efficacies in blocking voltage-gated sodium channels. Biochem. 49(23):4804-4812, (2010); Zhang et al., Synergistic and antagonistic interactions between tetrodotoxin and μ-conotoxin in blocking voltage-gated sodium channels, Channels 3(1):32-38, (2009)).

OD1 (SEQ ID NO:589) is an α-like toxin isolated from the venom of the Iranian yellow scorpion Odonthobuthus doriae. (See, Jalali et al., OD1, the first toxin isolated from the venom of the scorpion Odonthobuthus doriae active on voltage-gated Na+ channels, FEBS Lett. 579(19):4181-4186, (2005)). This peptide is 65 amino acids in length with an amidated C-terminus containing 6 cysteine residues that form 3 disulfide bonds. OD 1 has been characterized as an Na_(v)1.7 modulator that impairs fast inactivation (EC₅₀=4.5 nM), increases the peak current at all voltages, and induces a persistent current, with selectivity against Na_(v)1.8 and Na_(v)1.3. (See Maertens et al., Potent modulation of the voltage-gated sodium channel Nav1.7 by OD1, a toxin from the scorpion Odonthobuthus doriae, Mol. Pharm. 70(1):405-414, (2006)).

Huwentoxin-IV(HWTX-IV; SEQ ID NO:528) is a 35 residue C-terminal peptide amide with 3 disulfide bridges between 6 cysteine residues isolated from the venom of the Chinese bird spider, Selenocosmia huwena. (See, Peng et al., Function and solution structure of huwentoxin—IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from chinese bird spider Selenocosmia huwena, J. Biol. Chem. 277(49):47564-47571, (2002)). The disulfide bonding pattern (C1-C4, C2-05, C3-C6) and NMR solution structure place HWTX-IV in the ICK structural family since the C3-C6 disulfide bond passes through the 16-residue ring formed by the other two disulfide bridges (C1-C4 and C2-C5). HWTX-IV inhibits TTX-sensitive sodium currents in adult rat DRG neurons with an IC₅₀ value of 30 nM but has no effect on TTX-resistant VGSCs at up to a 100 nM concentration. (See, Peng et al., 2002). HWTX-IV was also 12-fold less potent against central neuronal sodium channels in rat hippocampus neurons, suggesting that it may be selective toward Na_(v)1.7. (See, Xiao et al., Synthesis and characterization of huwentoxin-IV, a neurotoxin inhibiting central neuronal sodium channels, Toxicon 51(2):230-239, (2008)). Testing HWTX-IV against VGSC sub-types determined the relative sensitivity to be hNav1.7 (IC₅₀=26 nM)>rNav1.2>>rNav1.3>rNav1.4>hNav1.5. (See Xiao et al., Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain II voltage sensor in the closed configuration, J. Biol. Chem. 283(40):27300-27313, (2008)). Site directed protein mutagenesis mapped the binding of HWTX-IV to neurotoxin site 4, the extracellular S3-S4 linker betweendomain II, and its behavior in response to changes in voltage and channel activation is consistent with binding to the voltage sensor of Nav1.7 and trapping it in the resting configuration. (See, Xiao et al., 2008). Huwentoxin-I (HWTX-I; SEQ ID NO:529), a related family member is less potent against VGSCs but is active against N-Type Ca_(v) channels. (See, Wang et al., The cross channel activities of spider neurotoxin huwentoxin I on rat dorsal root ganglion neurons, Biochem. Biophys. Res. Comm. 357(3):579-583, (2007); Chen et al., Antinociceptive effects of intrathecally administered huwentoxin-I, a selective N-type calcium channel blocker, in the formalin test in conscious rats, Toxicon 45(1):15-20, (2005); Liang et al., Properties and amino acid sequence of huwentoxin-I, a neurotoxin purified from the venom of the Chinese bird spider Selenocosmia huwena, Toxicon 31(8):969-78, (1993)).

ProTx-II (SEQ ID NO:531), isolated from the venom of the tarantula Thixopelma pruriens, is a 30 amino acid polypeptide with a C-terminal free acid and 6 cysteine residues that form 3 disulfide bonds. It differs from other members of the ICK family because it contains only three residues between the fifth and sixth cysteine residues instead of the normal 4-11. ProTx-II is a potent inhibitor of several Na_(v) channel sub-types including Na_(v)1.2, Na_(v)1.7 (IC₅₀<1 nM), Na_(v)1.5, and Na_(v)1.8, as well as Cav3.1 channels but not K_(v) channels. (See, Middleton et al., Two tarantula peptides inhibit activation of multiple sodium channels, Biochem. 41(50):14734-14747, (2002); Priest et al., ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels, Toxicon 49(2):194-201, (2007); Edgerton et al., Inhibition of the activation pathway of the T-type calcium channel CaV3.1 by ProTxII, Toxicon 56(4):624-636, (2010)). The “alanine scan” analogs of ProTx-II were tested against Nav1.5, identifying Meth, Trp7, Arg13, Met19, Val20, Arg22, Leu23, Trp24, Lys27, Leu29, and Trp30 as being important for activity. (See, Smith et al., Molecular interactions of the gating modifier toxin ProTx-II with Nav1.5: implied existence of a novel toxin binding site coupled to activation, J. Biol. Chem. 282(17):12687-12697, (2007)). Biophysical characterization showed that ProTx-II differs from HwTx-IV in its ability to interact with lipid membranes. (See, Smith et al., Differential phospholipid binding by site 3 and site 4 toxins: implications for structural variability between voltage-sensitive sodium channel comains, J. Biol. Chem. 280(12):11127-11133, (2005). Doses of 0.01 and 0.1 mg/kg i.v. of ProTx-II were well tolerated in rats, but 1 mg/kg doses were lethal. ProTx-II was not efficacious in a mechanical hyperalgesia study. (See, Schmalhofer et al., ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors, Mol. Pharm. 74(5):1476-1484, (2008)). Intrathecal administration was lethal at 0.1 mg/kg and not effective in the hyperalgesia study at lower doses. ProTx-II application to desheathed cutaneous nerves completely blocked the C-fiber compound action potential but had little effect on action potential propagation of the intact nerve. (See, Schmalhofer et al., 2008). ProTx-II is believed to bind to the S3-S4 linker of domain II of Na_(v)1.7 to inhibit channel activation but may also interact with the domain IV voltage sensor and affect sodium channel activation at higher concentrations. (See, Xiao et al., The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation, Mol. Pharm. 78(6):1124-1134, (2010); Sokolov et al., Inhibition of sodium channel gating by trapping the domain II voltage sensor with protoxin II, Mol. Pharm. 73(3):1020-1028, (2008); Edgerton et al., Evidence for multiple effects of ProTxII on activation gating in NaV1.5, Toxicon 52(3):489-500, (2008)).

Other peptide inhibitors of VGSCs isolated from spider venoms and peptide analogs were reported in Murray et al., Potent and selective inhibitors of Nav1.3 and Nav1.7, WO 2012/125973 A2; Meir et al., Novel peptides isolated from spider venom and uses thereof, US 2011/0065647 A1; Lampe et al., Analgesic peptides from venom of Grammostola spatulata and use thereof, U.S. Pat. No. 5,877,026; Park et al., Analogs of sodium channel peptide toxin, WO 2012/004664 A2; and Chen et al., Molecular diversity and evolution of cysteine knot toxins of the tarantula Chilobrachys jingzhao, cell. Mol. Life Sci. 65:2431-44 (2008).

Production of toxin peptides is a complex process in venomous organisms, and is an even more complex process synthetically. Due to their conserved disulfide structures and need for efficient oxidative refolding, toxin peptides present challenges to synthesis. (See, Steiner and Bulaj, Optimization of oxidative folding methods for cysteine-rich peptides: a study of conotoxins containing three disulfide bridges, J. Pept. Sci. 17(1): 1-7, (2011); Góngora-Benitez et al., Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide Linaclotide, Biopolymers Pept. Sci. 96(1):69-80, (2011)). Although toxin peptides have been used for years as highly selective pharmacological inhibitors of ion channels, the high cost of synthesis and refolding of the toxin peptides and their short half-life in vivo have impeded the pursuit of these peptides as a therapeutic modality. Far more effort has been expended to identify small molecule inhibitors as therapeutic antagonists of ion channels, than has been given the toxin peptides themselves. One exception is the approval of the small ω-conotoxin MVIIA peptide (Prialt®, ziconotide), an inhibitor of neuron-specific N-type voltage-sensitive calcium channels, for treatment of intractable pain. The synthetic and refolding production process for ziconotide, however, is costly and only results in a small peptide product with a very short half-life in vivo (about 4 hours).

A small clinical trial in humans showed that local, non-systemic injection of the non-peptide tetrodotoxin produced pain relief in patients suffering from pain due to cancer and/or to chemotherapy (Hagen et al., J Pain Symp Manag 34:171-182 (2007)). Tetrodotoxin is a non-CNS-penetrant inhibitor of sodium channels including Na_(v)1.3 and Na_(v)1.7; although it cannot be used systemically due to lack of selectivity among sodium channel subtypes, its efficacy provides further validation for treating chronic pain syndromes with inhibitors of Na_(v)1.7 and/or Na_(v)1.3 in peripheral neurons.

Polypeptides typically exhibit the advantage of greater target selectivity than is characteristic of small molecules. Non-CNS penetrant toxin peptides and peptide analogs selective for Nav1.7 are desired, and are provided by the present invention.

SUMMARY OF THE INVENTION

The present invention is directed to a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na_(v)1.7 inhibitor. In one embodiment, the isolated polypeptide is a selective inhibitor of Na_(v)1.7, a peptide analog of jingzhaotoxin-V (“JzTx-V”; YCQKWMWTCDSKRACCEGLRCKLWCRKII-NH₂//SEQ ID NO:2).

In some embodiments, the present invention is directed to a composition of matter comprising an isolated polypeptide comprising the amino acid sequence of the formula:

SEQ ID NO: 516 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰Leu²¹ X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹X_(aa) ³⁰X_(aa) ³¹ X_(aa) ³²Arg³³X_(aa) ³⁴// or a pharmaceutically acceptable salt thereof, wherein:

X_(aa) ¹X_(aa) ² is absent; or X_(aa) ¹ is any amino acid residue and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is absent and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is absent and X_(aa) ² is absent;

X_(aa) ³ is any amino acid residue;

X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if X_(aa) ¹⁸ is SeCys;

X_(aa) ⁵ is any neutral hydrophilic or basic amino acid residue;

X_(aa) ⁶ is any basic amino acid residue;

X_(aa) ⁷ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ⁸ is a Met, Nle, Nva, Leu, Ile, Val, or Phe residue;

X_(aa) ⁹ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ¹⁰ is a basic or neutral hydrophilic amino acid residue, or an Ala residue;

X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if X_(aa) ²³ is SeCys;

X_(aa) ¹³ is any amino acid residue except a hydrophobic residue;

X_(aa) ¹⁴ is a basic residue or an Ala residue;

X_(aa) ¹⁶ is any amino acid residue;

X_(aa) ¹⁷ is a Cys if X_(aa) ²⁷ is Cys; or X_(aa) ¹⁷ is a SeCys if X_(aa) ²⁷ is SeCys;

X_(aa) ¹⁸ is a Cys or SeCys;

X_(aa) ¹⁹ is any amino acid residue;

X_(aa) ²⁰ is a Gly or Ala residue;

X_(aa) ²² is an acidic, basic amino acid residue, or Ala residue;

X_(aa) ²³ is a Cys or SeCys residue;

X_(aa) ²⁴ is a basic amino acid or Ala residue;

X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ²⁷ is a Cys or SeCys residue;

X_(aa) ²⁸ is a basic amino acid residue;

X_(aa) ²⁹ is a basic amino acid residue;

X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue, if X_(aa) ²² is an acidic amino acid residue; or

X_(aa) ³⁰ is an acidic amino acid residue, if X_(aa) ²² is a basic amino acid residue or an Ala residue;

X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue;

each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently absent or is independently a hydrophobic amino acid residue;

and wherein:

if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸;

if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ¹¹ and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³;

if X_(aa) ¹⁷ and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; or if X_(aa) ¹⁷ and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷;

the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and

the carboxy-terminal residue is optionally amidated.

In some of these embodiments, X_(aa) ²² is an acidic amino acid residue, such as a Glu, Asp, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid residue.

In others of these embodiments, X_(aa) ²² is a basic amino acid residue (such as a histidine, lysine, homolysine, ornithine, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or an Ala residue; and X_(aa) ³⁰ is selected from Glu, Asp, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.

In particular embodiments, the composition of matter comprises an amino acid sequence selected from SEQ ID NOS:63, 69, 110-115, 131, 137, 139-147, 149-150, 152-154, 157, 159-172, 174-175, 177-179, 182, 184-246, 273-274, 277, 279, 284-295, 297-356, 392-397, 406-409, 411-422, 426, 435-437, 439-445, 447-452, 455-475, 518, 520, 521, 523, 524, 526, 527, 546-563, 565-566, 568, 573, 574, 576, and 577, as set forth in Table 5; or comprises an amino acid sequence selected from SEQ ID NOS:63, 69, 112-113, 115, 131, 137, 193-196, 200-203, 207-210, 214-217, 221-224, 228-231, 235-238, 242-246, 277, and 279, as set forth in Table 5, that does not include a non-canonical amino acid.

The present invention also encompasses a nucleic acid (e.g., DNA or RNA) encoding any of SEQ ID NOS:63, 69, 112-113, 115, 131, 137, 193-196, 200-203, 207-210, 214-217, 221-224, 228-231, 235-238, 242-246, 277, or 279, as set forth in Table 5, that does not include a non-canonical amino acid; an expression vector comprising the nucleic acid; and a recombinant host cell comprising the expression vector.

In different embodiments, the present invention is directed to a composition of matter comprising an isolated polypeptide comprising the amino acid sequence of the formula:

SEQ ID NO: 517 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰Leu²¹ X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹X_(aa) ³⁰ X_(aa) ³¹X_(aa) ³²X_(aa) ³³X_(aa) ³⁴// or a pharmaceutically acceptable salt thereof, wherein:

X_(aa) ¹ is absent; or X_(aa) ¹ is any amino acid residue;

X_(aa) ² is any hydrophobic amino acid residue, or a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue;

X_(aa) ³ is any amino acid residue;

X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if X_(aa) ¹⁸ is SeCys;

X_(aa) ⁵ is any neutral hydrophilic or basic amino acid residue;

X_(aa) ⁶ is any basic amino acid residue;

X_(aa) ⁷ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ⁸ is a Leu or Nle residue;

X_(aa) ⁹ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ¹⁰ is a basic or neutral hydrophilic amino acid residue, or an Ala residue;

X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if X_(aa) ²³ is SeCys;

X_(aa) ¹³ is any amino acid residue except a hydrophobic residue;

X_(aa) ¹⁴ is a basic residue or an Ala residue;

X_(aa) ¹⁶ is any amino acid residue;

X_(aa) ¹⁷ is a Cys if X_(aa) ²² is Cys; or X_(aa) ¹⁷ is a SeCys if X_(aa) ²² is SeCys;

X_(aa) ¹⁸ is a Cys or SeCys;

X_(aa) ¹⁹ is any amino acid residue;

X_(aa) ²⁰ is a Gly or Ala residue;

X_(aa) ²² is a basic amino acid residue, or Ala residue;

X_(aa) ²³ is a Cys or SeCys residue;

X_(aa) ²⁴ is a basic amino acid or Ala residue;

X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ²⁷ is a Cys or SeCys residue;

X_(aa) ²⁸ is a basic amino acid residue;

X_(aa) ²⁹ is a basic amino acid residue;

X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue;

X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue;

each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently absent or is independently a hydrophobic amino acid residue;

and wherein:

if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸;

if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ^(n) and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³;

if X_(aa) ¹² and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; or if X_(aa) ¹² and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷;

the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and

the carboxy-terminal residue is optionally amidated.

In particular embodiments, the composition of matter comprises an amino acid sequence selected from SEQ ID NOS:247, 296, 358, 360, 361, 363-370, 372-391, 398-405, 410, 423-425, 427, 431-434, 438, 446, 453, 454, 571, 579-587, and 588, as set forth in Table 5.

The compositions of the invention provide an effective method of treating, or preventing, pain, for example acute, persistent, or chronic pain. Selectivity against off-target sodium channels, particularly those governing cardiac excitability (Nav1.5) and skeletal muscle excitability (Na_(v)1.4), is cardinal for any systemically delivered therapeutic. This selectivity is a particularly high hurdle for a dual inhibitor. Compositions of the present invention provide such selectivity against Nav1.5 and Nav1.4.

Consequently, the present invention is also directed to a pharmaceutical composition or a medicament containing the inventive composition of matter, and a pharmaceutically acceptable carrier.

The JzTx-V peptide analogs of the present invention are also useful as research tools, e.g., as probes for correctly folded, functional Nav1.7 in the plasma membrane of live cells. As and its congeners inhibit Nav1.7 they clearly bind to the channel molecule with high potency and selectivity. Labeling with fluorescent or other tracer groups at the non-active sites of the JzTx-V peptide analogs as defined by NMR (see, e.g., Example 6 herein) and by residue substitution can provide research tools suitable for, but not limited to, localizing sodium channels, sorting cells that express sodium channels, and screening or panning for peptides that bind to Nav1.7.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the reversed phase (RP) HPLC chromatogram of UV absorbance at 214 nm from the LC-MS analysis of synthetic JzTx-V(1-29) (SEQ ID NO:2).

FIG. 2 shows the total ion count (TIC) chromatogram of the ESI-MS detector from the LC-MS analysis of synthetic JzTx-V(1-29) (SEQ ID NO:2).

FIG. 3 shows the ESI-MS analysis of the peak with the retention time (r_(t)) of 4.95 minutes in FIG. 2. The peaks with m/z ratios of 1803.3, 1202.4, and 902.2 represent the [M+2H]²⁺, [M+3H]³⁺ and [M+4H]⁴⁺ charge states, respectively, of JzTx-V(1-29), which has an average molecular weight of 3605.36 Da.

FIG. 4 shows the effect of JzTx-V(1-29) (SEQ ID NO:2) on hNav1.8 channels in inducible CHO cell. Cell was held at −85 mV and peak inward Nav currents were measured at 0 mV. “0.5 μM TTX Control” trace shows Nav current before JzTx-V(1-29) (SEQ ID NO:2), “0.5 μM TTX+1.0 μM Seq ID No. 2” trace shows Nav current after JzTx-V(1-29) (SEQ ID NO:2) addition, and “0.5 μM TTX+1.0 μM TTX-R inhibitor” shows Nav current after addition of a blocker of Nav1.8 channels that are resistant to block by TTX. Note that 0.5 μM JzTx-V(1-29) (SEQ ID NO:2) blocked approximately 50% of TTX-resistant hNav1.8 current. All solutions contained 0.5 μM TTX to block endogenous TTX-sensitive Nav currents.

FIG. 5 shows the time course of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.8 channels in inducible CHO cell. Peak inward Nav currents were measured at 0 mV every 10 seconds in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cell was held at either −120 mV (squares) or −85 mV (circles). “Ctrl” indicates Nav current in the absence of JzTx-V(1-29) (SEQ ID NO:2), “0.5 μM TTX” indicates Nav current in the presence of 0.5 μM TTX to block endogenous TTX-sensitive channels, “1.0 μM TTX-R inhibitor” indicates Nav current in the presence of a blocker of Nav1.8 channels that are resistant to block by TTX, and “Wash” indicates Nav current following removal of JzTx-V(1-29) (SEQ ID NO:2) and TTX. 0.5 μM TTX was present in all solutions when cells were held at −85 mV.

FIG. 6 shows the dose-response curves of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.8 channels in two separate inducible CHO cells. Peak inward Nav currents were measured at 0 mV in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2).

FIG. 7 shows the effect of JzTx-V(1-29) (SEQ ID NO:2) on hNav1.7 channels in HEK293 cell. Cell was held at −82 mV and peak inward Nav currents were measured at 0 mV. “Control” trace shows Nav1.7 current before JzTx-V(1-29) (SEQ ID NO:2), “1 μM Seq ID No. 2” trace shows Nav current after JzTx-V(1-29) (SEQ ID NO:2) addition.

FIG. 8 shows the time course of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.7 channels in HEK293 cell. Peak inward Nav currents were measured at 0 mV every 10 seconds in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cell was held at either −140 mV (squares), a voltage where Nav1.7 channels are completely non-inactivated, or −82 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav1.7 current in the absence of JzTx-V(1-29) (SEQ ID NO:2) and “Wash” indicates Nav1.7 current following removal of JzTx-V(1-29) (SEQ ID NO:2). Note that 1 μM JzTx-V(1-29) (SEQ ID NO:2) blocked all Nav1.7 current.

FIG. 9 shows the dose-response curves of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.7 channels in two separate HEK293 cells. Peak inward Nav1.7 currents were measured at 0 mV in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cells were held at a voltage that yielded 20% inactivation.

FIG. 10 shows the effect of JzTx-V(1-29) (SEQ ID NO:2) on hNav1.5 channels in HEK293 cell. Cell was held at −85 mV and peak inward Nav currents were measured at 0 mV. “Control” trace shows Nav1.5 current before JzTx-V(1-29) (SEQ ID NO:2), “3 μM Seq ID No. 2” trace shows Nav current after JzTx-V(1-29) (SEQ ID NO:2) addition. Note that 3 μM JzTx-V(1-29) (SEQ ID NO:2) blocked most Nav1.5 current.

FIG. 11 shows the time course of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.5 channels in HEK293 cell. Peak inward Nav currents were measured at 0 mV every 10 seconds in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cell was held at either −140 mV (squares), a voltage where Nav1.5 channels are completely non-inactivated, or −85 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav1.5 current in the absence of JzTx-V(1-29) (SEQ ID NO:2) and “Wash” indicates Nav1.5 current following removal of JzTx-V(1-29) (SEQ ID NO:2).

FIG. 12 shows the dose-response curves of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.5 channels in two separate HEK293 cells. Peak inward Nav1.5 currents were measured at 0 mV in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cells were held at a voltage that yielded 20% inactivation.

FIG. 13 shows the effect of JzTx-V(1-29) (SEQ ID NO:2) on hNav1.4 channels in HEK293 cell. Cell was held at −83 mV and peak inward Nav currents were measured at 0 mV. “Control” trace shows Nav1.4 current before JzTx-V(1-29) (SEQ ID NO:2), “100 nM Seq ID No. 2” trace shows Nav1.4 current after JzTx-V(1-29) (SEQ ID NO:2) addition. Note that 100 nM JzTx-V(1-29) (SEQ ID NO:2) completely blocked Nav1.4 current.

FIG. 14 shows the time course of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.4 channels in HEK293 cell. Peak inward Nav currents were measured at 0 mV every 10 seconds in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cell was held at either −140 mV (squares), a voltage where Nav1.4 channels are completely non-inactivated, or −88 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav1.4 current in the absence of JzTx-V(1-29) (SEQ ID NO:2) and “Wash” indicates Nav1.4 current following removal of JzTx-V(1-29) (SEQ ID NO:2).

FIG. 15 shows the dose-response curves of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.4 channels in two separate HEK293 cells. Peak inward Nav1.4 currents were measured at 0 mV in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cells were held at a voltage that yielded 20% inactivation.

FIG. 16 shows the effect of JzTx-V(1-29) (SEQ ID NO:2) on hNav1.3 channels in CHO cell. Cell was held at −80 mV and peak inward Nav currents were measured at 0 mV. “Control” trace shows Nav1.3 current before JzTx-V(1-29) (SEQ ID NO:2), “300 nM Seq ID No. 2” trace shows Nav1.3 current after JzTx-V(1-29) (SEQ ID NO:2) addition. Note that 300 nM JzTx-V(1-29) (SEQ ID NO:2) completely blocked Nav1.3 current.

FIG. 17 shows the time course of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.3 channels in CHO cell. Peak inward Nav currents were measured at 0 mV every 10 seconds in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cell was held at either −140 mV (squares), a voltage where Nav1.3 channels are completely non-inactivated, or −80 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav1.3 current in the absence of JzTx-V(1-29) (SEQ ID NO:2) and “Wash” indicates Nav1.3 current following removal of JzTx-V(1-29) (SEQ ID NO:2).

FIG. 18 shows the dose-response curves of JzTx-V(1-29) (SEQ ID NO:2) against hNav1.3 channels in two separate CHO cells. Peak inward Nav1.3 currents were measured at 0 mV in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cells were held at a voltage that yielded 20% inactivation.

FIG. 19 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) on hNav1.7 channels in HEK293 cell. Cell was held at −80 mV and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav1.7 current before [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) addition, and “100.0 nM SEQ ID No. 112” trace shows Nav current after [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) addition. Note that 100 nM [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) only blocked approximately 80% of Nav1.7 current.

FIG. 20 shows the time course of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) against hNav1.7 channel in HEK293 cell. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112); cell was held at either −120 mV (squares), a voltage where Nav1.7 channels are completely non-inactivated, or −80 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav1.7 current in the absence of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) and “Wash” indicates Nav1.7 current following removal of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112). Note that 100 nM [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) did not completely block Nav1.7 current.

FIG. 21 shows the dose-response curves of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) against hNav1.7 channels in two separate HEK293 cells. Peak inward Nav1.7 currents were measured at −10 mV in the presence of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112); cells were held at a voltage that yielded around 20% inactivation. IC₅₀ values are estimated since complete block of Nav1.7 was not observed at the highest concentration of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) tested.

FIG. 22 shows the effect of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) on hNav1.7 channels in HEK293 cell. Cell was held at −140 mV and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav1.7 current before Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) and ‘100 pM Seq ID No. 425’ trace shows Nav current after Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) addition. Note that 100 pM Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) fully blocked Nav1.7 current.

FIG. 23 shows the time course of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) against hNav1.7 channel in HEK293 cell. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425); cell was held at −140 mV, a voltage where Nav1.7 channels were fully non-inactivated. “Ctrl” indicates Nav1.7 current in the absence of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) and “Wash” indicates Nav1.7 current following removal of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425).

FIG. 24 shows the dose-response curves of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) against hNav1.7 channels in two separate HEK293 cells. Peak inward Nav1.7 currents were measured at −10 mV in the presence of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425); cells were held at −140 mV, a voltage where Nav1.7 channels were fully non-inactivated.

FIG. 25 shows the effect of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) on hNav1.7 channels in HEK293 cell. Cell was held at −77 mV (partially inactivated state) and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav1.7 current before Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) and “100 pM Seq ID No. 425” trace shows Nav current after Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) addition. Note that 100 pM Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) fully blocked Nav1.7 current.

FIG. 26 shows the time course of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) against hNav1.7 channel in HEK293 cell. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425); cell was held at either −140 mV (squares), a voltage where Nav1.7 channels are completely non-inactivated, or −77 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav1.7 current in the absence of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) and “Wash” indicates Nav1.7 current following removal of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425).

FIG. 27 shows the dose-response curves of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) against hNav1.7 channels in two separate HEK293 cells. Peak inward Nav1.7 currents were measured at −10 mV in the presence of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425); cells were held at a voltage that yielded around 20% inactivation.

FIG. 28 shows the effect of JzTx-V(1-29) (SEQ ID NO:2) on TTX-sensitive Nav channels in mouse DRG neuron. Cell was held at −100 mV and peak inward Nav currents were measured at 0 mV. “Control” trace shows Nav current before JzTx-V(1-29) (SEQ ID NO:2), “1 μM Seq ID No. 2” trace shows Nav current after JzTx-V(1-29) (SEQ ID NO:2) addition, and “0.5 μM TTX” trace shows Nav current after TTX. Note that 1 μM JzTx-V(1-29) (SEQ ID NO:2) and 0.5 μM TTX both completely blocked TTX-sensitive Nav current.

FIG. 29 shows the time course of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2) against TTX-sensitive Nav channels in mouse DRG neuron. Peak inward Nav currents were measured at 0 mV every 10 seconds in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cell was held at either −140 mV (squares), a voltage where Nav channels are completely non-inactivated, or −100 mV (circles), a voltage that yields approximately 25% inactivation. “Ctrl” indicates Nav current in the absence of JzTx-V(1-29) (SEQ ID NO:2), “TTX” indicates Nav current in the presence of 0.5 μM TTX, and “Wash” indicates Nav current following removal of JzTx-V(1-29) (SEQ ID NO:2) and TTX. Note that JzTx-V(1-29) (SEQ ID NO:2) blocked nearly all TTX-sensitive Nav current.

FIG. 30 shows the dose-response curves of JzTx-V(1-29) (SEQ ID NO:2) against TTX-sensitive Nav channels in two separate mouse DRG neurons. Peak inward Nav currents were measured at 0 mV in the presence of increasing concentrations of JzTx-V(1-29) (SEQ ID NO:2); cells were held at a voltage that yielded 20-25% inactivation.

FIG. 31 shows the effect of JzTx-V(1-29) (SEQ ID NO:2) on TTX-resistant Nav channels in mouse DRG neuron. Cell was held at −120 mV and peak inward Nav currents were measured at 0 mV. “Control” trace shows Nav current before JzTx-V(1-29) (SEQ ID NO:2), “0.5 μM TTX” trace shows Nav current after TTX, and “0.5 μM TTX+1.0 μM Seq ID No. 2” trace shows Nav current after TTX and JzTx-V(1-29) (SEQ ID NO:2) addition. Note that JzTx-V(1-29) (SEQ ID NO:2) had nominal effect on peak TTX-resistant current but prolonged the level of TTX-resistant current at 40 msec. IC₅₀ was not measurable.

FIG. 32 shows the time course of 1 μM JzTx-V(1-29) (SEQ ID NO:2) against TTX-resistant Nav channels in mouse DRG neuron (fully non-inactivated state). Peak (squares) and sustained inward Nav currents at 40 msec (circles) were measured at 0 mV from a holding potential of −120 mV every 10 seconds. “Control” indicates Nav current in the absence of JzTx-V(1-29) (SEQ ID NO:2); “TTX” indicates Nav current in the presence of 0.5 μM TTX, “1 μM Seq ID No. 2+0.5 μM TTX” indicates Nav current in the presence of JzTx-V(1-29) (SEQ ID NO:2) and TTX, and “Wash” indicates Nav current following removal of JzTx-V(1-29) (SEQ ID NO:2) and TTX. Note that JzTx-V(1-29) (SEQ ID NO:2) had nominal effect on peak TTX-resistant current but prolonged the level of TTX-resistant current at 40 msec. IC₅₀ was not measurable.

FIG. 33 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) on TTX-sensitive Nav channels in mouse DRG neuron cultured for 10 days. Cell was held at −85 mV and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav current before [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112), “300 nM Seq ID No. 112” trace shows Nav current after [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) addition, and “0.5 μM TTX” trace shows Nav current after TTX addition. Note that 300 nM [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) only blocked around half of TTX-sensitive Nav current.

FIG. 34 shows the time course of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) against TTX-sensitive Nav channels in mouse DRG neuron cultured for 10 days. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112); cell was held at either −120 mV (squares), a voltage where Nav channels are completely non-inactivated, or −85 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav current in the absence of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112), “0.5 μM TTX” indicates Nav current in the presence of 0.5 μM TTX, and “Wash” indicates Nav current following removal of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) and TTX.

FIG. 35 shows the dose-response curves of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) against TTX-sensitive Nav channels in two separate mouse DRG neurons cultured for 10 days. Peak inward Nav currents were measured at −10 mV in the presence of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112); cells were held at a voltage that yielded 20% inactivation.

FIG. 36 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) on TTX-sensitive Nav channels in acutely isolated mouse DRG neuron. Cell was held at −70 mV and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav current before [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112), “1 μM Seq ID No. 112” trace shows Nav current after [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) addition, and “0.5 μM TTX” trace shows Nav current after TTX addition. Note that 1 μM [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) only partially blocked TTX-sensitive Nav current. Current that remained following 0.5 μM TTX is TTX-resistant current.

FIG. 37 shows the time course of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) against TTX-sensitive Nav channels in acutely isolated mouse DRG neuron. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112); cell was held at either −120 mV (squares), a voltage where Nav channels are completely non-inactivated, or −70 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav current in the absence of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112), “0.5 μM TTX” indicates Nav current in the presence of 0.5 μM TTX, and “Wash” indicates Nav current following removal of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) and TTX.

FIG. 38 shows the dose-response curves of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) against TTX-sensitive Nav channels in acutely isolated mouse DRG neuron. Peak inward Nav currents were measured at −10 mV in the presence of increasing concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112); cells were held at a voltage that yielded 20% inactivation. TTX-sensitive currents were measured in reference to the current remaining after 0.5 μM TTX, which was taken as the zero point.

FIG. 39 shows the effect of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) on TTX-sensitive Nav channels in mouse DRG neuron cultured for 10 days. Cell was held at −75 mV and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav current before Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425), “100 nM Seq ID No. 425” trace shows Nav current after Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) addition, and “0.5 μM TTX” trace shows Nav current after TTX addition. Note that 100 nM Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) blocked most TTX-sensitive Nav current.

FIG. 40 shows the time course of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) against TTX-sensitive Nav channels in mouse DRG neuron cultured for 10 days. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425); cell was held at either −120 mV (squares), a voltage where Nav channels are completely non-inactivated, or −75 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav current in the absence of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425), “0.5 μM TTX” indicates Nav current in the presence of 0.5 μM TTX, and “Wash” indicates Nav current following removal of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) and TTX.

FIG. 41 shows the dose-response curves of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) against TTX-sensitive Nav channels in two separate mouse DRG neurons cultured for 10 days. Peak inward Nav currents were measured at −10 mV in the presence of increasing concentrations of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425); cells were held at a voltage that yielded around 20% inactivation.

FIG. 42 shows the effect of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392) on TTX-sensitive Nav channels in mouse DRG neuron. Cell was held at −88 mV and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav current before CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392), “300 nM Seq ID No. 392” trace shows Nav current after CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392) addition, and “0.5 μM TTX” trace shows Nav current after TTX addition. Note that 300 nM CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392) blocked most TTX-sensitive Nav current.

FIG. 43 shows the time course of increasing concentrations of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392) against TTX-sensitive Nav channels in mouse DRG neuron. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392); cell was held at either −120 mV (squares), a voltage where Nav channels are completely non-inactivated, or −88 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav current in the absence of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392), “0.5 μM TTX” indicates Nav current in the presence of 0.5 μM TTX, and “Wash” indicates Nav current following removal of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392) and TTX.

FIG. 44 shows the dose-response curves of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392) against TTX-sensitive Nav channels in two separate mouse DRG neurons. Peak inward Nav currents were measured at −10 mV in the presence of increasing concentrations of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) (SEQ ID NO:392); cells were held at a voltage that yielded around 20% inactivation.

FIG. 45 shows the effect of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395) on TTX-sensitive Nav channels in mouse DRG neuron. Cell was held at −77 mV and peak inward Nav currents were measured at −10 mV. “Control” trace shows Nav current before CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395), ‘300 nM Seq ID No. 395’ trace shows Nav current after CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395) addition, and “0.5 μM TTX” trace shows Nav current after TTX addition. Note that 300 nM CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395) fully blocked TTX-sensitive Nav current.

FIG. 46 shows the time course of increasing concentrations of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395) against TTX-sensitive Nav channels in mouse DRG neuron. Peak inward Nav currents were measured at −10 mV every 10 seconds in the presence of increasing concentrations of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395); cell was held at either −120 mV (squares), a voltage where Nav channels are completely non-inactivated, or −77 mV (circles), a voltage that yields approximately 20% inactivation. “Ctrl” indicates Nav current in the absence of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395), “0.5 μM TTX” indicates Nav current in the presence of 0.5 μM TTX, and “Wash” indicates Nav current following removal of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395) and TTX.

FIG. 47 shows the dose-response curves of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395) against TTX-sensitive Nav channels in two separate mouse DRG neurons. Peak inward Nav currents were measured at −10 mV in the presence of increasing concentrations of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) (SEQ ID NO:395); cells were held at a voltage that yielded around 20% inactivation.

FIG. 48 shows an overlay of the 20 lowest energy conformations of the peptide backbone for the NMR solution structure of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425).

FIG. 49 shows an overlay of the heavy atoms from the 20 lowest energy conformations of the peptide for the NMR solution structure of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425).

FIG. 50 shows a ribbon representation of the lowest energy conformation of the peptide backbone for the NMR solution structure of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425). The three disulfide bridges are represented as sticks.

FIG. 51 shows an overlay of the ribbon representations of the 20 lowest energy conformation of the peptide backbone for the NMR solution structure of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425). The three disulfide bridges are represented as sticks.

FIG. 52 shows a surface representation of the lowest energy conformation of the peptide for the NMR solution structure of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425). The image on the right is the hydrophobic face of the peptide, and the image on the left is the opposite face of the peptide (rotated 180° on the vertical axis).

FIG. 53 shows the IWQ Nav1.7 IC50 of the single substitution analogs of JzTx-V. Note that substitution of Meth, Trp7, Leu23, Trp24, and Ile29 result in the largest relative losses in potency, indicating that these positions are important for interaction with the Nav1.7 channel.

FIG. 54 shows the IWQ IC50 for each of the glutamic acid single substitution analogs against Nav1.7, Nav1.5, Nav1.4, and Nav1.3. Note that [Glu20]JzTx-V (SEQ ID NO:63) and [Glu28]JzTx-V (SEQ ID NO:69) had decreased activity relative to Nav1.7.

FIG. 55 shows the pharmacokinetic time course of plasma concentrations of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) following a 1 mg/kg s.c. dose in male CD-1 mice in relation to the hNav1.7 PX IC50.

FIG. 56 shows the timecourse of the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male CD-1 mice with a 1-hour pre-treatment dose of 0.1, 0.3, or 1.0 mg/kg s.c. The peptide had no effect in the first or acute phase (0-5 minutes post-formalin injection). The peptide had no effect on the time spent lifting and/or licking the affected paw during the second phase (5-40 minutes post-formalin injection, associated with spinal sensitization) compared to vehicle (PBS). The positive control, a 3 mg/kg s.c. dose of morphine was sufficient to significantly reduce pain response in the animals. The terminal plasma exposures (peptide plasma concentrations at 45 min post-formalin injection) for the peptide were 0.0278±0.0105, 0.121±0.0411, and 0.412±0.0858 μM for the 0.1, 0.3, or 1.0 mg/kg doses, respectively. Data Represent Mean±SEM; Outliers Removed (n=12).

FIG. 57 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male CD-1 mice with a 1-hour pre-treatment dose of 0.1, 0.3, or 1.0 mg/kg s.c. during the first phase (0-5 minutes post formalin injection). Neither the peptide nor the morphine positive control significantly reduced the time spent lifting and/or licking the affected paw during the first phase. It was observed that the 1 mg/kg dose of peptide may have slightly increased the pain response relative to the vehicle (phosphate buffered saline [PBS]). Pharmacological reductions in flinching during this first phase generally reflect nonspecific effects on animal movement, consciousness, or health rather than an actual reduction in pain. Data Represent Mean±SEM; * p<0.05 by ANOVA/DUNNETTS; Outliers Removed (n=12).

FIG. 58 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male CD-1 mice with a 1-hour pre-treatment dose of 0.1, 0.3, or 1.0 mg/kg s.c. during the second phase (5-40 minutes post formalin injection). The morphine control but not the peptide significantly reduced the time spent lifting and/or licking the affected paw during the second phase. Data Represent Mean±SEM; *** p<0.0001 by ANOVA/DUNNETTS; Outliers Removed (n=12).

FIG. 59 shows the timecourse of the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male CD-1 mice with a 1-hour pre-treatment dose of 5.0 mg/kg s.c. After a lack of efficacy was observed at peptide doses ≦1 mg/kg, the formalin pain model was repeated with an increased peptide dose of 5.0 mg/kg s.c. The peptide had no effect in the first or acute phase (0-5 minutes post formalin injection). The peptide had no effect on the time spent lifting and/or licking the affected paw during the second phase (5-40 minutes post formalin injection, associated with spinal sensitization) compared to vehicle (PBS). The positive control, a 3 mg/kg s.c. dose of morphine was sufficient to significantly reduce pain response in the animals. The terminal plasma exposure (peptide plasma concentrations at 45 min post formalin injection) for the peptide was 2.63±0.777 μM. Data Represent Mean±SEM; Outliers Removed (n=12).

FIG. 60 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male CD-1 mice with a 1-hour pre-treatment dose of 5.0 mg/kg s.c. (n=8) during the first phase (0-5 minutes post formalin injection). Neither the peptide nor the morphine positive control (s.c., 3 mg/kg, 30′ preTx, n=8) significantly reduced the time spent lifting and/or licking the affected paw during the first phase. Data Represent Mean±SEM; *** p<0.05 by ANOVA/DUNNETTS; Outliers Removed (n=12).

FIG. 61 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male CD-1 mice with a 1-hour pre-treatment dose of 5.0 mg/kg s.c. (n=8) during the second phase (5-40 minutes post formalin injection). The morphine control (s.c., 3 mg/kg, 30′ preTx, n=8) but not the peptide significantly reduced the time spent lifting and/or licking the affected paw during the second phase. Data Represent Mean±SEM; *** p<0.0001 by ANOVA/DUNNETTS; Outliers Removed (n=12).

FIG. 62 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the Complete Freund's Adjuvant (CFA) thermal hyperalgesia pain model (24 h postdose) in male CD-1 mice with a dose of 5.0 mg/kg s.c. (n=10). After a lack of efficacy was observed at peptide doses ≦5 mg/kg in the formalin pain model, the peptide was tested in a second pain model. The peptide had no effect on thermal latency compared to vehicle (PBS). The positive control, a 30 mg/kg oral dose of mexilitine was sufficient to significantly reverse thermal hyperalgesia in the animals. The terminal plasma exposure (peptide plasma concentrations at 2 h post-peptide injection) for the peptide was 1.75±0.536 μM. Data Represent Mean±SEM; *** p<0.0001 by ANOVA/DUNNETTS; Outliers Removed (n=12).

FIG. 63 shows the effects of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) at 0.1, 0.3, and 1.0 mg/kg s.c. doses with a 1-hour pre-treatment time on the total basic movement component of locomotor activity in male CD-1 mice. No doses of peptide significantly decreased exploratory behavior in relation to the vehicle control. Terminal exposures (peptide plasma concentrations at 2 h post peptide injection) were 0.0248±0.00668, 0.121±0.0296, and 0.419±0.226 μM for the 0.1, 0.3, and 1.0 mg/kg s.c. doses, respectively.

FIG. 64 shows the effects of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) at 0.1, 0.3, and 1.0 mg/kg s.c. doses with a 1-hour pre-treatment time on the total rearing component of locomotor activity in male CD-1 mice. No doses of peptide significantly decreased exploratory behavior in relation to the vehicle control.

FIG. 65 shows the effects of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) at a 5.0 mg/kg s.c. dose with a 1-hour pre-treatment time on the total basic movement component of locomotor activity in male CD-1 mice. The dose of peptide did not significantly decrease exploratory behavior in relation to the vehicle control. Terminal exposure (peptide plasma concentrations at 2 h post peptide injection) was 4.73±0.584 μM for the 5.0 mg/kg s.c. dose.

FIG. 66 shows the effects of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) at a 5.0 mg/kg s.c. dose with a 1-hour pre-treatment time on the total rearing component of locomotor activity in male CD-1 mice. The dose of peptide may have slightly decreased the rearing behavior in relation to the vehicle control.

FIG. 67 shows the timecourse of the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male Sprague-Dawley rats with a 1-hour pre-treatment dose of 5.0 mg/kg s.c. (n=8). After a lack of efficacy was observed at peptide doses ≦5 mg/kg in mice, the formalin pain model was repeated at a 5 mg/kg dose in a second species, Sprague-Dawley rats. The peptide had no effect in the first or acute phase (0-5 minutes post formalin injection). The peptide did not decrease and may have actually increased the time spent lifting and/or licking the affected paw during the second phase (5-40 minutes post formalin injection, associated with spinal sensitization) compared to vehicle (PBS). The positive control, a 2 mg/kg s.c. dose of morphine (n=8) was sufficient to significantly reduce pain response in the animals. The terminal plasma exposure (peptide plasma concentrations at 45 min post-formalin injection) for the peptide was 1.18±0.156 μM.

FIG. 68 shows the effect of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) in the formalin pain model in male Sprague-Dawley rats with a 1-hour pre-treatment dose of 5.0 mg/kg s.c. (n=8) during the second phase (5-40 minutes post formalin injection). The morphine control (s.c., 2 mg/kg, 30′ preTx, n=8), but not the peptide, significantly reduced the time spent lifting and/or licking the affected paw during the second phase. The peptide may have actually increased the pain response in the second phase of the formalin study. Data Represent Mean±SEM; *** p<0.0001 by ANOVA/DUNNETTS.

FIG. 69 shows the effects of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) at a 5.0 mg/kg s.c. dose with a 1-hour pre-treatment time on the total basic movement component of locomotor activity (tested in light-off condition) in male Sprague-Dawley rats (9 weeks of age). The dose of peptide did not significantly decrease exploratory behavior in relation to the vehicle control. Terminal exposure (peptide plasma concentrations at 2 h post peptide injection) was 0.994±0.184 μM for the 5.0 mg/kg s.c. dose. Data Represent Mean±SEM, n=8.

FIG. 70 shows the effects of [Glu20,Trp29]JzTx-V(1-29)(SEQ ID NO:112) at a 5.0 mg/kg s.c. dose with a 1-hour pre-treatment time on the total rearing component of locomotor activity (tested in light-off condition) in male Sprague-Dawley rats (9 weeks of age). The dose of peptide did not significantly decrease exploratory behavior in relation to the vehicle control. Data Represent Mean±SEM, n=8.

FIG. 71 shows representative block of Nav1.7 current with administration of 300 nM concentration of monomeric peptide GpTx-1 (SEQ ID NO:532 by manual electrophysiology (Nav1.7 whole cell patch clamp [WCPC] IC₅₀=0.003 μM).

FIG. 72 shows a representative time course of block of Nav1.7 current by addition of 10 and 300 nM concentrations of monomeric peptide GpTx-1 (SEQ ID NO:532 by manual electrophysiology (WCPC). Note the washout of peptide and recovery of current over time.

FIG. 73 shows representative block of Nav1.7 current with administration of 300 nM concentration of dimeric peptide Homodimeric Conjugate No. 3 by manual electrophysiology (Nav1.7 WCPC IC₅₀=0.00058 μM).

FIG. 74 shows a representative time course of block of Nav1.7 current by addition of 300 nM concentration of dimeric peptide Homodimeric Conjugate No. 3 by manual electrophysiology (WCPC). There was no washout of peptide and no recovery of current even after 45 minutes.

FIG. 75 shows the chemical structure of peptide dimer Homodimeric Conjugate No. 3.

FIG. 76 shows a schematic representation of a copper-catalyzed 1,3-dipolar cycloaddition reaction between an azide-containing linker and an alkyne-containing peptide to form a triazole linkage.

FIG. 77 shows the structure of a divalent, bifunctional linker design of the present invention.

FIG. 78A-B shows structures of a divalent, bifunctional linker designs of the present invention.

FIG. 79 shows a schematic conjugation of a peptidyl-linker with bromoacetamide to an engineered cysteine within a carrier protein, e.g., an immunoglobulin (IgG) protein.

FIG. 80 shows a reaction scheme for preparation of multivalent linkers.

FIG. 81A-C shows chemical structures of JzTx-V peptide analog SEQ ID NO:272 (FIG. 81A, upper row: i.e., R₁=H), plus a peptide linker sequence (SEQ ID NO:427; FIG. 81A, lower left), Homodimeric Conjugate No. 1 (FIG. 81A, lower middle), and Homodimeric Conjugate No. 2 (FIG. 81A, lower right), and schematic structures of Immunoglobulin Peptide Conjugate 1 (FIG. 81B-C). Within the scope of the invention, any other JzTx-V peptide analog sequence disclosed herein can be used in a conjugate instead of the illustrated SEQ ID NO:272.

FIG. 82 shows the structure of an exemplary polyazole. (See, also, Sharma, S. K. et al., Org. Chem. 66, 1030-1034 (2001)).

FIG. 83 shows examples of peptidyl linkers. (See, also, Chen, X. et al. Adv. Drug Deliv. Rev. 2012 doi: 10.1016/j.addr.2012.09.039.)

FIG. 84 shows chemical structures of exemplary peptidyl linkers, including helical and beta-hairpin scaffolds.

FIG. 85 shows a schematic representation of peptide sequences/structures of beta-hairpin linkers.

FIG. 86A-B shows exemplary generic (FIG. 86A) and representative (FIG. 86B) chemical structures of polyheterocyclic linkers for use in large-molecule-small-molecule conjugations.

FIG. 87A-B shows exemplary generic (FIG. 87A) and representative (FIG. 87B) chemical structures of multivalent linkers for use in conjugations.

FIG. 88 shows further examples of multivalent linkers.

FIG. 89A-B shows exemplary generic (FIG. 89A) and representative (FIG. 89B) chemical structures of further examples of multivalent linkers for use in conjugations.

FIG. 90 shows further examples of chemical structures of multivalent linkers.

FIG. 91 shows monovalent linkers of different lengths with mixed alkyl and PEG composition and PEG-only linkers of three different lengths.

FIG. 92A-B shows the results from the purification of the site specific conjugation reaction mixture of peptide-linker construct (Homodimeric Peptide No. 1) with anti-DNP mAb (E273C) hIgG1 (comprising immunoglobulin monomers SEQ ID NO:542; SEQ ID NO:543; SEQ ID NO:542; SEQ ID NO:543; see, Example 9 and Table 19). FIG. 92A shows the cation exchange chromatogram of UV absorbance at 280 nm of the conjugation reaction using a 5-mL HiTrap SP-HP column. FIG. 92B shows a reducing SDS-PAGE gel of the peaks from the cation exchange chromatogram. Peak 1 shows the heavy chain (HC) and light chain (LC) of the non-reacted antibody. Peak 3 shows approximately 50% of the HC shifted (HC*) indicating a monovalent antibody-JzTx-V peptide dimer conjugate. Peak 4 shows nearly 100% HC shifted indicating bivalent antibody-JzTx-V peptide dimer conjugate (Immunoglobulin Peptide Conjugate 1).

FIG. 93 shows a reducing SDS-PAGE gel of Immunoglobulin Peptide Conjugate 1 from the site specific conjugation reaction of peptide-linker construct (Homodimeric Peptide No. 1, see Example 5) with anti-DNP mAb (E273C) hIgG1 (comprising immunoglobulin monomers SEQ ID NO:542; SEQ ID NO:543; SEQ ID NO:542; SEQ ID NO:543, see Example 9) following purification on the SP-column.

FIG. 94A-N shows schematic structures of some embodiments of a composition of the invention that include one or more units of a pharmacologically active toxin, e.g., toxin (e.g., JzTx-V) peptide analog (squiggle) fused, via an optional peptidyl linker moiety such as but not limited to L5 or L10 described herein, with one or more domains of an immunoglobulin. These schematics show a more typical IgG1, although they are intended to apply as well to IgG2s, which will have 4 disulfide bonds in the hinge and a different arrangement of the disulfide bond linking the heavy and light chain, and IgG3s and IgG4s. FIG. 94A represents a monovalent heterodimeric Fc-toxin peptide analog fusion or conjugate with the toxin peptide analog fused or conjugated to the C-terminal end of one of the immunoglobulin Fc domain monomers. FIG. 94B represents a bivalent homodimeric Fc-toxin peptide analog fusion or conjugate, with toxin peptide analogs fused to the C-terminal ends of both of the immunoglobulin Fc domain monomers. FIG. 94C represents a monovalent heterodimeric toxin peptide analog-Fc fusion or conjugate with the toxin peptide analog fused or chemically conjugated to the N-terminal end of one of the immunoglobulin Fc domain monomers. FIG. 94D represents a bivalent homodimeric toxin peptide analog-Fc fusion or conjugate, with toxin peptide analogs fused to the N-terminal ends of both of the immunoglobulin Fc domain monomers. FIG. 94E represents a monovalent heterotrimeric Fc-toxin peptide analog/Ab comprising an immunoglobulin heavy chain (HC)+immunoglobulin light chain (LC)+an immunoglobulin Fc monomer with a toxin peptide analog fused to its C-terminal end. FIG. 94F represents a monovalent heterotetrameric (HT) antibody HC-toxin peptide analog fusion or conjugate, with a toxin peptide analog fused to the C-terminal end of one of the HC monomers. FIG. 94G represents a bivalent HT antibody Ab HC-toxin peptide analog fusion or conjugate having toxin peptide analogs on the C-terminal ends of both HC monomers. FIG. 94H represents a monovalent HT toxin peptide analog-LC Ab, with the toxin peptide analog fused to the N-terminal end of one of the LC monomers. FIG. 94I represents a monovalent HT toxin peptide analog-HC Ab, with the toxin peptide analog fused to the N-terminal end of one of the HC monomers. FIG. 94J represents a monovalent HT Ab LC-toxin peptide analog fusion or conjugate (i.e., LC-toxin peptide analog fusion or conjugate+LC+2(HC)), with the toxin peptide analog fused to the C-terminal end of one of the LC monomers. FIG. 94K represents a bivalent HT Ab LC-toxin peptide analog fusion or conjugate (i.e., 2(LC-toxin peptide analog fusion or conjugate)+2(HC)), with toxin peptide analogs fused to the C-terminal end of both of the LC monomers. FIG. 94L represents a trivalent HT Ab LC-toxin peptide analog/HC-toxin peptide analog (i.e., 2(LC-toxin peptide analog fusion or conjugate)+HC-toxin peptide analog fusion or conjugate+HC), with the toxin peptide analogs fused to the C-terminal ends of both of the LC monomers and one of the HC monomers. FIG. 94M represents a bivalent antibody with a toxin peptide analog moiety inserted into an internal loop of the immunoglobulin Fc domain of each HC monomer. FIG. 94N represents a monovalent antibody with a toxin peptide analog moiety inserted into an internal loop of the immunoglobulin Fc domain of one of the HC monomers. Dimers or trimers will form spontaneously in certain host cells upon expression of a deoxyribonucleic acid (DNA) construct encoding a single chain. In other host cells, the cells can be placed in conditions favoring formation of dimers/trimers or the dimers/trimers can be formed in vitro. If more than one HC monomer, LC monomer, or immunoglobulin Fc domain monomer is part of a single embodiment, the individual monomers can be, if desired, identical or different from each other.

FIG. 95 shows a schematic representation of a Fc-peptide conjugate embodiment for illustrative purposes only. A homology model of the immunoglobulin anti-DNP mAb (E52C) hIgG1 Fc domain (homodimer of SEQ ID NO:544) is constructed from an immunoglobulin crystal structure (1HZH.pdb) and is depicted as a solid ribbon. Cys52 of SEQ ID NO:544, the site of conjugation, is rendered in CPK format. PEG11 linker is depicted as a solid tube, in an arbitrary conformation in this embodiment, connecting the C52 residue in the immunoglobulin Fc domain to an Atz residue in the peptide. Any other linkers described herein can be substituted for the PEG11 linker, for example see FIG. 91. Homology models of the JzTx-V peptide analog are displayed as a solid ribbon and shown in arbitrary relative orientations to the immunoglobulin in this embodiment. One peptide is shown to reflect the monvalent nature of this immunoglobulin-peptide conjugate, however bivalent, trivalent, or other multivalent embodiments can be made.

FIG. 96 shows a schematic representation of a Fc-peptide conjugate embodiment for illustrative purposes only. A homology model of the anti-DNP mAb (E52C) hIgG1 Fc domain (homodimer of SEQ ID NO:544) is constructed from an immunoglobulin crystal structure (1HZH.pdb) and is depicted as a solid ribbon. Cys52 residues of both Fc domain monomers (SEQ ID NO:544), are used as the sites of conjugation, and are rendered in CPK format. PEG11 linkers are depicted as solid tubes in this embodiment in an arbitrary conformation connecting the C52 residues in the immunoglobulin Fc domain to an Atz residue in the peptides. Any other linkers described herein can be substituted for the PEG11 linker, for example see FIG. 91. Homology models of the JzTx-V peptide analog are displayed as a solid ribbon and shown in arbitrary relative orientations to the immunoglobulin in this embodiment. Two peptides are shown to reflect the bivalent nature of immunoglobulin-peptide conjugate. Multivalent linkers as described herein allow for the display of more than two peptides.

FIG. 97 shows a schematic representation of an immunoglobulin-peptide conjugate embodiment for illustrative purposes only. A homology model of the anti-DNP mAb (E273C) hIgG1 (comprising immunoglobulin monomers SEQ ID NO:542; SEQ ID NO:543; SEQ ID NO:542; SEQ ID NO:543) is constructed from an immunoglobulin crystal structure (1HZH.pdb) and is depicted as a solid ribbon. Cys273, the site of conjugation, is rendered in CPK format. In this embodiment, a PEG11 linker is depicted as a solid tube in an arbitrary conformation connecting the C273 residue in the immunoglobulin to an Atz residue in the peptide. Any other linkers described herein can be substituted for the PEG11 linker, for example see FIG. 91. Homology models of the JzTx-V peptide analog are displayed as a solid ribbon and shown in arbitrary relative orientations to the immunoglobulin in this embodiment. One peptide is shown to reflect the monvalent nature of this immunoglobulin-peptide conjugate, however bivalent, trivalent, or other multivalent embodiments can be made.

FIG. 98 shows a schematic representation of an immunoglobulin-peptide conjugate embodiment for illustrative purposes only. A homology model of the anti-DNP mAb (E273C) hIgG1 (comprising immunoglobulin monomers SEQ ID NO:542; SEQ ID NO:543; SEQ ID NO:542; SEQ ID NO:543) is constructed from an immunoglobulin crystal structure (1HZH.pdb) and is depicted as a solid ribbon. Both Cys273 residues, the sites of conjugation, are rendered in CPK format. In this embodiment, PEG11 linkers are depicted as solid tubes in an arbitrary conformation connecting the C273 residues in the immunoglobulin to an Atz residue in each of the peptides. Any other linkers described herein can be substituted for the PEG11 linker, for example see FIG. 91. Homology models of the JzTx-V peptide analog are displayed as a solid ribbon and shown in arbitrary relative orientations to the immunoglobulin in this embodiment. Two peptides are shown to reflect the bivalent nature of immunoglobulin-peptide conjugate. Multivalent linkers as described herein allow for the display of more than two peptides.

DETAILED DESCRIPTION OF EMBODIMENTS

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

DEFINITIONS

Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Thus, as used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the context clearly indicates otherwise. For example, reference to “a protein” includes a plurality of proteins; reference to “a cell” includes populations of a plurality of cells.

“Polypeptide” and “protein” are used interchangeably herein and include a molecular chain of two or more amino acids linked covalently through peptide bonds. The terms do not refer to a specific length of the product. Thus, “peptides,” and “oligopeptides,” are included within the definition of polypeptide. The terms include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, biotinylations, 4-pentynoylations, PEGylations, phosphorylations and the like. In addition, protein fragments, analogs, mutated or variant proteins, fusion proteins and the like are included within the meaning of polypeptide. The terms also include molecules in which one or more amino acid analogs or non-canonical or unnatural amino acids are included as can be expressed recombinantly using known protein engineering techniques. In addition, fusion proteins can be derivatized as described herein by well-known organic chemistry techniques.

A composition of the present invention that includes a peptide or polypeptide of the invention covalently linked, attached, or bound, either directly or indirectly through a linker moiety, to another peptide or polypeptide of the invention or to a half-life extending moiety is a “conjugate” or “conjugated” molecule, whether conjugated by chemical means (e.g., post-translationally or post-synthetically) or by recombinant fusion.

“Biotin” is a water-soluble B-complex vitamin, i.e., vitamin B7, that is composed of an ureido (tetrahydroimidizalone) ring fused with a tetrahydrothiophene ring (See, Formula I).

A valeric acid substituent is attached to one of the carbon atoms of the tetrahydrothiophene ring. In nature, biotin is a coenzyme in the metabolism of fatty acids and leucine, and it plays a role in vivo in gluconeogenesis. Biotin binds very tightly to the tetrameric protein avidin (e.g., Chicken avidin, bacterial streptavidin, and neutravidin), with a dissociation equilibrium constant K_(D) in the order of 10⁻¹⁴ M to 10⁻¹⁶ M, which is one of the strongest known protein-ligand interactions, approaching the covalent bond in strength. (Laitinen et al. Genetically engineered avidins and streptavidins, Cell Mol Life Sci. 63 (24): 2992-30177 (2006)). The biotin-avidin non-covalent interaction is often used in different biotechnological applications. (See, Laitinen et al., Genetically engineered avidins and streptavidins, Cell Mol Life Sci. 63 (24): 2992-30177 (2006)).

“Biotinylated” means that a substance is covalently conjugated to one or more biotin moieties. Biotinylated peptides useful in practicing the invention can be purchased commercially (e.g., Midwest Bio-Tech Inc.) or can be readily synthesized and biotinylated. Biotinylation of compounds, such as peptides, can be by any known chemical technique. These include primary amine biotinylation, sulfhydryl biotinylation, and carboxyl biotinylation. For example, amine groups on the peptide, which are present as lysine side chain epsilon-amines and N-terminal α-amines, are common targets for primary amine biotinylation biotinylation Amine-reactive biotinylation reagents can be divided into two groups based on water solubility.

-   -   1) N-hydroxysuccinimide (NHS)-esters of biotin have poor         solubility in aqueous solutions. For reactions in aqueous         solution, they must first be dissolved in an organic solvent,         then diluted into the aqueous reaction mixture. The most         commonly used organic solvents for this purpose are dimethyl         sulfoxide (DMSO) and dimethyl formamide (DMF), which are         compatible with most proteins at low concentrations.     -   2) Sulfo-NHS-esters of biotin are more soluble in water, and are         dissolved in water just before use because they hydrolyze         easily. The water solubility of sulfo-NHS-esters stems from         their sulfonate group on the N-hydroxysuccinimide ring and         eliminates the need to dissolve the reagent in an organic         solvent.         Chemical reactions of NHS- and sulfo-NHS-esters are essentially         the same: an amide bond is formed and NHS or sulfo-NHS become         leaving groups. Because the targets for the ester are         deprotonated primary amines, the reaction is prevalent above         pH 7. Hydrolysis of the NHS-ester is a major competing reaction,         and the rate of hydrolysis increases with increasing pH. NHS-         and sulfo-NHS-esters have a half-life of several hours at pH 7,         but only a few minutes at pH 9. The conditions for conjugating         NHS-esters to primary amines of peptides include incubation         temperatures in the range 4-37° C., reaction pH values in the         range 7-9, and incubation times from a few minutes to about 12         hours. Buffers containing amines (such as Tris or glycine) must         be avoided because they compete with the reaction. The HABA dye         (2-(4-hydroxyazobenzene) benzoic acid) method can be used to         determine the extent of biotinylation. Briefly, HABA dye is         bound to avidin and yields a characteristic absorbance. When         biotin, in the form of biotinylated protein or other molecule,         is introduced, it displaces the dye, resulting in a change in         absorbance at 500 nm. The absorbance change is directly         proportional to the level of biotin in the sample.

“4-pentynoylation” of an amino acid residue is typically by coupling 4-pentynoic acid via a standard amide bond reaction via the N-terminal or at a side chain. When appropriate for additional PEGylations, 4-pentynoylation can alternatively employ an alkyne in the copper-catalyzed 1,3-dipolar cycloaddition reaction (the so-called “Click” reaction) to react with the azide in the azido-PEG molecule to link the peptide and the PEG via a triazole.

An “isolated polypeptide” is a polypeptide molecule that is purified or separated from at least one contaminant polypeptide molecule with which it is ordinarily associated in the natural source of the polypeptide. An isolated polypeptide molecule is other than in the form or setting in which it is found in nature.

“Toxin peptides” include peptides and polypeptides having the same amino acid sequence of a naturally occurring pharmacologically active peptide or polypeptide that can be isolated from a venom, and also include modified peptide analogs of such naturally occurring molecules. (See, e.g., Kalman et al., ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide, J. Biol. Chem. 273(49):32697-707 (1998); Kem et al., U.S. Pat. No. 6,077,680; Mouhat et al., OsK1 derivatives, WO 2006/002850 A2; Chandy et al., Analogs of SHK toxin and their uses in selective inhibition of Kv1.3 potassium channels, WO 2006/042151; Sullivan et al., Toxin Peptide therapeutic agents, WO 2006/116156 A2, all of which are incorporated herein by reference in their entirety). Snakes, scorpions, spiders, bees, snails and sea anemone are a few examples of organisms that produce venom that can serve as a rich source of small bioactive toxin peptides or “toxins” that potently and selectively target ion channels and receptors. Some examples of toxins that inhibit voltage-gated sodium channels include JzTx-V (SEQ ID NO:2), JzTx-45 (YCQKWMWTCDSERKCCEGYVCELWCKYNL//SEQ ID NO:48), and JzTx-46 (YCQKWMWTCDSERKCCEGYVCELWCKYNM//SEQ ID NO:430), isolated from the venom of tarantula Chilobrachys jingzhao; GpTx-1 (Asp Cys Leu Gly Phe Met Arg Lys Cys Ile Pro Asp Asn Asp Lys Cys Cys Arg Pro Asn Leu Val Cys Ser Arg Thr His Lys Trp Cys Lys Tyr Val Phe-NH₂//SEQ ID NO:532) isolated from the venom of tarantula Grammostola porteri, Huwentoxin-IV (ECLEI FKACN PSNDQ CCKSS KLVCS RKTRW CKYQI-NH₂//SEQ ID NO:528) and Huwentoxin-I (ACKGV FDACT PGKNE CCPNR VCSDK HKWCK WKL//SEQ ID NO:529), isolated from the venom of tarantula Ornithoctonus huwena; KIIIA (CCNCS SKWCR DHSRC C—NH₂//SEQ ID NO:530) isolated from the venom of marine cone snail Conus kinoshitai; ProTxI (Glu Cys Arg Tyr Trp Leu Gly Gly Cys Ser Ala Gly Gln Thr Cys Cys Lys His Leu Val Cys Ser Arg Arg His Gly Trp Cys Val Trp Asp Gly Thr Phe Ser//SEQ ID NO:527) and ProTxII (YCQKW MWTCD SERKC CEGMV CRLWC KKKLW//SEQ ID NO:531) isolated from the venom of tarantula Thrixopelma pruriens. Another example is the alpha toxin OD1 (GVRDAYIADD KNCVYTCASN GYCNTECTKN GAESGYCQWI GRYGNACWCI KLPDEVPIRIPGKCR-NH₂//SEQ ID NO:589), a toxin isolated from the venom of the scorpion Odonthobuthus doriae. Another example of a toxin peptide is OSK1 (also known as OsK1), a toxin peptide isolated from Orthochirus scrobiculosus scorpion venom. (e.g., Mouhat et al., K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom, Biochem. J. 385:95-104 (2005); Mouhat et al., Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain, Molec. Pharmacol. 69:354-62 (2006); Mouhat et al., OsK1 derivatives, WO 2006/002850 A2). Another example is ShK, isolated from the venom of the sea anemone Stichodactyla helianthus, and its peptide analogs. (E.g., Tudor et al., Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin, Eur. J. Biochem. 251(1-2):133-41(1998); Pennington et al., Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin, Biochem. 38(44): 14549-58 (1999); Kem et al., ShK toxin compositions and methods of use, U.S. Pat. No. 6,077,680; Lebrun et al., Neuropeptides originating in scorpion, U.S. Pat. No. 6,689,749; Beeton et al., Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channnels for therapy of autoimmune diseases, Molec. Pharmacol. 67(4):1369-81 (2005); and Sullivan et al., Selective and potent peptide inhibitors of K_(v)1.3, WO 2010/108154 A2).

The toxin peptides are usually between about 20 and about 80 amino acids in length, contain 2-5 disulfide linkages and form a very compact structure. Toxin peptides (e.g., from the venom of scorpions, sea anemones and cone snails) have been isolated and characterized for their impact on ion channels. Such peptides appear to have evolved from a relatively small number of structural frameworks that are particularly well suited to addressing the critical issues of potency and stability. The majority of scorpion and Conus toxin peptides, for example, contain 10-40 amino acids and up to five disulfide bonds, forming extremely compact and constrained structure (microproteins) often resistant to proteolysis. The conotoxin and scorpion toxin peptides can be divided into a number of superfamilies based on their disulfide connections and peptide folds. The solution structure of many toxin peptides has been determined by NMR spectroscopy, illustrating their compact structure and verifying conservation of family folding patterns. (E.g., Tudor et al., Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin, Eur. J. Biochem. 251(1-2):133-41(1998); Pennington et al., Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin, Biochem. 38(44): 14549-58 (1999); Jaravine et al., Three-dimensional structure of toxin OSK1 from Orthochirus scrobiculosus scorpion venom, Biochem. 36(6):1223-32 (1997); del Rio-Portillo et al.; NMR solution structure of Cn12, a novel peptide from the Mexican scorpion Centruroides noxius with a typical beta-toxin sequence but with alpha-like physiological activity, Eur. J. Biochem. 271(12): 2504-16 (2004); Prochnicka-Chalufour et al., Solution structure of discrepin, a new K+-channel blocking peptide from the alpha-KTx15 subfamily, Biochem. 45(6):1795-1804 (2006)). Other examples are known in the art, or can be found in Sullivan et al., Toxin Peptide Therapeutic Agents, WO06116156 A2 or U.S. Pat. No. 7,833,979; Sullivan et al., Selective and potent peptide inhibitors of K_(v)1.3, WO 2010/108154 A2; Mouhat et al., OsK1 derivatives, WO 2006/002850 A2; Sullivan et al., U.S. patent application Ser. No. 11/978,076 (titled:, filed 25 Oct. 2007), Lebrun et al., U.S. Pat. No. 6,689,749, which are each incorporated by reference in their entireties.

The term “peptide analog” refers to a peptide having a sequence that differs from a peptide sequence existing in nature by at least one amino acid residue substitution, internal addition, or internal deletion of at least one amino acid, and/or amino- or carboxy-terminal end truncations or additions, and/or carboxy-terminal amidation. An “internal deletion” refers to absence of an amino acid from a sequence existing in nature at a position other than the N- or C-terminus. Likewise, an “internal addition” refers to presence of an amino acid in a sequence existing in nature at a position other than the N- or C-terminus

Embodiments of the inventive composition of matter includes a toxin peptide analog, or a pharmaceutically acceptable salt thereof “Toxin peptide analogs” contain modifications of a native toxin peptide sequence of interest (e.g., amino acid residue substitutions, internal additions or insertions, internal deletions, and/or amino- or carboxy-terminal end truncations, or additions as previously described above) relative to a native toxin peptide sequence of interest, such as JzTx-V (YCQKWMWTCDSKRACCEGLRCKLWCRKII-NH₂//SEQ ID NO:2). Toxin peptide analogs of the present invention are 20 to about 80 amino acid residues long and, in relation to SEQ ID NO:2, have C¹-C⁴, C²-C⁵ and C³-C⁶ disulfide (or diselenide) bonding in which, C¹, C², C³, C⁴, C⁵ and C⁶ represent the order of cysteine (or selenocysteine) residues appearing in the primary sequence of the toxin peptide stated conventionally with the N-terminus of the peptide(s) on the left, with the first and sixth cysteines (or selenocysteines) in the amino acid sequence forming a disulfide bond (or diselenide bond, if SeCys), the second and fourth cysteines (or selenocysteines) forming a disulfide bond (or diselenide bond, if SeCys), and the third and fifth cysteines (or selenocysteines) forming a disulfide bond (or diselenide bond, if SeCys). As described herein, the toxin peptide analogs of the present invention can also have additional amino acid residues at the N-terminal and/or C-terminal ends, in relation to SEQ ID NO:2.

By “physiologically acceptable salt” of the composition of matter, for example a salt of the toxin peptide analog, is meant any salt or salts that are known or later discovered to be pharmaceutically acceptable. Some non-limiting examples of pharmaceutically acceptable salts are: acetate; trifluoroacetate; hydrohalides, such as hydrochloride and hydrobromide; sulfate; citrate; maleate; tartrate; glycolate; gluconate; succinate; mesylate; besylate; salts of gallic acid esters (gallic acid is also known as 3,4, 5 trihydroxybenzoic acid) such as PentaGalloylGlucose (PGG) and epigallocatechin gallate (EGCG), salts of cholesteryl sulfate, pamoate, tannate and oxalate salts.

The term “fusion protein” indicates that the protein includes polypeptide components derived from more than one parental protein or polypeptide. Typically, a fusion protein is expressed from a fusion gene in which a nucleotide sequence encoding a polypeptide sequence from one protein is appended in frame with, and optionally separated by a linker from, a nucleotide sequence encoding a polypeptide sequence from a different protein. The fusion gene can then be expressed by a recombinant host cell as a single protein.

The terms “-mimetic peptide,” “peptide mimetic,” and “-agonist peptide” refer to a peptide or protein having biological activity comparable to a naturally occurring protein of interest, for example, but not limited to, a toxin peptide molecule. These terms further include peptides that indirectly mimic the activity of a naturally occurring peptide molecule, such as by potentiating the effects of the naturally occurring molecule.

The term “-antagonist peptide,” “peptide antagonist,” and “inhibitor peptide” refer to a peptide that blocks or in some way interferes with the biological activity of a receptor of interest, or has biological activity comparable to a known antagonist or inhibitor of a receptor of interest, such as, but not limited to, an ion channel (e.g., Nav1.7 or Nav1.3) or a G-Protein Coupled Receptor (GPCR).

A “domain” of a protein is any portion of the entire protein, up to and including the complete protein, but typically comprising less than the complete protein. A domain can, but need not, fold independently of the rest of the protein chain and/or be correlated with a particular biological, biochemical, or structural function or location (e.g., a ligand binding domain, or a cytosolic, transmembrane or extracellular domain).

As used herein “soluble” when in reference to a protein produced by recombinant DNA technology in a host cell is a protein that exists in aqueous solution; if the protein contains a twin-arginine signal amino acid sequence the soluble protein is exported to the periplasmic space in gram negative bacterial hosts, or is secreted into the culture medium by eukaryotic host cells capable of secretion, or by bacterial host possessing the appropriate genes (e.g., the kil gene). Thus, a soluble protein is a protein which is not found in an inclusion body inside the host cell. Alternatively, depending on the context, a soluble protein is a protein which is not found integrated in cellular membranes. In contrast, an insoluble protein is one which exists in denatured form inside cytoplasmic granules (called an inclusion body) in the host cell, or again depending on the context, an insoluble protein is one which is present in cell membranes, including but not limited to, cytoplasmic membranes, mitochondrial membranes, chloroplast membranes, endoplasmic reticulum membranes, etc.

A distinction is also drawn between proteins which are “soluble” (i.e., dissolved or capable of being dissolved) in an aqueous solution devoid of significant amounts of ionic detergents (e.g., SDS) or denaturants (e.g., urea, guanidine hydrochloride) and proteins which exist as a suspension of insoluble protein molecules dispersed within the solution. A “soluble” protein will not be removed from a solution containing the protein by centrifugation using conditions sufficient to remove cells present in a liquid medium (e.g., centrifugation at 5,000×g for 4-5 minutes). In some embodiments of the inventive composition, the toxin peptide analog is synthesized by the host cell and segregated in an insoluble form within cellular inclusion bodies, which can then be purified from other cellular components in a cell extract with relative ease, and the toxin peptide analog can in turn be solubilized, refolded and/or further purified.

A distinction is drawn between a “soluble” protein (i.e., a protein which when expressed in a host cell is produced in a soluble form) and a “solubilized” protein. An insoluble recombinant protein found inside an inclusion body or found integrated in a cell membrane may be solubilized (i.e., rendered into a soluble form) by treating purified inclusion bodies or cell membranes with denaturants such as guanidine hydrochloride, urea or sodium dodecyl sulfate (SDS). These denaturants must then be removed from the solubilized protein preparation to allow the recovered protein to renature (refold). Although the inventive compositions can be refolded in active form, not all proteins will refold into an active conformation after solubilization in a denaturant and removal of the denaturant. Many proteins precipitate upon removal of the denaturant. SDS may be used to solubilize inclusion bodies and cell membranes and will maintain the proteins in solution at low concentration. However, dialysis will not always remove all of the SDS (SDS can form micelles which do not dialyze out); therefore, SDS-solubilized inclusion body protein and SDS-solubilized cell membrane protein is soluble but not refolded.

A “secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a secretory signal peptide sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a “mature” protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage. In some other embodiments of the inventive composition, the toxin peptide analog can be synthesized by the host cell as a secreted protein, which can then be further purified from the extracellular space and/or medium.

The term “recombinant” indicates that the material (e.g., a nucleic acid or a polypeptide) has been artificially or synthetically (i.e., non-naturally) altered by human intervention. The alteration can be performed on the material within, or removed from, its natural environment or state. For example, a “recombinant nucleic acid” is one that is made by recombining nucleic acids, e.g., during cloning, DNA shuffling or other well known molecular biological procedures. Examples of such molecular biological procedures are found in Maniatis et al., Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982). A “recombinant DNA molecule,” is comprised of segments of DNA joined together by means of such molecular biological techniques. The term “recombinant protein” or “recombinant polypeptide” as used herein refers to a protein molecule which is expressed using a recombinant DNA molecule. A “recombinant host cell” is a cell that contains and/or expresses a recombinant nucleic acid.

The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers containing two or more nucleotide residues. The nucleotide residues comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2′,3′-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate and phosphoroamidate.

The term “oligonucleotide” means a polynucleotide comprising 200 or fewer nucleotide residues. In some embodiments, oligonucleotides are 10 to 60 bases in length. In other embodiments, oligonucleotides are 12,13, 14, 15, 16, 17, 18, 19, or 20 to 40 nucleotides in length. Oligonucleotides may be single stranded or double stranded, e.g., for use in the construction of a mutant gene. Oligonucleotides may be sense or antisense oligonucleotides. An oligonucleotide can include a label, including an isotopic label (e.g., ¹²⁵I, ¹⁴C, ¹³C, ³⁵S, ³H, ²H, ¹³N, ¹⁵N, ¹⁸O, ¹⁷O, etc.), for ease of quantification or detection, a fluorescent label, a hapten or an antigenic label, for detection assays. Oligonucleotides may be used, for example, as PCR primers, cloning primers or hybridization probes.

A “polynucleotide sequence” or “nucleotide sequence” or “nucleic acid sequence,” as used interchangeably herein, is the primary sequence of nucleotide residues in a polynucleotide, including of an oligonucleotide, a DNA, and RNA, a nucleic acid, or a character string representing the primary sequence of nucleotide residues, depending on context. From any specified polynucleotide sequence, either the given nucleic acid or the complementary polynucleotide sequence can be determined Included are DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Unless specified otherwise, the left-hand end of any single-stranded polynucleotide sequence discussed herein is the 5′ end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5′ direction. The direction of 5′ to 3′ addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA transcript that are 5′ to the 5′ end of the RNA transcript are referred to as “upstream sequences;” sequence regions on the DNA strand having the same sequence as the RNA transcript that are 3′ to the 3′ end of the RNA transcript are referred to as “downstream sequences.”

As used herein, an “isolated nucleic acid molecule” or “isolated nucleic acid sequence” is a nucleic acid molecule that is either (1) identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the nucleic acid or (2) cloned, amplified, tagged, or otherwise distinguished from background nucleic acids such that the sequence of the nucleic acid of interest can be determined. An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. However, an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express a polypeptide (e.g., an oligopeptide or antibody) where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

As used herein, the terms “nucleic acid molecule encoding,” “DNA sequence encoding,” and “DNA encoding” refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of ribonucleotides along the mRNA chain, and also determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the RNA sequence and for the amino acid sequence.

The term “gene” is used broadly to refer to any nucleic acid associated with a biological function. Genes typically include coding sequences and/or the regulatory sequences required for expression of such coding sequences. The term “gene” applies to a specific genomic or recombinant sequence, as well as to a cDNA or mRNA encoded by that sequence. A “fusion gene” contains a coding region that encodes a polypeptide with portions from different proteins that are not naturally found together, or not found naturally together in the same sequence as present in the encoded fusion protein (i.e., a chimeric protein). Genes also include non-expressed nucleic acid segments that, for example, form recognition sequences for other proteins. Non-expressed regulatory sequences including transcriptional control elements to which regulatory proteins, such as transcription factors, bind, resulting in transcription of adjacent or nearby sequences.

“Expression of a gene” or “expression of a nucleic acid” means transcription of DNA into RNA (optionally including modification of the RNA, e.g., splicing), translation of RNA into a polypeptide (possibly including subsequent post-translational modification of the polypeptide), or both transcription and translation, as indicated by the context.

As used herein the term “coding region” or “coding sequence” when used in reference to a structural gene refers to the nucleotide sequences which encode the amino acids found in the nascent polypeptide as a result of translation of an mRNA molecule. The coding region is bounded, in eukaryotes, on the 5′ side by the nucleotide triplet “ATG” which encodes the initiator methionine and on the 3′ side by one of the three triplets which specify stop codons (i.e., TAA, TAG, TGA).

The term “control sequence” or “control signal” refers to a polynucleotide sequence that can, in a particular host cell, affect the expression and processing of coding sequences to which it is ligated. The nature of such control sequences may depend upon the host organism. In particular embodiments, control sequences for prokaryotes may include a promoter, a ribosomal binding site, and a transcription termination sequence. Control sequences for eukaryotes may include promoters comprising one or a plurality of recognition sites for transcription factors, transcription enhancer sequences or elements, polyadenylation sites, and transcription termination sequences. Control sequences can include leader sequences and/or fusion partner sequences. Promoters and enhancers consist of short arrays of DNA that interact specifically with cellular proteins involved in transcription (Maniatis, et al., Science 236:1237 (1987)). Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad host range while others are functional in a limited subset of cell types (for review see Voss, et al., Trends Biochem. Sci., 11:287 (1986) and Maniatis, et al., Science 236:1237 (1987)).

The term “vector” means any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage or virus) used to transfer protein coding information into a host cell.

The term “expression vector” or “expression construct” as used herein refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid control sequences necessary for the expression of the operably linked coding sequence in a particular host cell. An expression vector can include, but is not limited to, sequences that affect or control transcription, translation, and, if introns are present, affect RNA splicing of a coding region operably linked thereto. Nucleic acid sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals. A secretory signal peptide sequence can also, optionally, be encoded by the expression vector, operably linked to the coding sequence of interest, so that the expressed polypeptide can be secreted by the recombinant host cell, for more facile isolation of the polypeptide of interest from the cell, if desired. Such techniques are well known in the art. (E.g., Goodey, Andrew R.; et al., Peptide and DNA sequences, U.S. Pat. No. 5,302,697; Weiner et al., Compositions and methods for protein secretion, U.S. Pat. No. 6,022,952 and U.S. Pat. No. 6,335,178; Uemura et al., Protein expression vector and utilization thereof, U.S. Pat. No. 7,029,909; Ruben et al., 27 human secreted proteins, US 2003/0104400 A1).

The terms “in operable combination”, “in operable order” and “operably linked” as used herein refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced. For example, a control sequence in a vector that is “operably linked” to a protein coding sequence is ligated thereto so that expression of the protein coding sequence is achieved under conditions compatible with the transcriptional activity of the control sequences.

The term “host cell” means a cell that has been transformed, or is capable of being transformed, with a nucleic acid and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present. Any of a large number of available and well-known host cells may be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial host cells in culture include bacteria (such as Escherichia coli sp.), yeast (such as Saccharomyces sp.) and other fungal cells, insect cells, plant cells, mammalian (including human) cells, e.g., CHO cells and HEK-293 cells. Modifications can be made at the DNA level, as well. The peptide-encoding DNA sequence may be changed to codons more compatible with the chosen host cell. For E. coli, optimized codons are known in the art. Codons can be substituted to eliminate restriction sites or to include silent restriction sites, which may aid in processing of the DNA in the selected host cell. Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art.

The term “transfection” means the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., 1973, Virology 52:456; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, supra; Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier; Chu et al., 1981, Gene 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

The term “transformation” refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain new DNA or RNA. For example, a cell is transformed where it is genetically modified from its native state by introducing new genetic material via transfection, transduction, or other techniques. Following transfection or transduction, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, or may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been “stably transformed” when the transforming DNA is replicated with the division of the cell.

The term “transgene” refers to an isolated nucleotide sequence, originating in a different species from the host, that may be inserted into one or more cells of a mammal or mammalian embryo. The transgene optionally may be operably linked to other genetic elements (such as a promoter, poly A sequence and the like) that may serve to modulate, either directly, or indirectly in conjunction with the cellular machinery, the transcription and/or expression of the transgene. Alternatively or additionally, the transgene may be linked to nucleotide sequences that aid in integration of the transgene into the chromosomal DNA of the mammalian cell or embryo nucleus (as for example, in homologous recombination). The transgene may be comprised of a nucleotide sequence that is either homologous or heterologous to a particular nucleotide sequence in the mammal's endogenous genetic material, or is a hybrid sequence (i.e. one or more portions of the transgene are homologous, and one or more portions are heterologous to the mammal's genetic material). The transgene nucleotide sequence may encode a polypeptide or a variant of a polypeptide, found endogenously in the mammal, it may encode a polypeptide not naturally occurring in the mammal (i.e. an exogenous polypeptide), or it may encode a hybrid of endogenous and exogenous polypeptides. Where the transgene is operably linked to a promoter, the promoter may be homologous or heterologous to the mammal and/or to the transgene. Alternatively, the promoter may be a hybrid of endogenous and exogenous promoter elements (enhancers, silencers, suppressors, and the like).

Peptides.

Recombinant DNA- and/or RNA-mediated protein expression and protein engineering techniques, or any other methods of preparing peptides, are applicable to the making of the inventive polypeptides, e.g., toxin peptide analogs and fusion protein conjugates thereof (e.g., fusion proteins containing a toxin peptide analog and an immunoglobulin Fc domain, transthyretin, or human serum albumin) For example, the peptides can be made in transformed host cells. Briefly, a recombinant DNA molecule, or construct, coding for the peptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences encoding the peptides can be excised from DNA using suitable restriction enzymes. Any of a large number of available and well-known host cells may be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial host cells in culture include bacteria (such as Escherichia coli sp.), yeast (such as Saccharomyces sp.) and other fungal cells, insect cells, plant cells, mammalian (including human) cells, e.g., CHO cells and HEK293 cells. Modifications can be made at the DNA level, as well. The peptide-encoding DNA sequence may be changed to codons more compatible with the chosen host cell. For E. coli, optimized codons are known in the art. Codons can be substituted to eliminate restriction sites or to include silent restriction sites, which may aid in processing of the DNA in the selected host cell. Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. In addition, the DNA optionally further encodes, 5′ to the coding region of a fusion protein, a signal peptide sequence (e.g., a secretory signal peptide) operably linked to the expressed toxin peptide analog. For further examples of appropriate recombinant methods and exemplary DNA constructs useful for recombinant expression of the inventive compositions by mammalian cells, including dimeric Fc fusion proteins (“peptibodies”) or chimeric immunoglobulin(light chain+heavy chain)-Fc heterotrimers (“hemibodies”), conjugated to pharmacologically active toxin peptide analogs of the invention, see, e.g., Sullivan et al., Toxin Peptide Therapeutic Agents, US2007/0071764 and Sullivan et al., Toxin Peptide Therapeutic Agents, PCT/US2007/022831, published as WO 2008/088422, which are both incorporated herein by reference in their entireties.

Peptide compositions of the present invention can also be made by synthetic methods. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides. For example, well known solid phase synthesis techniques include the use of protecting groups, linkers, and solid phase supports, as well as specific protection and deprotection reaction conditions, linker cleavage conditions, use of scavengers, and other aspects of solid phase peptide synthesis. Suitable techniques are well known in the art. (E.g., Merrifield (1973), Chem. Polypeptides, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), J. Am. Chem. Soc. 85: 2149; Davis et al. (1985), Biochem. Intl. 10: 394-414; Stewart and Young (1969), Solid Phase Peptide Synthesis; U.S. Pat. No. 3,941,763; Finn et al. (1976), The Proteins (3rd ed.) 2: 105-253; and Erickson et al. (1976), The Proteins (3rd ed.) 2: 257-527; “Protecting Groups in Organic Synthesis,” 3rd Edition, T. W. Greene and P. G. M. Wuts, Eds., John Wiley & Sons, Inc., 1999; NovaBiochem Catalog, 2000; “Synthetic Peptides, A User's Guide,” G. A. Grant, Ed., W.H. Freeman & Company, New York, N.Y., 1992; “Advanced Chemtech Handbook of Combinatorial & Solid Phase Organic Chemistry,” W. D. Bennet, J. W. Christensen, L. K. Hamaker, M. L. Peterson, M. R. Rhodes, and H. H. Saneii, Eds., Advanced Chemtech, 1998; “Principles of Peptide Synthesis, 2nd ed.,” M. Bodanszky, Ed., Springer-Verlag, 1993; “The Practice of Peptide Synthesis, 2nd ed.,” M. Bodanszky and A. Bodanszky, Eds., Springer-Verlag, 1994; “Protecting Groups,” P. J. Kocienski, Ed., Georg Thieme Verlag, Stuttgart, Germany, 1994; “Fmoc Solid Phase Peptide Synthesis, A Practical Approach,” W. C. Chan and P. D. White, Eds., Oxford Press, 2000, G. B. Fields et al., Synthetic Peptides: A User's Guide, 1990, 77-183). For further examples of synthetic and purification methods known in the art, which are applicable to making the inventive compositions of matter, see, e.g., Sullivan et al., Toxin Peptide Therapeutic Agents, US2007/0071764 and Sullivan et al., Toxin Peptide Therapeutic Agents, PCT/US2007/022831, published as WO 2008/088422 A2, which are both incorporated herein by reference in their entireties.

In further describing the toxin peptide analogs herein, a one-letter abbreviation system is frequently applied to designate the identities of the twenty “canonical” amino acid residues generally incorporated into naturally occurring peptides and proteins (Table 2). Such one-letter abbreviations are entirely interchangeable in meaning with three-letter abbreviations, or non-abbreviated amino acid names. Within the one-letter abbreviation system used herein, an upper case letter indicates a L-amino acid, and a lower case letter indicates a D-amino acid. For example, the abbreviation “R” designates L-arginine and the abbreviation “r” designates D-arginine.

TABLE 2 One-letter abbreviations for the canonical amino acids. Three-letter abbreviations are in parentheses. Alanine (Ala) A Glutamine (Gln) Q Leucine (Leu) L Serine (Ser) S Arginine (Arg) R Glutamic Acid (Glu) E Lysine (Lys) K Threonine (Thr) T Asparagine (Asn) N Glycine (Gly) G Methionine (Met) M Tryptophan (Trp) W Aspartic Acid (Asp) D Histidine (His) H Phenylalanine (Phe) F Tyrosine (Tyr) Y Cysteine (Cys) C Isoleucine (Ile) I Proline (Pro) P Valine (Val) V

An amino acid substitution in an amino acid sequence is typically designated herein with a one-letter abbreviation for the amino acid residue in a particular position, followed by the numerical amino acid position relative to a native sequence of interest, which is then followed by the one-letter symbol for the amino acid residue substituted in. For example, “T30D” symbolizes a substitution of a threonine residue by an aspartate residue at amino acid position 30, relative to the native sequence of interest.

Non-canonical amino acid residues can be incorporated into a peptide within the scope of the invention by employing known techniques of protein engineering that use recombinantly expressing cells. (See, e.g., Link et al., Non-canonical amino acids in protein engineering, Current Opinion in Biotechnology, 14(6):603-609 (2003)). The term “non-canonical amino acid residue” refers to amino acid residues in D- or L-form that are not among the 20 canonical amino acids generally incorporated into naturally occurring proteins, for example, β-amino acids, homoamino acids, cyclic amino acids and amino acids with derivatized side chains. Examples include (in the L-form or D-form) β-alanine, 3-aminopropionic acid, piperidinic acid, aminocaprioic acid, aminoheptanoic acid, aminopimelic acid, desmosine, diaminopimelic acid, N^(α)-ethylglycine, N^(α)-ethylaspargine, hydroxylysine, allo-hydroxylysine, isodesmosine, allo-isoleucine, ω-methylarginine, N^(α)-methylglycine, N^(α)-methylisoleucine, N^(α)-methylvaline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N^(α)-acetylserine, N^(α)-formylmethionine, 3-methylhistidine, 5-hydroxylysine, and other similar amino acids, and those listed in Table 3 below, and derivatized forms of any of these as described herein. Table 3 contains some exemplary non-canonical amino acid residues that are useful in accordance with the present invention and associated abbreviations as typically used herein, although the skilled practitioner will understand that different abbreviations and nomenclatures may be applicable to the same substance and appear interchangeably herein. Some amino acid sequences, as recited herein may include “{H}-” at the N-terminal, which represents an N-terminal amino group, and/or may include “-{Free Acid}” at the C-terminal, which represents a C-terminal carboxy group.

TABLE 3 Useful non-canonical amino acids for amino acid addition, insertion, or substitution into peptide sequences in accordance with the present invention. In the event an abbreviation listed in Table 3 differs from another abbreviation for the same substance disclosed elsewhere herein, both abbreviations are understood to be applicable. The amino acids listed in Table 3 can be in the L-form or D-form, unless otherwise noted. Amino Acid Abbreviation(s) Acetamidomethyl Acm Acetylarginine acetylarg α-aminoadipic acid Aad aminobutyric acid Abu 2-aminobutyric acid 2-Abu 6-aminohexanoic acid Ahx; εAhx L-azidohomoalanine Aha 3-amino-6-hydroxy-2-piperidone Ahp 2-aminoindane-2-carboxylic acid Aic α-amino-isobutyric acid Aib L-allylglycine AllylG 3-amino-2-naphthoic acid Anc 2-aminotetraline-2-carboxylic acid Atc Aminophenylalanine Aminophe; Amino-Phe 4-amino-phenylalanine (also known as para-aminophenylalanine) 4AmP; 4-AminoF; 4- Amino-Phe 4-amidino-phenylalanine 4AmPhe 2-amino-2-(1-carbamimidoylpiperidin-4-yl)acetic acid 4AmPig ω-N-methylarginine R(Me) Arg ψ(CH₂NH)-reduced amide bond rArg 3-(1,2,3-triazol-4-yl)Alanine Atz (S)-2-amino-3-(1-(1-bromo-2-oxo-6,9,12-trioxa-3- Atz(PEG3- azatetradecan-14-yl)-1H-1,2,3-triazol-4-yl)propanoic acid bromoacetamide) (S)-2-amino-3-(1-(1-amino-3,6,9,12,15,18,21,24,27,30- Atz(NPEG10) or decaoxatritriacontan-33-yl)-1H-1,2,3-triazol-4-yl)propanoic Atz(PEG10) or acid Pra(NPEG9) 3-(1-(O-(aminoethyl)-O′-(ethylene)-decaethyleneglycol)- Atz(amino-PEG₁₀) 1,2,3-triazol-4-yl)Alanine 3-(1-(O-(aminoethyl)-O′-(ethylene)-ethyleneglycol450avg)- Atz(20 kDa PEG) 1,2,3-triazol-4-yl)Alanine (S)-2-amino-3-(1-(2-oxo-6,9,12,15,18,21,24,27,30,33,36- Atz(PEG11- undecaoxa-3-azaoctatriacontan-38-yl)-1H-1,2,3-triazol-4- (acetamidomethyl) yl)propanoic acid (S)-2-amino-3-(1-(4-oxo-1-phenyl- Atz(PEG11- 8,11,14,17,20,23,26,29,32,35,38-undecaoxa-2-thia-5- benzylthioacetamide) azatetracontan-40-yl)-1H-1,2,3-triazol-4-yl)propanoic acid (S)-2-amino-3-(1-(1-hydroxy-5-oxo- Atz(PEG11-((2- 9,12,15,18,21,24,27,30,33,36,39-undecaoxa-3-thia-6- hydroxyethyl)thio)acetamide) azahentetracontan-41-yl)-1H-1,2,3-triazol-4-yl)propanoic acid (S)-2-amino-3-(1-(1-bromo-2-oxo- Atz(PEG11- 6,9,12,15,18,21,24,27,30,33,36-undecaoxa-3-azaoctatriacontan- bromoacetamide) 38-yl)-1H-1,2,3-triazol-4-yl)propanoic acid (2S,2′S)-3,3′-(1,1′-(1,1′-(5-((2- Bis-[Atz(PEG23)]- (benzylthio)acetamido)methyl)-1,3-phenylene)bis(1-oxo- benzylthioacetamide 5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62, 65,68,71-tricosaoxa-2-azatriheptacontane-73,1- diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-aminopropanoic acid) (S)-2-amino-6-(3-(1-(1-bromo-2-oxo- K(ethyl-triazole-PEG11- 6,9,12,15,18,21,24,27,30,33,36-undecaoxa-3-azaoctatriacontan- bromoacetamide) 38-yl)-1H-1,2,3-triazol-4-yl)propanamido)hexanoic acid L-azidolysine AzK β-alanine bA β-homoarginine bhArg β-homolysine bhomoK β-homo Tic BhTic β-homophenylalanine BhPhe β-homoproline BhPro β-homotryptophan BhTrp 4,4′-biphenylalanine; 4-phenyl-phenylalanine; or biphenylalanine Bip; 4Bip β,β-diphenyl-alanine BiPhA β-phenylalanine BPhe p-carboxyl-phenylalanine Cpa 4-chloro-L-phenylalanine 4-Cl—F Citrulline Cit Cyclohexylalanine Cha Cyclohexylglycine Chg Cyclopentylglycine Cpg L-cyano-β-alanine CyA 4-tert-butyl-L-phenylalanine 4tBu—F 4-benzoyl-L-phenylalanine 4-Bz-F 2-chloro-L-phenylalanine 2-Cl—F 4-trifluoromethyl-L-phenylalanine 4CF3-F 4-fluoro-L-phenylalanine 4-F—F 4-methyl-L-phenylalanine 4-Me—F 2-amino-3-guanidinopropanoic acid 3G-Dpr α,γ-diaminobutyric acid Dab 2,4-diaminobutyric acid Dbu diaminopropionic acid Dap 3,4-dichloro-L-phenylalanine DiCl—F 3,4-dimethoxy-L-phenylalanine DiMeO—F α,β-diaminopropionoic acid (or 2,3-diaminopropionic acid Dpr 3,3-diphenylalanine Dip 4-guanidino phenylalanine Guf 4-guanidino proline 4GuaPr Homoarginine hArg; hR Homocitrulline hCit Homoglutamine hQ Homoleucine hLeu; hL Homolysine hLys; hK; homoLys Homophenylalanine hPhe; homoPhe 4-hydroxyproline (or hydroxyproline) Hyp 2-indanylglycine (or indanylglycine) IgI indoline-2-carboxylic acid Idc Iodotyrosine I-Tyr (S)-2-amino-6-((S)-2-aminopent-4-ynamido)hexanoic acid Lys(Pra) or K(Pra) (S)-2-amino-6-(6-((S)-2-aminopent-4- Lys(Pra-Ahx) ynamido)hexanamido)hexanoic acid (4S,51S)-4,51-diamino-5,45-dioxo- Lys(Pra-NPEG11) 9,12,15,18,21,24,27,30,33,36,39,42-dodecaoxa-6,46- diazadopentacont-1-yn-52-oic acid (4S,27S)-4,27-diamino-5,21-dioxo-9,12,15,18-tetraoxa- Lys(Pra-NPEG3) or 6,22-diazaoctacos-1-yn-28-oic acid KPPG3 Lys ψ(CH₂NH)-reduced amide bond rLys (S)-6-((S)-2-acetamidopent-4-ynamido)-2-aminohexanoic acid K(Ac-Pra) N-ε-biotinyl-L-lysine K(Biotin) (S)-2,2′,2″-(10-(2-((5-amino-5-carboxypentyl)amino)-2- K(DOTA) oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (S)-2-amino-6-(pent-4-ynamido)hexanoic acid K(4-Pen) methionine oxide Met[O] methionine sulfone Met[O]₂ N^(α)-methylarginine NMeR Nα-[(CH₂)₃NHCH(NH)NH₂] substituted glycine N-Arg N^(α)-methylcitrulline NMeCit N^(α)-methylglutamine NMeQ N^(α)-methylhomocitrulline N^(α)-MeHoCit N^(α)-methylhomolysine NMeHoK N^(α)-methylleucine N^(α)-MeL; NMeL; NMeLeu; NMe-Leu N^(α)-methyllysine NMe-Lys Nε-methyl-lysine N-eMe-K Nε-ethyl-lysine N-eEt-K Nε-isopropyl-lysine N-eIPr-K N^(α)-methylnorleucine NMeNle; NMe-Nle N^(α)-methylornithine N^(α)-MeOrn; NMeOrn N^(α)-methylphenylalanine NMe-Phe 1′N-methyltryptophan 1′NMeW 4-methyl-phenylalanine MePhe α-methylphenyalanine AMeF N^(α)-methylthreonine NMe-Thr; NMeThr N^(α)-methylvaline NMeVal; NMe-Val Nε-(O-(aminoethyl)-O′-(2-propanoyl)-undecaethyleneglycol)- K(NPeg11) Lysine Nε-(O-(aminoethyl)-O′-(2-propanoyl)-(ethyleneglycol)27-Lysine K(NPeg27) 3-(1-naphthyl)alanine 1-Nal; 1Nal 3-(2-naphthyl)alanine 2-Nal; 2Nal nipecotic acid Nip Nitrophenylalanine nitrophe norleucine Nle norvaline Nva or Nvl O-methyltyrosine Ome-Tyr (S)-octylglycine OctylG octahydroindole-2-carboxylic acid Oic Ornithine Orn Orn ψ(CH2NH)-reduced amide bond rOrn pyroglutamic acid pGlu; PE; pE L-phosphoserine pS 4-piperidinylalanine 4PipA 4-pyridinylalanine 4Pal 3-pyridinylalanine 3Pal 2-pyridinylalanine 2Pal para-iodophenylalanine (or 4-iodophenylalanine) pI-Phe Phenylglycine Phg Propargylglycine Pra pipecolic acid Pip 4-amino-1-piperidine-4-carboxylic acid 4Pip Sarcosine Sar 1,2,3,4-tetrahydroisoquinoline Tic 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid Tiq 1,2,3,4-tetrahydroisoquinoline-7-hydroxy-3-carboxylic acid Hydroxyl-Tic 1,2,3,4-tetrahydronorharman-3-carboxylic acid Tpi thiazolidine-4-carboxylic acid Thz 3-thienylalanine Thi (S)-tert-butylglycine Tle symmetrical N′-ω-dimethyl arginine SDMA N-ε-dimethyl lysine K(Me2) 4-carboxyphenylalanine 4CO2-F

Nomenclature and Symbolism for Amino Acids and Peptides by the UPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) have been published in the following documents: Biochem. J., 1984, 219, 345-373; Eur. J. Biochem., 1984, 138, 9-37; 1985, 152, 1; 1993, 213, 2; Internat. J. Pept. Prot. Res., 1984, 24, following p 84; J. Biol. Chem., 1985, 260, 14-42; Pure Appl. Chem., 1984, 56, 595-624; Amino Acids and Peptides, 1985, 16, 387-410; Biochemical Nomenclature and Related Documents, 2nd edition, Portland Press, 1992, pages 39-69.

The one or more useful modifications to peptide domains of the inventive compositions can include amino acid additions or insertions, amino acid deletions, peptide truncations, amino acid substitutions, and/or chemical derivatization of amino acid residues, accomplished by known chemical techniques. For example, the thusly modified amino acid sequence includes at least one amino acid residue inserted or substituted therein, relative to the amino acid sequence of the native sequence of interest, in which the inserted or substituted amino acid residue has a side chain comprising a nucleophilic or electrophilic reactive functional group by which the peptide is covalently conjugated to a linker and/or half-life extending moiety. In accordance with the invention, useful examples of such a nucleophilic or electrophilic reactive functional group include, but are not limited to, a thiol, a primary amine, a seleno, a hydrazide, an aldehyde, a carboxylic acid, a ketone, an aminooxy, a masked (protected) aldehyde, or a masked (protected) keto functional group. Examples of amino acid residues having a side chain comprising a nucleophilic reactive functional group include, but are not limited to, a lysine residue, a homolysine, an α,β-diaminopropionic acid residue, an α,γ-diaminobutyric acid residue, an ornithine residue, a cysteine, a homocysteine, a glutamic acid residue, an aspartic acid residue, or a selenocysteine (“SeCys”) residue.

Amino acid residues are commonly categorized according to different chemical and/or physical characteristics. The term “acidic amino acid residue” refers to amino acid residues in D- or L-form having side chains comprising acidic groups. Exemplary acidic residues include aspartic acid and glutamic acid residues. The term “alkyl amino acid residue” refers to amino acid residues in D- or L-form having C₁₋₆alkyl side chains which may be linear, branched, or cyclized, including to the amino acid amine as in proline, wherein the C₁₋₆alkyl is substituted by 0, 1, 2 or 3 substituents selected from C₁₋₄haloalkyl, halo, cyano, nitro, —C(═O)R^(b), —C(═O)OR^(a), —C(═O)NR^(a)R^(a), —C(═NR^(a))NR^(a)R^(a), —NR^(a)C(═NR^(a))NR^(a)R^(a), —OR^(a), —OC(═O)R^(b), —OC(═O)NR^(a)R^(a), —OC₂₋₆alkylNR^(a)R^(a), —OC₂₋₆alkylOR^(a), —SR^(a), —S(═O)R^(b), —S(═O)₂R^(b), —S(═O)₂NR^(a)R^(a), —NR^(a)R^(a), —N(R^(a))C(═O)R^(b), —N(R^(a))C(═O)OR^(b), —N(R^(a))C(═O)NR^(a)R^(a), —N(R^(a))C(═NR^(a))NR^(a)R^(a), —N(R^(a))S(═O)₂R^(b), —N(R^(a))S(═O)₂NR^(a)R^(a), —NR^(a)C₂₋₆alkylNR^(a)R^(a) and —NR^(a)C₂₋₆alkylOR^(a); wherein R^(a) is independently, at each instance, H or R^(b); and R^(b) is independently, at each instance C₁₋₆alkyl substituted by 0, 1, 2 or 3 substituents selected from halo, C₁₋₄alk, C₁₋₃haloalk, —OC₁₋₄alk, —NH₂, —NHC₁₋₄alk, and —N(C₁₋₄alk)C₁₋₄alk; or any protonated form thereof, including alanine, valine, leucine, isoleucine, proline, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, cysteine, methionine, hydroxyproline, cyclohexylalanine, norleucine, norvaline, 2-aminobutyric acid, but which residues do not contain an aryl or aromatic group. The term “aromatic amino acid residue” refers to amino acid residues in D- or L-form having side chains comprising aromatic groups. Exemplary aromatic residues include tryptophan, tyrosine, 3-(1-naphthyl)alanine, histidine, or phenylalanine residues. The term “basic amino acid residue” refers to amino acid residues in D- or L-form having side chains comprising basic groups. Exemplary basic amino acid residues include histidine, lysine, homolysine, ornithine, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, and homoarginine (hR) residues. The term “hydrophilic amino acid residue” refers to amino acid residues in D- or L-form having side chains comprising polar groups. Exemplary hydrophilic residues include cysteine, serine, threonine, histidine, lysine, asparagine, aspartate, glutamate, glutamine, and citrulline (Cit) residues. The terms “lipophilic amino acid residue” refers to amino acid residues in D- or L-form having sidechains comprising uncharged, aliphatic or aromatic groups. Exemplary lipophilic sidechains include phenylalanine, isoleucine, leucine, methionine, valine, tryptophan, and tyrosine. Alanine (A) is amphiphilic—it is capable of acting as a hydrophilic, or lipophilic (i.e., hydrophobic), residue. Alanine, therefore, is included within the definition of both “lipophilic” (i.e., “hydrophobic”) residue and “hydrophilic” residue. The term “nonfunctional” or “neutral” amino acid residue refers to amino acid residues in D- or L-form having side chains that lack acidic, basic, or aromatic groups. Exemplary neutral amino acid residues include methionine, glycine, alanine, valine, isoleucine, leucine, and norleucine (Nle) residues.

Additional useful embodiments of toxin peptide analogs can result from conservative modifications of the amino acid sequences of the toxin polypeptides disclosed herein. Conservative modifications will produce half-life extending moiety-conjugated peptides having functional, physical, and chemical characteristics similar to those of the conjugated (e.g., PEG-conjugated) peptide from which such modifications are made. Such conservatively modified forms of the conjugated toxin peptide analogs disclosed herein are also contemplated as being an embodiment of the present invention.

In contrast, substantial modifications in the functional and/or chemical characteristics of peptides may be accomplished by selecting substitutions in the amino acid sequence that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the region of the substitution, for example, as an α-helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the size of the molecule.

For example, a “conservative amino acid substitution” may involve a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Furthermore, any native residue in the polypeptide may also be substituted with alanine, as has been previously described for “alanine scanning mutagenesis” (see, for example, MacLennan et al., Acta Physiol. Scand. Suppl., 643:55-67 (1998); Sasaki et al., 1998, Adv. Biophys. 35:1-24 (1998), which discuss alanine scanning mutagenesis).

In some useful embodiments of the compositions of the invention, the amino acid sequence of the toxin peptide is modified in one or more ways relative to a native toxin peptide sequence of interest, such as, but not limited to, a native JzTx-V sequence (SEQ ID NO:2), a peptide analog of JzTx-V, or any other toxin peptides having amino acid sequences as set forth in Table 5, or elsewhere herein. The one or more useful modifications can include amino acid additions or insertions, amino acid deletions, peptide truncations, amino acid substitutions, and/or chemical derivatization of amino acid residues, accomplished by known chemical techniques. Such modifications can be, for example, for the purpose of enhanced potency, selectivity, and/or proteolytic stability, or the like. Those skilled in the art are aware of techniques for designing peptide analogs with such enhanced properties, such as alanine scanning, rational design based on alignment mediated mutagenesis using known toxin peptide sequences and/or molecular modeling.

The term “protease” is synonymous with “peptidase”. Proteases comprise two groups of enzymes: the endopeptidases which cleave peptide bonds at points within the protein, and the exopeptidases, which remove one or more amino acids from either N- or C-terminus respectively. The term “proteinase” is also used as a synonym for endopeptidase. The four mechanistic classes of proteinases are: serine proteinases, cysteine proteinases, aspartic proteinases, and metallo-proteinases. In addition to these four mechanistic classes, there is a section of the enzyme nomenclature which is allocated for proteases of unidentified catalytic mechanism. This indicates that the catalytic mechanism has not been identified.

Cleavage subsite nomenclature is commonly adopted from a scheme created by Schechter and Berger (Schechter I. & Berger A., On the size of the active site in proteases. I. Papain, Biochemical and Biophysical Research Communication, 27:157 (1967); Schechter I. & Berger A., On the active site of proteases. 3. Mapping the active site of papain; specific inhibitor peptides of papain, Biochemical and Biophysical Research Communication, 32:898 (1968)). According to this model, amino acid residues in a substrate undergoing cleavage are designated P1, P2, P3, P4 etc. in the N-terminal direction from the cleaved bond. Likewise, the residues in the C-terminal direction are designated P1′, P2′, P3′, P4′, etc.

The skilled artisan is aware of a variety of tools for identifying protease binding or protease cleavage sites of interest. For example, the PeptideCutter software tool is available through the ExPASy (Expert Protein Analysis System) proteomics server of the Swiss Institute of Bioinformatics (SIB; www.expasy.org/tools/peptidecutter). PeptideCutter searches a protein sequence from the SWISS-PROT and/or TrEMBL databases or a user-entered protein sequence for protease cleavage sites. Single proteases and chemicals, a selection or the whole list of proteases and chemicals can be used. Different forms of output of the results are available: tables of cleavage sites either grouped alphabetically according to enzyme names or sequentially according to the amino acid number. A third option for output is a map of cleavage sites. The sequence and the cleavage sites mapped onto it are grouped in blocks, the size of which can be chosen by the user. Other tools are also known for determining protease cleavage sites. (E.g., Turk, B. et al., Determination of protease cleavage site motifs using mixture-based oriented peptide libraries, Nature Biotechnology, 19:661-667 (2001); Barrett A. et al., Handbook of proteolytic enzymes, Academic Press (1998)).

The serine proteinases include the chymotrypsin family, which includes mammalian protease enzymes such as chymotrypsin, trypsin or elastase or kallikrein. The serine proteinases exhibit different substrate specificities, which are related to amino acid substitutions in the various enzyme subsites interacting with the substrate residues. Some enzymes have an extended interaction site with the substrate whereas others have a specificity restricted to the P1 substrate residue.

Trypsin preferentially cleaves at R or K in position P1. A statistical study carried out by Keil (1992) described the negative influences of residues surrounding the Arg- and Lys-bonds (i.e. the positions P2 and P1′, respectively) during trypsin cleavage. (Keil, B., Specificity of proteolysis, Springer-Verlag Berlin-Heidelberg-NewYork, 335 (1992)). A proline residue in position P1′ normally exerts a strong negative influence on trypsin cleavage. Similarly, the positioning of R and K in P1′ results in an inhibition, as well as negatively charged residues in positions P2 and P1′.

Chymotrypsin preferentially cleaves at a W, Y or F in position P1 (high specificity) and to a lesser extent at L, M or H residue in position P1. (Keil, 1992). Exceptions to these rules are the following: When W is found in position P1, the cleavage is blocked when M or P are found in position P1′ at the same time. Furthermore, a proline residue in position P1′ nearly fully blocks the cleavage independent of the amino acids found in position P1. When an M residue is found in position P1, the cleavage is blocked by the presence of a Y residue in position P1′. Finally, when H is located in position P1, the presence of a D, M or W residue also blocks the cleavage.

Membrane metallo-endopeptidase (NEP; neutral endopeptidase, kidney-brush-border neutral proteinase, enkephalinase, EC 3.4.24.11) cleaves peptides at the amino side of hydrophobic amino acid residues. (Connelly, J C et al., Neutral Endopeptidase 24.11 in Human Neutrophils: Cleavage of Chemotactic Peptide, PNAS, 82(24):8737-8741 (1985)).

Thrombin preferentially cleaves at an R residue in position P1. (Keil, 1992). The natural substrate of thrombin is fibrinogen. Optimum cleavage sites are when an R residue is in position P1 and Gly is in position P2 and position P1′. Likewise, when hydrophobic amino acid residues are found in position P4 and position P3, a proline residue in position P2, an R residue in position P1, and non-acidic amino acid residues in position P1′ and position P2′. A very important residue for its natural substrate fibrinogen is a D residue in P10.

Caspases are a family of cysteine proteases bearing an active site with a conserved amino acid sequence and which cleave peptides specifically following D residues. (Earnshaw W C et al., Mammalian caspases: Structure, activation, substrates, and functions during apoptosis, Annual Review of Biochemistry, 68:383-424 (1999)).

The Arg-C proteinase preferentially cleaves at an R residue in position P1. The cleavage behavior seems to be only moderately affected by residues in position P1′. (Keil, 1992). The Asp-N endopeptidase cleaves specifically bonds with a D residue in position P1′. (Keil, 1992).

The foregoing is merely exemplary and by no means an exhaustive treatment of knowledge available to the skilled artisan concerning protease binding and/or cleavage sites that the skilled artisan may be interested in eliminating in practicing the invention.

Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. For example, amino acid substitutions can be used to identify important residues of the peptide sequence, or to increase or decrease the affinity of the peptide or vehicle-conjugated peptide molecules described herein.

Naturally occurring residues may be divided into classes based on common side chain properties:

-   -   1) hydrophobic: norleucine (Nor or Nle), Met, Ala, Val, Leu,         Ile;     -   2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;     -   3) acidic: Asp, Glu;     -   4) basic: His, Lys, Arg;     -   5) residues that influence chain orientation: Gly, Pro; and     -   6) aromatic: Trp, Tyr, Phe.

Conservative amino acid substitutions may involve exchange of a member of one of these classes with another member of the same class. Conservative amino acid substitutions may encompass non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties.

Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class. Such substituted residues may be introduced into regions of the toxin peptide analog.

In making such changes, according to certain embodiments, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is understood in the art (see, for example, Kyte et al., 1982, J. Mol. Biol. 157:105-131). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, in certain embodiments, the substitution of amino acids whose hydropathic indices are within ±2 is included. In certain embodiments, those that are within ±1 are included, and in certain embodiments, those within ±0.5 are included.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional protein or peptide thereby created is intended for use in immunological embodiments, as disclosed herein. In certain embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., with a biological property of the protein.

The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5±1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5) and tryptophan (−3.4). In making changes based upon similar hydrophilicity values, in certain embodiments, the substitution of amino acids whose hydrophilicity values are within ±2 is included, in certain embodiments, those that are within ±1 are included, and in certain embodiments, those within ±0.5 are included. One may also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to as “epitopic core regions.”

Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine norleucine, alanine, or methionine for another, the substitution of one polar (hydrophilic) amino acid residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic amino acid residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another. The phrase “conservative amino acid substitution” also includes the use of a chemically derivatized residue in place of a non-derivatized residue, provided that such polypeptide displays the requisite bioactivity. Other exemplary amino acid substitutions that can be useful in accordance with the present invention are set forth in Table 4 below.

TABLE 4 Some Useful Amino Acid Substitutions. Original Exemplary Residues Substitutions Ala Val, Leu, Ile, Gly Arg Lys, Gln, Asn, His Asn Gln Asp Glu Cys Ser, Ala Gln Asn Glu Asp Gly Pro, Ala His Asn, Gln, Lys, Arg Ile Leu, Val, Met, Ala, Phe, Norleucine Leu Norleucine, Ile, Val, Met, Ala, Phe Lys Arg, 1,4-Diamino- butyric Acid, Gln, Asn, His Met Leu, Phe, Ile Phe Leu, Val, Ile, Ala, Tyr Pro Ala Ser Thr, Ala, Cys Thr Ser Trp Tyr, Phe Tyr Trp, Phe, Thr, Ser Val Ile, Met, Leu, Phe, Ala, Norleucine

By way of illustration, some embodiments of the present invention are directed to a composition of matter comprising an isolated polypeptide comprising the amino acid sequence of the formula:

SEQ ID NO: 516 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰ Leu²¹X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹ X_(aa) ³⁰X_(aa) ³¹X_(aa) ³²Arg³³X_(aa) ³⁴// or a pharmaceutically acceptable salt thereof, wherein:

X_(aa) ¹X_(aa) ² is absent; or X_(aa) ¹ is any amino acid residue and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is absent and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is absent and X_(aa) ² is absent (e.g., if present, X_(aa) ¹ or X_(aa) ² can be selected from Ala, Asp, Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, Dab, Dap, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-£-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ³ is any amino acid residue (e.g., X_(aa) ³ can be selected from Ala, Asp, Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, Dap, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if X_(aa) ¹⁸ is SeCys;

X_(aa) ⁵ is any neutral hydrophilic (e.g., X_(aa) ⁵ is a Gln, Asn, Ser, Thr, or Cit residue) or basic (e.g., X_(aa) ⁵ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) amino acid residue;

X_(aa) ⁶ is any basic amino acid residue (e.g., X_(aa) ⁶ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue);

X_(aa) ⁷ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ⁸ is a Met, Nle, Nva, Leu, Ile, Val, or Phe residue;

X_(aa) ⁹ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ¹⁰ is a basic (e.g., X_(aa) ¹⁰ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or neutral hydrophilic (e.g., X_(aa) ¹⁰ is a Gln, Asn, Ser, Thr, or Cit residue) amino acid residue, or an Ala residue;

X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if X_(aa) ²³ is SeCys;

X_(aa) ¹³ is any amino acid residue except a hydrophobic residue (e.g., X_(aa) ¹³ can be selected from Asp, Glu, His, Lys, Asn, Pro, Gln, Arg, Ser, Thr, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, Dap, norleucine, norvaline, Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ¹⁴ is a basic residue (e.g., X_(aa) ¹⁴ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or an Ala residue;

X_(aa) ¹⁶ is any amino acid residue (e.g., X_(aa) ¹⁶ can be selected from Ala, Asp, Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, Dab, Dap, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-£-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ¹⁷ is a Cys if X_(aa) ²⁷ is Cys; or X_(aa) ¹⁷ is a SeCys if X_(aa) ²⁷ is SeCys;

X_(aa) ¹⁸ is a Cys or SeCys;

X_(aa) ¹⁹ is any amino acid residue (e.g., X_(aa) ¹⁹ can be selected from Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, Dab, Dap, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-£-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ²⁰ is a Gly or Ala residue;

X_(aa) ²² is an acidic (e.g., X_(aa) ²² is a Glu, Asp, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid residue), basic amino acid residue (e.g., X_(aa) ²² is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue), or Ala residue;

X_(aa) ²³ is a Cys or SeCys residue;

X_(aa) ²⁴ is a basic amino acid (e.g., X_(aa) ²⁴ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or Ala residue;

X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ²² is a Cys or SeCys residue;

X_(aa) ²⁸ is a basic amino acid residue (e.g., X_(aa) ²⁸ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue);

X_(aa) ²⁹ is a basic amino acid residue (e.g., X_(aa) ²⁹ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue);

X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue, if X_(aa) ²² is an acidic amino acid residue; or

X_(aa) ³⁰ is an acidic amino acid residue (e.g., X_(aa) ³⁰ is a Glu, Asp, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid residue), if X_(aa) ²² is a basic amino acid residue or an Ala residue;

X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue;

each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently absent or is independently a hydrophobic amino acid residue (e.g., Ala, Phe, Ile, Leu, Met, Val, Trp, Tyr, proline, thiaproline, methionine, glycine, 1-Nal, 2-Nal, 1′NMe-Trp, cyclopentylglycine (Cpg), phenylglycine, N-methylleucine, N-methylphenylalanine, N-methylvaline, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-chloro-phenylalanine, 4-chloro-phenylalanine, 3,4-dichlorophenylalanine, 4-trifluoromethyl-phenylalanine, and 4-phenyl-phenylalanine (Bip) residues);

and wherein:

if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸;

if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ^(n) and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³;

if X_(aa) ¹⁷ and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹² and residue X_(aa) ²⁷; or if X_(aa) ¹⁷ and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹² and residue X_(aa) ²⁷;

the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and the carboxy-terminal residue is optionally amidated. Carboxy-terminally amidated embodiments are among particularly useful ones for therapeutic use. Many examples of such C-terminally amidated peptide analogs appear in Table 5.

In some useful embodiments, (i) X_(aa) ¹ is a Pra, Aha, AzK, thiaproline, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue, and X_(aa) ² is any amino acid residue (e.g., X_(aa) ² can be selected from Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 4-phenyl-phenylalanine (Bip), Pra, Aha, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues); or (ii) X_(aa) ¹ is absent and X_(aa) ² is a Pra, Aha, AzK, thiaproline, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue.

In other embodiments, (i) X_(aa) ¹ can be selected from Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip) residues, and X_(aa) ² is any amino acid residue (e.g., Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), or 4-phenyl-phenylalanine (Bip) residue); or (ii) X_(aa) ¹ is absent and X_(aa) ² can be selected from Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip) residues.

Another example of an inventive composition of the present invention is the composition of matter wherein the isolated polypeptide comprises the amino acid sequence of the formula:

SEQ ID NO: 517 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰Leu²¹ X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹X_(aa) ³⁰ X_(aa) ³¹X_(aa) ³²X_(aa) ³³X_(aa) ³⁴//

or a pharmaceutically acceptable salt thereof,

wherein:

X_(aa) ¹ is absent; or X_(aa) ¹ is any amino acid residue (e.g., X_(aa) ¹ can be selected from Ala, Asp, Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, Dap, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ² is any hydrophobic amino acid residue, or a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue;

X_(aa) ³ is any amino acid residue (e.g., X_(aa) ³ can be selected from Ala, Asp, Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, Dap, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if X_(aa) ¹⁸ is SeCys;

X_(aa) ⁵ is any neutral hydrophilic (e.g., X_(aa) ⁵ is a Gln, Asn, Ser, Thr, or Cit residue) or basic (e.g., X_(aa) ⁵ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) amino acid residue;

X_(aa) ⁶ is any basic amino acid residue (e.g., X_(aa) ⁶ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue);

X_(aa) ⁷ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ⁸ is a Leu or Nle residue;

X_(aa) ⁹ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ¹⁶ is a basic (e.g., X_(aa) ¹⁰ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or neutral hydrophilic (e.g., X_(aa) ¹⁰ is a Gln, Asn, Ser, Thr, or Cit residue) amino acid residue, or an Ala residue;

X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if X_(aa) ²³ is SeCys;

X_(aa) ¹³ is any amino acid residue except a hydrophobic residue (e.g., X_(aa) ¹³ can be selected from Asp, Glu, His, Lys, Asn, Pro, Gln, Arg, Ser, Thr, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, Dap, norleucine, norvaline, Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ¹⁴ is a basic residue (e.g., X_(aa) ¹⁴ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or an Ala residue;

X_(aa) ¹⁶ is any amino acid residue (e.g., X_(aa) ¹⁶ can be selected from Ala, Asp, Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, Dab, Dap, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-£-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ¹² is a Cys if X_(aa) ²⁷ is Cys; or X_(aa) ¹² is a SeCys if X_(aa) ²⁷ is SeCys;

X_(aa) ¹⁸ is a Cys or SeCys;

X_(aa) ¹⁹ is any amino acid residue (e.g., X_(aa) ¹⁹ can be selected from Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, Dab, Dap, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-£-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 4-phenyl-phenylalanine (Bip), Pra, Aha, AzK, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residues);

X_(aa) ²⁰ is a Gly or Ala residue;

X_(aa) ²² is a basic amino acid residue (e.g., X_(aa) ²² is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or an Ala residue;

X_(aa) ²³ is a Cys or SeCys residue;

X_(aa) ²⁴ is a basic amino acid residue (e.g., X_(aa) ²⁴ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue) or an Ala residue;

X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;

X_(aa) ²⁷ is a Cys or SeCys residue;

X_(aa) ²⁸ is a basic amino acid residue (e.g., X_(aa) ²⁸ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue);

X_(aa) ²⁹ is a basic amino acid residue (e.g., X_(aa) ²⁹ is a histidine, lysine, homolysine, ornithine, Dab, Dap, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, or homoarginine residue);

X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue;

X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue;

each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently absent or is independently a hydrophobic amino acid residue (e.g., Ala, Phe, Ile, Leu, Met, Val, Trp, Tyr, proline, thiaproline, methionine, glycine, 1-Nal, 2-Nal, 1′NMe-Trp, cyclopentylglycine (Cpg), phenylglycine, N-methylleucine, N-methylphenylalanine, N-methylvaline, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-chloro-phenylalanine, 4-chloro-phenylalanine, 3,4-dichlorophenylalanine, 4-trifluoromethyl-phenylalanine, and 4-phenyl-phenylalanine (Bip) residues);

and wherein:

if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸;

if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ¹¹ and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³;

if X_(aa) ¹⁷ and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; or if X_(aa) ¹⁷ and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷;

the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and the carboxy-terminal residue is optionally amidated. Carboxy-terminally amidated embodiments are among particularly useful ones for therapeutic use. Many examples of such C-terminally amidated peptide analogs appear in Table 5.

In some useful embodiments, X_(aa) ² is a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, Atz, Ala, Phe, Ile, Leu, Met, Val, Trp, Tyr, proline, thiaproline, methionine, glycine, 1-Nal, 2-Nal, 1′NMe-Trp, cyclopentylglycine (Cpg), phenylglycine, N-methylleucine, N-methylphenylalanine, N-methylvaline, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-chloro-phenylalanine, 4-chloro-phenylalanine, 3,4-dichlorophenylalanine, 4-trifluoromethyl-phenylalanine, or 4-phenyl-phenylalanine (Bip) residue.

In other useful embodiments, (i) X_(aa) ¹ is a Pra, Aha, Abu, Nva, Nle Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue, and X_(aa) ² is any hydrophobic amino acid residue (e.g., X_(aa) ² can be selected from Phe, Ile, Leu, Met, Val, Trp, Tyr, thiaproline, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip)), or a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, and Atz residue; or (ii) X_(aa) ¹ is absent and X_(aa) ² is a Pra, Aha, AzK, thiaproline, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue.

In other embodiments, (i) X_(aa) ¹ can be selected from Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr, thiaproline, phosphoserine, phosphotyrosine, or gamma-carboxyglutamic acid, homolysine, ornithine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, homoarginine, N-methyl-lysine, N-ε-methyl lysine, Dab, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip) residues, and X_(aa) ² is any hydrophobic amino acid residue (e.g., Phe, Ile, Leu, Met, Val, Trp, Tyr, thiaproline, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), or 4-phenyl-phenylalanine (Bip) residue) or a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue; or (ii) X_(aa) ¹ is absent and X_(aa) ² can be selected from Phe, Ile, Leu, Met, Val, Trp, Tyr, thiaproline, norleucine, norvaline, 1-Nal, 2-Nal, cyclohexylglycine (Chg), cyclohexylalanine (Cha), and 4-phenyl-phenylalanine (Bip) residues.

Other exemplary embodiments of the inventive composition are unconjugated and conjugated peptide analogs of JzTx-V having one of the amino acid sequences as set forth in Table 5. Particular embodiments of the inventive isolated polypeptides include those having an amino acid sequence selected from SEQ ID NOS:63, 69, 110-115, 131, 137, 139-147, 149-150, 152-154, 157, 159-172, 174-175, 177-179, 182, 184-246, 273-274, 277, 279, 284-295, 297-356, 392-397, 406-409, 411-422, 426, 435-437, 439-445, 447-452, 455-475, 518, 520, 521, 523, 524, 526, 527, 546-563, 565-566, 568, 573, 574, 576, and 577, as set forth in Table 5; or comprises an amino acid sequence selected from SEQ ID NOS:63, 69, 112-113, 115, 131, 137, 193-196, 200-203, 207-210, 214-217, 221-224, 228-231, 235-238, 242-246, 277, and 279, as set forth in Table 5, that does not include a non-canonical amino acid. Other particular embodiments of the inventive isolated polypeptides include those having an amino acid sequence selected from SEQ ID NOS: 247, 296, 358, 360, 361, 363-370, 372-391, 398-405, 410, 423-425, 427, 431-434, 438, 446, 453, 454, 571, 579-587, and 588, as set forth in Table 5.

Any of these further comprising an optional linker moiety and a pharmaceutically acceptable, covalently linked half-life extending moiety, as described herein, are also encompassed within the present invention. A pharmaceutical composition comprising any of these polypeptides (with or without a covalently linked half-life extending moiety) and a pharmaceutically acceptable carrier is also encompassed within the present invention.

TABLE 5 Amino acid sequences of JzTx-V and JzTx-V peptide analogs. {H}- = amino group of N-terminal; -{Amide} = amidated C-terminal; Ac- = acetylated N- terminal; -{Free Acid} = carboxylated C-terminal; {biotin}- = biotinylated N-terminal; {4-Pen}- = 4-pentynoylated N-terminal; {bromoacetamide-PEG11- triazole}- = 3-(1-(1-bromo-2-oxo-6,9,12,15,18,21,24,27,30,33,36-undecaoxa- 3-azaoctatriacontan-38-yl)-1H-1,2,3-triazol-4-yl)propanoyl covalently conjugated to N-terminal SEQ ID NO. Designation Amino Acid Sequence 1 JzTx-V(1-29)-FreeAcid {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKII- {FreeAcid} 2 JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 3 [Ala1]JzTx-V(1-29) {H}- ACQKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 4 [Ala3]JzTx-V(1-29) {H}- YCAKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 5 [Ala4]JzTx-V(1-29) {H}- YCQAWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 6 [Ala5]JzTx-V(1-29) {H}- YCQKAMWTCDSKRACCEGLRCKLWCRKII- {Amide} 7 [Ala6]JzTx-V(1-29) {H}- YCQKWAWTCDSKRACCEGLRCKLWCRKII- {Amide} 8 [Ala7]JzTx-V(1-29) {H}- YCQKWMATCDSKRACCEGLRCKLWCRKII- {Amide} 9 [Ala8]JzTx-V(1-29) {H}- YCQKWMWACDSKRACCEGLRCKLWCRKII- {Amide} 10 [Ala10]JzTx-V(1-29) {H}- YCQKWMWTCASKRACCEGLRCKLWCRKII- {Amide} 11 [Ala11]JzTx-V(1-29) {H}- YCQKWMWTCDAKRACCEGLRCKLWCRKII- {Amide} 12 [Ala12]JzTx-V(1-29) {H}- YCQKWMWTCDSARACCEGLRCKLWCRKII- {Amide} 13 [Ala13]JzTx-V(1-29) {H}- YCQKWMWTCDSKAACCEGLRCKLWCRKII- {Amide} 14 [Ala17]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCAGLRCKLWCRKII- {Amide} 15 [Ala18]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEALRCKLWCRKII- {Amide} 16 [Ala19]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGARCKLWCRKII- {Amide} 17 [Ala20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLACKLWCRKII- {Amide} 18 [Ala22]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCALWCRKII- {Amide} 19 [Ala23]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKAWCRKII- {Amide} 20 [Ala24]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLACRKII- {Amide} 21 [Ala26]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCAKII- {Amide} 22 [Ala27]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRAII- {Amide} 23 [Ala28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKAI- {Amide} 24 [Ala29]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKIA- {Amide} 25 [1-Nal1]JzTx-V(1-29) {H}-[1- Nal]CQKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 26 [1-Nal3]JzTx-V(1-29) {H}-YC[1- Nal]KWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 27 [1-Nal4]JzTx-V(1-29) {H}-YCQ[1- Nal]WMWTCDSKRACCEGLRCKLWCRKII- {Amide} 28 [1-Nal5]JzTx-V(1-29) {H}-YCQK[1- Nal]MWTCDSKRACCEGLRCKLWCRKII- {Amide} 29 [1-Nal6]JzTx-V(1-29) {H}-YCQKW[1- Nal]WTCDSKRACCEGLRCKLWCRKII-{Amide} 30 [1-Nal7]JzTx-V(1-29) {H}-YCQKWM[1- Nal]TCDSKRACCEGLRCKLWCRKII-{Amide} 31 [1-Nal8]JzTx-V(1-29) {H}-YCQKWMW[1- Nal]CDSKRACCEGLRCKLWCRKII-{Amide} 32 [1-Nal10]JzTx-V(1-29) {H}-YCQKWMWTC[1- Nal]SKRACCEGLRCKLWCRKII-{Amide} 33 [1-Nal11]JzTx-V(1-29) {H}-YCQKWMWTCD[1- Nal]KRACCEGLRCKLWCRKII-{Amide} 34 [1-Nal12]JzTx-V(1-29) {H}-YCQKWMWTCDS[1- Nal]-RACCEGLRCKLWCRKII-{Amide} 35 [1-Nal13]JzTx-V(1-29) {H}-YCQKWMWTCDSK[1- Nal]ACCEGLRCKLWCRKII-{Amide} 36 [1-Nal14]JzTx-V(1-29) {H}-YCQKWMWTCDSKR[1- Nal]CCEGLRCKLWCRKII-{Amide} 37 [1-Nal17]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACC[1- Nal]GLRCKLWCRKII-{Amide} 38 [1-Nal18]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCE[1- Nal]LRCKLWCRKII-{Amide} 39 [1-Nal19]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCEG[1- Nal]RCKLWCRKII-{Amide} 40 [1-Nal20]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCEGL[1- Nal]CKLWCRKII-{Amide} 41 [1-Nal22]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCEGLRC[1- Nal]-LWCRKII-{Amide} 42 [1-Nal23]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCEGLRCK[1- Nal]WCRKII-{Amide} 43 [1-Nal24]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCEGLRCKL[1- Nal]CRKII-{Amide} 44 [1-Nal26]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCEGLRCKLWC[1- Nal]KII-{Amide} 45 [1-Nal27]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCR[1- Nal]H-{Amide} 46 [1-Nal28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRK[1- Nal]I-{Amide} 47 [1-Nal29]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKI[1- Nal]-{Amide} 49 [Glu1]JzTx-V(1-29) {H}- ECQKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 50 [Glu3]JzTx-V(1-29) {H}- YCEKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 51 [Glu4]JzTx-V(1-29) {H}- YCQEWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 52 [Glu5]JzTx-V(1-29) {H}- YCQKEMWTCDSKRACCEGLRCKLWCRKII- {Amide} 53 [Glu6]JzTx-V(1-29) {H}- YCQKWEWTCDSKRACCEGLRCKLWCRKII- {Amide} 54 [Glu7]JzTx-V(1-29) {H}- YCQKWMETCDSKRACCEGLRCKLWCRKII- {Amide} 55 [Glu8]JzTx-V(1-29) {H}- YCQKWMWECDSKRACCEGLRCKLWCRKII- {Amide} 56 [Glu10]JzTx-V(1-29) {H}- YCQKWMWTCESKRACCEGLRCKLWCRKII- {Amide} 57 [Glu11]JzTx-V(1-29) {H}- YCQKWMWTCDEKRACCEGLRCKLWCRKII- {Amide} 58 [Glu12]JzTx-V(1-29) {H}- YCQKWMWTCDSERACCEGLRCKLWCRKII- {Amide} 59 [Glu13]JzTx-V(1-29) {H}- YCQKWMWTCDSKEACCEGLRCKLWCRKII- {Amide} 60 [Glu14]JzTx-V(1-29) {H}- YCQKWMWTCDSKRECCEGLRCKLWCRKII- {Amide} 61 [Glu18]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEELRCKLWCRKII- {Amide} 62 [Glu19]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGERCKLWCRKII- {Amide} 63 [Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKII- {Amide} 64 [Glu22]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCELWCRKII- {Amide} 65 [Glu23]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKEWCRKII- {Amide} 66 [Glu24]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLECRKII- {Amide} 67 [Glu26]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCEKII- {Amide} 68 [Glu27]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCREII- {Amide} 69 [Glu28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKEI- {Amide} 70 [Glu29]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKIE- {Amide} 71 [Lys1]JzTx-V(1-29) {H}- KCQKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 72 [Lys3]JzTx-V(1-29) {H}- YCKKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 73 [Lys5]JzTx-V(1-29) {H}- YCQKKMWTCDSKRACCEGLRCKLWCRKII- {Amide} 74 [Lys6]JzTx-V(1-29) {H}- YCQKWKWTCDSKRACCEGLRCKLWCRKII- {Amide} 75 [Lys7]JzTx-V(1-29) {H}- YCQKWMKTCDSKRACCEGLRCKLWCRKII- {Amide} 76 [Lys8]JzTx-V(1-29) {H}- YCQKWMWKCDSKRACCEGLRCKLWCRKII- {Amide} 77 [Lys10]JzTx-V(1-29) {H}- YCQKWMWTCKSKRACCEGLRCKLWCRKII- {Amide} 78 [Lys11]JzTx-V(1-29) {H}- YCQKWMWTCDKKRACCEGLRCKLWCRKII- {Amide} 79 [Lys13]JzTx-V(1-29) {H}- YCQKWMWTCDSKKACCEGLRCKLWCRKII- {Amide} 80 [Lys14]JzTx-V(1-29) {H}- YCQKWMWTCDSKRKCCEGLRCKLWCRKII- {Amide} 81 [Lys17]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCKGLRCKLWCRKII- {Amide} 82 [Lys18]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEKLRCKLWCRKII- {Amide} 83 [Lys19]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGKRCKLWCRKII- {Amide} 84 [Lys20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLKCKLWCRKII- {Amide} 85 [Lys23]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKKWCRKII- {Amide} 86 [Lys24]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLKCRKII- {Amide} 87 [Lys26]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCKKII- {Amide} 88 [Lys28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKKI- {Amide} 89 [Lys29]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKIK- {Amide} 90 [Arg1]JzTx-V(1-29) {H}- RCQKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 91 [Arg3]JzTx-V(1-29) {H}- YCRKWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 92 [Arg4]JzTx-V(1-29) {H}- YCQRWMWTCDSKRACCEGLRCKLWCRKII- {Amide} 93 [Arg5]JzTx-V(1-29) {H}- YCQKRMWTCDSKRACCEGLRCKLWCRKII- {Amide} 94 [Arg6]JzTx-V(1-29) {H}- YCQKWRWTCDSKRACCEGLRCKLWCRKII- {Amide} 95 [Arg7]JzTx-V(1-29) {H}- YCQKWMRTCDSKRACCEGLRCKLWCRKII- {Amide} 96 [Arg8]JzTx-V(1-29) {H}- YCQKWMWRCDSKRACCEGLRCKLWCRKII- {Amide} 97 [Arg10]JzTx-V(1-29) {H}- YCQKWMWTCRSKRACCEGLRCKLWCRKII- {Amide} 98 [Arg11]JzTx-V(1-29) {H}- YCQKWMWTCDRKRACCEGLRCKLWCRKII- {Amide} 99 [Arg12]JzTx-V(1-29) {H}- YCQKWMWTCDSRRACCEGLRCKLWCRKII- {Amide} 100 [Arg14]JzTx-V(1-29) {H}- YCQKWMWTCDSKRRCCEGLRCKLWCRKII- {Amide} 101 [Arg17]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCRGLRCKLWCRKII- {Amide} 102 [Arg18]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCERLRCKLWCRKII- {Amide} 103 [Arg19]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGRRCKLWCRKII- {Amide} 104 [Arg22]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCRLWCRKII- {Amide} 105 [Arg23]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKRWCRKII- {Amide} 106 [Arg24]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLRCRKII- {Amide} 107 [Arg27]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRRII- {Amide} 108 [Arg28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKRI- {Amide} 109 [Arg29]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLRCKLWCRKIR- {Amide} 110 [Nle6;Glu20]JzTx-V(1-29) {H}- YCQKW[Nle]WTCDSKRACCEGLECKLWCRKII- {Amide} 111 [Nva6;Glu20]JzTx-V(1-29) {H}- YCQKW[Nva]WTCDSKRACCEGLECKLWCRKII- {Amide} 112 [Glu20;Trp29]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKIW- {Amide} 113 [Glu20]JzTx-V(1-29)-Trp {H}- YCQKWMWTCDSKRACCEGLECKLWCRKIIW- {Amide} 114 [Cpa20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGL[Cpa]CKLWCRKII- {Amide} 115 [Asp20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLDCKLWCRKII- {Amide} 116 [4-Cl—F20]JzTx-V(1-29) {H}-YCQKWMWTCDSKRACCEGL[4-Cl—F] CKLWCRKII-{Amide} 117 [Abu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGL[Abu]CKLWCRKI I-{Amide} 118 [Ile20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLICKLWCRKII- {Amide} 119 [Leu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLLCKLWCRKII- {Amide} 120 [Val20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLVCKLWCRKII- {Amide} 121 [Gly20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLGCKLWCRKII- {Amide} 122 [Cit20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGL[Cit]CKLWCRKII- {Amide} 123 [Nva20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGL[Nva]CKLWCRKI I-{Amide} 124 [Tyr20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLYCKLWCRKII- {Amide} 125 [Ser20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLSCKLWCRKII- {Amide} 126 [Glu20,28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKEI- {Amide} 127 [Glu20;Cpa28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRK[Cpa] I-{Amide} 128 [Glu20;Asp28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKDI- {Amide} 129 [Glu20;4-Cl—F28]JzTx-V(1- {H}- 29) YCQKWMWTCDSKRACCEGLECKLWCRK[4- Cl—F]I-{Amide} 130 [Glu20;Abu28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRK[Abu] I-{Amide} 131 [Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKII- {Amide} 132 [Glu20;Leu28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKLI- {Amide} 133 [Glu20;Val28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKVI- {Amide} 134 [Glu20;Gly28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKGI- {Amide} 135 [Glu20;Cit28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRK[Cit]I- {Amide} 136 [Glu20;Nva28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRK[Nva] I-{Amide} 137 [Glu20;Tyr28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKYI- {Amide} 138 [Glu20;Ser28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKSI- {Amide} 139 4-Pen-[Glu20]JzTx-V(1-29) {4- Pen}YCQKWMWTCDSKRACCEGLECKLWCRKI I-{Amide} 140 [Pra1;Glu20]JzTx-V(1-29) {H}- [Pra]CQKWMWTCDSKRACCEGLECKLWCRKII- {Amide} 141 [Pra3;Glu20]JzTx-V(1-29) {H}- YC[Pra]KWMWTCDSKRACCEGLECKLWCRKII- {Amide} 142 [Pra4;Glu20]JzTx-V(1-29) {H}- YCQ[Pra]WMWTCDSKRACCEGLECKLWCRKII- {Amide} 143 [Pra5;Glu20]JzTx-V(1-29) {H}- YCQK[Pra]MWTCDSKRACCEGLECKLWCRKII- {Amide} 144 [Pra6;Glu20]JzTx-V(1-29) {H}- YCQKW[Pra]WTCDSKRACCEGLECKLWCRKII- {Amide} 145 [Pra7;Glu20]JzTx-V(1-29) {H}- YCQKWM[Pra]TCDSKRACCEGLECKLWCRKII- {Amide} 146 [Pra8;Glu20]JzTx-V(1-29) {H}- YCQKWMW[Pra]CDSKRACCEGLECKLWCRKII- {Amide} 147 [Pra9;Glu20]JzTx-V(1-29) {H}- YCQKWMWT[Pra]DSKRACCEGLECKLWCRKII- {Amide} 148 [Pra10;Glu20]JzTx-V(1-29) {H}- YCQKWMWTC[Pra]SKRACCEGLECKLWCRKII- {Amide} 149 [Pra11;Glu20]JzTx-V(1-29) {H}- YCQKWMWTCD[Pra]KRACCEGLECKLWCRKII- {Amide} 150 [Pra12;Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDS[Pra]RACCEGLECKLWCRKII- {Amide} 151 [Pra13;Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDSK[Pra]ACCEGLECKLWCRKII- {Amide} 152 [Pra14;Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKR[Pra]CCEGLECKLWCRKII- {Amide} 153 [Pra17;Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACC[Pra]GLECKLWCRKII- {Amide} 154 [Pra18;Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCE[Pra]LECKLWCRKII- {Amide} 155 [Pra19;Glu20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEG[Pra]ECKLWCRKII- {Amide} 156 [Pra20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGL[Pra]CKLWCRKII- {Amide} 157 [Glu20;Pra22]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLEC[Pra]LWCRKII- {Amide} 158 [Glu20;Pra23]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECK[Pra]WCRKII- {Amide} 159 [Glu20;Pra24]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKL[Pra]CRKII- {Amide} 160 [Glu20;Pra26]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWC[Pra]KII- {Amide} 161 [Glu20;Pra27]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCR[Pra]II- {Amide} 162 [Glu20;Pra28]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRK[Pra]I- {Amide} 163 [Glu20;Pra29]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGLECKLWCRKI[Pra]- {Amide} 164 4-Pen-[Glu20]JzTx-V(1-29) {4- Pen}YCQKWMWTCDSKRACCEGLECKLWCRKI I-{Amide} 165 [Pra(NPeg9)1;Glu20]JzTx- {H}- V(1-29) [Atz(PEG10)CQKWMWTCDSKRACCEGLECKL WCRKII-{Amide} 166 [Pra(NPeg9)3;Glu20]JzTx- {H}- V(1-29) YC[Atz(PEG10)KWMWTCDSKRACCEGLECKL WCRKII-{Amide} 167 [Pra(NPeg9)4;Glu20]JzTx- {H}- V(1-29) YCQ[Atz(PEG10)WMWTCDSKRACCEGLECKL WCRKII-{Amide} 168 [Pra(NPeg9)5;Glu20]JzTx- {H}- V(1-29) YCQK[Atz(PEG10)MWTCDSKRACCEGLECKLW CRKII-{Amide} 169 [Pra(NPeg9)6;Glu20]JzTx- {H}- V(1-29) YCQKW[Atz(PEG10)WTCDSKRACCEGLECKL WCRKII-{Amide} 170 [Pra(NPeg9)7;Glu20]JzTx- {H}- V(1-29) YCQKWM[Atz(PEG10)TCDSKRACCEGLECKLW CRKII-{Amide} 171 [Pra(NPeg9)8;Glu20]JzTx- {H}- V(1-29) YCQKWMW[Atz(PEG10)CDSKRACCEGLECKL WCRKII-{Amide} 172 [Pra(NPeg9)9;Glu20]JzTx- {H}- V(1-29) YCQKWMWT[Atz(PEG10)DSKRACCEGLECKL WCRKII-{Amide} 173 [Pra(NPeg9)10;Glu20]JzTx- {H}- V(1-29) YCQKWMWTC[Atz(PEG10)SKRACCEGLECKL WCRKII-{Amide} 174 [Pra(NPeg9)11;Glu20]JzTx- {H}- V(1-29) YCQKWMWTCD[Atz(PEG10)KRACCEGLECKL WCRKII-{Amide} 175 [Pra(NPeg9)12;Glu20]JzTx- {H}- V(1-29) YCQKWMWTCDS[Atz(PEG10)RACCEGLECKL WCRKII-{Amide} 176 [Pra(NPeg9)13;Glu20]JzTx- {H}- V(1-29) YCQKWMWTCDSK[Atz(PEG10)ACCEGLECKL WCRKII-{Amide} 177 [Pra(NPeg9)14;Glu20]JzTx- {H}- V(1-29) YCQKWMWTCDSKR[Atz(PEG10)CCEGLECKL WCRKII-{Amide} 178 [Pra(NPeg9)17;Glu20]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACC[Atz(PEG10)GLECKL WCRKII-{Amide} 179 [Pra(NPeg9)18;Glu20]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCE[Atz(PEG10)LECKL WCRKII-{Amide} 180 [Pra(NPeg9)19;Glu20]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEG[Atz(PEG10)ECKL WCRKII-{Amide} 181 [Pra(NPeg9)20]JzTx-V(1-29) {H}- YCQKWMWTCDSKRACCEGL[Atz(PEG10)CKL WCRKII-{Amide} 182 [Glu20;Pra(NPeg9)22]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLEC[Atz(PEG10)L WCRKII-{Amide} 183 [Glu20;Pra(NPeg9)23]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECK[Atz(PEG10) WCRKII-{Amide} 184 [Glu20;Pra(NPeg9)24]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKL[Atz(PEG10) CRKII-{Amide} 185 [Glu20;Pra(NPeg9)26]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWC[Atz(PEG10) KII-{Amide} 186 [Glu20;Pra(NPeg9)27]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCR[Atz(PEG10) II-{Amide} 187 [Glu20;Pra(NPeg9)28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK[Atz (PEG10)I-{Amide} 188 [Glu20;Pra(NPeg9)29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKI[Atz (PEG10)-{Amide} 189 [Nle6;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLECKLWCRKYI- {Amide} 190 [1-Nal5;Glu20;Tyr28]JzTx- {H}-YCQK[1- V(1-29) Nal]MWTCDSKRACCEGLECKLWCRKYI- {Amide} 191 [2-Nal5;Glu20;Tyr28]JzTx- {H}-YCQK[2- V(1-29) Nal]MWTCDSKRACCEGLECKLWCRKYI- {Amide} 192 [pI-Phe5;Glu20;Tyr28]JzTx- {H}-YCQK[pI- V(1-29) Phe]MWTCDSKRACCEGLECKLWCRKYI- {Amide} 193 [Phe5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKFMWTCDSKRACCEGLECKLWCRKYI- {Amide} 194 [Tyr5,28;Glu20]JzTx-V(1- {H}- 29) YCQKYMWTCDSKRACCEGLECKLWCRKYI- {Amide} 195 [Val5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKVMWTCDSKRACCEGLECKLWCRKYI- {Amide} 196 [Leu5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKLMWTCDSKRACCEGLECKLWCRKYI- {Amide} 197 [Nle5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQK[Nle]MWTCDSKRACCEGLECKLWCRKYI- {Amide} 198 [Nva5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQK[Nva]MWTCDSKRACCEGLECKLWCRKY I-{Amide} 199 [Cit5;Glu20;Tyr28]JzTx-V(1- {H}- 29) YCQK[Cit]MWTCDSKRACCEGLECKLWCRKYI- {Amide} 200 [Lys5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKKMWTCDSKRACCEGLECKLWCRKYI- {Amide} 201 [Asn5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKNMWTCDSKRACCEGLECKLWCRKYI- {Amide} 202 [Ser5;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKSMWTCDSKRACCEGLECKLWCRKYI- {Amide} 203 [Glu5,20;Tyr28]JzTx-V(1- {H}- 29) YCQKEMWTCDSKRACCEGLECKLWCRKYI- {Amide} 204 [1-Nal7;Glu20;Tyr28]JzTx- {H}-YCQKWM[1- V(1-29) Nal]TCDSKRACCEGLECKLWCRKYI-{Amide} 205 [2-Nal7;Glu20;Tyr28]JzTx- {H}-YCQKWM[2- V(1-29) Nal]TCDSKRACCEGLECKLWCRKYI-{Amide} 206 [pI-Phe7;Glu20;Tyr28]JzTx- {H}-YCQKWM[pI- V(1-29) Phe]TCDSKRACCEGLECKLWCRKYI-{Amide} 207 [Phe7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWMFTCDSKRACCEGLECKLWCRKYI- {Amide} 208 [Tyr7,28;Glu20]JzTx-V(1- {H}- 29) YCQKWMYTCDSKRACCEGLECKLWCRKYI- {Amide} 209 [Val7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWMVTCDSKRACCEGLECKLWCRKYI- {Amide} 210 [Leu7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWMLTCDSKRACCEGLECKLWCRKYI- {Amide} 211 [Nle7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWM[Nle]TCDSKRACCEGLECKLWCRKYI- {Amide} 212 [Nva7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWM[Nva]TCDSKRACCEGLECKLWCRKY I-{Amide} 213 [Cit7;Glu20;Tyr28]JzTx-V(1- {H}- 29) YCQKWM[Cit]TCDSKRACCEGLECKLWCRKYI- {Amide} 214 [Lys7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWMKTCDSKRACCEGLECKLWCRKYI- {Amide} 215 [Asn7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWMNTCDSKRACCEGLECKLWCRKYI- {Amide} 216 [Ser7;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKWMSTCDSKRACCEGLECKLWCRKYI- {Amide} 217 [Glu7,20;Tyr28]JzTx-V(1- {H}- 29) YCQKWMETCDSKRACCEGLECKLWCRKYI- {Amide} 218 [Glu20;1-Nal24;Tyr28]JzTx- {H}-YCQKWMWTCDSKRACCEGLECKL[1- V(1-29) Nal]CRKYI-{Amide} 219 [Glu20;2-Nal24;Tyr28]JzTx- {H}-YCQKWMWTCDSKRACCEGLECKL[2- V(1-29) Nal]CRKYI-{Amide} 220 Glu20;pI-Phe24;Tyr28]JzTx- {H}-YCQKWMWTCDSKRACCEGLECKL[pI- V(1-29) Phe]CRKYI-{Amide} 221 [Glu20;Phe24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLFCRKYI- {Amide} 222 [Glu20;Tyr24,28]JzTx-V(1- {H}- 29) YCQKWMWTCDSKRACCEGLECKLYCRKYI- {Amide} 223 [Glu20;Val24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLVCRKYI- {Amide} 224 [Glu20;Leu24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLLCRKYI- {Amide} 225 [Glu20;Nle24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKL[Nle]CRKYI- {Amide} 226 [Glu20;Nva24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKL[Nva]CRKY I-{Amide} 227 [Glu20;Cit24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKL[Cit]CRKYI- {Amide} 228 [Glu20;Lys24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLKCRKYI- {Amide} 229 [Glu20;Asn24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLNCRKYI- {Amide} 230 [Glu20;Ser24;Tyr28]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLSCRKYI- {Amide} 231 [Glu20,24;Tyr28]JzTx-V(1- {H}- 29) YCQKWMWTCDSKRACCEGLECKLECRKYI- {Amide} 232 [Glu20;Tyr28;1-Nal29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY[1- Nal]-{Amide} 233 [Glu20;Tyr28;2-Nal29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY[2- Nal]-{Amide} 234 [Glu20;Tyr28;pI-Phe29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY[pI- Phe]-{Amide} 235 [Glu20;Tyr28;Phe29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYF- {Amide} 236 [Glu20;Tyr28,29]JzTx-V(1- {H}- 29) YCQKWMWTCDSKRACCEGLECKLWCRKYY- {Amide} 237 [Glu20;Tyr28;Val29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYV- {Amide} 238 [Glu20;Tyr28;Leu29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYL- {Amide} 239 [Glu20;Tyr28;Nle29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY[Nle]- {Amide} 240 [Glu20;Tyr28;Nva29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY[Nva]- {Amide} 241 [Glu20;Tyr28;Cit29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY[Cit]- {Amide} 242 [Glu20;Tyr28;Lys29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYK- {Amide} 243 [Glu20;Tyr28;Asn29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYN- {Amide} 244 [Glu20;Tyr28;Ser29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYS- {Amide} 245 [Glu20,29;Tyr28]JzTx-V(1- {H}- 29) YCQKWMWTCDSKRACCEGLECKLWCRKYE- {Amide} 246 [Glu20;Tyr28;Trp29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYW- {Amide} 247 Atz(PEG10)-[Nle6]JzTx-V(1- {H}- 29) [Atz(PEG10)YCQKW[Nle]WTCDSKRACCEGLRC KLWCRKII-{Amide} 248 [Atz(PEG10)1;Nle6]JzTx- {H} V(1-29) [Atz(PEG10)CQKW[Nle]WTCDSKRACCEGLRCK LWCRKII-{Amide} 249 [Atz(PEG10)3;Nle6]JzTx- {H}- V(1-29) YC[Atz(PEG10)KW[Nle]WTCDSKRACCEGLRCK LWCRKII-{Amide} 250 [Atz(PEG10)4;Nle6]JzTx- {H}- V(1-29) YCQ[Atz(PEG10)W[Nle]WTCDSKRACCEGLRCK LWCRKII-{Amide} 251 [Atz(PEG10)5;Nle6]JzTx- {H}- V(1-29) YCQK[Atz(PEG10)[Nle]WTCDSKRACCEGLRCK LWCRKII-{Amide} 252 [Atz(PEG10)6]JzTx-V(1-29) {H}- YCQKW[Atz(PEG10)WTCDSKRACCEGLRCKL WCRKII-{Amide} 253 [Nle6;Atz(PEG10)7]JzTx- {H}- V(1-29) YCQKW[Nle][Atz(PEG10)TCDSKRACCEGLRCK LWCRKII-{Amide} 254 [Nle6;Atz(PEG10)8]JzTx- {H}- V(1-29) YCQKW[Nle]W[Atz(PEG10)CDSKRACCEGLRC KLWCRKII-{Amide} 255 [Nle6;Atz(PEG10)10]JzTx- {H}- V(1-29) YCQKW[Nle]WTC[Atz(PEG10)SKRACCEGLRCK LWCRKII-{Amide} 256 [Nle6;Atz(PEG10)11]JzTx- {H}- V(1-29) YCQKW[Nle]WTCD[Atz(PEG10)KRACCEGLRC KLWCRKII-{Amide} 257 [Nle6;Atz(PEG10)12]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDS[Atz(PEG10)RACCEGLRCK LWCRKII-{Amide} 258 [Nle6;Atz(PEG10)13]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSK[Atz(PEG10)ACCEGLRCK LWCRKII-{Amide} 259 [Nle6;Atz(PEG10)14]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKR[Atz(PEG10)CCEGLRCK LWCRKII-{Amide} 260 [Nle6;Atz(PEG10)17]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[Atz(PEG10)GLRC KLWCRKII-{Amide} 261 [Nle6;Atz(PEG10)18]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCE[Atz(PEG10)LRCK LWCRKII-{Amide} 262 [Nle6;Atz(PEG10)19]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEG[Atz(PEG10)RC KLWCRKII-{Amide} 263 [Nle6;Atz(PEG10)20]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGL[Atz(PEG10)CK LWCRKII-{Amide} 264 [Nle6;Atz(PEG10)22]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLRC[Atz(PEG10) LWCRKII-{Amide} 265 [Nle6;Atz(PEG10)23]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCK[Atz(PEG10) WCRKII-{Amide} 266 [Nle6;Atz(PEG10)24]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCKL[Atz(PEG10) CRKII-{Amide} 267 [Nle6;Atz(PEG10)26]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCKLWC[Atz (PEG10)KII-{Amide} 268 [Nle6;Atz(PEG10)27]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCKLWCR[Atz (PEG10)II-{Amide} 269 [Nle6;Atz(PEG10)28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCKLWCRK[Atz (PEG10)I-{Amide} 270 [Nle6;Atz(PEG10)29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI [Atz(PEG10)-{Amide} 271 [Nle6]JzTx-V(1-29)- {H}- Atz(PEG10) YCQKW[Nle]WTCDSKRACCEGLRCKLWCRKII [Atz(PEG10)-{Amide} 272 [Nle6]JzTx-V(1-29) {H}- YCQKW[Nle]WTCDSKRACCEGLRCKLWCRKII- {Amide} 273 [Nle6;Glu20]JzTx-V(1-29) {H}- YCQKW[Nle]WTCDSKRACCEGLECKLWCRKII- {Amide} 274 [Nle6;Glu20;Trp29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLECKLWCRKI W-{Amide} 275 [Nle6;Glu20;Ser28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLECKLWCRKSI- {Amide} 276 [Glu20;Ser28;Trp29]JzTx- {H}- V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKSW- {Amide} 277 [Glu1,20;Tyr28]JzTx-V(1- {H}- 29) ECQKWMWTCDSKRACCEGLECKLWCRKYI- {Amide} 278 [Glu1;Tyr28]JzTx-V(1-29) {H}- ECQKWMWTCDSKRACCEGLRCKLWCRKYI- {Amide} 279 [Glu1,20;Tyr28;Trp29]JzTx- {H}- V(1-29) ECQKWMWTCDSKRACCEGLECKLWCRKYW- {Amide} 280 [Glu1;Tyr28;Trp29]JzTx- {H}- V(1-29) ECQKWMWTCDSKRACCEGLRCKLWCRKYW- {Amide} 281 [Glu1;1-Nal7]JzTx-V(1-29) {H}-ECQKWM[1- Nal]TCDSKRACCEGLRCKLWCRKII-{Amide} 282 [Glu1;1-Nal7;Trp29]JzTx- {H}-ECQKWM‘- V(1-29) Nal]TCDSKRACCEGLRCKLWCRKIW-{Amide} 283 [Nle6,Pra14]JzTx-V(1-29) {H}- YCQKW[Nle]WTCDSKR[Pra]CCEGLRCKLWCR KII-{Amide} 284 [Nle6;Pra17;Glu20;Trp29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[Pra]GLECKLWCR KIW-{Amide} 285 [Nle6;Lys14;Glu20;Trp29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSK(ivDde)RKCCEGLECKLW CRKIW-{Amide} 286 [Nle6;Lys(Pra- {H}-YCQKW[Nle]WTCDSKRK(Pra- Ahx)14;Glu20;Trp29]JzTx- Ahx)CCEGLECKLWCRKIW-{Amide} V(1-29) 287 [Nle6;Lys(Pra)14;Glu20;Trp29] {H}- JzTx-V(1-29) YCQKW[Nle]WTCDSKRK(Pra)CCEGLECKLWC RKIW-{Amide} 288 [Nle6;Lys14;Glu20;Trp29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRK(ivDde)CCEGLECKLW CRKIW-{Amide} 289 [Nle6;Lys17;Glu20;Trp29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCK(ivDde)GLECKL WCRKIW-{Amide} 290 [Nle6;Lys(Pra- {H}- NPEG11)14;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKR[KPPG11]CCEGLECKL V(1-29) WCRKIW-{Amide} 291 [Nle6;Lys(Pra- {H}- NPEG3)14;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKR[KPPG3]CCEGLECKLW V(1-29) CRKIW-{Amide} 292 [Nle6;Lys(Pra- {H}- NPEG11)17;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKRACC[KPPG11]GLECKL V(1-29) WCRKIW-{Amide} 293 [Nle6;Lys(Pra- {H}- NPEG3)17;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKRACC[KPPG3]GLECKLW V(1-29) CRKIW-{Amide} 294 [Nle6;Glu20;Trp29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACCEGLECKLWCRKI W-{Amide} 295 Pra-[Glu20;Trp29]JzTx-V(1- {H}- 29) [Pra]YCQKWMWTCDSKRACCEGLECKLWCRKI W-{Amide} 296 Pra-[Nle6;Trp29]JzTx-V(1- {H}- 29) [Pra]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKIW-{Amide} 297 Pra-[Nle6;Glu20]JzTx-V(1- {H}- 29) [Pra]YCQKW[Nle]WTCDSKRACCEGLECKLWC RKII-{Amide} 298 Pra-[Phe6;Glu20;Trp29]JzTx- {H}- V(1-29) [Pra]YCQKWFWTCDSKRACCEGLECKLWCRKI W-{Amide} 299 Pra- {H}- [Leu6;Glu20;Trp29]JzTx- [Pra]YCQKWLWTCDSKRACCEGLECKLWCRKI V(1-29) W-{Amide} 300 Pra- {H}- [Nva6;Glu20;Trp29]JzTx- [Pra]YCQKW[Nva]WTCDSKRACCEGLECKLWC V(1-29) RKIW-{Amide} 301 Pra-[Nle6;Glu20;Phe29]JzTx- {H}- V(1-29) [Pra]YCQKW[Nle]WTCDSKRACCEGLECKLWC RKIF-{Amide} 302 [Nle6;Pra11;Glu20;Trp29]JzTx- {H}- V(1-29) YCQKW[Nle]WTCD[Pra]KRACCEGLECKLWCR KIW-{Amide} 303 AzK- {H}- [Nle6;Glu20;Trp29]JzTx- [AzK]YCQKW[Nle]WTCDSKRACCEGLECKLW V(1-29) CRKIW-{Amide} 304 [AzK1;Nle6;Glu20;Trp29]JzTx- [AzK]CQKW[Nle]WTCDSKRACCEGLECKLWCR V(1-29) KIW-{Amide} 305 [Nle6;AzK11;Glu20;Trp29]JzTx- {H} V(1-29) YCQKW[Nle]WTCD[AzK]KRACCEGLECKLWC RKIW-{Amide} 306 [Nle6;AzK14;Glu20;Trp29]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKR[AzK]CCEGLECKLWCR KIW-{Amide} 307 [Nle6;AzK17;Glu20;Trp29]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKRACC[AzK]GLECKLWC RKIW-{Amide} 308 Aha- {H}- [Nle6;Glu20;Trp29]JzTx- [Aha]YCQKW[Nle]WTCDSKRACCEGLECKLWC V(1-29) RKIW-{Amide} 309 [Aha1;Nle6;Glu20;Trp29]JzTx- {H} V(1-29) [Aha]CQKW[Nle]WTCDSKRACCEGLECKLWCR KIW-{Amide} 310 [Nle6;Aha11;Glu20;Trp29]JzTx- {H} V(1-29) YCQKW[Nle]WTCD[Aha]KRACCEGLECKLWCR KIW-{Amide} 311 [Nle6;Aha14;Glu20;Trp29]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKR[Aha]CCEGLECKLWCR KIW-{Amide} 312 [Nle6;Aha17;Glu20;Trp29]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKRACC[Aha]GLECKLWCR KIW-{Amide} 313 Pra-[Nle6;Glu20;Tyr28]JzTx- {H} V(1-29) [Pra]YCQKW[Nle]WTCDSKRACCEGLECKLWC RKYI-{Amide} 314 [Pra1;Nle6;Glu20;Tyr28]JzTx- {H} V(1-29) [Pra]CQKW[Nle]WTCDSKRACCEGLECKLWCR KYI-{Amide} 315 [Nle6;Pra11;Glu20;Tyr28]JzTx- {H} V(1-29) YCQKW[Nle]WTCD[Pra]KRACCEGLECKLWCR KYI-{Amide} 316 [Nle6;Pra14;Glu20;Tyr28]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKR[Pra]CCEGLECKLWCR KYI-{Amide} 317 [Nle6;Pra17;Glu20;Tyr28]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKRACC[Pra]GLECKLWCR KYI-{Amide} 318 AzK- {H}- [Nle6;Glu20;Tyr28]JzTx- [AzK]YCQKW[Nle]WTCDSKRACCEGLECKLW V(1-29) CRKYI-{Amide} 319 [AzK1;Nle6;Glu20;Tyr28]JzTx- {H}- V(1-29) [AzK]CQKW[Nle]WTCDSKRACCEGLECKLWCR KYI-{Amide} 320 [Nle6;AzK11;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCD[AzK]KRACCEGLECKLWC RKYI-{Amide} 321 [Nle6;AzK14;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKR[AzK]CCEGLECKLWCR KYI-{Amide} 322 [Nle6;AzK17;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[AzK]GLECKLWC RKYI-{Amide} 323 Aha- {H}- [Nle6;Glu20;Tyr28]JzTx- [Aha]YCQKW[Nle]WTCDSKRACCEGLECKLWC V(1-29) RKYI-{Amide} 324 [Aha1;Nle6;Glu20;Tyr28]JzTx- {H} V(1-29) [Aha]CQKW[Nle]WTCDSKRACCEGLECKLWCR KYI-{Amide} 325 [Nle6;Aha11;Glu20;Tyr28]JzTx- {H} V(1-29) YCQKW[Nle]WTCD[Aha]KRACCEGLECKLWCR KYI-{Amide} 326 [Nle6;Aha14;Glu20;Tyr28]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKR[Aha]CCEGLECKLWCR KYI-{Amide} 327 [Nle6;Aha17;Glu20;Tyr28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[Aha]GLECKLWCR KYI-{Amide} 328 Pra-[Nle6;Glu28]JzTx-V(1- {H} 29) [Pra]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKEI-{Amide} 329 [Pra1;Nle6;Glu28]JzTx-V(1- {H} 29) [Pra]CQKW[Nle]WTCDSKRACCEGLRCKLWCR KEI-{Amide} 330 [Nle6;Pra11;Glu28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCD[Pra]KRACCEGLRCKLWCR KEI-{Amide} 331 [Nle6;Pra14;Glu28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKR[Pra]CCEGLRCKLWCR KEI-{Amide} 332 [Nle6;Pra17;Glu28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[Pra]GLRCKLWCR KEI-{Amide} 333 AzK-[Nle6;Glu28]JzTx-V(1- {H} 29) [AzK]YCQKW[Nle]WTCDSKRACCEGLRCKLW CRKEI-{Amide} 334 [AzK1;Nle6;Glu28]JzTx- {H}- V(1-29) [AzK]CQKW[Nle]WTCDSKRACCEGLRCKLWC RKEI-{Amide} 335 [Nle6;AzK11;Glu28]JzTx- {H} V(1-29) YCQKW[Nle]WTCD[AzK]KRACCEGLRCKLWC RKEI-{Amide} 336 [Nle6;AzK14;Glu28]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKR[AzK]CCEGLRCKLWC RKEI-{Amide} 337 [Nle6;AzK17;Glu28]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[AzK]GLRCKLWC RKEI-{Amide} 338 Aha-[Nle6;Glu28]JzTx-V(1- {H}- 29) [Aha]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKEI-{Amide} 339 [Aha1;Nle6;Glu28]JzTx-V(1- {H} 29) [Aha]CQKW[Nle]WTCDSKRACCEGLRCKLWCR KEI-{Amide} 340 [Nle6;Aha11;Glu28]JzTx- {H} V(1-29) YCQKW[Nle]WTCD[Aha]KRACCEGLRCKLWCR KEI-{Amide} 341 [Nle6;Aha14;Glu28]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKR[Aha]CCEGLRCKLWCR KEI-{Amide} 342 [Nle6;Aha17;Glu28]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKRACC[Aha]GLRCKLWCR KEI-{Amide} 343 [Pra1;Nle6;Glu20]JzTx-V(1- {H} 29) [Pra]CQKW[Nle]WTCDSKRACCEGLECKLWCR KII-{Amide} 344 [Nle6;Pra11;Glu20]JzTx- {H}- V(1-29) YCQKW[Nle]WTCD[Pra]KRACCEGLECKLWCR KII-{Amide} 345 [Nle6;Pra14;Glu20]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKR[Pra]CCEGLECKLWCR KII-{Amide} 346 [Nle6;Pra17;Glu20]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[Pra]GLECKLWCR KII-{Amide} 347 AzK-[Nle6;Glu20]JzTx-V(1- {H} 29) [AzK]YCQKW[Nle]WTCDSKRACCEGLECKLW CRKII-{Amide} 348 [AzK1;Nle6;Glu20]JzTx- {H}- V(1-29) [AzK]CQKW[Nle]WTCDSKRACCEGLECKLWCR KII-{Amide} 349 [Nle6;AzK11;Glu20]JzTx- {H} V(1-29) YCQKW[Nle]WTCD[AzK]KRACCEGLECKLWC RKII-{Amide} 350 [Nle6;AzK14;Glu20]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKR[AzK]CCEGLECKLWCR KII-{Amide} 351 [Nle6;AzK17;Glu20]JzTx- {H} V(1-29) YCQKW[Nle]WTCDSKRACC[AzK]GLECKLWC RKII-{Amide} 352 Aha-[Nle6;Glu20]JzTx-V(1- {H} 29) [Aha]YCQKW[Nle]WTCDSKRACCEGLECKLWC RKII-{Amide} 353 [Aha1;Nle6;Glu20]JzTx-V(1- {H} 29) [Aha]CQKW[Nle]WTCDSKRACCEGLECKLWCR KII-{Amide} 354 [Nle6;Aha11;Glu20]JzTx- {H}- V(1-29) YCQKW[Nle]WTCD[Aha]KRACCEGLECKLWCR KII-{Amide} 355 [Nle6;Aha14;Glu20]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKR[Aha]CCEGLECKLWCR KII-{Amide} 356 [Nle6;Aha17;Glu20]JzTx- {H}- V(1-29) YCQKW[Nle]WTCDSKRACC[Aha]GLECKLWCR KII-{Amide} 357 Ala-[Nle6]JzTx-V(1-29) {H}- AYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 358 Phe-[Nle6]JzTx-V(1-29) {H}- FYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 359 Gly-[Nle6]JzTx-V(1-29) {H}- GYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 360 Ile-[Nle6]JzTx-V(1-29) {H}- IYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKII- {Amide} 361 Leu-[Nle6]pzTx-V(1-29) {H}- LYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 362 Pro-[Nle6]JzTx-V(1-29) {H}- PYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 363 Val-[Nle6]JzTx-V(1-29) {H}- VYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 364 Trp-[Nle6]JzTx-V(1-29) {H}- WYCQKW[Nle]WTCDSKRACCEGLRCKLWCRK II-{Amide} 365 Tyr-[Nle6]JzTx-V(1-29) {H}- YYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 366 CyA-[Nle6]JzTx-V(1-29) {H}- [CyA]YCQKW[Nle]WTCDSKRACCEGLRCKLW CRKII-{Amide} 367 AllylG-[Nle6]JzTx-V(1-29) {H}- [AllylG]YCQKW[Nle]WTCDSKRACCEGLRCKL WCRKII-{Amide} 368 Abu-[Nle6]JzTx-V(1-29) {H}- [Abu]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKII-{Amide} 369 Nva-[Nle6]JzTx-V(1-29) {H}- [Nva]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKII-{Amide} 370 Nle-[Nle6]JzTx-V(1-29) {H}- [Nle]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKII-{Amide} 371 OctylG-[Nle6]JzTx-V(1-29) {H}- [OctylG]YCQKW[Nle]WTCDSKRACCEGLRCKL WCRKII-{Amide} 372 D-Ala-[Nle6]JzTx-V(1-29) {H}- aYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKI I-{Amide} 373 D-Leu-[Nle6]JzTx-V(1-29) {H}- lYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKII- {Amide} 374 D-Phe-[Nle6]JzTx-V(1-29) {H}- fYCQKW[Nle]WTCDSKRACCEGLRCKLWCRKII- {Amide} 375 Sar-[Nle6]JzTx-V(1-29) {H}- [Sar]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKII-{Amide} 376 bAla-[Nle6]JzTx-V(1-29) {H}- [bAla]YCQKW[Nle]WTCDSKRACCEGLRCKLW CRKII-{Amide} 377 hLeu-[Nle6]JzTx-V(1-29) {H}- [hLeu]YCQKW[Nle]WTCDSKRACCEGLRCKLW CRKII-{Amide} 378 4-Cl-F-[Nle6]JzTx-V(1-29) {H}-[4-Cl- F]YCQKW[Nle]WTCDSKRACCEGLRCKLWCRK II-{Amide} 379 hPhe-[Nle6]JzTx-V(1-29) {H}- [hPhe]YCQKW[Nle]WTCDSKRACCEGLRCKLW CRKII-{Amide} 380 CyA-[Nle6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [CyA]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLR CKLWCRKII-{Amide} 381 AllylG-[Nle6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [AllylG]YCQKW[Nle]WTCDSKR[KPPG3]CCEGL RCKLWCRKII-{Amide} 382 Abu-[Nle6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [Abu]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLRC KLWCRKII-{Amide} 383 Nva-[Nle6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [Nva]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLRC KLWCRKII-{Amide} 384 Pra-[Nle6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [Pra]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLRC KLWCRKII-{Amide} 385 CyA-[Nle6,Lys(Pra- {H}- NPEG3)17]JzTx-V(1-29) [CyA]YCQKW[Nle]WTCDSKRACC[KPPG3]GLR CKLWCRKII-{Amide} 386 Pra-[Nle6,Lys(Pra- {H}- NPEG3)17]JzTx-V(1-29) [Pra]YCQKW[Nle]WTCDSKRACC[KPPG3]GLRC KLWCRKII-{Amide} 387 Pra-[Nle6,Pra17]JzTx-V(1- {H}- 29) [Pra]YCQKW[Nle]WTCDSKRACC[Pra]GLRCKL WCRKII-{Amide} 388 CyA-[Nle6,Pra17]JzTx-V(1- {H}- 29) [CyA]YCQKW[Nle]WTCDSKRACC[Pra]GLRCKL WCRKII-{Amide} 389 CyA-[Nle6,Pra11]JzTx-V(1- {H}- 29) [CyA]YCQKW[Nle]WTCD[Pra]KRACCEGLRCKL WCRKII-{Amide} 390 Pra-[Nle6,Pra11]JzTx-V(1- {H}- 29) [Pra]YCQKW[Nle]WTCD[Pra]KRACCEGLRCKL WCRKII-{Amide} 391 CyA-[Pra1,Nle6]JzTx-V(1- {H}- 29) [CyA][Pra]CQKW[Nle]WTCDSKRACCEGLRCKL WCRKII-{Amide} 392 CyA- {H}- [Nle6,Lys(Pra)14,Glu28]JzTx- [CyA]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK V(1-29) LWCRKEI-{Amide} 393 CyA- {H}- [Nle6,Lys(Pra)14,Glu20]JzTx- [CyA]YCQKW[Nle]WTCDSKRK(Pra)CCEGLECK V(1-29) LWCRKII-{Amide} 394 CyA- {H}- [Nle6,Lys(Pra)14,Glu20,Tyr28] [CyA]YCQKW[Nle]WTCDSKRK(Pra)CCEGLECK JzTx-V(1-29) LWCRKYI-{Amide} 395 CyA- {H}- [Nle6,Pra17,Glu28]JzTx-V(1- [CyA]YCQKW[Nle]WTCDSKRACC[Pra]GLRCKL 29) WCRKEI-{Amide} 396 CyA- {H}- [Nle6,Pra17,Glu20]JzTx-V(1- [CyA]YCQKW[Nle]WTCDSKRACC[Pra]GLECKL 29) WCRKII-{Amide} 397 CyA- {H}- [Nle6,Pra17,Glu20,Tyr28]JzTx- [CyA]YCQKW[Nle]WTCDSKRACC[Pra]GLECKL V(1-29) WCRKYI-{Amide} 398 CyA-[Nle6,Lys(Pra)14]JzTx- {H}- V(1-29) [CyA]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK LWCRKII-{Amide} 399 AllylG- {H}- [Nle6,Lys(Pra)14]JzTx-V(1- [AllylG]YCQKW[Nle]WTCDSKRK(Pra)CCEGLR 29) CKLWCRKII-{Amide} 400 Abu-Nle6,Lys(Pra)14]JzTx- {H}- V(1-29) [Abu]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK LWCRKII-{Amide} 401 Nva-[Nle6,Lys(Pra)14]JzTx- {H}- V(1-29) [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK LWCRKII-{Amide} 402 AllylG-[Nle6,Pra17]JzTx- {H}- V(1-29) [AllylG]YCQKW[Nle]WTCDSKRACC[Pra]GLRC KLWCRKII-{Amide} 403 Nva-[Nle6,Pra17]JzTx-V(1- {H}- 29) [Nva]YCQKW[Nle]WTCDSKRACC[Pra]GLRCKL WCRKII-{Amide} 404 Nva-[Nle6,Lys(Pra)14]JzTx- {H}- V(1-29) [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK LWCRKII-{Amide} 405 Nva-[Nle6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [Nva]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLRC KLWCRKII-{Amide} 406 [Nle6;Atz(NPeg10)17;Glu28] {H}- JzTx-V(1-29) YCQKW[Nle]WTCDSKRACC[Atz(PEG10)GLRC KLWCRKEI-{Amide} 407 [Atz(NPeg10)1;Nle6;Glu20]JzTx- {H}- V(1-29) [Atz(PEG10)CQKW[Nle]WTCDSKRACCEGLECK LWCRKII-{Amide} 408 [Nle6;Atz(NPeg10)11;Glu20] {H}- JzTx-V(1-29) YCQKW[Nle]WTCD[Atz(PEG10)KRACCEGLEC KLWCRKII-{Amide} 409 [Nle6;Atz(NPeg10)17;Glu20] {H}- JzTx-V(1-29) YCQKW[Nle]WTCDSKRACC[Atz(PEG10)GLECK LWCRKII-{Amide} 410 CyA- {H}- [Nle6,Lys(Atz(NPeg10)- [CyA]YCQKW[Nle]WTCDSKR[KAP3P10]CCEGL NPEG3)14]JzTx-V(1-29) RCKLWCRKII-{Amide} 411 Nva- {H}- [Nle6;Lys(Pra)14;Glu28]JzTx- [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK V(1-29) LWCRKEI-{Amide} 412 Nva- {H}- [Leu6;Lys(Pra)14;Glu28]JzTx- [Nva]YCQKWLWTCDSKRK(Pra)CCEGLRCKLW V(1-29) CRKEI-{Amide} 413 Nva- {H}- [Nle6;Lys(Pra)14;Glu20;Tyr28] [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLECK JzTx-V(1-29) LWCRKYI-{Amide} 414 Nva- {H}- [Leu6;Lys(Pra)14;Glu20;Tyr28] [Nva]YCQKWLWTCDSKRK(Pra)CCEGLECKLW JzTx-V(1-29) CRKYI-{Amide} 415 Nva-[Nle6,Lys(Pra- {H}- NPEG3)14;Glu28]JzTx-V(1- [Nva]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLRC 29) KLWCRKEI-{Amide} 416 Nva-[Leu6,Lys(Pra- {H}- NPEG3)14;Glu28]JzTx-V(1- [Nva]YCQKWLWTCDSKR[KPPG3]CCEGLRCKL 29) WCRKEI-{Amide} 417 Nva-[Nle6,Lys(Pra- {H}- NPEG3)14;Glu20;Tyr28]JzTx- [Nva]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLEC V(1-29) KLWCRKYI-{Amide} 418 Nva-[Leu6,Lys(Pra- {H}- NPEG3)14;Glu20;Tyr28]JzTx- [Nva]YCQKWLWTCDSKR[KPPG3]CCEGLECKL V(1-29) WCRKYI-{Amide} 419 Nva- {H}- [Nle6;Lys(Pra)14;Glu20,Trp29] [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLECK JzTx-V(1-29) LWCRKIW-{Amide} 420 Nva- {H}- [Leu6;Lys(Pra)14;Glu20;Trp29] [Nva]YCQKWLWTCDSKRK(Pra)CCEGLECKLW JzTx-V(1-29) CRKIW-{Amide} 421 Nva-[Nle6,Lys(Pra- {H}- NPEG3)14;Glu20;Trp29]JzTx- [Nva]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLEC V(1-29) KLWCRKIW-{Amide} 422 Nva-[Leu6,Lys(Pra- {H}- NPEG3)14;Glu20;Trp29]JzTx- [Nva]YCQKWLWTCDSKR[KPPG3]CCEGLECKL V(1-29) WCRKIW-{Amide} 423 Nva-[Leu6;Lys(Pra)14]JzTx- {H}- V(1-29) [Nva]YCQKWLWTCDSKRK(Pra)CCEGLRCKLW CRKII-{Amide} 424 Nva-[Leu6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [Nva]YCQKWLWTCDSKR[KPPG3]CCEGLRCKL WCRKII-{Amide} 425 Pra-[Nle6]JzTx-V {H}- [Pra]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKII-{Amide} 426 Pra-[Nle6,Glu20,Trp29]JzTx-V {H}- [Pra]YCQKW[Nle]WTCDSKRACCEGLECKLWC RKIW-{Amide} 427 Atz(PEG11- {H}-[Atz(PEG11- benzylthioacetamide)- benzylthioacetamide)]YCQKW[Nle]WTCDSKRAC [Nle6]JzTx-V(1-29) CEGLRCKLWCRKII-{Amide} 431 Nva-[Nle6,Lys(Pra)14]JzTx- {H}- V(1-29) [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK LWCRKII{Amide} 432 Nva-[Nle6,Lys(Pra- {H}- NPEG3)14]JzTx-V(1-29) [Nva]YCQKW[Nle]WTCDSKR[KPPG3]CCEGLRC KLWCRKII{Amide} 433 Nva- {H}- [Nle6,Lys(Atz(NPEG10))14] [Nva]YCQKW[Nle]WTCDSKR[KAtzNP10]CCEGL JzTx-V(1-29) RCKLWCRKII{Amide} 434 Nva- {H}- [Nle6,Lys(Atz(NPEG10)- [Nva]YCQKW[Nle]WTCDSKR[KAP4P10]CCEGL NPEG4)14]JzTx-V(1-29) RCKLWCRKII{Amide} 435 Nva- {H}- [Nle6;Lys(Pra)14;Glu28]JzTx- [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK V(1-29) LWCRKEI{Amide} 436 Nva- {H}- [Nle6;Lys(Pra)14;Glu20;Tyr28] [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLECK JzTx-V(1-29) LWCRKYI{Amide} 437 Nva- {H}- [Nle6;Lys(Pra)14;Glu20,Trp29] [Nva]YCQKW[Nle]WTCDSKRK(Pra)CCEGLECK JzTx-V(1-29) LWCRKIW{Amide} 438 Nva-[Leu6,Lys(Pra)14]JzTx-V {H}- [Nva]YCQKWLWTCDSKRK(Pra)CCEGLRCKLW CRKII{Amide} 439 Nva- {H}- [Leu6;Lys(Pra)14;Glu28]JzTx- [Nva]YCQKWLWTCDSKRK(Pra)CCEGLRCKLW V(1-29) CRKEI{Amide} 440 Nva- {H}- [Leu6;Lys(Pra)14;Glu20;Tyr28] [Nva]YCQKWLWTCDSKRK(Pra)CCEGLECKLW JzTx-V(1-29) CRKYI{Amide} 441 Nva- {H}- [Leu6;Lys(Pra)14;Glu20;Trp29] [Nva]YCQKWLWTCDSKRK(Pra)CCEGLECKLW JzTx-V(1-29) CRKIW{Amide} 442 Nva-[Leu6,Lys(Pra- {H}-[Nva]YCQKWLWTCDSKRK(Pra- NPEG4)14;Glu28]JzTx-V(1- NPEG4)CCEGLRCKLWCRKEI{Amide} 29) 443 CyA- {H}- [Nle6,Atz(NPEG10)17,Glu28] [CyA]YCQKW[Nle]WTCDSKRACC[Atz(NPEG10)] JzTx-V(1-29) GLRCKLWCRKEI{Amide} 444 CyA- {H}- [Nle6,Lys(Atz(NPEG10))14, [CyA]YCQKW[Nle]WTCDSKRK(Atz(NPEG10))C Glu28]JzTx-V(1-29) CEGLRCKLWCRKEI{Amide} 445 CyA- {H}- [Nle6,Lys(Atz(NPEG10))14, [CyA]YCQKW[Nle]WTCDSKRK(Atz(NPEG10))C Glu20,Tyr28]JzTx-V(1-29) CEGLECKLWCRKYI{Amide} 446 Nva- {H}- [Leu6;Lys(Atz(NPEG10))14] [Nva]YCQKWLWTCDSKRK(Atz(NPEG10))CCEG JzTx-V(1-29) LRCKLWCRKII{Amide} 447 Nva- {H}- [Leu6,Lys(Atz(NPEG10))14; [Nva]YCQKWLWTCDSKRK(Atz(NPEG10))CCEG Glu28]JzTx-V LRCKLWCRKEI{Amide} 448 Nva- {H}- [Nle6;Lys(Atz(NPEG10))14; [Nva]YCQKW[Nle]WTCDSKRK(Atz(NPEG10))C Glu28]JzTx-V(1-29) CEGLRCKLWCRKEI{Amide} 449 CyA- {H}- [Leu6,Lys(Pra)14,Glu28]JzTx- [CyA]YCQKWLWTCDSKRK(Pra)CCEGLRCKLW V(1-29) CRKEI{Amide} 450 Pra-[Nle6;Glu28;Trp29]JzTx- {H}- V(1-29) [Pra]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKEW{Amide} 451 CyA- {H}- [Nle6;Lys(Pra)14;Glu28;Trp29] [CyA]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK JzTx-V(1-29) LWCRKEW{Amide} 452 CyA- {H}- [Nle6;Pra17;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTCDSKRACC[Pra]GLRCKL V(1-29) WCRKEW{Amide} 453 CyA- {H}- [Nle6;Lys(Pra)14;Trp29]JzTx- [CyA]YCQKW[Nle]WTCDSKRK(Pra)CCEGLRCK V(1-29) LWCRKIW{Amide} 454 CyA- {H}- [Nle6;Pra17;Trp29]JzTx-V(1- [CyA]YCQKW[Nle]WTCDSKRACC [Pra]GLRCKL 29) WCRKIW{Amide} 455 CyA- {H}- [Nle6;Lys(NPEG11)14;Glu28] [CyA]YCQKW[Nle]WTCDSKRK(NPeg11)CCEGL JzTx-V(1-29) RCKLWCRKEI{Amide} 456 CyA- {H}- [Nle6;Lys(NPEG11)17;Glu28] [CyA]YCQKW[Nle]WTCDSKRACCK(NPeg11)GL JzTx-V(1-29) RCKLWCRKEI{Amide} 457 Lys(NPEG11)- {H}- [Nle6;Glu28]JzTx-V(1-29) K(NPeg11)YCQKW[Nle]WTCDSKRACCEGLRCK LWCRKEI{Amide} 458 CyA- {H}- [Nle6;Lys(NPEG11)14;Glu28; [CyA]YCQKW[Nle]WTCDSKRK(NPeg11)CCEGL Trp29]JzTx-V(1-29) RCKLWCRKEW{Amide} 459 CyA- {H}- [Nle6;Lys(NPEG11)17;Glu28; [CyA]YCQKW[Nle]WTCDSKRACCK(NPeg11)GL Trp29]JzTx-V(1-29) RCKLWCRKEW{Amide} 460 Lys(NPEG11)- {H}- [Nle6;Glu28;Trp29]JzTx- K(NPeg11)YCQKW[Nle]WTCDSKRACCEGLRCK V(1-29) LWCRKEW{Amide} 461 Leu- {H}- [Nle6;Lys(NPEG11)14;Glu28] LYCQKW[Nle]WTCDSKRK(NPeg11)CCEGLRCK JzTx-V(1-29) LWCRKEI{Amide} 462 Leu- {H}- [Nle6;Lys(NPEG11)17;Glu28] LYCQKW[Nle]WTCDSKRACCK(NPeg11)GLRCK JzTx-V(1-29) LWCRKEI{Amide} 463 D-Leu- {H}- [Nle6;Lys(NPEG11)14;Glu28] lYCQKW[Nle]WTCDSKRK(NPeg11)CCEGLRCK JzTx-V(1-29) LWCRKEI{Amide} 464 D-Leu- {H}- [Nle6;Lys(NPEG11)17;Glu28] lYCQKW[Nle]WTCDSKRACCK(NPeg11)GLRCK JzTx-V(1-29) LWCRKEI{Amide} 465 NMeLeu- {H}- [Nle6;Lys(NPEG11)14;Glu28] [NMeLeu]YCQKW[Nle]WTCDSKRK(NPeg11)CC JzTx-V(1-29) EGLRCKLWCRKEI{Amide} 466 NMeLeu- {H}- [Nle6;Lys(NPEG11)17;Glu28] [NMeLeu]YCQKW[Nle]WTCDSKRACCK(NPeg11) JzTx-V(1-29) GLRCKLWCRKEI{Amide} 467 1-Ach- {H}[1- [Nle6;Lys(NPEG11)14;Glu28] Ach]YCQKW[Nle]WTCDSKRK(NPeg11)CCEGLR JzTx-V(1-29) CKLWCRKEI{Amide} 468 1-Ach- {H}[1- [Nle6;Lys(NPEG11)17;Glu28] Ach]YCQKW[Nle]WTCDSKRACCK(NPeg11)GLR JzTx-V(1-29) CKLWCRKEI{Amide} 469 Leu-Lys(NPEG11)- {H}- [Nle6;Gly28]JzTx-V(1-29) LK(NPeg11)YCQKW[Nle]WTCDSKRACCEGLRC KLWCRKEI{Amide} 470 Leu-Nva- {H}- [Nle6;Lys(NPEG11)14;Glu28] L[Nva]YCQKW[Nle]WTCDSKRK(NPeg11)CCEG JzTx-V(1-29) LRCKLWCRKEI{Amide} 471 Leu-Nva- {H}- [Nle6;Lys(NPEG11)17;Glu28] L[Nva]YCQKW[Nle]WTCDSKRACCK(NPeg11)G JzTx-V(1-29) LRCKLWCRKEI{Amide} 472 D-Leu-Nva- {H}- [Nle6;Lys(NPEG11)14;Glu28] l[Nva]YCQKW[Nle]WTCDSKRK(NPeg11)CCEGL JzTx-V(1-29) RCKLWCRKEI{Amide} 473 D-Leu-Nva- {H}- [Nle6;Lys(NPEG11)17;Glu28] l[Nva]YCQKW[Nle]WTCDSKRACCK(NPeg11)GL JzTx-V(1-29) RCKLWCRKEI{Amide} 474 Phe-Nva- {H}- [Nle6;Lys(NPEG11)14;Glu28] F[Nva]YCQKW[Nle]WTCDSKRK(NPeg11)CCEG JzTx-V(1-29) LRCKLWCRKEI{Amide} 475 Phe-Nva- {H}- [Nle6;Lys(NPEG11)17;Glu28] F[Nva]YCQKW[Nle]WTCDSKRACCK(NPeg11)G JzTx-V(1-29) LRCKLWCRKEI{Amide} 476 CyA- {H}- [Nle6;Lys(NPEG11)20;Trp29] [CyA]YCQKW[Nle]WTCDSKRACCEGLK(NPeg11) PzTx-V(1-29) CKLWCRKIW{Amide} 518 CyA-[Pra1;Nle6;Glu28]JzTx- {H}[CyA][Pra]CQKW[Nle]WTCDSKRACCEGLR V(1-29) CKLWCRKEI{Amide} 519 CyA- {H}- [Nle6;Pra10;Glu28]JzTx- [CyA]YCQKW[Nle]WTC[Pra]SKRACCEGLRCKL V(1-29) WCRKEI{Amide} 520 CyA- {H}- [Nle6;Pra11;Glu28]JzTx- [CyA]YCQKW[Nle]WTCD[Pra]KRACCEGLRCKL V(1-29) WCRKEI{Amide} 521 CyA- {H}- [Nle6;Pra12;Glu28]JzTx- [CyA]YCQKW[Nle]WTCDS[Pra]RACCEGLRCKL V(1-29) WCRKEI{Amide} 522 CyA- {H}- [Nle6;Pra13;Glu28]JzTx- [CyA]YCQKW[Nle]WTCDSK[Pra]ACCEGLRCKL V(1-29) WCRKEI{Amide} 523 CyA- {H}- [Nle6;Pra18;Glu28]JzTx- [CyA]YCQKW[Nle]WTCDSKRACCE[Pra]LRCKL V(1-29) WCRKEI{Amide} 524 CyA- {H}- [Nle6;Pra19;Glu28]JzTx- [CyA]YCQKW[Nle]WTCDSKRACCEG[Pra]RCKL V(1-29) WCRKEI{Amide} 525 CyA- {H}- [Nle6;Pra20;Glu28]JzTx- [CyA]YCQKW[Nle]WTCDSKRACCEGL[Pra]CKL V(1-29) WCRKEI{Amide} 526 CyA- {H}- [Pra1;Nle6;Glu28;Trp29]JzTx- [CyA][Pra]CQKW[Nle]WTCDSKRACCEGLRCKL V(1-29) WCRKEW{Amide} 527 CyA- {H}- [Nle6;Pra10;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTC[Pra]SKRACCEGLRCKL V(1-29) WCRKEW{Amide} 545 CyA- {H}- [Nle6;Lys(NPEG11)20]JzTx- [CyA]YCQKW[Nle]WTCDSKRACCEGLK(NPeg11) V(1-29) CKLWCRKII{Amide} 546 CyA- {H}- [Nle6;Va18;Lys(NPEG11)14; [CyA]YCQKW[Nle]WVCDSKRK(NPeg11)CCEGL Glu28]JzTx-V(1-29) RCKLWCRKEI{Amide} 547 CyA- {H}- [Nle6;Val8;Lys(NPEG11)17; [CyA]YCQKW[Nle]WVCDSKRACCK(NPeg11)GL Glu28]JzTx-V(1-29) RCKLWCRKEI{Amide} 548 CyA- {H}- [Leu3;Nle6;Lys(NPEG11)14; [CyA]YCLKW[Nle]WTCDSKRK(NPeg11)CCEGL Glu28]JzTx-V(1-29) RCKLWCRKEI{Amide} 549 CyA- {H}- [Leu3;Nle6;Lys(NPEG11)17; [CyA]YCLKW[Nle]WTCDSKRACCK(NPeg11)GL Glu28]JzTx-V(1-29) RCKLWCRKEI{Amide} 550 CyA- {H}- [Phe1;Nle6;Lys(NPEG11)14; [CyA]FCQKW[Nle]WTCDSKRK(NPeg11)CCEGL Glu28]JzTx-V(1-29) RCKLWCRKEI{Amide} 551 CyA- {H}- [Phe1;Nle6;Lys(NPEG11)17; [CyA]FCQKW[Nle]WTCDSKRACCK(NPeg11)GL Glu28]JzTx-V(1-29) RCKLWCRKEI{Amide} 552 CyA- {H}- [Nle4,6;Lys(NPEG11)14;Glu28] [CyA]YCQ[Nle]W[Nle]WTCDSKRK(NPeg11)CCE JzTx-V(1-29) GLRCKLWCRKEI{Amide} 553 CyA- {H}- [Nle4,6;Lys(NPEG11)17;Glu28] [CyA]YCQ[Nle]W[Nle]WTCDSKRACCK(NPeg11) JzTx-V(1-29) GLRCKLWCRKEI{Amide} 554 CyA- {H}- [Nle6,22;Lys(NPEG11)14;Glu28] [CyA]YCQKW[Nle]WTCDSKRK(NPeg11)CCEGL JzTx-V(1-29) RC[Nle]LWCRKEI{Amide} 555 CyA- {H}- [Nle6,22;Lys(NPEG11)17;Glu28] [CyA]YCQKW[Nle]WTCDSKRACCK(NPeg11)GL JzTx-V(1-29) RC[Nle]LWCRKEI{Amide} 556 CyA- {H}- [Nle6,27;Lys(NPEG11)14;Glu28] [CyA]YCQKW[Nle]WTCDSKRK(NPeg11)CCEGL JzTx-V(1-29) RCKLWCR[Nle]EI{Amide} 557 CyA- {H}- [Nle6,27;Lys(NPEG11)17;Glu28] [CyA]YCQKW[Nle]WTCDSKRACCK(NPeg11)GL JzTx-V(1-29) RCKLWCR[Nle]EI{Amide} 558 CyA- {H}- [Nle6;Lys(NPEG11)14,26;Glu28] [CyA]YCQKW[Nle]WTCDSKRK(NPeg11)CCEGL JzTx-V(1-29) RCKLWCKKEI{Amide} 559 CyA- {H}- [Nle6;Lys(NPEG11)17,26;Glu28] [CyA]YCQKW[Nle]WTCDSKRACCK(NPeg11)GL JzTx-V(1-29) RCKLWCKKEI{Amide} 560 CyA- {H}- [Nle6,12;Lys(NPEG11)14;Glu28] [CyA]YCQKW[Nle]WTCDS[Nle]RK(NPeg11)CCE JzTx-V(1-29) GLRCKLWCRKEI{Amide} 561 CyA- {H}- [Nle6,12;Lys(NPEG11)17;Glu28] [CyA]YCQKW[Nle]WTCDS[Nle]RACCK(NPeg11) JzTx-V(1-29) GLRCKLWCRKEI{Amide} 562 CyA- {H}- [Nle6;Phe14;Lys(NPEG11)17; [CyA]YCQKW[Nle]WTCDSKRFCCK(NPeg11)GL Glu28]JzTx-V(1-29) RCKLWCRKEI{Amide} 563 CyA- {H}- [Lys(NPEG11);Nle6;Glu28]JzTx- [CyA]K(NPeg11)CQKW[Nle]WTCDSKRACCEGL V(1-29) RCKLWCRKEI{Amide} 564 CyA- {H}- [Nle6;Lys(NPEG11)10;Glu28] [CyA]YCQKW[Nle]WTCK(NPeg11)SKRACCEGL JzTx-V(1-29) RCKLWCRKEI{Amide} 565 CyA- {H}- [Nle6;Lys(NPEG11)11;Glu28] [CyA]YCQKW[Nle]WTCDK(NPeg11)KRACCEGL JzTx-V(1-29) RCKLWCRKEI{Amide} 566 CyA- {H}- [Nle6;Lys(NPEG11)12;Glu28] [CyA]YCQKW[Nle]WTCDSK(NPeg11)RACCEGL JzTx-V(1-29) RCKLWCRKEI{Amide} 567 CyA- {H}- [Nle6;Lys(NPEG11)13;Glu28] [CyA]YCQKW[Nle]WTCDSKK(NPeg11)ACCEGL JzTx-V(1-29) RCKLWCRKEI{Amide} 568 CyA- {H}- [Nle6;Lys(NPEG11)18;Glu28] [CyA]YCQKW[Nle]WTCDSKRACCEK(NPeg11)L JzTx-V(1-29) RCKLWCRKEI{Amide} 569 CyA- {H}- [Nle6;Lys(NPEG11)19;Glu28] [CyA]YCQKW[Nle]WTCDSKRACCEGK(NPeg11) JzTx-V(1-29) RCKLWCRKEI{Amide} 570 CyA- {H}- [Nle6;Lys(NPEG11)20;Glu28] [CyA]YCQKW[Nle]WTCDSKRACCEGLK(NPeg11) JzTx-V(1-29) CKLWCRKEI{Amide} 571 Atz-[Nle6]JzTx-V {H}- [Atz]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKII-{Amide} 572 Atz-[Nle6]JzTx-V {H}- [Atz]YCQKW[Nle]WTCDSKRACCEGLRCKLWC RKII-{Amide} 573 CyA- {H}- [Nle6;Pra11;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTCD[Pra]KRACCEGLRCKL V(1-29) WCRKEW{Amide} 574 CyA- {H}- [Nle6;Pra12;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTCDS[Pra]RACCEGLRCKL V(1-29) WCRKEW{Amide} 575 CyA- {H}- [Nle6;Pra13;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTCDSK[Pra]ACCEGLRCKL V(1-29) WCRKEW{Amide} 576 CyA- {H}- [Nle6;Pra18;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTCDSKRACCE[Pra]LRCKL V(1-29) WCRKEW{Amide} 577 CyA- {H}- [Nle6;Pra19;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTCDSKRACCEG[Pra]RCKL V(1-29) WCRKEW{Amide} 578 CyA- {H}- [Nle6;Pra20;Glu28;Trp29]JzTx- [CyA]YCQKW[Nle]WTCDSKRACCEGL[Pra]CKL V(1-29) WCRKEW{Amide} 579 CyA-[Pra1;Nle6]JzTx-V(1- {H}- 29) [CyA][Pra]CQKW[Nle]WTCDSKRACCEGLRCKL WCRKII{Amide} 580 Nva-[Pra1;Nle6]JzTx-V(1- {H}- 29) [Nva][Pra]CQKW[Nle]WTCDSKRACCEGLRCKL WCRKII{Amide} 581 Leu-[Pra1;Nle6]JzTx-V(1-29) {H}- L[Pra]CQKW[Nle]WTCDSKRACCEGLRCKLWC RKII{Amide} 582 D-Leu-[Pra1;Nle6]JzTx-V(1- {H} 29) l[Pra]CQKW[Nle]WTCDSKRACCEGLRCKLWCR KII{Amide} 583 Leu-Leu-[Pra1;Nle6]JzTx- {H}- V(1-29) LL[Pra]CQKW[Nle]WTCDSKRACCEGLRCKLW CRKII{Amide} 584 CyA-[Pra1;Leu6]JzTx-V(1- {H}- 29) [CyA][Pra]CQKWLWTCDSKRACCEGLRCKLWC RKII{Amide} 585 Nva-[Pra1;Leu6]JzTx-V(1- {H}- 29) [Nva][Pra]CQKWLWTCDSKRACCEGLRCKLWC RKII{Amide} 586 Leu-[Pra1;Leu6]JzTx-V(1- {H}- 29) L[Pra]CQKWLWTCDSKRACCEGLRCKLWCRKII {Amide} 587 D-Leu-[Pra1;Leu6]JzTx-V(1- {H}- 29) l[Pra]CQKWLWTCDSKRACCEGLRCKLWCRKII {Amide} 588 Leu-Leu-[Pra1;Leu6]JzTx- {H}- V(1-29) LL[Pra]CQKWLWTCDSKRACCEGLRCKLWCRK II{Amide}

As stated herein above, in accordance with the present invention, the peptide portions of the inventive composition of matter can also be chemically derivatized at one or more amino acid residues by known organic chemistry techniques. “Chemical derivative” or “chemically derivatized” refers to a subject peptide having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty canonical amino acids, whether in L- or D-form. For example, 4-hydroxyproline may be substituted for proline; 5-hydroxylysine maybe substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.

Useful derivatizations include, in some embodiments, those in which the amino terminal of the peptide is chemically blocked so that conjugation with the vehicle will be prevented from taking place at an N-terminal free amino group. There may also be other beneficial effects of such a modification, for example a reduction in the toxin peptide analog's susceptibility to enzymatic proteolysis. The N-terminus can be acylated or modified to a substituted amine, or derivatized with another functional group, such as an aromatic moiety (e.g., an indole acid, benzyl (Bzl or Bn), dibenzyl (DiBzl or Bn₂), or benzyloxycarbonyl (Cbz or Z)), N,N-dimethylglycine or creatine. For example, in some embodiments, an acyl moiety, such as, but not limited to, a formyl, acetyl (Ac), propanoyl, butanyl, heptanyl, hexanoyl, octanoyl, or nonanoyl, can be covalently linked to the N-terminal end of the peptide, which can prevent undesired side reactions during conjugation of the vehicle to the peptide. Other exemplary N-terminal derivative groups include —NRR¹ (other than —NH₂), —NRC(O)R¹, —NRC(O)OR¹, —NRS(O)₂R¹, —NHC(O)NHR¹, succinimide, or benzyloxycarbonyl-NH-(Cbz-NH—), wherein R and R¹ are each independently hydrogen or lower alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, chloro, and bromo.

In some embodiments, one or more peptidyl [—C(O)NR-] linkages (bonds) between amino acid residues can be replaced by a non-peptidyl linkage. Exemplary non-peptidyl linkages are —CH₂-carbamate [—CH₂—OC(O)NR-], phosphonate, —CH₂-sulfonamide [—CH₂—S(O)₂NR-], urea [—NHC(O)NH-], —CH₂-secondary amine, and alkylated peptide [—C(O)NR⁶— wherein R⁶ is lower alkyl].

In some embodiments, one or more individual amino acid residues can be derivatized. Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below by way of example.

Lysinyl residues and amino terminal residues may be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Arginyl residues may be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

Specific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form 0-acetyl tyrosyl species and 3-nitro derivatives, respectively.

Carboxyl sidechain groups (aspartyl or glutamyl) may be selectively modified by reaction with carbodiimides (R′—N═C═N—R′) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Glutaminyl and asparaginyl residues may be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

Cysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking. (See, e.g., Bhatnagar et al., J. Med. Chem., 39:3814-3819 (1996)).

Derivatization with bifunctional agents is useful for cross-linking the peptides or their functional derivatives to a water-insoluble support matrix, if desired, or to other macromolecular vehicles. Commonly used cross-linking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3′-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates, e.g., as described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440, are employed for protein immobilization.

Other possible modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains. Creighton, Proteins: Structure and Molecule Properties (W. H. Freeman & Co., San Francisco), 79-86 (1983).

The above examples of derivatizations are not intended to be an exhaustive treatment, but merely illustrative.

The production of the composition of matter can also involve suitable protein purification techniques, when applicable. In some embodiments of the composition of matter of the invention, the molecule can be prepared to include a suitable isotopic label (e.g., ¹²⁵I, ¹⁴C, ¹³C, ³⁵S, ³H, ²H, ¹³N, ¹⁵N, ¹⁸O, ¹⁷O, etc.), for ease of quantification or detection.

Half-Life Extending Moieties.

Optionally, for modulation of the pharmacokinetic profile of the molecule to fit the therapeutic need, the composition of the present invention can include one or more half-life extending moieties of various masses and configurations, which half-life extending moiety, or moieties, can be covalently fused, attached, linked or conjugated to the toxin peptide analog. A “half-life extending moiety” refers to a molecule that prevents or mitigates in vivo degradation by proteolysis or other activity-diminishing chemical modification, increases in vivo half-life or other pharmacokinetic properties such as but not limited to increasing the rate of absorption, reduces toxicity, reduces immunogenicity, improves solubility, increases biological activity and/or target selectivity of the toxin peptide analog with respect to a target of interest, and/or increases manufacturability, compared to an unconjugated form of the toxin peptide analog. In accordance with the invention, the half-life extending moiety is one that is pharmaceutically acceptable.

The half-life extending moiety can be selected such that the inventive composition achieves a sufficient hydrodynamic size to prevent clearance by renal filtration in vivo. For example, a half-life extending moiety can be selected that is a polymeric macromolecule, which is substantially straight chain, branched-chain (br), or dendritic in form. Alternatively, a half-life extending moiety can be selected such that, in vivo, the inventive composition of matter will bind to a serum protein to form a complex, such that the complex thus formed avoids substantial renal clearance. The half-life extending moiety can be, for example, a lipid; a cholesterol group (such as a steroid); a carbohydrate or oligosaccharide; or any natural or synthetic protein, polypeptide or peptide that binds to a salvage receptor.

Exemplary half-life extending moieties that can be used, in accordance with the present invention, include an immunoglobulin Fc domain, or a portion thereof, or a biologically suitable polymer or copolymer, for example, a polyalkylene glycol compound, such as a polyethylene glycol (PEG) or a polypropylene glycol. Other appropriate polyalkylene glycol compounds include, but are not limited to, charged or neutral polymers of the following types: dextran, polylysine, colominic acids or other carbohydrate based polymers, polymers of amino acids, and biotin derivatives. In some monomeric fusion or conjugate protein embodiments an immunoglobulin (including light and heavy chains) or a portion thereof, can be used as a half-life-extending moiety, preferably an immunoglobulin of human origin, and including any of the immunoglobulins, such as, but not limited to, IgG1, IgG2, IgG3 or IgG4.

Other examples of the half-life extending moiety, in accordance with the invention, include a copolymer of ethylene glycol, a copolymer of propylene glycol, a carboxymethylcellulose, a polyvinyl pyrrolidone, a poly-1,3-dioxolane, a poly-1,3,6-trioxane, an ethylene maleic anhydride copolymer, a polyaminoacid (e.g., polylysine or polyornithine), a dextran n-vinyl pyrrolidone, a poly n-vinyl pyrrolidone, a propylene glycol homopolymer, a propylene oxide polymer, an ethylene oxide polymer, a polyoxyethylated polyol, a polyvinyl alcohol, a linear or branched glycosylated chain, a polyacetal, a long chain fatty acid, a long chain hydrophobic aliphatic group, or a polysialic acid (e.g., PolyXen™ technology; Gregoriadis et al., Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids, Intl. J. Pharmaceutics, 300:125-30 (2005), incorporated herein by reference in its entirety).

In other embodiments of the composition of matter, the half-life extending moiety is an anionically charged chemical entity, covalently linked to the N-terminus of the toxin peptide analog, which anionically charged chemical entities include, but are not limited to, phosphotyrosine, phosphoserine, p-phosphono(difluoro-methyl)-phenylalanine (Pfp), p-phosphono-methyl-phenylalanine (Pmp), p-phosphatidyl-phenylalanine (Ppa), or p-phosphono-methylketo-phenylalanine (Pkp), which can be covalently linked to the N-terminal of the toxin peptide analog, optionally indirectly, via an AEEA linker or other linker as described herein. (See, Chandy et al., Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels, WO 2006/042151 A2; Beeton et al., Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases, Molec. Pharmacol. 67(4):1369-81 (2005); Pennington et al., Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes, Molecular Pharmacology Fast Forward, published Jan. 2, 2009 as doi:10.1124/mol.108.052704 (2009), all of which references are incorporated herein by reference in their entireties). AEEA is 2-(2-(2-aminoethoxy)ethoxy)acetic acid (also known as 8-Amino-3,6-Dioxaoctanoic Acid). (See, e.g., Beeton et al., Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases, Molec. Pharmacol. 67(4):1369-81 (2005)).

Other embodiments of the half-life extending moiety, in accordance with the invention, include peptide ligands or small (organic) molecule ligands that have binding affinity for a long half-life serum protein under physiological conditions of temperature, pH, and ionic strength. Examples include an albumin-binding peptide or small molecule ligand, a transthyretin-binding peptide or small molecule ligand, a thyroxine-binding globulin-binding peptide or small molecule ligand, an antibody-binding peptide or small molecule ligand, or another peptide or small molecule that has an affinity for a long half-life serum protein. (See, e.g., Blaney et al., Method and compositions for increasing the serum half-life of pharmacologically active agents by binding to transthyretin-selective ligands, U.S. Pat. No. 5,714,142; Sato et al., Serum albumin binding moieties, US 2003/0069395 A1; Jones et al., Pharmaceutical active conjugates, U.S. Pat. No. 6,342,225). A “long half-life serum protein” is one of the hundreds of different proteins dissolved in mammalian blood plasma, including so-called “carrier proteins” (such as albumin, transferrin and haptoglobin), fibrinogen and other blood coagulation factors, complement components, immunoglobulins, enzyme inhibitors, precursors of substances such as angiotensin and bradykinin and many other types of proteins. The invention encompasses the use of any single species of pharmaceutically acceptable half-life extending moiety, such as, but not limited to, those described herein, or the use of a combination of two or more different half-life extending moieties, such as PEG and immunoglobulin Fc domain or a portion thereof (see, e.g., Feige et al., Modified peptides as therapeutic agents, U.S. Pat. No. 6,660,843), such as a CH2 domain of Fc, albumin (e.g., human serum albumin (HSA); see, e.g., Rosen et al., Albumin fusion proteins, U.S. Pat. No. 6,926,898 and US 2005/0054051; Bridon et al., Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components, U.S. Pat. No. 6,887,470), a transthyretin (TTR; see, e.g., Walker et al., Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins, US 2003/0195154 A1; 2003/0191056 A1), or a thyroxine-binding globulin (TBG), or a combination such as immunoglobulin(light chain+heavy chain) and Fc domain (the heterotrimeric combination a so-called “hemibody”), for example as described in Sullivan et al., Toxin Peptide Therapeutic Agents, PCT/US2007/022831, published as WO 2008/088422, which is incorporated herein by reference in its entirety.

Conjugation of the toxin peptide analogs(s) to the half-life extending moiety, or moieties, can be via the N-terminal and/or C-terminal of the toxin peptide, or can be intercalary as to its primary amino acid sequence, F1 being linked closer to the toxin peptide analog's N-terminus

Particularly useful half-life extending moieties include immunoglobulins (e.g., human immunoglobulin, including IgG1, IgG2, IgG3 or IgG4). The term “immunoglobulin” encompasses full antibodies comprising two dimerized heavy chains (HC), each covalently linked to a light chain (LC); a single undimerized immunoglobulin heavy chain and covalently linked light chain (HC+LC); or a chimeric immunoglobulin (light chain+heavy chain)-Fc heterotrimer (a so-called “hemibody”). FIGS. 94A-N illustrate several different embodiments of such immunoglobulin-toxin peptide conjugates.

Recombinant fusion or chemical conjugation of the inventive JzTx-V peptide analogs to a recombinant immunoglobulin of any of the IgG1, IgG2, IgG3 or IgG4 isotypes can be useful to extend pharmacokinetic half life. (See, e.g., Doellgast et al., WO 2010/108153 A2). Any of the carrier immunoglobulins disclosed in Doellgast et al., WO 2010/108153 A2 or Walker et al., PCT/US2011/052841, or isotype conversions of any of them comprising different isotype constant domains, or other carrier immunoglobulins known in the art, can be used as half life extending moieties within the scope of the invention.

One example of a human IgG2 heavy chain (HC) constant domain has the amino acid sequence:

SEQ. ID NO: 533 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKC KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK//.

Constant region sequences of other IgG isotypes are known in the art for an IgG1, IgG2, IgG3, or IgG4 immunoglobulin isotype, if desired. In general, human IgG2 can be used for targets where effector functions are not desired, and human IgG1 in situations where such effector functions (e.g., antibody-dependent cytotoxicity (ADCC)) are desired. Human IgG3 has a relatively short half life and human IgG4 forms antibody “half-molecules.” There are four known allotypes of human IgG1. The preferred allotype is referred to as “hIgGlz”, also known as the “KEEM” allotype. Human IgG1 allotypes “hIgGlza” (KDEL), “hIgGlf” (REEM), and “hIgGlfa” are also useful; all appear to have ADCC effector function.

Human hIgGlz heavy chain (HC) constant domain has the amino acid sequence:

SEQ ID NO: 534 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK//.

Human hIgGlza heavy chain (HC) constant domain has the amino acid sequence:

SEQ ID NO: 535 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK//.

Human hIgGlf heavy chain (HC) constant domain has the amino acid sequence:

SEQ ID NO: 536 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK//.

Human hIgGlfa heavy chain (HC) constant domain has the amino acid sequence:

SEQ ID NO: 537 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK//.

One example of a human immunoglobulin light chain (LC) constant region sequence is the following (designated “CL-1”):

SEQ ID NO: 538 GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVK AGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECS//.

CL-1 is useful to increase the pI of antibodies and is convenient. There are three other human immunoglobulin light chain constant regions, designated “CL-2”, “CL-3” and “CL-7”, which can also be used within the scope of the present invention. CL-2 and CL-3 are more common in the human population.

CL-2 human light chain (LC) constant domain has the amino acid sequence:

SEQ ID NO: 539 GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPV KAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEK TVAPTECS//.

CL-3 human LC constant domain has the amino acid sequence:

SEQ ID NO: 540 GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPV KAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEK TVAPTECS//.

CL-7 human LC constant domain has the amino acid sequence:

SEQ ID NO: 541 GQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPV KVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEK TVAPAECS//.

Variable regions of immunoglobulin chains generally exhibit the same overall structure, comprising relatively conserved framework regions (FR) joined by three hypervariable regions, more often called “complementarity determining regions” or CDRs. The CDRs from the two chains of each heavy chain/light chain pair mentioned above typically are aligned by the framework regions to form a structure that binds specifically with a specific epitope or domain on the target protein, if any. From N-terminal to C-terminal, naturally-occurring light and heavy chain variable regions both typically conform with the following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. A numbering system has been devised for assigning numbers to amino acids that occupy positions in each of these domains. This numbering system is defined in Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, Md.), or Chothia & Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:878-883.

An “antibody”, or interchangeably “Ab”, is a tetrameric glycoprotein. In a naturally-occurring antibody, each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” chain of about 220 amino acids (about 25 kDa) and one “heavy” chain of about 440 amino acids (about 50-70 kDa). The amino-terminal portion of each chain includes a “variable” (“V”) region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function. The variable region differs among different antibodies. The constant region is the same among different antibodies. Within the variable region of each heavy or light chain, there are three hypervariable subregions that help determine the antibody's specificity for antigen. The variable domain residues between the hypervariable regions are called the framework residues and generally are somewhat homologous among different antibodies. Immunoglobulins can be assigned to different classes depending on the amino acid sequence of the constant domain of their heavy chains. Human light chains are classified as kappa (K) and lambda (2) light chains. Within light and heavy chains, the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids. See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)). Within the scope of the invention, an “antibody” also encompasses a recombinantly made antibody, and antibodies that are lacking glycosylation.

The term “light chain” or “immunoglobulin light chain” includes a full-length light chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length light chain includes a variable region domain, VL, and a constant region domain, CL. The variable region domain of the light chain is at the amino-terminus of the polypeptide. Light chains include kappa chains and lambda chains. The term “heavy chain” or “immunoglobulin heavy chain” includes a full-length heavy chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length heavy chain includes a variable region domain, V_(H), and three constant region domains, C_(H)1, C_(H)2, and C_(H)3. The V_(H) domain is at the amino-terminus of the polypeptide, and the C_(H) domains are at the carboxyl-terminus, with the C_(H)3 being closest to the carboxy-terminus of the polypeptide. Heavy chains are classified as mu (μ), delta (Δ), gamma (γ), alpha (α), and epsilon (ε), and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. In separate embodiments of the invention, heavy chains may be of any isotype, including IgG (including IgG1, IgG2, IgG3 and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM and IgE. Several of these may be further divided into subclasses or isotypes, e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The variable regions of each light/heavy chain pair typically form the antigen binding site of an antibody, but a useful carrier antibody need not have a known antigen binding site to be useful. (See, e.g., Doellgast et al., WO 2010/108153 A2; Walker et al., PCT/US2011/052841). Different IgG isotypes may have different effector functions (mediated by the Fc region), such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In ADCC, the Fc region of an antibody binds to Fc receptors (FcγRs) on the surface of immune effector cells such as natural killers and macrophages, leading to the phagocytosis or lysis of the targeted cells. In CDC, the antibodies kill the targeted cells by triggering the complement cascade at the cell surface.

An “Fe region”, or used interchangeably herein, “Fe domain” or “immunoglobulin Fc domain”, contains two heavy chain fragments, which in a full antibody comprise the C_(H)1 and C_(H)2 domains of the antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the C_(H)3 domains.

The term “salvage receptor binding epitope” refers to an epitope of the Fc region of an IgG molecule (e.g., IgG₁, IgG₂, IgG₃, or IgG₄) that is responsible for increasing the in vivo serum half-life of the IgG molecule.

“Allotypes” are variations in antibody sequence, often in the constant region, that can be immunogenic and are encoded by specific alleles in humans. Allotypes have been identified for five of the human IGHC genes, the IGHG1, IGHG2, IGHG3, IGHA2 and IGHE genes, and are designated as G1m, G2m, G3m, A2m, and Em allotypes, respectively. At least 18 Gm allotypes are known: nG1m(1), nG1m(2), G1m (1, 2, 3, 17) or G1m (a, x, f, z), G2m (23) or G2m (n), G3m (5, 6, 10, 11, 13, 14, 15, 16, 21, 24, 26, 27, 28) or G3m (b1, c3, b5, b0, b3, b4, s, t, g1, c5, u, v, g5). There are two A2m allotypes A2m(1) and A2m(2).

For a detailed description of the structure and generation of antibodies, see Roth, D. B., and Craig, N. L., Cell, 94:411-414 (1998), herein incorporated by reference in its entirety. Briefly, the process for generating DNA encoding the heavy and light chain immunoglobulin sequences occurs primarily in developing B-cells. Prior to the rearranging and joining of various immunoglobulin gene segments, the V, D, J and constant (C) gene segments are found generally in relatively close proximity on a single chromosome. During B-cell-differentiation, one of each of the appropriate family members of the V, D, J (or only V and J in the case of light chain genes) gene segments are recombined to form functionally rearranged variable regions of the heavy and light immunoglobulin genes. This gene segment rearrangement process appears to be sequential. First, heavy chain D-to-J joints are made, followed by heavy chain V-to-DJ joints and light chain V-to-J joints. In addition to the rearrangement of V, D and J segments, further diversity is generated in the primary repertoire of immunoglobulin heavy and light chains by way of variable recombination at the locations where the V and J segments in the light chain are joined and where the D and J segments of the heavy chain are joined. Such variation in the light chain typically occurs within the last codon of the V gene segment and the first codon of the J segment. Similar imprecision in joining occurs on the heavy chain chromosome between the D and J_(H) segments and may extend over as many as 10 nucleotides. Furthermore, several nucleotides may be inserted between the D and J_(H) and between the V_(H) and D gene segments which are not encoded by genomic DNA. The addition of these nucleotides is known as N-region diversity. The net effect of such rearrangements in the variable region gene segments and the variable recombination which may occur during such joining is the production of a primary antibody repertoire.

The term “hypervariable” region refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region comprises amino acid residues from a complementarity determining region or CDR [i.e., residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain as described by Kabat et al., Sequences of Proteins of Immunological Interest, 5^(th) Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)]. Even a single CDR may recognize and bind antigen, although with a lower affinity than the entire antigen binding site containing all of the CDRs.

An alternative definition of residues from a hypervariable “loop” is described by Chothia et al., J. Mol. Biol. 196: 901-917 (1987) as residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain.

“Framework” or “FR” residues are those variable region residues other than the hypervariable region residues.

“Antibody fragments” comprise a portion of an intact full length antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab′, F(ab′)₂, and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein Eng., 8(10):1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment which contains the constant region. The Fab fragment contains all of the variable domain, as well as the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. The Fc fragment displays carbohydrates and is responsible for many antibody effector functions (such as binding complement and cell receptors), that distinguish one class of antibody from another.

Pepsin treatment yields an F(ab′)₂ fragment that has two “Single-chain Fv” or “scFv” antibody fragments comprising the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Fab fragments differ from Fab′ fragments by the inclusion of a few additional residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Preferably, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the Fv to form the desired structure for antigen binding. For a review of scFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

A “Fab fragment” is comprised of one light chain and the C_(H)1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.

A “Fab′ fragment” contains one light chain and a portion of one heavy chain that contains the V_(H) domain and the C_(H)1 domain and also the region between the C_(H)1 and C_(H)2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab′ fragments to form an F(ab′)₂ molecule.

A “F(ab′)₂ fragment” contains two light chains and two heavy chains containing a portion of the constant region between the C_(H)1 and C_(H)2 domains, such that an interchain disulfide bond is formed between the two heavy chains. A F(ab′)₂ fragment thus is composed of two Fab′ fragments that are held together by a disulfide bond between the two heavy chains.

“Fv” is the minimum antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH VL dimer. A single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

“Single-chain antibodies” are Fv molecules in which the heavy and light chain variable regions have been connected by a flexible linker to form a single polypeptide chain, which forms an antigen-binding region. Single chain antibodies are discussed in detail in International Patent Application Publication No. WO 88/01649 and U.S. Pat. No. 4,946,778 and No. 5,260,203, the disclosures of which are incorporated by reference in their entireties.

“Single-chain Fv” or “scFv” antibody fragments comprise the V_(H) and V_(L) domains of antibody, wherein these domains are present in a single polypeptide chain, and optionally comprising a polypeptide linker between the V_(H) and V_(L) domains that enables the Fv to form the desired structure for antigen binding (Bird et al., Science 242:423-426, 1988, and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988). An “Fd” fragment consists of the V_(H) and C_(H)1 domains.

The term “diabodies” refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

A “domain antibody” is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more V_(H) regions are covalently joined with a peptide linker to create a bivalent domain antibody. The two V_(H) regions of a bivalent domain antibody may target the same or different antigens.

The term “epitope” is the portion of a molecule that is bound by an antigen binding protein (for example, an antibody). The term includes any determinant capable of specifically binding to an antigen binding protein, such as an antibody or to a T-cell receptor. An epitope can be contiguous or non-contiguous (e.g., in a single-chain polypeptide, amino acid residues that are not contiguous to one another in the polypeptide sequence but that within the context of the molecule are bound by the antigen binding protein). In certain embodiments, epitopes may be mimetic in that they comprise a three dimensional structure that is similar to an epitope used to generate the antigen binding protein, yet comprise none or only some of the amino acid residues found in that epitope used to generate the antigen binding protein. Most often, epitopes reside on proteins, but in some instances may reside on other kinds of molecules, such as nucleic acids. Epitope determinants may include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three dimensional structural characteristics, and/or specific charge characteristics. Generally, antibodies specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of proteins and/or macromolecules.

The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) must be addressed by a particular mathematical model or computer program (i.e., an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. 48:1073. For example, sequence identity can be determined by standard methods that are commonly used to compare the similarity in position of the amino acids of two polypeptides. Using a computer program such as BLAST or FASTA, two polypeptide or two polynucleotide sequences are aligned for optimal matching of their respective residues (either along the full length of one or both sequences, or along a pre-determined portion of one or both sequences). The programs provide a default opening penalty and a default gap penalty, and a scoring matrix such as PAM 250 [a standard scoring matrix; see Dayhoff et al., in Atlas of Protein Sequence and Structure, vol. 5, supp. 3 (1978)] can be used in conjunction with the computer program. For example, the percent identity can then be calculated as: the total number of identical matches multiplied by 100 and then divided by the sum of the length of the longer sequence within the matched span and the number of gaps introduced into the longer sequences in order to align the two sequences. In calculating percent identity, the sequences being compared are aligned in a way that gives the largest match between the sequences.

The GCG program package is a computer program that can be used to determine percent identity, which package includes GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or two polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3× the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. In certain embodiments, a standard comparison matrix (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.

Recommended parameters for determining percent identity for polypeptides or nucleotide sequences using the GAP program include the following:

Algorithm: Needleman et al., 1970, J. Mol. Biol. 48:443-453; Comparison matrix: BLOSUM 62 from Henikoff et al., 1992, supra; Gap Penalty: 12 (but with no penalty for end gaps)

Gap Length Penalty: 4 Threshold of Similarity: 0

Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (GAP program) can be adjusted if so desired to result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide.

The term “modification” when used in connection withimmmunoglobulins, including antibodies and antibody fragments, of the invention, include, but are not limited to, one or more amino acid changes (including substitutions, insertions or deletions); chemical modifications; covalent modification by conjugation to therapeutic or diagnostic agents; labeling (e.g., with radionuclides or various enzymes); covalent polymer attachment such as PEGylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of non-natural amino acids.

The term “derivative” when used in connection with an immunoglobulin (including antibodies and antibody fragments) within the scope of the invention refers to immunoglobulin proteins that are covalently modified by conjugation to therapeutic or diagnostic agents, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as PEGylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of non-natural amino acids. Derivatives of the invention will retain the binding properties of underivatized molecules of the invention.

In some embodiments of the invention, the half-life extending moiety is an immunoglobulin Fc domain (e.g., a human immunoglobulin Fc domain, including Fc of allotype IgG1, IgG2, IgG3 or IgG4) or a portion thereof (e.g., CH2 domain of the Fc domain), human serum albumin (HSA), or poly(ethylene glycol) (PEG), in particular PEG of molecular weight of about 1000 Da to about 100000 Da.

Monovalent dimeric or bivalent dimeric Fc-toxin peptide analog fusions or conjugates are useful embodiments of the inventive composition of matter. A “monovalent dimeric” Fc-toxin peptide analog fusion or conjugate, or interchangeably, “monovalent dimer”, or interchangeably, “monovalent heterodimer”, is a Fc-toxin peptide analog fusion or conjugate that includes a toxin peptide analog conjugated with only one of the dimerized Fc domains (e.g., as represented schematically in FIG. 2B of Sullivan et al., Toxin Peptide Therapeutic Agents, US2007/0071764 and Sullivan et al., Toxin Peptide Therapeutic Agents, PCT/US2007/022831, published as WO 2008/088422, which are both incorporated herein by reference in their entireties). A “bivalent dimeric” Fc-toxin peptide analog fusion, or interchangeably, “bivalent dimer” or “bivalent homodimer”, is a Fc-toxin peptide analog fusion or conjugate having both of the dimerized Fc domains each conjugated separately with a toxin peptide analog (e.g., as represented schematically in FIG. 2C of Sullivan et al., Toxin Peptide Therapeutic Agents, US2007/0071764 and Sullivan et al., Toxin Peptide Therapeutic Agents, PCT/US2007/022831, published as WO 2008/088422).

Immunoglobulin Fc domains include Fc variants, which are suitable half-life extending moieties within the scope of this invention. A native Fc can be extensively modified to form an Fc variant in accordance with this invention, provided binding to the salvage receptor is maintained; see, for example WO 97/34631, WO 96/32478, and WO 04/110 472. In such Fc variants, one can remove one or more sites of a native Fc that provide structural features or functional activity not required by the fusion or conjugate molecules of this invention. One can remove these sites by, for example, substituting or deleting residues, inserting residues into the site, or truncating portions containing the site. The inserted or substituted residues can also be altered amino acids, such as peptidomimetics or D-amino acids. Fc variants can be desirable for a number of reasons, several of which are described below. Exemplary Fc variants include molecules and sequences in which:

1. Sites involved in disulfide bond formation are removed. Such removal can avoid reaction with other cysteine-containing proteins present in the host cell used to produce the molecules of the invention. For this purpose, the cysteine-containing segment at the N-terminus can be truncated or cysteine residues can be deleted or substituted with other amino acids (e.g., alanyl, seryl). In particular, one can truncate the N-terminal 20-amino acid segment of SEQ ID NO: 478:

SEQ ID NO: 478 Met Glu Trp Ser Trp Val Phe Leu Phe Phe Leu Ser Val Thr Thr Gly Val His Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys//. or delete or substitute the cysteine residues at positions 7 and 10 of SEQ ID NO: 478. Even when cysteine residues are removed, the single chain Fc domains can still form a dimeric Fc domain that is held together non-covalently.

2. A native Fc is modified to make it more compatible with a selected host cell. For example, one can remove the PA dipeptide sequence near the N-terminus of a typical native Fc, which can be recognized by a digestive enzyme in E. coli such as proline iminopeptidase. One can also add an N-terminal methionine residue, especially when the molecule is expressed recombinantly in a bacterial cell such as E. coli. The Fc domain of SEQ ID NO: 478 is one such Fc variant.

3. A portion of the N-terminus of a native Fc is removed to prevent N-terminal heterogeneity when expressed in a selected host cell. For this purpose, one can delete any of the first 20 amino acid residues at the N-terminus, particularly those at positions 1, 2, 3, 4 and 5.

4. One or more glycosylation sites are removed. Residues that are typically glycosylated (e.g., asparagine) can confer cytolytic response. Such residues can be deleted or substituted with unglycosylated residues (e.g., alanine).

5. Sites involved in interaction with complement, such as the C1q binding site, are removed. For example, one can delete or substitute the EKK tripeptide sequence of human IgG1. Complement recruitment may not be advantageous for the molecules of this invention and so can be avoided with such an Fc variant.

6. Sites are removed that affect binding to Fc receptors other than a salvage receptor. A native Fc can have sites for interaction with certain white blood cells that are not required for the fusion or conjugate molecules of the present invention and so can be removed.

7. The ADCC site is removed to decrease or eliminate ADCC effector function, or alternatively, modified for enhanced ADCC effector function by non-fucosylation or de-fucosylation. ADCC sites are known in the art; see, for example, Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgG1. These sites, as well, are not required for the fusion or conjugate molecules of the present invention and so can be removed, or enhanced for ADCC effector function, as may be desired. (See, Iida et al., Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood, BMC Cancer 9:58 doi:10.1186/1471-2407-9-58 (2009)).

8. When the native Fc is derived from a non-human antibody, the native Fc can be humanized. Typically, to humanize a native Fc, one will substitute selected residues in the non-human native Fc with residues that are normally found in human native Fc. Techniques for antibody humanization are well known in the art.

9. One or more toxin peptide analog sequences can be inserted into an internal conjugation site, or sites, within a loop region of an immunoglobulin Fc domain, as disclosed in U.S. Pat. Nos. 7,442,778; 7,645,861; 7,655,764; 7,655,765; 7,662,931; 7,750,127, and 7,750,128. The term “loop” region or “Fc-loop” region refers to a primary sequence of amino acid residues which connects two regions comprising secondary structure, such as an α-helix or a β-sheet, in the immediate N-terminal and C-terminal directions of primary structure from the loop region. Examples include, but are not limited to, CH2 or CH3 loop regions. One of skill in the art understands that a loop region, while not itself comprising secondary structure, may influence or contribute to secondary or higher order protein structure. The term “internal” conjugation site means that the toxin peptide analog moiety, or moieties, is non-terminal, i.e., not through the α-amino site or the α-carboxy site of the Fc domain, although there optionally can also be additional moieties conjugated terminally at the N-terminal and/or C-terminal of the Fc domain.

10. A linker of suitable length and neutral charge, such as “L25” (GGGGSGGGGSGGGGSGGGGSGGGGS; SEQ ID NO:493) or “L20” (GGGGSGGGGSGGGGSGGGGS; SEQ ID NO:477), can be covalently fused between the C-terminal of one monomer of an Fc domain and the N-terminal of a second Fc domain monomer, with a toxin peptide analog fused to the N-terminal of the first Fc domain monomer or the C-terminal of the second Fc domain monomer, or within a loop region of the first and/or second Fc domain monomer. Such a molecule can be recombinantly expressed in bacterial or mammalian cells to produce a variant “monovalent dimeric” Fc-toxin peptide analog fusion or conjugate with the typical disulfide bond formation between the Fc monomers. (See, e.g., Example 13 herein). Other examples of Fc variants include the following: In SEQ ID NO: 478, the leucine at position 15 can be substituted with glutamate; the glutamate at position 99, with alanine; and the lysines at positions 101 and 103, with alanines. In addition, phenyalanine residues can replace one or more tyrosine residues. For purposes of the invention, a variant Fc domain can also be part of a monomeric immunoglobulin heavy chain, an antibody, or a heterotrimeric hemibody (LC+HC+Fc).

An alternative half-life extending moiety would be a protein, polypeptide, peptide, antibody, antibody fragment, or small molecule (e.g., a peptidomimetic compound) capable of binding to a salvage receptor. For example, one could use as a half-life extending moiety a polypeptide as described in U.S. Pat. No. 5,739,277, issued Apr. 14, 1998 to Presta et al. Peptides could also be selected by phage display for binding to the FcRn salvage receptor. Such salvage receptor-binding compounds are also included within the meaning of “half-life extending moiety” and are within the scope of this invention. Such half-life extending moieties should be selected for increased half-life (e.g., by avoiding sequences recognized by proteases) and decreased immunogenicity (e.g., by favoring non-immunogenic sequences, as discovered in antibody humanization).

As noted above, polymer half-life extending moieties can also be used. Various means for attaching chemical moieties useful as half-life extending moieties are currently available, see, e.g., Patent Cooperation Treaty (“PCT”) International Publication No. WO 96/11953, entitled “N-Terminally Chemically Modified Protein Compositions and Methods,” herein incorporated by reference in its entirety. This PCT publication discloses, among other things, the selective attachment of water-soluble polymers to the N-terminus of proteins.

In some embodiments of the inventive compositions, the polymer half-life extending moiety is polyethylene glycol (PEG), covalently linked at the N-terminal, C-terminal or at one or more intercalary side chains of toxin peptide analog. Some embodiments of the inventive composition of matter further include one or more PEG moieties conjugated to a non-PEG half-life extending moiety or to the toxin peptide analog, or to any combination of any of these. For example, an Fc domain or portion thereof in the inventive composition can be made mono-PEGylated, di-PEGylated, or otherwise multi-PEGylated, by the process of reductive alkylation.

Covalent conjugation of proteins and peptides with poly(ethylene glycol) (PEG) has been widely recognized as an approach to significantly extend the in vivo circulating half-lives of therapeutic proteins. PEGylation achieves this effect predominately by retarding renal clearance, since the PEG moiety adds considerable hydrodynamic radius to the protein. (Zalipsky, S., et al., Use of functionalized poly(ethylene glycol)s for modification of polypeptides., in poly(ethylene glycol) chemistry: Biotechnical and biomedical applications., J. M. Harris, Ed., Plenum Press: New York., 347-370 (1992)). Additional benefits often conferred by PEGylation of proteins and peptides include increased solubility, resistance to proteolytic degradation, and reduced immunogenicity of the therapeutic polypeptide. The merits of protein PEGylation are evidenced by the commercialization of several PEGylated proteins including PEG-Adenosine deaminase (Adagen™/Enzon Corp.), PEG-L-asparaginase (Oncaspar™/Enzon Corp.), PEG-Interferon α-2b (PEG-Intron™/Schering/Enzon), PEG-Interferon α-2a (PEGASYS™/Roche) and PEG-G-CSF (Neulasta™/Amgen) as well as many others in clinical trials.

By “PEGylated peptide” or “PEGylated protein” is meant a peptide having a polyethylene glycol (PEG) moiety covalently bound to an amino acid residue of the peptide itself or to a peptidyl or non-peptidyl linker that is covalently bound to a residue of the peptide, either directly or indirectly through another linker moiety. A non-limiting example is N-terminal conjugation of the peptide with 3-(1-(1-bromo-2-oxo-6,9,12,15,18,21,24,27,30,33,36-undecaoxa-3-azaoctatriacontan-38-yl)-1H-1,2,3-triazol-4-yl)propanoyl (designated herein by the abbreviation “{bromoacetamide-PEG11-triazole}-”).

By “polyethylene glycol” or “PEG” is meant a polyalkylene glycol compound or a derivative thereof, with or without coupling agents or derivatization with coupling or activating moieties (e.g., with aldehyde, hydroxysuccinimidyl, hydrazide, thiol, triflate, tresylate, azirdine, oxirane, orthopyridyl disulphide, vinylsulfone, iodoacetamide or a maleimide moiety). In accordance with the present invention, useful PEG includes substantially linear, straight chain PEG, branched PEG (brPEG), or dendritic PEG. (See, e.g., Merrill, U.S. Pat. No. 5,171,264; Harris et al., Multiarmed, monofunctional, polymer for coupling to molecules and surfaces, U.S. Pat. No. 5,932,462; Shen, N-maleimidyl polymer derivatives, U.S. Pat. No. 6,602,498).

Briefly, the PEG groups are generally attached to the peptide portion of the composition of the invention via acylation or reductive alkylation (or reductive amination) through a reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the inventive compound (e.g., an aldehyde, amino, or ester group). A useful strategy for the PEGylation of synthetic peptides consists of combining, through forming a conjugate linkage in solution, a peptide and a PEG moiety, each bearing a special functionality that is mutually reactive toward the other. The peptides can be easily prepared with conventional solid phase synthesis (see, for example, FIGS. 5 and 6 and the accompanying text herein). The peptides are “preactivated” with an appropriate functional group at a specific site. The precursors are purified and fully characterized prior to reacting with the PEG moiety. Ligation of the peptide with PEG usually takes place in aqueous phase and can be easily monitored by reverse phase analytical HPLC. The PEGylated peptides can be easily purified by preparative HPLC and characterized by analytical HPLC, amino acid analysis and laser desorption mass spectrometry.

PEG is a well-known, water soluble polymer that is commercially available or can be prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler and Karo, Polymer Synthesis, Academic Press, New York, Vol. 3, pages 138-161). In the present application, the term “PEG” is used broadly to encompass any polyethylene glycol molecule, in mono-, bi-, or poly-functional form, without regard to size or to modification at an end of the PEG, and can be represented by the formula:

X—O(CH₂CH₂O)_(n-1)CH₂CH₂OH,  (I)

where n is 20 to 2300 and X is H or a terminal modification, e.g., a C₁₋₄ alkyl.

In some useful embodiments, a PEG used in the invention terminates on one end with hydroxy or methoxy, i.e., X is H or CH₃ (“methoxy PEG”). It is noted that the other end of the PEG, which is shown in formula (I) terminating in OH, covalently attaches to an activating moiety via an ether oxygen bond, an amine linkage, or amide linkage. When used in a chemical structure, the term “PEG” includes the formula (I) above without the hydrogen of the hydroxyl group shown, leaving the oxygen available to react with a free carbon atom of a linker to form an ether bond. More specifically, in order to conjugate PEG to a peptide, the peptide must be reacted with PEG in an “activated” form. Activated PEG can be represented by the formula:

(PEG)-(A)  (II)

where PEG (defined supra) covalently attaches to a carbon atom of the activation moiety (A) to form an ether bond, an amine linkage, or amide linkage, and (A) contains a reactive group which can react with an amino, azido, alkyne, imino, maleimido, N-succinimidyl, carboxyl, aminooxy, seleno, or thiol group on an amino acid residue of a peptide or a linker moiety covalently attached to the peptide, e.g., the toxin peptide analog.

Techniques for the preparation of activated PEG and its conjugation to biologically active peptides are well known in the art. (E.g., see U.S. Pat. Nos. 5,643,575, 5,919,455, 5,932,462, and U.S. Pat. No. 5,990,237; Kinstler et al., N-terminally chemically modified protein compositions and methods, U.S. Pat. Nos. 5,985,265, and 5,824,784; Thompson et al., PEGylation of polypeptides, EP 0575545 B1; Petit, Site specific protein modification, U.S. Pat. Nos. 6,451,986, and 6,548,644; S. Herman et al., Poly(ethylene glycol) with reactive endgroups: I. Modification of proteins, J. Bioactive Compatible Polymers, 10:145-187 (1995); Y. Lu et al., PEGylated peptides III: Solid-phase synthesis with PEGylating reagents of varying molecular weight: synthesis of multiply PEGylated peptides, Reactive Polymers, 22:221-229 (1994); A. M. Felix et al., PEGylated Peptides IV: Enhanced biological activity of site-directed PEGylated GRF analogs, Int. J. Peptide Protein Res., 46:253-264 (1995); A. M. Felix, Site-specific poly(ethylene glycol)ylation of peptides, ACS Symposium Series 680(poly(ethylene glycol)): 218-238 (1997); Y. Ikeda et al., Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides, EP 0473084 B1; G. E. Means et al., Selected techniques for the modification of protein side chains, in: Chemical modification of proteins, Holden Day, Inc., 219 (1971)).

Activated PEG, such as PEG-aldehydes or PEG-aldehyde hydrates, can be chemically synthesized by known means or obtained from commercial sources, e.g., Shearwater Polymers, (Huntsville, Al) or Enzon, Inc. (Piscataway, N.J.).

An example of a useful activated PEG for purposes of the present invention is a PEG-aldehyde compound (e.g., a methoxy PEG-aldehyde), such as PEG-propionaldehyde, which is commercially available from Shearwater Polymers (Huntsville, Al). PEG-propionaldehyde is represented by the formula PEG-CH₂CH₂CHO. (See, e.g., U.S. Pat. No. 5,252,714). Also included within the meaning of “PEG aldehyde compound” are PEG aldehyde hydrates, e.g., PEG acetaldehyde hydrate and PEG bis aldehyde hydrate, which latter yields a bifunctionally activated structure. (See., e.g., Bentley et al., Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines, U.S. Pat. No. 5,990,237) (See., e.g., Bentley et al., Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines, U.S. Pat. No. 5,990,237). An activated multi-branched PEG-aldehyde compound can be used (PEG derivatives comprising multiple arms to give divalent, trivalent, tetravalent, octavalent constructs). Using a 4-arm PEG derivative four (4) toxin peptide analogs are attached to each PEG molecule. For example, in accordance with the present invention, the toxin peptide analog can be conjugated to a polyethylene glycol (PEG) at 1, 2, 3 or 4 amino functionalized sites of the PEG.

In being conjugated in accordance with the inventive method, the polyethylene glycol (PEG), as described herein, is covalently bound by reductive amination directly to at least one solvent-exposed free amine moiety of an amino acid residue of the toxin peptide analog itself. In some embodiments of the inventive method, the toxin peptide analog is conjugated to a PEG at one or more primary or secondary amines on the toxin peptide analog, or to two PEG groups at a single primary amine site on the toxin peptide analog (e.g., this can occur when the reductive amination reaction involves the presence of excess PEG-aldehyde compound). We have observed that when PEGylation by reductive amination is at a primary amine on the peptide, it is not uncommon to have amounts (1 to 100% range) of reaction product that have two or more PEGs present per molecule, and if the desired PEGylation product is one with only one PEG per molecule, then this “over-PEGylation” may be undesirable. When PEGylated product with a single PEG per PEGylation product molecule is desired, an embodiment of the inventive method can be employed that involves PEGylation using secondary amines of the pharmacologically active peptide, because only one PEG group per molecule will be transferred in the reductive amination reaction.

Amino acid residues that can provide a primary amine moiety include residues of lysine, homolysine, ornithine, α,β-diaminopropionic acid (Dap), α,β-diaminopropionoic acid (Dpr), and α,γ-diaminobutyric acid (Dab), aminobutyric acid (Abu), and α-amino-isobutyric acid (Aib). The polypeptide N-terminus also provides a useful α-amino group for PEGylation. Amino acid residues that can provide a secondary amine moiety include ε-N-alkyl lysine, α-N-alkyl lysine, δ-N-alkyl ornithine, α-N-alkyl ornithine, or an N-terminal proline, where the alkyl is C₁ to C₆.

Another useful activated PEG for generating the PEGylated toxin peptide analogs of the present invention is a PEG-maleimide compound, such as, but not limited to, a methoxy PEG-maleimide, such as maleimido monomethoxy PEG, are particularly useful for generating the PEG-conjugated peptides of the invention. (E.g., Shen, N-maleimidyl polymer derivatives, U.S. Pat. No. 6,602,498; C. Delgado et al., The uses and properties of PEG-linked proteins., Crit. Rev. Therap. Drug Carrier Systems, 9:249-304 (1992); S. Zalipsky et al., Use of functionalized polyethylene glycol)s for modification of polypeptides, in: Polyethylene glycol) chemistry: Biotechnical and biomedical applications (J. M. Harris, Editor, Plenum Press: New York, 347-370 (1992); S. Herman et al., Poly(ethylene glycol) with reactive endgroups: I. Modification of proteins, J. Bioactive Compatible Polymers, 10:145-187 (1995); P. J. Shadle et al., Conjugation of polymer to colony stimulating factor-1, U.S. Pat. No. 4,847,325; G. Shaw et al., Cysteine added variants IL-3 and chemical modifications thereof, U.S. Pat. No. 5,166,322 and EP 0469074 B1; G. Shaw et al., Cysteine added variants of EPO and chemical modifications thereof, EP 0668353 A1; G. Shaw et al., Cysteine added variants G-CSF and chemical modifications thereof, EP 0668354 A1; N. V. Katre et al., Interleukin-2 muteins and polymer conjugation thereof, U.S. Pat. No. 5,206,344; R. J. Goodson and N. V. Katre, Site-directed pegylation of recombinant interleukin-2 at its glycosylation site, Biotechnology, 8:343-346 (1990)).

A polyethylene glycol) vinyl sulfone is another useful activated PEG for generating the PEG-conjugated toxin peptide analogs of the present invention by conjugation at thiolated amino acid residues, e.g., at C residues. (E.g., M. Morpurgo et al., Preparation and characterization of polyethylene glycol) vinyl sulfone, Bioconj. Chem., 7:363-368 (1996); see also Harris, Functionalization of polyethylene glycol for formation of active sulfone-terminated PEG derivatives for binding to proteins and biologically compatible materials, U.S. Pat. Nos. 5,446,090; 5,739,208; 5,900,461; 6,610,281 and 6,894,025; and Harris, Water soluble active sulfones of polyethylene glycol), WO 95/13312 A1). Another activated form of PEG that is useful in accordance with the present invention, is a PEG-N-hydroxysuccinimide ester compound, for example, methoxy PEG-N-hydroxysuccinimidyl (NHS) ester.

Heterobifunctionally activated forms of PEG are also useful. (See, e.g., Thompson et al., PEGylation reagents and biologically active compounds formed therewith, U.S. Pat. No. 6,552,170).

In still other embodiments of the inventive method of producing a composition of matter, the toxin peptide analog is reacted by known chemical techniques with an activated PEG compound, such as but not limited to, a thiol-activated PEG compound, a diol-activated PEG compound, a PEG-hydrazide compound, a PEG-oxyamine compound, or a PEG-bromoacetyl compound. (See, e.g., S. Herman, Poly(ethylene glycol) with Reactive Endgroups: I. Modification of Proteins, J. Bioactive and Compatible Polymers, 10:145-187 (1995); S. Zalipsky, Chemistry of Polyethylene Glycol Conjugates with Biologically Active Molecules, Advanced Drug Delivery Reviews, 16:157-182 (1995); R. Greenwald et al., Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review, Critical Reviews in Therapeutic Drug Carrier Systems, 17:101-161 (2000)).

An even more preferred activated PEG for generating the PEG-conjugated toxin peptide analogs of the present invention is a multivalent PEG having more than one activated residues. Preferred multivalent PEG moieties include, but are not limited to, those shown below:

In still other embodiments of making the composition of matter, the inventive toxin peptide analog is reacted by known chemical techniques with an activated multi-branched PEG compound (PEG derivatives comprising multiple arms to give divalent, trivalent, tetravalent, octavalent constructs), such as but not limited to, pentaerythritol tetra-polyethyleneglycol ether. Functionalization and activated derivatives, such as, but not limited to, N-succinimidyloxycarbonyl)propyl, p-nitrophenyloxycarbonyl, (—CO₂-p-C₆H₄NO₂), 3-(N-maleimido)propanamido, 2-sulfanylethyl, and 3-aminopropyl. Using a 4-arm PEG derivative, four toxin peptide analogs are attached to each PEG molecule. For example, in accordance with the present invention, the toxin peptide analog can be conjugated to a polyethylene glycol (PEG) at:

(a) 1, 2, 3 or 4 amino functionalized sites of the PEG; (b) 1, 2, 3 or 4 thiol functionalized sites of the PEG; (c) 1, 2, 3 or 4 maleimido functionalized sites of the PEG; (d) 1, 2, 3 or 4 N-succinimidyl functionalized sites of the PEG; (e) 1, 2, 3 or 4 carboxyl functionalized sites of the PEG; or (f) 1, 2, 3 or 4 p-nitrophenyloxycarbonyl functionalized sites of the PEG.

The smallest practical size of PEG is about 500 Daltons (Da), below which PEG becomes toxic. Above about 500 Da, any molecular mass for a PEG can be used as practically desired, e.g., from about 1,000 Daltons (Da) to 100,000 Da (n is 20 to 2300). The number of PEG monomers (n) is approximated from the average molecular mass using a MW=44 Da for each monomer. It is preferred that the combined molecular mass of PEG on an activated linker is suitable for pharmaceutical use. Thus, the combined molecular mass of the PEG molecule should not exceed about 100,000 Da. In some embodiments, the combined or total average molecular mass of PEG used in a PEG-conjugated toxin peptide analog of the present invention is from about 3,000 Da to 60,000 Da (total n is from 70 to 1,400), more preferably from about 10,000 Da to 40,000 Da (total n is about 230 to about 910). The most preferred combined mass for PEG is from about 20,000 Da to 30,000 Da (total n is about 450 to about 680).

It will be appreciated that “multimers” of the composition of matter can be made, since the half-life extending moiety employed for conjugation to the toxin peptide analog (with or without an intervening linker moiety) can be multivalent (e.g., bivalent, trivalent, tetravalent or a higher order valency) as to the number of amino acid residues at which the half-life extending moiety can be conjugated. In some embodiments the peptide portion of the inventive composition of matter can be multivalent (e.g., bivalent, trivalent, tetravalent or a higher order valency), and, thus, some “multimers” of the inventive composition of matter may have more that one half life extending moiety. Consequently, it is possible by the inventive method of producing a composition of matter to produce a variety of conjugated half-life extending moiety peptide structures. By way of example, a univalent half-life extending moiety and a univalent peptide will produce a 1:1 conjugate; a bivalent peptide and a univalent half-life extending moiety may form conjugates wherein the peptide conjugates bear two half-life extending moiety moieties, whereas a bivalent half-life extending moiety and a univalent peptide may produce species where two peptide entities are linked to a single half-life extending moiety; use of higher-valence half-life extending moiety can lead to the formation of clusters of peptide entities bound to a single half-life extending moiety, whereas higher-valence peptides may become encrusted with a plurality of half-life extending moiety moieties. By way of further example, if the site of conjugation of a multivalent half-life extending moiety to the toxin peptide analog is a cysteine or other aminothiol the methods disclosed by D'Amico et al. may be employed (D'Amico et al., Method of conjugating aminothiol containing molecules to vehicles, published as US 2006/0199812, which application is incorporated herein by reference in its entirety).

The peptide moieties may have more than one reactive group which will react with the activated half-life extending moiety and the possibility of forming complex structures must always be considered; when it is desired to form simple structures such as 1:1 adducts of half-life extending moiety and peptide, or to use bivalent half-life extending moiety to form peptide:half-life extending moiety:peptide adducts, it will be beneficial to use predetermined ratios of activated half-life extending moiety and peptide material, predetermined concentrations thereof and to conduct the reaction under predetermined conditions (such as duration, temperature, pH, etc.) so as to form a proportion of the described product and then to separate the described product from the other reaction products. The reaction conditions, proportions and concentrations of the reagents can be obtained by relatively simple trial-and-error experiments which are within the ability of an ordinarily skilled artisan with appropriate scaling-up as necessary. Purification and separation of the products is similarly achieved by conventional techniques well known to those skilled in the art.

Additionally, physiologically acceptable salts of the half-life extending moiety-fused or conjugated to the toxin peptide analogs of this invention are also encompassed within the composition of matter of the present invention.

The above-described half-life extending moieties and other half-life extending moieties described herein are useful, either individually or in combination, and as further described in the art, for example, in Sullivan et al., Toxin Peptide Therapeutic Agents, US2007/0071764 and Sullivan et al., Toxin Peptide Therapeutic Agents, PCT/US2007/022831, published as WO 2008/088422, which are both incorporated herein by reference in their entireties. The invention encompasses the use of any single species of pharmaceutically acceptable half-life extending moiety, such as, but not limited to, those described herein, in conjugation with the toxin peptide analog, or the use of a combination of two or more like or different half-life extending moieties.

Linkers

A “linker moiety” as used herein refers to a biologically acceptable peptidyl or non-peptidyl organic group that is covalently bound to an amino acid residue of a toxin peptide analog or other polypeptide chain (e.g., an immunoglobulin HC or LC or immunoglobulin Fc domain) contained in the inventive composition, which linker moiety covalently joins or conjugates the toxin peptide analog or other polypeptide chain to another peptide or polypeptide chain in the composition, or to a half-life extending moiety. In some embodiments of the composition, a half-life extending moiety, as described herein, is conjugated, i.e., covalently bound directly to an amino acid residue of the toxin peptide analog itself, or optionally, to a peptidyl or non-peptidyl linker moiety (including but not limited to aromatic or aryl linkers) that is covalently bound to an amino acid residue of the toxin peptide analog. The presence of any linker moiety is optional. When present, its chemical structure is not critical, since it serves primarily as a spacer to position, join, connect, or optimize presentation or position of one functional moiety in relation to one or more other functional moieties of a molecule of the inventive composition. The presence of a linker moiety can be useful in optimizing pharamcologial activity of some embodiments of the inventive composition. The linker, if present, can be made up of amino acids linked together by peptide bonds. The linker moiety, if present, can be independently the same or different from any other linker, or linkers, that may be present in the inventive composition. In some embodiments the linker can be a multivalent linker that facilitates multivalent display of toxin peptide analogs of the present invention; multivalent display of such biologically active compounds can increase binding affinity and/or potency through avidity. The in vivo properties of a therapuetic can be altered (i.e., specific targeting, half-life extension, distribution profile, etc.) through conjugation to a polymer or protein.

Peptidyl linkers.

As stated above, the linker moiety, if present (whether within the primary amino acid sequence of the toxin peptide analog, or as a linker for attaching a half-life extending moiety to the toxin peptide analog), can be “peptidyl” in nature (i.e., made up of amino acids linked together by peptide bonds) and made up in length, preferably, of from 1 up to about 40 amino acid residues, more preferably, of from 1 up to about 20 amino acid residues, and most preferably of from 1 to about 10 amino acid residues. Preferably, but not necessarily, the amino acid residues in the linker are from among the twenty canonical amino acids, more preferably, cysteine, glycine, alanine, proline, asparagine, glutamine, and/or serine. Even more preferably, a peptidyl linker is made up of a majority of amino acids that are sterically unhindered, such as glycine, serine, and alanine linked by a peptide bond. It is also desirable that, if present, a peptidyl linker be selected that avoids rapid proteolytic turnover in circulation in vivo. Some of these amino acids may be glycosylated, as is well understood by those in the art. For example, a useful linker sequence constituting a sialylation site is X₁X₂NX₄X₅G (SEQ ID NO:479), wherein X₁, X₂, X₄ and X₅ are each independently any amino acid residue.

In other embodiments, the 1 to 40 amino acids of the peptidyl linker moiety are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. Preferably, a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine. Thus, preferred linkers include polyglycines, polyserines, and polyalanines, or combinations of any of these. Some exemplary peptidyl linkers are poly(Gly)₁₋₈, particularly (Gly)₃, (Gly)₄ (SEQ ID NO:480), (Gly)₅ (SEQ ID NO:481) and (Gly) (SEQ ID NO:482), as well as, GlySer and poly(Gly)₄Ser, such as “L15” (GGGGSGGGGSGGGGS; SEQ ID NO:483), poly(Gly-Ala)₂₋₄ and poly(Ala)₁₋₈. Other specific examples of peptidyl linkers include (Gly)₅Lys (SEQ ID NO:484), and (Gly)₅LysArg (SEQ ID NO:485). Other examples of useful peptidyl linkers are: Other examples of useful peptidyl linkers are:

(Gly)₃Lys(Gly)₄; (SEQ ID NO: 486) (Gly)₃AsnGlySer(Gly)₂; (SEQ ID NO: 487) (Gly)₃Cys(Gly)₄; (SEQ ID NO: 488) and GlyProAsnGlyGly. (SEQ ID NO: 489) To explain the above nomenclature, for example, (Gly)₃Lys(Gly)₄ means Gly-Gly-Gly-Lys-Gly-Gly-Gly-Gly (SEQ ID NO:490). Other combinations of Gly and Ala are also useful.

Other preferred linkers are those identified herein as “L5” (GGGGS; or “G₄S”; SEQ ID NO:491), “L10” (GGGGSGGGGS; SEQ ID NO:492); “L20” (GGGGSGGGGSGGGGSGGGGS; SEQ ID NO:477); “L25” (GGGGSGGGGSGGGGSGGGGSGGGGS; SEQ ID NO:493) and any linkers used in the working examples hereinafter.

In some embodiments of the compositions of this invention, which comprise a peptide linker moiety, acidic residues, for example, glutamate or aspartate residues, are placed in the amino acid sequence of the linker moiety. Examples include the following peptide linker sequences:

GGEGGG; (SEQ ID NO: 494) GGEEEGGG; (SEQ ID NO: 495) GEEEG; (SEQ ID NO: 496) GEEE; (SEQ ID NO: 497) GGDGGG; (SEQ ID NO: 498) GGDDDGG; (SEQ ID NO: 499) GDDDG; (SEQ ID NO: 500) GDDD; (SEQ ID NO: 501) GGGGSDDSDEGSDGEDGGGGS; (SEQ ID NO: 502) WEWEW; (SEQ ID NO: 503) FEFEF; (SEQ ID NO: 504) EEEWWW; (SEQ ID NO: 505) EEEFFF; (SEQ ID NO: 506) WWEEEWW; (SEQ ID NO: 507) or FFEEEFF. (SEQ ID NO: 508)

In other embodiments, the linker constitutes a phosphorylation site, e.g., X₁X₂YX₄X₅G (SEQ ID NO:509), wherein X₁, X₂, X₄, and X₅ are each independently any amino acid residue; X₁X₂SX₄X₅G (SEQ ID NO:510), wherein X₁, X₂, X₄ and X₅ are each independently any amino acid residue; or X₁X₂TX₄X₅G (SEQ ID NO:511), wherein X₁, X₂, X₄ and X₅ are each independently any amino acid residue.

The linkers shown here are exemplary; peptidyl linkers within the scope of this invention may be much longer and may include other residues. A peptidyl linker can contain, e.g., a cysteine, another thiol, or nucleophile for conjugation with a half-life extending moiety. In another embodiment, the linker contains a cysteine or homocysteine residue, or other 2-amino-ethanethiol or 3-amino-propanethiol moiety for conjugation to maleimide, iodoacetaamide or thioester, functionalized half-life extending moiety.

Another useful peptidyl linker is a large, flexible linker comprising a random Gly/Ser/Thr sequence, for example: GSGSATGGSGSTASSGSGSATH (SEQ ID NO:512) or HGSGSATGGSGSTASSGSGSAT (SEQ ID NO:513), that is estimated to be about the size of a 1 kDa PEG molecule. Alternatively, a useful peptidyl linker may be comprised of amino acid sequences known in the art to form rigid helical structures (e.g., Rigid linker: -AEAAAKEAAAKEAAAKAGG-//SEQ ID NO:514). Additionally, a peptidyl linker can also comprise a non-peptidyl segment such as a 6 carbon aliphatic molecule of the formula —CH₂—CH₂—CH₂—CH₂—CH₂—CH₂—. The peptidyl linkers can be altered to form derivatives as described herein.

Non-Peptidyl Linkers.

Optionally, a non-peptidyl linker moiety is also useful for conjugating the half-life extending moiety to the peptide portion of the half-life extending moiety-conjugated toxin peptide analog. For example, alkyl linkers such as —NH—(CH₂)_(s)—C(O)—, wherein s=2-20 can be used. These alkyl linkers may further be substituted by any non-sterically hindering group such as lower alkyl (e.g., C₁-C₆) lower acyl, halogen (e.g., Cl, Br), CN, NH₂, phenyl, etc. Exemplary non-peptidyl linkers are PEG linkers (e.g., shown below):

wherein n is such that the linker has a molecular weight of about 100 to about 5000 Daltons (Da), preferably about 100 to about 500 Da.

In one embodiment, the non-peptidyl linker is aryl. The linkers may be altered to form derivatives in the same manner as described herein. In addition, PEG moieties may be attached to the N-terminal amine or selected side chain amines by either reductive alkylation using PEG aldehydes or acylation using hydroxysuccinimido or carbonate esters of PEG, or by thiol conjugation.

“Aryl” is phenyl or phenyl vicinally-fused with a saturated, partially-saturated, or unsaturated 3-, 4-, or 5 membered carbon bridge, the phenyl or bridge being substituted by 0, 1, 2 or 3 substituents selected from C₁₋₈ alkyl, C₁₋₄ haloalkyl or halo. “Heteroaryl” is an unsaturated 5, 6 or 7 membered monocyclic or partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10- or 11 membered bicyclic ring, wherein at least one ring is unsaturated, the monocyclic and the bicyclic rings containing 1, 2, 3 or 4 atoms selected from N, O and S, wherein the ring is substituted by 0, 1, 2 or 3 substituents selected from C₁₋₈ alkyl, C₁₋₄ haloalkyl and halo.

Non-peptide portions of the inventive composition of matter, such as non-peptidyl linkers or non-peptide half-life extending moieties can be synthesized by conventional organic chemistry reactions.

Multivalent Linkers.

The linker size/length, flexibility, stoichiometry, stability, etc. can have a trememdous impact on the overall activity profile of the conjugate. We have designed and prepared a series of multivalent bifunctional linkers of varied lengths that can be loaded with multiple copies of a molecule of therapeutic interest and then site specifically conjugated to a protein of interest. The utility of these linker molecules has been demonstrated in improving the potency of Nav1.7 inhibitory peptide conjugates, e.g., with Fc domain and IgG conjugates, but they are useful in the development of other peptide-large molecule, small molecule-large molecule, or peptide-small molecule conjugates.

The multivalent linkers described herein are peptidyl or peptido-mimetic in nature and serve to control the distance between the inhibitor and LM, as well as the geometric relationship between the two by virtue of the conformation of the linker (i.e. extended, partially extended, helical, beta-hairpin, rigid, or flexible). The linkers are chemically differentiated on either end to accommodate orthogonal coupling chemistries (i.e. azide “Click”, amide coupling, thioether formation by alkylation with maleimide or haloacetamide, oxime formation, reductive amination, etc.). Generic examples of linkers are shown in FIG. 77 and FIG. 78.

Other peptides with well-defined secondary structure may provide the necessary rigidity to limit unfavorable interactions between the Nav1.7 inhibitory toxin peptide analog and the remainder of the construct. A general structure (KXXXD//SEQ ID NO:515, where K is linked to D through the amino acid side-chains) for cyclic alpha-helical peptides from Harrison, et. al. Proc. Natl. Acad. Sci. 2010, 107, 11686 may be modified to give desirable properties. X=alanine is the starting point of this reference, but X may be any amino acid for the purposes of the present invention. Additionally, the individual 5 amino-acid subunits may be spaced with other amino acids to affect properties of the overall molecule. (KXXXD)n(X)y where K and D have been cyclized. (See FIG. 84).

Some additional embodiments involve using a beta-hairpin peptide as a rigid linker between the toxin peptide analog and half life extending moiety. (See, e.g., Russel, et. al. J. Am. Chem. Soc. 2003, 125:388 and Ciani, et. al. J. Am. Chem. Soc. 2003, 125:9038). Modifications can be made at either end of the peptide and the asparagine residue in the middle of each sequence. (See, FIG. 85). Each of the above linkers can be modified with suitable functional groups to allow conjugation to both the toxin peptide analog and the (protein) half life extending moiety. This can be through a bromoacetamide on one protion of the molecule and an azide on another portion of the molecule, but other suitable functionalities can also be used. The multivalent linkers can be covalently linked to the toxin peptide analog and half life extending moiety through either their C or N termini or via any of the side-chains of the peptide sequence.

Other embodiments of the multivalent linker comprise a rigid polyheterocyclic core of controlled length. The linkers are chemically differentiated on either end to accommodate orthogonal coupling chemistries (i.e. azide “Click”, amide coupling, thioether formation by alkylation with maleimide or haloacetamide, oxime formation, reductive amination, etc.). (See, FIG. 86A-B).

Still other embodiments of the multivalent linkers described herein are comprised of a multivalent core to which two or more toxin peptide analogs can be covalently linked directly, or indirectly through PEG or peptidyl or peptido-mimetic linkers, such as those described above, to a half life extending moiety. These linkers are chemically differentiated on either end to accommodate orthogonal coupling chemistries (i.e. azide “Click”, amide coupling, thioether formation by alkylation with maleimide or haloacetamide, oxime formation, reductive amination, etc.). (See, e.g., FIG. 87A-B, FIG. 88, FIGS. 89A-B, and FIG. 90).

Additional embodiments of the multivalent linkers are described in Example 10 herein.

The above is merely illustrative and not an exhaustive treatment of the kinds of linkers that can optionally be employed in accordance with the present invention.

Compositions of this invention incorporating the isolated polypeptide antagonists of the voltage-gated sodium channel Na_(v)1.3 and/or Na_(v)1.7, in particular JzTx-V toxin peptide analogs of the present invention, whether or not conjugated to a half-life extending moiety, are useful as therapeutic agents in the treatment of pain, for example in humans. Clinical genetic information, replicated independently by several groups, shows unambiguously that the product of the Nav1.7 (SCN9A) gene is a key control point for the perception of pain. In humans, loss-of-function truncation mutations of the gene lead to complete insensitivity to all forms of pain measured, whereas the human chronic pain syndromes primary erythromelalgia and paroxysmal extreme pain disorder are caused by gain-of-function mutations in Na_(v)1.7 that lead to easier or more prolonged Nav1.7 channel opening. Remarkably, no other major neurological abnormalities are present in patients carrying either truncation or gain-of-function mutations in Na_(v)1.7 (Goldberg et al., Clin Genet 71:311-319 (2007); Cox et al., Nature 444:894-898 (2006); Ahmad et al., Hum Mol Genet 16:2114-2121 (2007); Fertleman et al., Neurology 69:586-595 (2007)). Accordingly, a therapeutic that blocks Na_(v)1.7 can be expected to be of great utility for the treatment of pain in humans.

Specific clinical chronic pain syndromes include, but are not limited to, pain associated with, or due to, cancer, chemotherapy, osteoarthritis, fibromyalgia, primary erythromelalgia, post-herpetic neuralgia, painful diabetic neuropathy, idiopathic painful neuropathy, neuromas, paroxysmal extreme pain disorder, migraine, trigeminal neuralgia, orofacial pain, cluster or other headaches, complex regional pain syndrome (CRPS), failed back surgery syndrome, sciatica (including lower back pain), interstitial cystitis and pelvic pain, inflammation-induced pain including cellulitis, and rheumatic or joint pain. A Na_(v)1.7 inhibitor can also have great utility for treatment of acute or persistent pain, including but not limited to pain following trauma, burns, or surgery. Notably, inhibition of Na_(v)1.7 is not expected to result in the adverse effects on cognition and on the gastrointestinal system that limit the use of opioid drugs. Again unlike opioids, Na_(v)1.7 inhibitors should not produce respiratory depression, patient tolerance, or addiction. Moreover, Na_(v)1.7 expression in humans and in non-human primates is overwhelmingly in the peripheral nervous system, with little or no message or protein in the brain or spinal cord (Ahmad et al., Hum Mol Genet 16:2114-2121, 2007). Consistent with these studies, our data show that among CNS areas from post-mortem humans examined with in situ hybridization, message RNA for Na_(v)1.7 was found only in light amounts in hypothalamic nuclei and in ventral motor areas of the spinal cord and spinal ependyma, areas with no known involvement in the pain response. By contrast, no Na_(v)1.7 was found in cerebral cortex, cerebellum, adrenal medulla, pituitary, or dorsal or deep regions of lumbar spinal cord. Strong Na_(v)1.7 expression was found in peripheral nerves including dorsal root ganglia, trigeminal ganglia, and myenteric plexes of the stomach and intestine. (See, Murray et al., Potent and selective inhibitors of Nav1.3 and Nav1.7, WO 2012/125973 A2, at FIG. 13A-F therein). This suggests that an inhibitor of Na_(v)1.7 would exert analgesic efficacy via the peripheral nervous system without a need for CNS penetrance. As peptides generally do not cross the blood-brain barrier, a peptide inhibitor thus has an advantage over small molecules with some CNS-penetrance in that a peptide should not produce common off-target side effects mediated by the brain such as dizziness, confusion, or sedation.

Accordingly, the present invention also relates to the use of one or more of the inventive compositions of matter in the manufacture of a medicament for the treatment or prevention of a disease, disorder, or other medical condition described herein, for example, but not limited to, chronic pain, acute pain, or persistent pain, or any of the pain syndromes described herein.

Such pharmaceutical compositions can be configured for administration to a patient by a wide variety of delivery routes, e.g., an intravascular delivery route such as by injection or infusion, subcutaneous (“s.c.”), intravenous (“i.v.”), intramuscular, intraperitoneal (“i.p.”), epidural, or intrathecal delivery routes, or for oral, enteral, pulmonary (e.g., inhalant), intranasal, transmucosal (e.g., sublingual administration), transdermal or other delivery routes and/or forms of administration known in the art. Delivery of a drug or pharmaceutical composition containing a JzTx-V peptide analog, or other compositions of matter of the invention, may take place via standard injectable modalities, whether self-administered or in hospital setting, or also via an implantable delivery pump to achieve the most accurate dosing and the most stable plasma exposure levels. The inventive pharmaceutical compositions may be prepared in liquid form, or may be in dried powder form, such as lyophilized form, or crystalline form. For oral or enteral use, the pharmaceutical compositions can be configured, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, elixirs or enteral formulas.

Pharmaceutical Compositions

In General.

The present invention also provides pharmaceutical compositions comprising the inventive composition of matter and a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be configured for administration to a patient by a wide variety of delivery routes, e.g., an intravascular delivery route such as by injection or infusion, subcutaneous, intramuscular, intraperitoneal, epidural, or intrathecal delivery routes, or for oral, enteral, pulmonary (e.g., inhalant), intranasal, transmucosal (e.g., sublingual administration), transdermal or other delivery routes and/or forms of administration known in the art. The inventive pharmaceutical compositions may be prepared in liquid form, or may be in dried powder form, such as lyophilized form. For oral or enteral use, the pharmaceutical compositions can be configured, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, elixirs or enteral formulas.

In the practice of this invention the “pharmaceutically acceptable carrier” is any physiologically tolerated substance known to those of ordinary skill in the art useful in formulating pharmaceutical compositions, including, any pharmaceutically acceptable diluents, excipients, dispersants, binders, fillers, glidants, anti-frictional agents, compression aids, tablet-disintegrating agents (disintegrants), suspending agents, lubricants, flavorants, odorants, sweeteners, permeation or penetration enhancers, preservatives, surfactants, solubilizers, emulsifiers, thickeners, adjuvants, dyes, coatings, encapsulating material(s), and/or other additives singly or in combination. Such pharmaceutical compositions can include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween® 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol®, benzyl alcohol) and bulking substances (e.g., lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712, which are herein incorporated by reference in their entirety. The compositions can be prepared in liquid form, or can be in dried powder, such as lyophilized form. Implantable sustained release formulations are also useful, as are transdermal or transmucosal formulations. Additionally (or alternatively), the present invention provides compositions for use in any of the various slow or sustained release formulations or microparticle formulations known to the skilled artisan, for example, sustained release microparticle formulations, which can be administered via pulmonary, intranasal, or subcutaneous delivery routes. (See, e.g., Murthy et al., Injectable compositions for the controlled delivery of pharmacologically active compound, U.S. Pat. No. 6,887,487; Manning et al., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same, U.S. Pat. Nos. 5,770,559 and 5,981,474; Lieberman et al., Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds, U.S. Pat. No. 5,002,936; Gen, Formative agent of protein complex, US 2002/0119946 A1; Goldenberg et al., Sustained release formulations, WO 2005/105057 A1).

One can dilute the inventive compositions or increase the volume of the pharmaceutical compositions of the invention with an inert material. Such diluents can include carbohydrates, especially, mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may also be used as fillers, including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

A variety of conventional thickeners are useful in creams, ointments, suppository and gel configurations of the pharmaceutical composition, such as, but not limited to, alginate, xanthan gum, or petrolatum, may also be employed in such configurations of the pharmaceutical composition of the present invention. A permeation or penetration enhancer, such as polyethylene glycol monolaurate, dimethyl sulfoxide, N-vinyl-2-pyrrolidone, N-(2-hydroxyethyl)-pyrrolidone, or 3-hydroxy-N-methyl-2-pyrrolidone can also be employed. Useful techniques for producing hydrogel matrices are known. (E.g., Feijen, Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents, U.S. Pat. No. 4,925,677; Shah et al., Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents, WO 00/38651 A1). Such biodegradable gel matrices can be formed, for example, by crosslinking a proteinaceous component and a polysaccharide or mucopolysaccharide component, then loading with the inventive composition of matter to be delivered.

Liquid pharmaceutical compositions of the present invention that are sterile solutions or suspensions can be administered to a patient by injection, for example, intramuscularly, intrathecally, epidurally, intravascularly (e.g., intravenously or intraarterially), intraperitoneally or subcutaneously. (See, e.g., Goldenberg et al., Suspensions for the sustained release of proteins, U.S. Pat. No. 6,245,740 and WO 00/38652 A1). Sterile solutions can also be administered by intravenous infusion. The inventive composition can be included in a sterile solid pharmaceutical composition, such as a lyophilized powder, which can be dissolved or suspended at a convenient time before administration to a patient using sterile water, saline, buffered saline or other appropriate sterile injectable medium.

Implantable sustained release formulations are also useful embodiments of the inventive pharmaceutical compositions. For example, the pharmaceutically acceptable carrier, being a biodegradable matrix implanted within the body or under the skin of a human or non-human vertebrate, can be a hydrogel similar to those described above. Alternatively, it may be formed from a poly-alpha-amino acid component. (Sidman, Biodegradable, implantable drug delivery device, and process for preparing and using same, U.S. Pat. No. 4,351,337). Other techniques for making implants for delivery of drugs are also known and useful in accordance with the present invention.

In powder forms, the pharmaceutically acceptable carrier is a finely divided solid, which is in admixture with finely divided active ingredient(s), including the inventive composition. For example, in some embodiments, a powder form is useful when the pharmaceutical composition is configured as an inhalant. (See, e.g., Zeng et al., Method of preparing dry powder inhalation compositions, WO 2004/017918; Trunk et al., Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them, U.S. Pat. No. 6,900,317).

One can dilute or increase the volume of the compound of the invention with an inert material. These diluents could include carbohydrates, especially mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts can also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo™ Emdex™, STA-Rx™ 1500, Emcompress™ and Avicell™

Disintegrants can be included in the formulation of the pharmaceutical composition into a solid dosage form. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab™ Sodium starch glycolate, Amberlite™, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite can all be used. Insoluble cationic exchange resin is another form of disintegrant. Powdered gums can be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

Binders can be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic. An antifrictional agent can be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants can be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants can also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants can include starch, talc, pyrogenic silica and hydrated silicoaluminate.

To aid dissolution of the compound of this invention into the aqueous environment a surfactant might be added as a wetting agent. Surfactants can include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.

Oral Dosage Forms.

Also useful are oral dosage forms of the inventive compositionss. If necessary, the composition can be chemically modified so that oral delivery is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the compound and increase in circulation time in the body. Moieties useful as covalently attached half-life extending moieties in this invention can also be used for this purpose. Examples of such moieties include: PEG, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. See, for example, Abuchowski and Davis (1981), Soluble Polymer-Enzyme Adducts, Enzymes as Drugs (Hocenberg and Roberts, eds.), Wiley-Interscience, New York, N.Y., pp 367-83; Newmark, et al. (1982), J. Appl. Biochem. 4:185-9. Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are PEG moieties.

For oral delivery dosage forms, it is also possible to use a salt of a modified aliphatic amino acid, such as sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC), as a carrier to enhance absorption of the therapeutic compounds of this invention. The clinical efficacy of a heparin formulation using SNAC has been demonstrated in a Phase II trial conducted by Emisphere Technologies. See U.S. Pat. No. 5,792,451, “Oral drug delivery composition and methods.”

In one embodiment, the pharmaceutically acceptable carrier can be a liquid and the pharmaceutical composition is prepared in the form of a solution, suspension, emulsion, syrup, elixir or pressurized composition. The active ingredient(s) (e.g., the inventive composition of matter) can be dissolved, diluted or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both, or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as detergents and/or solubilizers (e.g., Tween 80, Polysorbate 80), emulsifiers, buffers at appropriate pH (e.g., Tris-HCl, acetate, phosphate), adjuvants, anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol), sweeteners, flavoring agents, suspending agents, thickening agents, bulking substances (e.g., lactose, mannitol), colors, viscosity regulators, stabilizers, electrolytes, osmolutes or osmo-regulators. Additives can also be included in the formulation to enhance uptake of the inventive composition. Additives potentially having this property are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

Useful are oral solid dosage forms, which are described generally in Remington's Pharmaceutical Sciences (1990), supra, in Chapter 89, which is hereby incorporated by reference in its entirety. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation can be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673). Liposomal encapsulation can be used and the liposomes can be derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given in Marshall, K., Modern Pharmaceutics (1979), edited by G. S. Banker and C. T. Rhodes, in Chapter 10, which is hereby incorporated by reference in its entirety. In general, the formulation will include the inventive compound, and inert ingredients that allow for protection against the stomach environment, and release of the biologically active material in the intestine.

The composition of this invention can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

Colorants and flavoring agents can all be included. For example, the protein (or derivative) can be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

In tablet form, the active ingredient(s) are mixed with a pharmaceutically acceptable carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain up to 99% of the active ingredient(s). Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Controlled release formulation can be desirable. The composition of this invention can be incorporated into an inert matrix that permits release by either diffusion or leaching mechanisms e.g., gums. Slowly degenerating matrices can also be incorporated into the formulation, e.g., alginates, polysaccharides. Another form of a controlled release of the compositions of this invention is by a method based on the Oros™ therapeutic system (Alza Corp.), i.e., the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.

Other coatings can be used for the formulation. These include a variety of sugars that could be applied in a coating pan. The therapeutic agent could also be given in a film-coated tablet and the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and include methylcellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxymethyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric materials that are commonly esters of phthalic acid.

A mix of materials might be used to provide the optimum film coating. Film coating can be carried out in a pan coater or in a fluidized bed or by compression coating.

Pulmonary Delivery Forms.

Pulmonary delivery of the inventive compositions is also useful. The protein (or derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. (Other reports of this include Adjei et al., Pharma. Res. (1990) 7: 565-9; Adjei et al. (1990), Internatl. J. Pharmaceutics 63: 135-44 (leuprolide acetate); Braquet et al. (1989), J. Cardiovasc. Pharmacol. 13 (suppl.5): s.143-146 (endothelin-1); Hubbard et al. (1989), Annals Int. Med. 3: 206-12 (α1-antitrypsin); Smith et al. (1989), J. Clin. Invest. 84: 1145-6 (α1-proteinase); Oswein et al. (March 1990), “Aerosolization of Proteins,” Proc. Symp. Resp. Drug Delivery II, Keystone, Colo. (recombinant human growth hormone); Debs et al. (1988), J. Immunol. 140: 3482-8 (interferon-γ and tumor necrosis factor α) and Platz et al., U.S. Pat. No. 5,284,656 (granulocyte colony stimulating factor).

Useful in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Mass. (See, e.g., Helgesson et al., Inhalation device, U.S. Pat. No. 6,892,728; McDerment et al., Dry powder inhaler, WO 02/11801 A1; Ohki et al., Inhalant medicator, U.S. Pat. No. 6,273,086). All such devices require the use of formulations suitable for the dispensing of the inventive compound. Typically, each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants and/or carriers useful in therapy.

The inventive compound should most advantageously be prepared in particulate form with an average particle size of less than 10 μm (or microns), most preferably 0.5 to 5 μm, for most effective delivery to the distal lung.

Pharmaceutically acceptable excipients include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations can include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants can be used. PEG can be used (even apart from its use in derivatizing the protein or analog). Dextrans, such as cyclodextran, can be used. Bile salts and other related enhancers can be used. Cellulose and cellulose derivatives can be used Amino acids can be used, such as use in a buffer formulation.

Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.

Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise the inventive compound dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation can also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation can also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the inventive compound suspended in a propellant with the aid of a surfactant. The propellant can be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid can also be useful as a surfactant. (See, e.g., Backstrom et al., Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides, U.S. Pat. No. 6,932,962).

Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the inventive compound and can also include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.

Nasal Delivery Forms.

In accordance with the present invention, intranasal delivery of the inventive composition of matter and/or pharmaceutical compositions is also useful, which allows passage thereof to the blood stream directly after administration to the inside of the nose, without the necessity for deposition of the product in the lung. Formulations suitable for intransal administration include those with dextran or cyclodextran, and intranasal delivery devices are known. (See, e.g, Freezer, Inhaler, U.S. Pat. No. 4,083,368).

Transdermal and Transmucosal (e.g., Buccal) Delivery Forms).

In some embodiments, the inventive composition is configured as a part of a pharmaceutically acceptable transdermal or transmucosal patch or a troche. Transdermal patch drug delivery systems, for example, matrix type transdermal patches, are known and useful for practicing some embodiments of the present pharmaceutical compositions. (E.g., Chien et al., Transdermal estrogen/progestin dosage unit, system and process, U.S. Pat. Nos. 4,906,169 and 5,023,084; Cleary et al., Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same, U.S. Pat. No. 4,911,916; Teillaud et al., EVA-based transdermal matrix system for the administration of an estrogen and/or a progestogen, U.S. Pat. No. 5,605,702; Venkateshwaran et al., Transdermal drug delivery matrix for coadministering estradiol and another steroid, U.S. Pat. No. 5,783,208; Ebert et al., Methods for providing testosterone and optionally estrogen replacement therapy to women, U.S. Pat. No. 5,460,820). A variety of pharmaceutically acceptable systems for transmucosal delivery of therapeutic agents are also known in the art and are compatible with the practice of the present invention. (E.g., Heiber et al., Transmucosal delivery of macromolecular drugs, U.S. Pat. Nos. 5,346,701 and 5,516,523; Longenecker et al., Transmembrane formulations for drug administration, U.S. Pat. No. 4,994,439).

Buccal delivery of the inventive compositions is also useful. Buccal delivery formulations are known in the art for use with peptides. For example, known tablet or patch systems configured for drug delivery through the oral mucosa (e.g., sublingual mucosa), include some embodiments that comprise an inner layer containing the drug, a permeation enhancer, such as a bile salt or fusidate, and a hydrophilic polymer, such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, dextran, pectin, polyvinyl pyrrolidone, starch, gelatin, or any number of other polymers known to be useful for this purpose. This inner layer can have one surface adapted to contact and adhere to the moist mucosal tissue of the oral cavity and can have an opposing surface adhering to an overlying non-adhesive inert layer. Optionally, such a transmucosal delivery system can be in the form of a bilayer tablet, in which the inner layer also contains additional binding agents, flavoring agents, or fillers. Some useful systems employ a non-ionic detergent along with a permeation enhancer. Transmucosal delivery devices may be in free form, such as a cream, gel, or ointment, or may comprise a determinate form such as a tablet, patch or troche. For example, delivery of the inventive composition can be via a transmucosal delivery system comprising a laminated composite of, for example, an adhesive layer, a backing layer, a permeable membrane defining a reservoir containing the inventive composition, a peel seal disc underlying the membrane, one or more heat seals, and a removable release liner. (E.g., Ebert et al., Transdermal delivery system with adhesive overlay and peel seal disc, U.S. Pat. No. 5,662,925; Chang et al., Device for administering an active agent to the skin or mucosa, U.S. Pat. Nos. 4,849,224 and 4,983,395). These examples are merely illustrative of available transmucosal drug delivery technology and are not limiting of the present invention.

Dosages.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, the daily regimen should be in the range of 0.1-1000 micrograms of the inventive compound per kilogram of body weight, preferably 0.1-150 micrograms per kilogram.

By way of further illustration, the following numbered embodiments are encompassed by the present invention:

1. A composition of matter comprising an isolated polypeptide comprising the amino acid sequence of the formula:

SEQ ID NO: 516 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰Leu²¹ X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹X_(aa) ³⁰X_(aa) ³¹ X_(aa) ³²X_(aa) ³³X_(aa) ³⁴// or a pharmaceutically acceptable salt thereof, wherein:

-   -   X_(aa) ¹X_(aa) ² is absent; or X_(aa) ¹ is any amino acid         residue and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is         absent and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is         absent and X_(aa) ² is absent;     -   X_(aa) ³ is any amino acid residue;     -   X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if         X_(aa) ¹⁸ is SeCys;     -   X_(aa) ⁵ is any neutral hydrophilic or basic amino acid residue;     -   X_(aa) ⁶ is any basic amino acid residue;     -   X_(a): is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp,         6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;     -   X_(aa) ⁸ is a Met, Nle, Nva, Leu, Ile, Val, or Phe residue;     -   X_(aa) ⁹ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp,         6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;     -   X_(aa) ¹⁰ is a basic or neutral hydrophilic amino acid residue,         or an Ala residue;     -   X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if         X_(aa) ²³ is SeCys;     -   X_(aa) ¹³ is any amino acid residue except a hydrophobic         residue;     -   X_(aa) ¹⁴ is a basic residue or an Ala residue;     -   X_(aa) ¹⁶ is any amino acid residue;     -   X_(aa) ¹⁷ is a Cys if X_(aa) ²⁷ is Cys; or X_(aa) ¹⁷ is a SeCys         if X_(aa) ²⁷ is SeCys;     -   X_(aa) ¹⁸ is a Cys or SeCys;     -   X_(aa) ¹⁹ is any amino acid residue;     -   X_(aa) ²⁰ is a Gly or Ala residue;     -   X_(aa) ²² is an acidic, basic amino acid residue, or Ala         residue;     -   X_(aa) ²³ is a Cys or SeCys residue;     -   X_(aa) ²⁴ is a basic amino acid or Ala residue;     -   X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp,         6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;     -   X_(aa) ²⁷ is a Cys or SeCys residue;     -   X_(aa) ²⁸ is a basic amino acid residue;     -   X_(aa) ²⁹ is a basic amino acid residue;     -   X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp,         5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal         residue, if X_(aa) ²² is an acidic amino acid residue; or     -   X_(aa) ³⁰ is an acidic amino acid residue, if X_(aa) ²² is a         basic amino acid residue or an Ala residue;     -   X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp,         5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal         residue;     -   each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently         absent or is independently a hydrophobic amino acid residue;     -   and wherein:

if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸;

if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ¹¹ and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³;

if X_(aa) ¹⁷ and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; or if X_(aa) ¹⁷ and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷;

the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and

the carboxy-terminal residue is optionally amidated.

2. The composition of matter of Embodiment 1, wherein X_(aa) ²² is an acidic amino acid residue.

3. The composition of matter of Embodiment 2, wherein X_(aa) ²² is selected from Glu, Asp, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.

4. The composition of matter of Embodiments 1-3, wherein X_(aa) ²² is a Glu residue.

5. The composition of matter of any of Embodiments 2-4, wherein X_(aa) ³⁰ is an Ile, Trp, or Tyr residue.

6. The composition of matter of Embodiment 1, wherein X_(aa) ²² is a basic amino acid residue or an Ala residue.

7. The composition of matter of Embodiment 6, wherein X_(aa) ²² is selected from histidine, lysine, homolysine, ornithine, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, and homoarginine residues, and X_(aa) ³⁰ is selected from Glu, Asp, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.

8. The composition of matter of Embodiment 1, wherein X_(aa) ²² is an Arg residue or Ala residue, and X_(aa) ³⁰ is a Glu residue.

9. The composition of matter of any of Embodiment 6 or Embodiment 7, wherein X_(aa) ³⁰ is selected from Glu, Asp, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.

10. The composition of matter of Embodiment 9, wherein X_(aa) ³⁰ is a Glu residue.

11. The composition of matter of Embodiments 1-10, wherein X_(aa) ³¹ is an Ile, Trp or Tyr residue.

12. The composition of matter of Embodiments 1-11, wherein X_(aa) ⁸ is an Nle or Leu residue.

13. The composition of matter of Embodiments 1-12, wherein the carboxy-terminal residue is amidated.

14. The composition of matter of Embodiments 1-13, wherein:

(i) X_(aa) ¹ is a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue, and X_(aa) ² is any amino acid residue; or

(ii) X_(aa) ¹ is absent and X_(aa) ² is a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, Atz, Ala, Phe, Ile, Leu, Met, Val, Trp, Tyr, proline, thiaproline, methionine, glycine, 1-Nal, 2-Nal, 1′NMe-Trp, cyclopentylglycine (Cpg), phenylglycine, N-methylleucine, N-methylphenylalanine, N-methylvaline, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-chloro-phenylalanine, 4-chloro-phenylalanine, 3,4-dichlorophenylalanine, 4-trifluoromethyl-phenylalanine, or 4-phenyl-phenylalanine (Bip) residue.

15. The composition of matter of Embodiment 1, comprising an amino acid sequence selected from SEQ ID NO:63, SEQ ID NO:69, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:131, SEQ ID NO:137, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:182, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:277, SEQ ID NO:279, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:394, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:406, SEQ ID NO:407, SEQ ID NO:408, SEQ ID NO:409, SEQ ID NO:411, SEQ ID NO:412, SEQ ID NO:413, SEQ ID NO:414, SEQ ID NO:415, SEQ ID NO:416, SEQ ID NO:417, SEQ ID NO:418, SEQ ID NO:419, SEQ ID NO:420, SEQ ID NO:421, SEQ ID NO:422, SEQ ID NO:426, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:439, SEQ ID NO:440, SEQ ID NO:441, SEQ ID NO:442, SEQ ID NO:443, SEQ ID NO:444, SEQ ID NO:445, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:449, SEQ ID NO:450, SEQ ID NO:451, SEQ ID NO:452, SEQ ID NO:455, SEQ ID NO:456, SEQ ID NO:457, SEQ ID NO:458, SEQ ID NO:459, SEQ ID NO:460, SEQ ID NO:461, SEQ ID NO:462, SEQ ID NO:463, SEQ ID NO:464, SEQ ID NO:465, SEQ ID NO:466, SEQ ID NO:467, SEQ ID NO:468, SEQ ID NO:469, SEQ ID NO:470, SEQ ID NO:471, SEQ ID NO:472, SEQ ID NO:473, SEQ ID NO:474, SEQ ID NO:475, SEQ ID NO:518, SEQ ID NO:520, SEQ ID NO:521, SEQ ID NO:523, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:546, SEQ ID NO:547, SEQ ID NO:548, SEQ ID NO:549, SEQ ID NO:550, SEQ ID NO:551, SEQ ID NO:552, SEQ ID NO:553, SEQ ID NO:554, SEQ ID NO:555, SEQ ID NO:556, SEQ ID NO:557, SEQ ID NO:558, SEQ ID NO:559, SEQ ID NO:560, SEQ ID NO:561, SEQ ID NO:562, SEQ ID NO:563, SEQ ID NO:565, SEQ ID NO:566, SEQ ID NO:568, SEQ ID NO:573, SEQ ID NO:574, SEQ ID NO:576, and SEQ ID NO:577, as set forth in Table 5.

16. An isolated nucleic acid encoding any of SEQ ID NO:63, SEQ ID NO:69, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:131, SEQ ID NO:137, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:277, or SEQ ID NO:279, as set forth in Table 5, that does not include a non-canonical amino acid.

17. An expression vector comprising the nucleic acid of Embodiment 16.

18. A recombinant host cell comprising the expression vector of Embodiment 17.

19. The composition of matter of any of Embodiments 1-16, further comprising an optional linker moiety and a pharmaceutically acceptable, covalently linked half-life extending moiety.

20. The composition of matter of Embodiment 19, wherein the optional linker moiety is covalently linked at:

(a) the N-terminal residue;

(b) the C-terminal residue; or

(c) X_(aa) ³, X_(aa) ¹³, X_(aa) ¹⁶, or X_(aa) ¹⁹.

21. The composition of matter of Embodiments 19-20, wherein the optional linker moiety is a multivalent linker.

22. The composition of matter of Embodiments 19-21, wherein the half-life extending moiety is polyethylene glycol of molecular weight of about 1000 Da to about 100000 Da, an IgG Fc domain, a transthyretin, or a human serum albumin.

23. The composition of matter of Embodiments 19-21, wherein the half-life extending moiety comprises a human immunoglobulin or a human immunoglobulin Fc domain, or both.

24. The composition of matter of Embodiment 23 having a configuration as set forth in any of FIG. 81A-C, FIG. 94A-N, FIG. 95, FIG. 96, FIG. 97, or FIG. 98.

25. The composition of matter of Embodiment 23, wherein the composition comprises a monovalent immunoglobulin-peptide or Fc-peptide conjugate.

26. The composition of matter of Embodiment 23, wherein the composition comprises a bivalent immunoglobulin-peptide or Fc-peptide conjugate.

27. A pharmaceutical composition, comprising the composition of matter of any of Embodiments 1-15 or 19-27, and a pharmaceutically acceptable carrier.

28. A method of preventing pain, comprising administering a prophylactically effective amount of the composition of any of Embodiments 1-15 or 19-27.

29. A method of treating pain, comprising administering a therapeutically effective amount of the composition of any of Embodiments 1-15 or 19-27.

30. The method of Embodiment 29, wherein the pain is chronic pain, acute pain, or persistent pain.

31. The method of Embodiment 30, wherein the chronic pain is associated with cancer, chemotherapy, osteoarthritis, fibromyalgia, primary erythromelalgia, post-herpetic neuralgia, painful diabetic neuropathy, idiopathic painful neuropathy, neuromas, paroxysmal extreme pain disorder, migraine, trigeminal neuralgia, orofacial pain, cluster headaches, complex regional pain syndrome (CRPS), failed back surgery syndrome, sciatica, interstitial cystitis, pelvic pain, lower back pain, inflammation-induced pain, or joint pain.

32. The method of Embodiment 30, wherein the acute or persistent pain is associated with trauma, burn, or surgery.

33. A composition of matter comprising an isolated polypeptide comprising the amino acid sequence of the formula:

SEQ ID NO: 517 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰Leu²¹ X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹X_(aa) ³⁰X_(aa) ³¹ X_(aa) ³²X_(aa) ³³X_(aa) ³⁴// or a pharmaceutically acceptable salt thereof, wherein:

-   -   X_(aa) ¹ is absent; or X_(aa) ¹ is any amino acid residue;     -   X_(aa) ² is any hydrophobic amino acid residue, or a Pra, Aha,         Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla,         AllylG, CyA, or Atz residue;     -   X_(aa) ³ is any amino acid residue;     -   X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if         X_(aa) ¹⁸ is SeCys;     -   X_(aa) ⁵ is any neutral hydrophilic or basic amino acid residue;     -   X_(aa) ⁶ is any basic amino acid residue;     -   X_(aa) ⁷ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp,         6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;     -   X_(aa) ⁸ is a Leu or Nle residue;     -   X_(aa) ⁹ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp,         6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;     -   X_(aa) ¹⁰ is a basic or neutral hydrophilic amino acid residue,         or an Ala residue;     -   X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if         X_(aa) ²³ is SeCys;     -   X_(aa) ¹³ is any amino acid residue except a hydrophobic         residue;     -   X_(aa) ¹⁴ is a basic residue or an Ala residue;     -   X_(aa) ¹⁶ is any amino acid residue;     -   X_(aa) ¹⁷ is a Cys if X_(aa) ²² is Cys; or X_(aa) ¹⁷ is a SeCys         if X_(aa) ²² is SeCys;     -   X_(aa) ¹⁸ is a Cys or SeCys;     -   X_(aa) ¹⁹ is any amino acid residue;     -   X_(aa) ²⁰ is a Gly or Ala residue;     -   X_(aa) ²² is a basic amino acid residue or Ala residue;     -   X_(aa) ²³ is a Cys or SeCys residue;     -   X_(aa) ²⁴ is a basic amino acid residue or Ala residue;     -   X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp,         6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue;     -   X_(aa) ²⁷ is a Cys or SeCys residue;     -   X_(aa) ²⁸ is a basic amino acid residue;     -   X_(aa) ²⁹ is a basic amino acid residue;     -   X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp,         5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal         residue;     -   X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp,         5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal         residue;     -   each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently         absent or is independently a hydrophobic amino acid residue;     -   and wherein:

if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸;

if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ¹¹ and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³;

if X_(aa) ¹⁷ and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹² and residue X_(aa) ²⁷; or if X_(aa) ¹⁷ and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹² and residue X_(aa) ²⁷;

the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and

the carboxy-terminal residue is optionally amidated.

34. The composition of matter of Embodiment 33, wherein X_(aa) ² is a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, Atz, Ala, Phe, Ile, Leu, Met, Val, Trp, Tyr, proline, thiaproline, methionine, glycine, 1-Nal, 2-Nal, 1′NMe-Trp, cyclopentylglycine (Cpg), phenylglycine, N-methylleucine, N-methylphenylalanine, N-methylvaline, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-chloro-phenylalanine, 4-chloro-phenylalanine, 3,4-dichlorophenylalanine, 4-trifluoromethyl-phenylalanine, or 4-phenyl-phenylalanine (Bip) residue.

35. The composition of matter of any of Embodiments 33-34, wherein X_(aa) ³⁰ is an Ile, Trp, or Tyr residue.

36. The composition of matter of Embodiments 33-36, wherein the carboxy-terminal residue is amidated.

37. The composition of matter of Embodiment 33, comprising an amino acid sequence selected from SEQ ID NO:247, SEQ ID NO:296, SEQ ID NO:358, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:370, SEQ ID NO:372, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:391, SEQ ID NO:398, SEQ ID NO:399, SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:404, SEQ ID NO:405, SEQ ID NO:410, SEQ ID NO:423, SEQ ID NO:424, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:433, SEQ ID NO:434, SEQ ID NO:438, SEQ ID NO:446, SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:571, SEQ ID NO:579, SEQ ID NO:580, SEQ ID NO:581, SEQ ID NO:582, SEQ ID NO:583, SEQ ID NO:584, SEQ ID NO:585, SEQ ID NO:586, SEQ ID NO:587, and SEQ ID NO:588, as set forth in Table 5.

38. The composition of matter of any of Embodiments 33-37, further comprising an optional linker moiety and a pharmaceutically acceptable, covalently linked half-life extending moiety.

39. The composition of matter of Embodiment 38, wherein the optional linker moiety is covalently linked at:

(a) the N-terminal residue;

(b) the C-terminal residue; or

(c) X_(aa) ³, X_(aa) ¹³, X_(aa) ¹⁶, or X_(aa) ¹⁹.

40. The composition of matter of Embodiments 38-39, wherein the optional linker moiety is a multivalent linker.

41. The composition of matter of Embodiments 38-40, wherein the half-life extending moiety is polyethylene glycol of molecular weight of about 1000 Da to about 100000 Da, an IgG Fc domain, a transthyretin, or a human serum albumin.

42. The composition of matter of Embodiments 38-40, wherein the half-life extending moiety comprises a human immunoglobulin or a human immunoglobulin Fc domain, or both.

43. The composition of matter of Embodiment 42 having a configuration as set forth in any of FIG. 81A-C, FIG. 94A-N, FIG. 95, FIG. 96, FIG. 97, or FIG. 98.

44. The composition of matter of Embodiment 42, wherein the composition comprises a monovalent immunoglobulin-peptide or Fc-peptide conjugate.

45. The composition of matter of Embodiment 42, wherein the composition comprises a bivalent immunoglobulin-peptide or Fc-peptide conjugate.

46. A pharmaceutical composition, comprising the composition of matter of any of Embodiments 33-46, and a pharmaceutically acceptable carrier.

47. A method of preventing pain, comprising administering a prophylactically effective amount of the composition of any of Embodiments 33-46.

48. A method of treating pain, comprising administering a therapeutically effective amount of the composition of any of Embodiments 33-46.

49. The method of Embodiment 48, wherein the pain is chronic pain, acute pain, or persistent pain.

50. The method of Embodiment 48, wherein the chronic pain is associated with cancer, chemotherapy, osteoarthritis, fibromyalgia, primary erythromelalgia, post-herpetic neuralgia, painful diabetic neuropathy, idiopathic painful neuropathy, neuromas, paroxysmal extreme pain disorder, migraine, trigeminal neuralgia, orofacial pain, cluster headaches, complex regional pain syndrome (CRPS), failed back surgery syndrome, sciatica, interstitial cystitis, pelvic pain, lower back pain, inflammation-induced pain, or joint pain.

51. The method of Embodiment 48, wherein the acute or persistent pain is associated with trauma, burn, or surgery.

The following working examples are illustrative and not to be construed in any way as limiting the scope of the present invention.

EXAMPLES Example 1 Isolation and Purification of JzTx-V (SEQ ID NO:2) from Venom

Venom Sample Preparation.

Venom from the tarantula Chilobrachys jingzhao was extracted via electrical stimulation of an anesthetized spider. Venom samples were collected, lyophilized, and dissolved in 0.1% trifluoroacetic acid (TFA) in water to approximately 1 mg venom/mL. The crude venom solutions were desalted by solid-phase extraction (SPE) with Sep-Pak C18 cartridges (Waters, Milford, Mass., USA) equilibrated in 0.1% TFA, and eluted with 60% aqueous acetonitrile and then evaporated. The dried material was dissolved in 0.1% TFA to 1 mg venom/mL concentration and higher molecular components removed with a 10 kDa molecular weight cut-off Ultrafree-CL (Millipore). The <10 kDa venom extract was then dried under in vacuo and stored at −80° C.

Fractionation.

The crude venom was fractionated by reversed phase (RP) HPLC, collecting 84 samples in time slices. Less than 10 kDa venom extracts were dissolved in 0.1% TFA to approximately 1 mg venom/mL, and then separated by C18 RP HPLC chromatography and collected into approximately 1 minute wide fractions. HPLC method: Buffer A (0.1% TFA in water) and buffer B (90% acetonitrile/10% water containing 0.1% TFA) at 1 mL/min with a 1%/min gradient 0-100% buffer B. The fractions were then transferred into a plate format, dried under in vacuo, and then stored at −80° C.

The venom fractions were screened for activity in the Na_(v)1.7 IonWorks® Quatrro (IWQ) assays. Several fractions with significant (>50% of control) Nav1.7 inhibitory activity were identified. A second aliquot of the fractions was tested in the Na_(v)1.7, Na_(v)1.4, and Na_(v)1.5 IWQ assays to confirm the activity of the “hit” and evaluate selectivity. The most potent and selective fractions were then separated by RP-HPLC, and the corresponding sub-fractions were screened for activity in the Na_(v)1.7, Nav1.4, and Na_(v)1.5 assays. Deconvolution of the most active sub-fraction revealed the primary peptide sequence of JzTx-V (SEQ ID NO:2). As with all proteins, JzTx-V is expected to have essentially zero access to the central nervous system.

JzTx-45 (YCQKWMWTCDSERKCCEGYVCELWCKYNL//SEQ ID NO:48) and JzTx-46 (YCQKWMWTCDSERKCCEGYVCELWCKYNM//SEQ ID NO:430) were identified through transcriptomic analysis of the venom gland of Chilobrachys jingzhao using expressed sequence tag methodologies. (See, Chen J, Deng M, He Q, Meng E, Jiang L, Liao Z, Rong M, Liang S, “Molecular diversity and evolution of cystine knot toxins of the tarantula Chilobrachys jingzhao”, Cellular and Molecular Life Sciences 2008, 65:2431-2444; Siang A S, Doley R, Vonk F J, Kini R M., “Transcriptomic analysis of the venom gland of the red-headed krait (Bungarus flaviceps) using expressed sequence tags”, BMC Molecular Biology 2010, 11:24; Jiang Y, Li Y, Lee W, Xu X, Zhang Y, Zhao R, Zhang Y, Wang W., “Venom gland transcriptomes of two elapid snakes (Bungarus multicinctus and Naja atra) and evolution of toxin genes”, BMC Genomics 2011, 12:1; Wagstaff S C, Sanz L, Juárez P, Harrison R A, Calvete J J., “Combined snake venomics and venom gland transcriptomic analysis of the ocellated carpet viper, Echis ocellatus.”, J Proteomics. 2009 71(6):609-23; Magalhaes G S, Junqueira-de-Azevedo I L, Lopes-Ferreira M, Lorenzini D M, Ho P L, Moura-da-Silva A M. “Transcriptome analysis of expressed sequence tags from the venom glands of the fish Thalassophryne nattereri”, Biochimie 2006 88(6):693-9; Wagstaff S C, Harrison R A., “Venom gland EST analysis of the saw-scaled viper, Echis ocellatus, reveals novel alpha9beta1 integrin-binding motifs in venom metalloproteinases and a new group of putative toxins, renin-like aspartic proteases.” Gene 2006 377:21-32).

Peptide Sequencing: Edman Degradation and De Novo MS/MS.

N-terminal sequencing of peptides were performed by Edman degradation (Reference: (1) Edman, P. (1950), “Method for determination of the amino acid sequence in peptides”, Acta Chem. Scand. 4: 283-293; (2) Niall, H. D. (1973). “Automated Edman degradation: the protein sequenator”. Meth. Enzymol. 27: 942-1010). Phenylthiohydantoin (PTH)— amino acid derivatives were analyzed with an Applied Biosystems automatic 473A sequencer.

De novo peptide sequencing was accomplished by tandem mass spectrometry (References: Vlado Dan{hacek over (c)}ik, Theresa A. Addona, Karl R. Clausen James E. Vath, Pavel A. Pevzner., J. Comp. Biol., Volume 6, 3/4, (1999); (2) Favreau, P., Menin, L., Michalet, S., Perret, F., Cheneval, Stöcklin, M., Bulet, A. and Stöcklin, R., Toxicon, 47(6), 676-687, (2006), (3) Favreau, P., Cheneval, O., Menin, L., Michalet, S., Gaertner, H., Principaud, F., Thai, R., Ménez, A., Bulet, P. and Stöcklin, R. (2007), The venom of the snake genus Atheris contains a new class of peptides with clusters of histidine and glycine residues. Rapid Communications in Mass Spectrometry, 21: 406-412).

Example 2 Synthesis of JzTx-V Peptide Analogs

Small-Scale Peptide Synthesis.

Peptides were assembled using N^(α)-Fmoc solid-phase peptide synthesis methodologies with appropriate orthogonal protection and resin linker strategies. The peptides were synthesized on a 0.012 mmol scale using Rink Amide MBHA resin (100-200 mesh, 1% DVB, RFR-1063-PI, 0.52 meq/g initial loading, 408291, Peptides International, Louisville, Ky.). Dry resin (17 mg per well) was added to a Phenomenex deep well protein precipitation plate (CEO-7565, 38710-1) using a resin loader (Radley) Amino acids were added to the growing peptide chain by stepwise addition using standard solid phase methods on an automated peptide synthesizer (Intavis Multipep). Amino acids (5 molar equivalents, 120 μL, 0.5 M in DMF) were pre-activated (1 min) with (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU®; 5 molar equivalents, 170 μL, 0.35 M in dimethylformamide (DMF)) and N,N-Diisopropylethylamine (DIEA; 7.5 molar equivalents, 70 μL, 1.25 M in dichloromethane (DCM)). Pre-activated amino acids were transferred to the appropriate well. Resins were incubated for 30 min, drained, and the cycle repeated. Following the 2^(nd) amino acid incubation the plates were drained and washed with DMF 8 times (3 mL per column of 8 wells). The Fmoc protecting groups were then removed by 2 sequential incubations in 500 μL of a 20% piperidine in DMF solution. The 1^(st) incubation was 5 min, the resin drained, and the 2^(nd) incubation was for 20 min. The resin was drained and washed with DMF 10 times (3 mL per column of 8 wells). After removal of the final Fmoc protecting group, the resin was washed with DCM 5 times (3 mL per column of 8 wells) and allowed to air dry.

Cleavage.

To the bottom of the filter plate was affixed a drain port sealing mat (ArcticWhite, AWSM-1003DP). To the resin in each well was added triisopropylsilane (100 μL), DODT (100 μL), and water (100 μL) using a multichannel pipette. To the resin in each well was added TFA (1 mL) using a Dispensette Organic dispenser. A second sealing mat was affixed to the top of the plate, and the solution was mixed for 3 h on a shaker. The sealing mats were removed from the top then the bottom, and the cleavage solution was eluted into a solid bottom 96-well deep well plate. The resin in each well was washed with and additional 1 mL of TFA. The solutions were concentrated using rotary evaporation (Genevac). To each well in a new 96-well filter plate with a bottom sealing mat attached was added 1 mL of cold diethyl ether using a Dispensette Organic dispenser. To the ether was added the concentrated peptide solutions using a multichannel pipette with wide bore tips. The solution was agitated with the pipette to ensure complete mixing and precipitation. The white solid was filtered, washed with a second 1 mL of cold ether, filtered, and dried under vacuum.

Folding.

To the crude peptide in each well was added 0.9 mL of 50:50 water/acetonitrile with a multichannel pipette and a micro stir bar. The mixture was stirred for 1 h. The solution was filtered into a solid bottom 96-well deep well plate. To the crude peptide in each well was added another 0.9 mL of 50:50 water/acetonitrile with a multichannel pipette. The solution was filtered into the same solid bottom 96-well deep well plate. In a 4 L bottle was prepared 4.0 L of folding buffer (3.3 L water, 300 mL acetonitrile, 2.0 g oxidized glutathione, 1.0 g reduced glutathione, 400 mL 1 M Tris-HCl pH 7.5). To 96 50-mL centrifuge tubes was added 40 mL of peptide folding buffer using a Dispensette dispenser. To the folding buffer was added the 1.8 mL of dissolved peptide using the Tecan automated liquid handler. The pH of the folding solutions was measured to about 7.7. The folding reactions were allowed to stand overnight. To each tube was added 1 mL of glacial acetic acid. To a 96-well filter plate was added SP Sepharose High Performance as a slurry (1 mL per well) with a multichannel pipette. Using the Tecan automated liquid handler, the gel was conditioned with folding buffer (3×0.9 mL), loaded with the folded peptide solution (50×0.9 mL, pH=4.0, on the Tecan automated liquid handler), washed (4×0.9 mL, 20 mM NaOAc, pH=4.0), and eluted manually on a vacuum manifold with 2×1 mL (1 M NaCl, 20 mM NaOAc, pH=4.0) into a solid bottom 96-well deep well plate.

Conjugation of Peptides to PEG.

Some JzTx-V peptide analogs were conjugated to azido-NPEG10 (e.g., see, FIG. 76, Table 9 and Table 13, below). To 1 mL of the folded peptide in the IEX elution buffer was added in order 32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-amine (70 μL, 50 mM aq.), tris(2-phenyl-1-(1H-1,2,3-triazol-4-yl)ethyl)amine (TBTA; 88 μL, 10 mM in DMSO), L-ascorbic acid sodium salt (438 μL, 75 mM aq.), and copper(ii) sulfate, anhydrous, powder (188 μL, 35 mM aq.). The reaction mixture turned slightly cloudy after the addition of the TBTA. After overnight incubation, the plate was centrifuged for 1 h at 1600 rpm to pellet any precipitate. The supernatant was transferred to a 96-well filter plate with a multichannel pipette and filtered into a solid bottom 96-well plate.

Purification and Characterization of Molecules.

The folded (conjugated) peptide (2 mL) was purified by mass-triggered semi-prep HPLC (Agilent 1100/LEAP, Jupiter 5u C18 300 A, 100×10 mm 5 micron) with a gradient of 15-35% B over 45 min, with a 5 min flush, and 5 min equilibration at 8 mL/min. The collected fractions were pooled and reformatted into vials on the Tecan. Final QC (Phenomenex Jupiter 20×2 mm, 100 Å, 5 micron column eluted with a 10 to 60% B over 10 min gradient at a 0.750 mL/min flow rate monitoring absorbance at 220 nm) and CLND quantification were performed. Peptides with >95% purity and correct (m/z) ratio were screened. (See FIG. 1, FIG. 2, and FIG. 3 for LC-MS characterization of synthetic JzTx-V).

In subsequent synthesis runs, to protocol was modified in order to improve the overall success rate of obtaining folded peptide analogs in sufficient purity for assay submission. Peptides were synthesized in duplicate, triplicate, or quadruplicate on the Intavis synthesizer. The crude linear peptide was combined, dissolved in DMSO, and purified immediately by prep LC/MS (Phenomenex Synergi 4 μm MAX-RP 80A AXIA, 250×30 mm) at 30 mL/min, Agilent/LEAP prep LC-MS, 10-40% B gradient over 60 min, followed by a 10 min flush and a 10 min equilibration). The fractions were analyzed by LC-MS, pooled, and lyophilized to afford pure linear peptide. The pure linear peptide was dissolved in 2 mL of acetonitrile and 2 mL of water and folded as described previously for the crude peptide. After quenching, the folded peptide solution was loaded directly onto a semi-prep HPLC column using a prep loading pump at 8 mL/min. The column was flushed with 10% acetonitrile in water with 0.1% trifluoroacetic acid (TFA) to remove the acetic acid and then attached to the semi-prep LC-MS and purified as described previously.

Large-Scale Peptide Synthesis.

Rink Amide Chem Matrix resin (0.2 mmol, 0.45 mmol/g loading, 0.444 g, Matrix Innovation) was weighed into a CS BIO reaction vessel. The reaction vessel was connected to a channel of the CS BIO 336X automated peptide synthesizer, and the resin was washed 2×DMF and allowed to swell in DMF for 15 min. Fmoc-amino acid (1.0 mmol, Midwest Biotech or Novabiochem) was dissolved in 2.5 mL of 0.4 M 6-chloro-1-hydroxybenzotriazole (6-C1-HOBt, Matrix Innovation) in DMF. To the solution was added 1.0 mL of 1.0 M 1,3-diisopropylcarbodiimide (DIC, Sigma-Aldrich) in DMF. The solution was agitated with nitrogen bubbling for 15 min to accomplish pre-activation and then added to the resin. The mixture was shaken for 2 h. The resin was filtered and washed 3×DMF, 2×DCM, and 3×DMF. Fmoc-removal was accomplished by treatment with 20% piperdine in DMF (5 mL, 2×15 min, Fluka). The resin was filtered and washed 3×DMF. All residues were single coupled through repetition of the Fmoc-amino acid coupling and Fmoc removal steps described above.

Cleavage and Linear Peptide Purification.

After final Fmoc-removal from the N-terminal residue, resin-bound linear peptide (0.2 mmol scale) was transferred to a 25 mL solid phase extraction (SPE) filter tube, washed 3×DMF and 3×DCM, and dried under vacuum. To the resin was added triisopropylsilane (1.0 mL), 3,6-dioxa-1,8-octane-dithiol (DODT, 1.0 mL), water (1.0 mL), trifluoroacetic acid (TFA, 15 mL), and a stir bar, and the mixture was stirred for 3 h. The mixture was filtered into a 50 mL centrifuge tube. The resin was washed with TFA (˜5 mL), and the combined filtrate was concentrated by rotary evaoporation in a Genevac HT-12 (30° C. chamber temperature, pressure ramp from 500 to 50 mbar over 40 min and a final pressure of 8 mbar for 2 h). To the residue (−5 mL) was added 40 mL cold diethyl ether. A white precipitate formed. The solid was stirred in the ether. The mixture was centrifuged (4 min, 4,400 rpm), and the ether was decanted. To the tube was added another 40 mL of cold ether, and the precipitate was stirred. The mixture was centrifuged, and the ether was decanted. The solid was dried overnight under vacuum. The crude linear peptide was purified by preparative LC-MS. The filtered sample (300 mg in 5 mL DMSO) was injected onto a preparative HPLC column (Phenomenex Synergi 4 μm MAX-RP 80A AXIA, 250×30 mm) The peptide was eluted with a 10-40% B over 60 min gradient at 30 mL/min, followed by a 10 min flush and a 10 min equilibration. The fractions were analyzed by LC-MS, pooled, and lyophilized to afford pure the linear peptide precursor.

Folding.

In a 1-L PP bottle was prepared a folding buffer with water (800 mL), acetonitrile (100 mL), cysteine (1 mL of a 1 M stock solution in water), and cystine dihydrochloride (6.667 mL of a 150 mM stock solution in water). To the pure linear peptide (100 mg) was added 5 mL acetonitrile and 5 mL water. The mixture was vortexed to complete dissolution of the peptide. The peptide solution was added to the buffer followed by 1M Tris-HCl pH 8.0 (100 mL), (0.1 mg/mL peptide concentration, 1 mM cysteine, 1 mM cystine, 10% v/v acetonitrile, 0.1 M Tris pH 8.0). The pH value was measured to be 8.0. The folding mixture was allowed to stand at 4° C. for 18 to 72 h. A small aliquot was removed and the sample was analyzed by LC-MS to ensure that the folding was complete. The solution was quenched by the addition of 4 mL AcOH and 4 mL TFA (pH=2.5). The aqueous solution was filtered (0.45 nM cellulose membrane).

Purification.

The filtered solution (1000 mL, 100 mg peptide) was loaded onto a preparative HPLC column (Phenomenex Synergi 4 nm MAX-RP 80A AXIA, 250×30 mm) at 30 mL/min using an Agilent preparative loading pump. The column was was flushed for 10 min with 10% B at 30 mL/min to elute the AcOH/TFA. The column was attached to a prep HPLC, Agilent/LEAP prep LC-MS, and the peptide was eluted with a 10-40% B gradient over 60 min, followed by a 10 min flush and a 10 min equilibration. The fractions were analyzed by LC-MS, pooled, and lyophilized to afford pure folded peptide.

Counterion Exchange for Peptide In Vivo Studies.

A 4 mL SPE tube containing VariPure IPE (Varian, PL-HCO3 MP-Resin, polymer-supported hydrogencarbonate, 1.8 mmol/g, 100A, 150-300 nm) was pre-conditioned with 2 mL of MeOH, followed by 2 mL of water, draining by gravity. 2.0 mL of a ≦5.0 mM solution of purified folded peptide in water was applied to the bed. The device was washed with 4×2.0 mL of water to elute all of the peptide. To the eluent was added 50 μL of acetic acid. The solution was concentrated by rotary evaporation (Genevac) to afford the acetate salt of the purified folded peptide. A 100 mM stock solution of trifluoroethanol (TFE) in deuterium oxide (D20) was prepared fresh by weighing 50 mg of TFE into a 5 mL volumetric flask, followed by addition of D20 to a final volume of 5 mL. A 5 mM solution of TFE in D20 was then prepared by dilution for dissolving all samples for 19F-NMR. The solution was used to dissolve peptide to a concentration of 1 mM, and the sample was analyzed by 19F-NMR using a fluorine long delay (d1=5 sec) method. The TFE integral (triplet at −76.75 ppm) was normalized to 5 and the integral of TFA (singlet at −75.6) recorded. NMR tube was cut, and sample was recovered by rotary evaporation (Genevac).

Example 3 Electrophysiology

Cell Lines Expressing Nav Channels.

Stable cell lines constitutively expressing human (h) voltage-gated sodium (Nav) channels (CHO-hNav1.3, HEK293-hNav1.4, HEK293-hNav1.5, and HEK293-hNav1.7) or CHO cells expressing hNav1.8 under an inducible promoter were used for experiments.

Ion-Works® Quatro Population Patch Clamp Electrophysiology.

Adherent cells were isolated from tissue culture flasks using 0.25% trypsin-EDTA treatment for 10 minutes and were resuspended in external solution consisting of 140 mM NaCl, 5.0 mM KCl, 10 mM HEPES, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM Glucose, pH 7.4. Internal solution consisted of 70 mM KCl, 70 mM KF, 10 HEPES, 5 mM EDTA, pH 7.3. Cells were voltage clamped, using the perforated patch clamp configuration at room temperature (−22° C.), to −110 mV and depolarized to −10 mV before and 5 min after test compound addition. Compound dilutions contained 0.1% bovine serum albumin to minimize non-specific binding. Peak inward currents were measured from different cells for each compound concentration and IC₅₀ values were calculated with Excel software. All compounds were tested in duplicate (n=2).

PatchXpress® 7000A Electrophysiology.

Adherent cells were isolated from tissue culture flasks using 1:10 diluted 0.25% trypsin-EDTA treatment for 2-3 minutes and then were incubated in complete culture medium containing 10% fetal bovine serum for at least 15 minutes prior to resuspension in external solution consisting of 70 mM NaCl, 140 mM D-Mannitol, 10 mM HEPES, 2 mM CaCl₂, 1 mM MgCl₂, pH 7.4 with NaOH. Internal solution consisted of 62.5 mM CsCl, 75 mM CsF, 10 HEPES, 5 mM EGTA, 2.5 mM MgCl₂, pH 7.25 with CsOH. Cells were voltage clamped using the whole cell patch clamp configuration at room temperature (−22° C.) at a holding potential of −125 mV with test potentials to −10 mV (hNav1.3, hNav1.4, and hNav1.7) or −20 mV (hNav1.5). To record from partially inactivated channels, cells were switched to a voltage that yielded ˜20% channel inactivation. Test compounds were added and Nav currents were monitored at 0.1 Hz at the appropriate test potential. All compound dilutions contained 0.1% bovine serum albumin to minimize non-specific binding. Cells were used for additional compound testing if currents recovered to >80% of starting values following compound washout. IC₅₀ values were calculated by pooling single point determinations at different compound concentrations and fitting the resulting dataset with a Hill (4-parameter logistic) fit in DataXpress 2.0 software.

Whole Cell Patch Clamp Electrophysiology.

Cells were voltage clamped using the whole cell patch clamp configuration at room temperature (−22° C.). Pipette resistances were between 1.5 and 2.0 Ma Whole cell capacitance and series resistance were uncompensated. Currents were digitized at 50 kHz and filtered (4-pole Bessel) at 10 kHz using pClamp10.2. Cells were lifted off the culture dish and positioned directly in front of a micropipette connected to a solution exchange manifold for compound perfusion. To record from non-inactivated channels, cells were held at −140 mV or −120 mV and depolarized to −10 mV or 0 mV. To record from partially inactivated channels, cells were held at −140 mV or −120 mV initially and then switched to a voltage that yielded ˜20% channel inactivation. 10 ms pulses were delivered every 10 seconds and peak inward currents were recorded before and after compound addition. Compound dilutions contained 0.1% bovine serum albumin to minimize non-specific binding. For hNav1.8 channel recordings, tetrodotoxin (TTX, 0.5 uM) was added to inhibit endogenous TTX-sensitive voltage-gated sodium channels and record only Nav1.8-mediated TTX-resistant currents. External solution consisted of: 140 mM NaCl, 5.0 mM KCl, 2.0 mM CaCl₂, 1.0 mM MgCl₂, 10 mM HEPES, and 11 mM Glucose, pH 7.4 by NaOH. Internal solution consisted of: 62.5 mM CsCl, 75 mM CsF, 2.5 mM MgCl₂, 5 mM EGTA, and 10 mM HEPES, pH 7.25 by CsOH. Escalating compound concentrations were analyzed on the same cell and IC₅₀ values were calculated with Clampfit 10.2 software and by fitting the resulting dataset with a Hill (4-parameter logistic) fit in Origin Pro 8 software.

DRG Neuron Isolation.

Adult male and female C57BL/6 mice (Harlan Laboratories, Indianapolis, Ind.) were euthanized with sodium pentobarbital (Nembutal, 80 mg/kg, i.p., Western Med Supply, Arcadia, Calif.) followed by decapitation. DRG from cervical, thoracic and lumbar regions were removed, placed in Ca²⁺ and Mg²⁺-free Hanks' Balanced Salt Solution (Invitrogen, Carlsbad, Calif.), and trimmed of attached fibers under a dissecting microscope. DRG were sequentially digested at 37° C. with papain (20 U/ml, Worthington Biochemical Corporation, Lakewood, N.J.) and L-cysteine (25 μM) in Ca²⁺ and Mg²⁺-free Hanks' (pH 7.4) for 20-30 min and then with collagenase type 2 (0.9% w/v, Worthington Biochemical Corporation) for 20-30 min. Digestions were quenched with a 1:1 mixture of DMEM and Ham's F-12 Nutrient Mixture (Invitrogen) supplemented with 10% calf serum (Invitrogen), and cells were triturated with a fire-polished Pasteur pipette prior to plating on Poly-D-Lysine-coated glass coverslips (Cole-Parmer, Vernon Hills, Ill.). Cells were used for recordings following 1-2 hours of recovery (acute isolation) or maintained in a humidified incubator at 28° C. with 5% CO₂ for up to 10 days in the presence of 1% NSF-1 (Lonza, Basel, Switzerland) to increase the expression of tetrodotoxin-sensitive sodium channel currents.

Manual Patch-Clamp Electrophysiology for DRG Neurons.

DRG neurons were voltage clamped using the whole-cell patch clamp configuration at room temperature (21-24° C.) using an Axopatch 200 B or MultiClamp 700 B amplifier and DIGIDATA 1322A with pCLAMP software (Molecular Devices, Sunnyvale, Calif.). Pipettes, pulled from borosilicate glass capillaries (World Precision Instruments, Sarasota, Fla.), had resistances between 1.0 and 3.0 MΩ. Voltage errors were minimized using >80% series resistance compensation. A P/4 protocol was used for leak subtraction. Currents were digitized at 50 kHz and filtered (4-pole Bessel) at 10 kHz. Cells were lifted off the culture dish and positioned directly in front of a micropipette connected to a solution exchange manifold for compound perfusion. Cells were held at −120 mV or a voltage yielding approximately 20% inactivation and depolarized to −10 or 0 mV for 40 msec every 10 seconds. Tetrodotoxin (TTX, Sigma) was used following peptide addition to block any residual TTX-sensitive sodium currents. Pipette solution contained (in mM): 62.5 CsCl, 75 CsF, 2.5 MgCl₂, 5 EGTA, and 10 HEPES, pH 7.25 by CsOH. Bath solution contained (in mM): 70 NaCl, 5.0 KCl, 2.0 CaCl₂, 1.0 MgCl₂, 10 HEPES, and 11 glucose, 140 mannitol, pH 7.4 by NaOH. Data were analyzed with Clampfit and Origin Pro8 (OriginLab Corp, Northampton, Mass.).

Results of Electrophysiology Studies and Structure-Activity Relationship.

Results of electrophysiology studies are shown in Table 6, Table 7, Table 8, Table 9, Table 10 (IWQ), Table 11, Table 12, Table 13 (PX), and Table 14 (WCPC), below. Extensive systematic analoging using high-throughput peptide synthesis, parallel oxidative folding, and mass-triggered semi-prep HPLC purification for peptide analog preparation has given considerable insight into how individual positions within JzTx-V(1-29) (SEQ ID NO:2) contribute to its overall VGSC activity profile. Concerning the overall molecular framework, the disulfide bonds (or diselenide bonds) between Cys2 (or SeCys2) and Cys16 (or SeCys16) (C1-C4), between Cys9 (or SeCys9) and Cys21 (or SeCys21) (C2-C5) and between Cys15 (or SeCys15) and Cys25 (or SeCys25) (C3-C6) are essential for full function.

The N-terminal portion of JzTx-V(1-29) (SEQ ID NO:2), including the Tyr1, Gln3, and Lys4, is amenable to modification without affecting either VGSC potency or selectivity in comparison with wild type JzTx-V. (See, Table 6). Extension of the polypeptide chain by coupling an additional amino acid or acidss to the N-terminus is well-tolerated and even improves the potency of the peptide against hNav1.7. (See Table 10). A set of N-terminally extended [Nle6]JzTx-V peptide analogs was prepared and tested in the hNav1.7, hNav1.4, and hNav1.5 PX assays. (See Table 11). Several peptides containing a hydrophobic residue at the N-terminus had improved potency against hNav1.7. They also had improved selectivities against hNav1.4 and hNav1.5 due to their increased hNav1.7 activity. Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) is nearly 200-fold more potent than the wild type JzTx-V(1-29) (SEQ ID NO:2) against hNav1.7 in the WCPC format with IC₅₀ values of 0.845 pM and 162 pM, respectively. (See Table 14). Tyr1 of JzTx-V can be substituted with a variety of amino acids with no impact on potency at Na_(v)1.7 or selectivity against Na_(v)1.4 and Na_(v)1.5. (See Table 6). [Glu1]JzTx-V(1-29) (SEQ ID NO:49) may have slightly increased potency against hNav1.7 with an accompanying small increase in selectivity against hNav1.4 and hNav1.5 in the PX assay format. (See Table 11). Gln3 and Lys4 in JzTx-V may be individually replaced with a basic amino acid such as arginine and still retain potency against Na_(v)1.7. (See Table 6).

Hydrophobic residues at positions 5, 6, and 7 (Trp5, Meth, and Trp7 in JzTx-V), in relation to SEQ ID NO:2, are essential to Na_(v)1.7 inhibitory potency. Only [1-Nal7]JzTx-V (SEQ ID NO:30) retained hNav1.7 activity similar to the wild type peptide. (See Table 6 and Table 11). A variety of hydrophobic residues including norleucine, leucine and phenylalanine can be incorporated at position 6 to maintain good potency against Nav1.7 and selectivity against Nav1.4 in the PX assay format without the potential liability of oxidation by the native methionine residue. (See Table 10, Table 11, and Table 12).

While each position has recognizable preferences, the sequence of amino acids from Thr8 to Lys22 is quite tolerant of individual substitutions, with possible exceptions for the cysteines (SeCys substitutions permitted), Asp10, and Leu19 relative to SEQ ID NO:2. (See Table 6). Peptides synthesized without an aspartic acid residue at position 10 or a leucine residue at position 19 of JzTx-V have not been isolated in sufficiently pure form for screening, indicating this residue may be critical for proper folding of the peptide. Basic or neutral hydrophilic amino acids are acceptable as substitutions for Thr8 and Ser11, relative to SEQ ID NO:2, to maintain Na_(v)1.7 inhibitory potency. (See Table 6). However, substitution of glutamic acid for Ser11 decreases potency against hNav1.7. (See Table 6). Arg13 appears to be the most sensitive in this portion of the seqeunce as substitution with either alanine or lysine caused a significant loss in potency. Lys12, Ala14, and Glu17, relative to SEQ ID NO:2, can be substituted with a variety of amino acids including attachment of a large PEG moiety with little effect on potency against Na_(v)1.7. (See Table 6, Table 9, Table 12, and Table 13). Gly18 is somewhat sensitive to substitution as even incorporation of alanine at this position resulted in a slight loss of Nav1.7 potency. (See Table 6). Substitution of an acidic residue for arginine at position 20 relative to SEQ ID NO:2 greatly improves selectivity against hNav1.4 to greater than 1000-fold relative to hNav1.7, i.e., [Glu20]JzTx-V (SEQ ID NO:63) has an IC50 value of 1.25 nM against hNav1.4 in the PX assay format compared to an average IC50 value of 2 nM for JzTx-V(1-29) (SEQ ID NO:2). (See Table 6 and Table 11). Lys22 relative to SEQ ID NO:1, may be substituted with a basic amino acid and retain full Nav1.7inhibitory potency. (See Table 6).

The C-terminal portion of the JzTx-V sequence is critical for the activity of the peptide against Na_(v)1.7. A leucine at position 23 and a trytophan at position 24 of JzTx-V (SEQ ID NO:2) appear to be very important to obtaining high levels of potency against Na_(v)1.7. (See Table 6). Even an analog with a large hydrophobic substitution, [1-Nal24]JzTx-V(1-29) (SEQ ID NO:43), loses considerable activity against hNav1.7. (See Table 6 and Table 11). Peptides synthesized without an arginine residue at position 26 of JzTx-V have not been isolated in sufficiently pure form for screening, indicating this residue may be critical for proper folding of the peptide. Lys27, relative to SEQ ID NO:2, is may be substituted with a basic residue and retain Nav1.7 inhibitory potency. (See Table 6). The isoleucine at position 28 of JzTx-V (SEQ ID NO:2) can be substituted with a variety of amino acid residues with retention of potency against Na_(v)1.7, but the substitution of glutamic acid at this position increases selectivity by reducing activity against Na_(v)1.4. (See Table 6 and Table 11). The isoleucine at position 29 of JzTx-V(1-29) (SEQ ID NO:2) can only be substituted with other hydrophobic amino acids without losing potency against Na_(v)1.7, with large hydrophobic amino acids tending to slightly increase potency. (See Table 6). The combination analog [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) retains the excellent Nav1.4 selectivity (>1000-fold) characteristic of the substitution of glutamic acid at position 20 but has hNav1.7 potency similar to wild type JzTx-V with an average hNav1.7 IC50 value of 1.5 nM in the PX format. (See Table 7 and Table 11). Additional analogs of JzTx-V(1-29) (SEQ ID NO:2) that combine individual substitutions have demonstrated further improvements in selectivity against Na_(v)1.4 and Na_(v)1.5 and potency toward Nav1.7, i.e., [Glu20,Tyr28]JzTx-V(1-29) (SEQ ID NO:137) and [Glu20,Ser28]JzTx-V(1-29) (SEQ ID NO:138). (See Table 7, Table 8, and Table 11).

Manual whole cell patch clamp electrophysiology was performed on JzTx-V(1-29) (SEQ ID NO:2) on human clones of Nav1.8, Nav1.7, Nav1.5, Nav1.4, and Nav1.3. (See Table 14.) Testing with 1.0 μM JzTx-V with 0.5 μM TTX showed only partial inhibition of the hNav1.8 current. (See, FIG. 4). The effects of JzTx-V addition in increasing concentrations and wash out on hNav1.8 current were recorded. (See, FIG. 5). The average IC₅₀ value of hNav1.8 inhibition for JzTx-V was 530 nM. (See, FIG. 6). Testing with 1 nM JzTx-V showed complete inhibition of the hNav1.7 current. (See, FIG. 7). The effects of JzTx-V addition in increasing concentrations and wash out on hNav1.7 current were recorded. (See FIG. 8). The average IC₅₀ value of hNav1.7 inhibition for JzTx-V was 0.1615 nM. (See FIG. 9). Testing with 3.0 μM JzTx-V showed nearly complete inhibition of the hNav1.5 current. (See FIG. 10). The effects of JzTx-V addition in increasing concentrations and wash out on hNav1.5 current were recorded. (See FIG. 11). The average IC₅₀ value of hNav1.5 inhibition for JzTx-V was 426.5 nM. (See FIG. 12). Testing with 100 nM JzTx-V showed complete inhibition of the hNav1.4 current. (See FIG. 13). The effects of JzTx-V addition in increasing concentrations and wash out on hNav1.4 current were recorded. (See FIG. 14). The average IC₅₀ value of hNav1.4 inhibition for JzTx-V was 9.35 nM for the partially inactivated state. (See FIG. 15). Testing with 300 nM JzTx-V showed complete inhibition of the hNav1.3 current. (See FIG. 16). The effects of JzTx-V addition in increasing concentrations and wash out on hNav1.3 current were recorded. (See FIG. 17). The average IC₅₀ value of hNav1.3 inhibition for JzTx-V was 12.25 nM. (See FIG. 18). These results demonstrate that JzTx-V (SEQ ID NO:2) is a potent peptide inhibitor of hNav1.7 with 50-fold selectivity against hNav1.3 and hNav1.4 and 2000-fold selectivity against hNav1.5 and hNav1.8. Manual whole cell patch clamp electrophysiology was also performed on [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) and Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) on the human clone of Nav1.7. Testing with 100 nM [Glu20,Trp29]JzTx-V(1-29) showed only partial inhibition of the hNav1.7 current. (See FIG. 19). The effects of [Glu20,Trp29]JzTx-V(1-29) addition in increasing concentrations and wash out on hNav1.7 current were recorded. (See FIG. 20). The average IC₅₀ value of hNav1.7 inhibition for [Glu20,Trp29]JzTx-V(1-29) was 0.23 nM. (See FIG. 21). These results demonstrate that [Glu20,Trp29]JzTx-V(1-29) is also a potent inhibitor of hNav1.7. Testing with 100 pM Pra-[Nle6]JzTx-V(1-29) showed complete inhibition of the hNav1.7 current (fully non-inactivated state). (See FIG. 22). The effects of Pra-[Nle6]JzTx-V(1-29) addition in increasing concentrations and wash out on hNav1.7 current (fully non-inactivated state) were recorded. (See FIG. 23). The average IC₅₀ value of hNav1.7 inhibition (fully non-inactivated state) for Pra-[Nle6]JzTx-V(1-29) was 0.4085 pM. (See FIG. 24). Testing with 100 pM Pra-[Nle6]JzTx-V(1-29) showed complete inhibition of the hNav1.7 current (partially inactivated state). (See FIG. 25). The effects of Pra-[Nle6]JzTx-V(1-29) addition in increasing concentrations and wash out on hNav1.7 current (partially inactivated state) were recorded. (See FIG. 26). The average IC₅₀ value of hNav1.7 inhibition (partially inactivated state) for Pra-[Nle6]JzTx-V(1-29) was 0.8445 pM. (See FIG. 27). These results demonstrate that Pra-[Nle6]JzTx-V(1-29) is an extremely potent inhibitor of hNav1.7 in the WCPC format with a 190-fold improvement in potency over the wild type JzTx-V.

Manual patch clamp electrophysiology was performed on JzTx-V(1-29) (SEQ ID NO:2), [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112), Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425), CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V (SEQ ID NO:392), and CyA-[Nle6,Pra17,Glu28]JzTx-V (SEQ ID NO:395) on isolated mouse DRG neurons. (See Table 14.) Testing with 1 μM JzTx-V showed almost complete inhibition of the TTX-sensitive sodium current in mouse DRG neurons. (See, FIG. 28). The effects of JzTx-V addition in increasing concentrations and wash out on TTX-sensitive sodium channel current in mouse DRG neurons were recorded. (See FIG. 29). The IC₅₀ value of TTX-sensitive sodium channel current inhibition for JzTx-V was 18 nM. (See FIG. 30). Testing of 1 μM JzTx-V with 0.5 μM TTX showed only partial inhibition of the TTX-resistant sodium current in mouse DRG neurons. (See, FIG. 31). The effects of JzTx-V addition in increasing concentrations and wash out on TTX-resistant sodium channel current in mouse DRG neurons were recorded. (See FIG. 32). The IC₅₀ value of TTX-resistant sodium channel current inhibition for JzTx-V was not measurable. Testing with 300 nM [Glu20,Trp29]JzTx-V(1-29) showed only partial inhibition of the TTX-sensitive sodium current in cultured (10 days) mouse DRG neurons. (See, FIG. 33). The effects of [Glu20,Trp29]JzTx-V(1-29) addition in increasing concentrations and wash out on TTX-sensitive sodium channel current in cultured mouse DRG neurons (10 days) were recorded. (See FIG. 34). The IC₅₀ value of TTX-sensitive sodium channel current inhibition in cultured DRG neurons (10 days) for [Glu20,Trp29]JzTx-V(1-29) was 279 nM. (See FIG. 35). Testing with 1 μM [Glu20,Trp29]JzTx-V(1-29) showed only partial inhibition of the TTX-sensitive sodium current in acutely isolated mouse DRG neurons. (See, FIG. 36). The effects of [Glu20,Trp29]JzTx-V(1-29) addition in increasing concentrations and wash out on TTX-sensitive sodium channel current in acutely isolated mouse DRG neurons were recorded. (See FIG. 37). The IC₅₀ value of TTX-sensitive sodium channel current inhibition in acutely isolated DRG neurons for [Glu20,Trp29]JzTx-V(1-29) was 211 nM. (See FIG. 38). Testing with 1 nM Pra-[Nle6]JzTx-V(1-29) showed almost complete inhibition of the TTX-sensitive sodium current in mouse DRG neurons. (See, FIG. 39). The effects of Pra-[Nle6]JzTx-V(1-29) addition in increasing concentrations and wash out on TTX-sensitive sodium channel current in mouse DRG neurons were recorded. (See FIG. 40). The IC₅₀ value of TTX-sensitive sodium channel current inhibition with a holding voltage yielding 20% inactivation for Pra-[Nle6]JzTx-V(1-29) was 5.35 nM. (See FIG. 41). Testing with 300 nM CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) showed almost complete inhibition of the TTX-sensitive sodium current in mouse DRG neurons. (See, FIG. 42). The effects of CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) addition in increasing concentrations and wash out on TTX-sensitive sodium channel current in mouse DRG neurons were recorded. (See FIG. 43). The IC₅₀ value of TTX-sensitive sodium channel current inhibition with a holding voltage yielding 20% inactivation for CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) was 46.6 nM. (See FIG. 44). Testing with 300 nM CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) showed complete inhibition of the TTX-sensitive sodium current in mouse DRG neurons. (See, FIG. 45). The effects of CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) addition in increasing concentrations and wash out on TTX-sensitive sodium channel current in mouse DRG neurons were recorded. (See FIG. 46). The IC₅₀ value of TTX-sensitive sodium channel current inhibition with a holding voltage yielding 20% inactivation for CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) was 15.9 nM. (See FIG. 47). These results show that JzTx-V(1-29) is a potent inhibitor of TTX-sensitive but not TTX-resistant sodium channel current in mouse DRG neurons. [Glu20,Trp29]JzTx-V(1-29) is a much less potent inhibitor of TTX-sensitive sodium channel current in mouse DRG neurons than the wild type peptide with a nearly 1000-fold loss in potency relative to the human clone of Nav1.7. Pra-[Nle6]JzTx-V(1-29) is about 3-fold more potent than JzTx-V in the inhibition of TTX-sensitive sodium channel current in mouse DRG neurons. CyA-[Nle6,Pra17,Glu28]JzTx-V(1-29) is equipotent with the wild type peptide in the inhibition of TTX-sensitive sodium channel current in mouse DRG neurons. CyA-[Nle6,Lys(Pra)14,Glu28]JzTx-V(1-29) is about 3-fold less potent than JzTx-V in the inhibition of TTX-sensitive sodium channel current in mouse DRG neurons.

TABLE 6 Electrophysiology by IonWorks ® Quattro: comparison of JzTx-V (SEQ ID NO: 2) and single substitution JzTx-V peptide analogs.

TABLE 7 Electrophysiology by IonWorks ® Quattro position 20 substitutions and combinations relative to SEQ ID NO: 2. SEQ IC50 (μM) Nav1.4/ ID NO. Designation Sequence Nav1.7 Nav1.5 Nav1.4 Nav1.3 Nav1.7 2 JzTx-V(1-29) YCQKWMWTCDSKRACCEGLRCKLWCRKII 0.02 7.2 0.2 0.31 13 125 [Ser20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLSCKLWCRKII 0.03 9.2 0.4 0.29 17 122 [Cit20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGL[Cit]CKLWCRKII 0.04 6.8 0.5 0.35 15 117 [Abu20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGL[Abu]CKLWCRKII 0.05 10.6 0.9 0.97 19 121 [Gly20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLGCKLWCRKII 0.06 9.8 1.9 0.98 29 119 [Leu20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLLCKLWCRKII 0.07 8.3 1.0 2.51 14 118 [Ile20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLICKLWCRKII 0.09 8.6 1.3 2.20 15 124 [Tyr20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLYCKLWCRKII 0.09 10.8 4.0 >5.00 43 115 [Asp20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLDCKLWCRKII 0.09 11.1 >5.0 >5.00 53 120 [Val20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLVCKLWCRKII 0.10 7.1 3.0 3.37 31 123 [Nva20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGL[Nva]CKLWCRKII 0.17 10.4 3.1 >5.00 19 114 [Cpa20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGL[Cpa]CKLWCRKII 0.21 14.2 >5.0 >5.00 24 63 [Glu20]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKII 0.36 9.8 >5.0 >5.00 14 112 [Glu20;Trp29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKIW 0.03 6.9 >5.0 3.62 178 136 [Glu20;Nva28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK[Nva]I 0.08 8.9 >5.0 >5.00 66 133 [Glu20;Val28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKVI 0.08 12.0 4.0 4.85 51 138 [Glu20;Ser28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKSI 0.08 13.9 >5.0 >5.00 62 137 [Glu20;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYI 0.09 8.0 >3.5 2.01 41 135 [Glu20;Cit28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK[Cit]I 0.11 12.0 >5.0 >5.00 46 136 [Glu20;Nva28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK[Nva]I 0.15 15.8 >5.0 >5.00 34 138 [Glu20;Ser28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKSI 0.15 9.2 >5.0 >5.00 34 113 [Glu20]JzTx-V(1-29)-Trp YCQKWMWTCDSKRACCEGLECKLWCRKIIW 0.17 11.1 >5.0 >5.00 30 130 [Glu20;Abu28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK[Abu]I 0.17 8.2 >5.0 >5.00 29 130 [Glu20;Abu28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK[Abu]I 0.21 11.1 >5.0 >5.00 24 134 [Glu20;Gly28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKGI 0.30 10.9 >5.0 >5.00 17 134 [Glu20;Gly28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKGI 0.37 11.1 >5.0 >5.00 13 132 [Glu20;Leu28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKLI 0.41 6.7 >5.0 >5.00 12 111 [Nva6;Glu20]JzTx-V(1-29) YCQKW[Nva]WTCDSKRACCEGLECKLWCRKII 0.69 9.2 >5.0 >5.00 7 126 [Glu20,28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKEI 0.95 15.8 >5.0 >5.00 5 128 [Glu20;Asp28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKDI 1.34 13.9 >5.0 >5.00 4 126 [Glu20,28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKEI 1.44 7.5 >5.0 >5.00 3 127 [Glu20;Cpa28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK[Cpa]I 2.35 16.7 >5.0 >5.00 2

TABLE 8 Electrophysiology by IonWorks ® Quattro Position 20 substitutions relative to SEQ ID NO: 2. SEQ ID IC50 (μM) Nav1.4/ NO. Designation Sequence Nav1.7 Nav1.5 Nav1.4 Nav1.3 Nav1.7 2 JzTx-V(1-29) YCQKWMWTCDSKRACCEGLRCKLWCRKII 0.04 >7 0.20 0.12 5 192 [pl-Phe5;Glu20;Tyr28]JzTx-V(1-29) YCQK[pl-Phe]MWTCDSKRACCEGLECK 0.11 >5 3.4 1.3 30 LWCRKYI 193 [Phe5;Glu20;Tyr28]JzTx-V(1-29) YCQKFMWTCDSKRACCEGLECKLWCRKYI 0.16 >5 >5 >5 193 [Phe5;Glu20;Tyr28]JzTx-V(1-29) YCQKFMWTCDSKRACCEGLECKLWCRKYI 0.23 >5 >5 >5 194 [Tyr5,28;Glu20]JzTx-V(1-29) YCQKYMWTCDSKRACCEGLECKLWCRKYI 0.91 >5 >5 >5 194 [Tyr5,28;Glu20]JzTx-V(1-29) YCQKYMWTCDSKRACCEGLECKLWCRKYI 2.5 >5 >5 >5 195 [Val5;Glu20;Tyr28]JzTx-V(1-29) YCQKVMWTCDSKRACCEGLECKLWCRKYI 3.8 >5 >5 >5 196 [Leu5;Glu20;Tyr28]JzTx-V(1-29) YCQKLMWTCDSKRACCEGLECKLWCRKYI >5 >5 >5 >5 198 [Nva5;Glu20;Tyr28]JzTx-V(1-29) YCQK[Nva]MWTCDSKRACCEGLECKLWC 3.3 >5 >5 >5 RKYI 199 [Cit5;Glu20;Tyr28]JzTx-V(1-29) YCQK[Cit]MWTCDSKRACCEGLECKLWC >5 >5 >5 >5 RKYI 200 [Lys5;Glu20;Tyr28]JzTx-V(1-29) YCQKKMWTCDSKRACCEGLECKLWCRKYI >5 >5 >5 >5 201 [Asn5;Glu20;Tyr28]JzTx-V(1-29) YCQKNMWTCDSKRACCEGLECKLWCRKYI 4.2 >5 >5 >5 201 [Asn5;Glu20;Tyr28]JzTx-V(1-29) YCQKNMWTCDSKRACCEGLECKLWCRKYI >5 >5 >5 >5 203 [Glu5,20;Tyr28]JzTx-V(1-29) YCQKEMWTCDSKRACCEGLECKLWCRKYI >7 >7 >7 >7 212 [Nva7;Glu20;Tyr28]JzTx-V(1-29) YCQKWM[Nva]TCDSKRACCEGLECKLWC 4.5 >7 >7 >7 RKYI 213 [Cit7;Glu20;Tyr28]JzTx-V(1-29) YCQKWM[Cit]TCDSKRACCEGLECKLWC 5.8 >7 >7 >7 RKYI 214 [Lys7;Glu20;Tyr28]JzTx-V(1-29) YCQKWMKTCDSKRACCEGLECKLWCRKYI 2.7 >7 >7 >7 215 [Asn7;Glu20;Tyr28]JzTx-V(1-29) YCQKWMNTCDSKRACCEGLECKLWCRKYI 5.0 >7 6.1 >7 1 216 [Ser7;Glu20;Tyr28]JzTx-V(1-29) YCQKWMSTCDSKRACCEGLECKLWCRKYI 4.7 >7 >7 >7 216 [Ser7;Glu20;Tyr28]JzTx-V(1-29) YCQKWMSTCDSKRACCEGLECKLWCRKYI 6.6 5.4 >7 >7 217 [Glu7,20;Tyr28]JzTx-V(1-29) YCQKWMETCDSKRACCEGLECKLWCRKYI >7 >7 >7 >7 217 [Glu7,20;Tyr28]JzTx-V(1-29) YCQKWMETCDSKRACCEGLECKLWCRKYI >7 >7 >7 >7 218 [Glu20;1-Nal24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKL 0.30 >7 >7 >7 [1-Nal]CRKYI 219 [Glu20;2-Nal24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKL 0.86 >7 >7 >7 [2-Nal]CRKYI 219 [Glu20;2-Nal24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKL 1.0 >7 >7 >7 [2-Nal]CRKYI 223 [Glu20;Val24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLVCRKYI >5 >5 >5 >5 224 [Glu20;Leu24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLLCRKYI >5 >5 >5 >5 225 [Glu20;Nle24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKL[Nle]C >5 >5 >5 >5 RKYI 226 [Glu20;Nva24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKL[Nva]C >5 >5 >5 >5 RKYI 228 [Glu20;Lys24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLKCRKYI 2.7 >5 >5 >5 229 [Glu20;Asn24;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLNCRKYI >5 >5 >5 >5 232 [Glu20;Tyr28;1-Nal29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY 0.050 4.6 4.6 2.1 91 [1-Nal] 233 [Glu20;Tyr28;2-Nal29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY 0.044 >5 >5 2.2 [2-Nal] 238 [Glu20;Tyr28;Leu29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYL 0.084 >5 4.5 3.0 238 [Glu20;Tyr28;Leu29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYL 0.23 >5 >5 >5 239 [Glu20;Tyr28;Nle29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY 0.079 >5 >5 4.0 [Nle] 241 [Glu20;Tyr28;Cit29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKY 1.2 >5 >5 >5 [Cit] 242 [Glu20;Tyr28;Lys29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYK 0.45 >5 >5 >5 242 [Glu20;Tyr28;Lys29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYK 0.63 >5 >5 >5 243 [Glu20;Tyr28;Asn29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYN 0.52 >5 >5 >5 244 [Glu20;Tyr28;Ser29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYS 0.34 >5 >5 >5 245 [Glu20,29;Tyr28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKYE 4.7 >5 >5 >5 272 [Nle6]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCKLWC >5 >5 >5 >5 RKII 273 [Nle6;Glu20]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACCEGLECKLWC 0.19 >5 >5 4.1 RKII 277 [Glu1,20;Tyr28]JzTx-V(1-29) ECQKWMWTCDSKRACCEGLECKLWCRKYI 0.21 2.0 >5 >5 278 [Glu1;Tyr28]JzTx-V(1-29) ECQKWMWTCDSKRACCEGLRCKLWCRKYI 0.046 >5 0.7 0.3 16 281 [Glu1;1-Nal7]JzTx-V(1-29) ECQKWM[1-Nal]TCDSKRACCEGLRCKL 0.032 >5 0.7 0.4 21 WCRKII 281 [Glu1;1-Nal7]JzTx-V(1-29) ECQKWM[1-Nal]TCDSKRACCEGLRCKL 0.047 >5 0.5 0.5 10 WCRKII

TABLE 9 Electrophysiology by IonWorks ® Quattro: PEGylated JzTx-V peptide analogs. SEQ ID IC50 (μM) Nav1.4/ NO. Designation Sequence Nav1.7 Nav1.5 Nav1.4 Nav1.3 Nav1.7 165 [Atz(NPEG10)1;Glu20]JzTx-V(1-29) [Atz(NPEG10)]CQKWMWTCDSKRACCEGL 0.18 15.1 >5 >5 28 ECKLWCRKII 171 [Atz(NPEG10)8;Glu20]JzTx-V(1-29) YCQKWMW[Atz(NPEG10)]CDSKRACCEGL 5.00 18.7 >5 >5 1 ECKLWCRKII 178 [Atz(NPEG10)17;Glu20]JzTx-V(1-29) YCQKWMWTCDSKRACC[Atz(NPEG10)]GL 0.18 15.1 >5 >5 28 ECKLWCRKII 183 [Glu20;Atz(NPEG10)23]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECK 5.00 19.2 >5 >5 1 [Atz(NPEG10)]WCRKII 187 [Glu20;Atz(NPEG10)28]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRK 1.77 15.4 >5 >5 3 [Atz(NPEG10)]I 188 [Glu20;Atz(NPEG10)29]JzTx-V(1-29) YCQKWMWTCDSKRACCEGLECKLWCRKI 5.00 20.1 >5 >5 1 [Atz(NPEG10)] 247 Atz(NPEG10)-[Nle6]JzTx-V(1-29) [Atz-NPEG10]YCQKW[Nle]WTCDSKR 0.07 4.3 0.15 0.13 2 ACCEGLRCKLWCRKII 248 [Atz(NPEG10)1;Nle6]JzTx-V(1-29) [Atz-NPEG10]CQKW[Nle]WTCDSKRA 0.10 >7 0.39 0.16 4 CCEGLRCKLWCRKII 248 [Atz(NPEG10)1;Nle6]JzTx-V(1-29) [Atz-NPEG10]CQKW[Nle]WTCDSKRA 0.14 >7 0.45 0.13 3 CCEGLRCKLWCRKII 251 [Atz(NPEG10)5;Nle6]JzTx-V(1-29) YCQK[Atz-NPEG10][Nle]WTCDSKRA >7 >7 >7 >7 CCEGLRCKLWCRKII 253 [Nle6;Atz(NPEG10)7]JzTx-V(1-29) YCQKW[Nle][Atz-NPEG10]TCDSKR 4.6 >7 >7 >7 ACCEGLRCKLWCRKII 254 [Nle6;Atz(NPEG10)8]JzTx-V(1-29) YCQKW[Nle]W[Atz-NPEG10]CDSKRA 6.4 >7 >7 >7 CCEGLRCKLWCRKII 256 [Nle6;Atz(NPEG10)11]JzTx-V(1-29) YCQKW[Nle]WTCD[Atz(NPEG10)]KRA 0.096 >5 0.4 0.2 4 CCEGLRCKLWCRKII 256 [Nle6;Atz(NPEG10)11]JzTx-V(1-29) YCQKW[Nle]WTCD[Atz(NPEG10)]KRA 0.12 >5 0.5 0.4 4 CCEGLRCKLWCRKII 264 [Nle6;Atz(NPEG10)22]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACCEGLRC >7 >7 >7 >7 [Atz-NPEG10]LWCRKII 265 [Nle6;Atz(NPEG10)23]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCK 4.8 >7 >7 5.6 [Atz-NPEG10]WCRKII 270 [Nle6;Atz(NPEG10)29]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACCEGLRCKLWCRK 0.40 >7 0.75 3.9 2 I[Atz-NPEG10] 283 [Nle6,Pra14]JzTx-V(1-29) YCQKW[Nle]WTCDSKR[Pra]CCEGLRCKL 0.07 >7 0.09 0.06 1 WCRKII

TABLE 10 Electrophysiology by IonWorks ® Quattro: JzTx-V analogs for conjugation. SEQ Nav1.7 ID IC50 NO. Designation Sequence (μM) 425 Pra-[Nle6]JzTx-V [Pra]YCQKW[Nle]WTCDSKRACCEGLRCKLWCRKII 0.008 425 Pra-[Nle6]JzTx-V [Pra]YCQKW[Nle]WTCDSKRACCEGLRCKLWCRKII 0.013 112 [Glu20,Trp29]JzTx-V YCQKWMWTCDSKRACCEGLECKLWCRKIW 0.017 295 Pra-[Glu20;Trp29]JzTx-V(1-29) [Pra]YCQKWMWTCDSKRACCEGLECKLWCRKIW 0.018 296 Pra-[Nle6;Trp29]JzTx-V(1-29) [Pra]YCQKW[Nle]WTCDSKRACCEGLRCKLWCRKIW 0.019 294 [Nle6;Glu20;Trp29]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACCEGLECKLWCRKIW 0.024 294 [Nle6;Glu20;Trp29]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACCEGLECKLWCRKIW 0.026 302 [Nle6;Pra11;Glu20;Trp29]JzTx-V(1-29) YCQKW[Nle]WTCD[Pra]KRACCEGLECKLWCRKIW 0.026 291 [Nle6;Lys(Pra-NPEG3)14;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKR[KPPG3]CCEGLECKLWCRKIW 0.028 V(1-29) 301 Pra-[Nle6;Glu20;Phe29]JzTx-V(1-29) [Pra]YCQKW[Nle]WTCDSKRACCEGLECKLWCRKIF 0.035 293 [Nle6;Lys(Pra-NPEG3)17;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKRACC[KPPG3]GLECKLWCRKIW 0.041 V(1-29) 290 [Nle6;Lys(Pra-NPEG11)14;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKR[KPPG11]CCEGLECKLWCRKIW 0.052 V(1-29) 322 [Nle6;AzK17;Glu20;Tyr28]JzTx-V(1-29) YCQKW[Nle]WTCDSKRACC[AzK]GLECKLWCRKYI 0.067 292 [Nle6;Lys(Pra-NPEG11)17;Glu20;Trp29]JzTx- YCQKW[Nle]WTCDSKRACC[KPPG11]GLECKLWCRKIW 0.082 V(1-29)

TABLE 11 Electrophysiology by PatchXpress ® (PX) of single substitution and combination JzTx-V analogs. PX PX PX SEQ hNav1.7 hNav1.4 hNav1.5 ID Tonic IC50 Tonic IC50 Tonic IC50 Nav1.4/ Nav1.5/ NO. Designation (μM) (μM) (μM) Nav1.7 Nav1.7 2 JzTx-V(1-29) 0.001000 0.0030 2.21 3 2210 2 JzTx-V(1-29) 0.000200 0.0020 3.25 10 16250 2 JzTx-V(1-29) 0.000700 0.0020 1.60 3 2286 2 JzTx-V(1-29) 0.000570 48 JzTx-45 0.122000 0.3210 7.46 3 61 17 [Ala20]JzTx-V(1-29) 0.012000 0.1000 2.75 8 229 30 [1-Nal7]JzTx-V(1-29) 0.000400 0.0009 1.42 2 3550 49 [Glu1]JzTx-V(1-29) 0.000300 0.0080 6.44 27 21467 63 [Glu20]JzTx-V(1-29) 0.007000 1.2500 9.33 179 1333 69 [Glu28]JzTx-V(1-29) 0.001000 0.3000 8.80 300 8800 70 [Glu29]JzTx-V(1-29) 0.261000 11.3000 >10.00 43 >38 112 [Glu20; Trp29]JzTx-V(1-29) 0.002800 1.1300 3.42 404 1221 112 [Glu20; Trp29]JzTx-V(1-29) 0.000670 0.8240 3.95 1230 5896 112 [Glu20; Trp29]JzTx-V(1-29) 0.001300 1.0500 4.41 808 3392 112 [Glu20; Trp29]JzTx-V(1-29) 0.000500* 1.3470 1.32 2694 2644 112 [Glu20, Trp29]JzTx-V 0.001411 112 [Glu20, Trp29]JzTx-V 0.002154 112 [Glu20; Trp29]JzTx-V(1-29) 0.001821 112 [Glu20, Trp29]JzTx-V 0.002115 2.3651 1.62 1118 767 115 [Asp20]JzTx-V(1-29) 0.749000 7.6000 3.20 10 4 121 [Gly20]JzTx-V(1-29) 0.007800 0.1970 14.10 25 1808 124 [Tyr20]JzTx-V(1-29) 0.005900 1.5700 >10.00 266 >1695 133 [Glu20; Val28]JzTx-V(1-29) 0.004100 1.3100 5.50 320 1341 135 [Glu20; Cit28]JzTx-V(1-29) 0.005600 6.0200 >10.00 1075 >1786 136 [Glu20; Nva28]JzTx-V(1-29) 0.012800 5.1900 7.82 405 611 137 [Glu20; Tyr28]JzTx-V(1-29) 0.000900 1.2700 11.40 1411 12667 138 [Glu20; Ser28]JzTx-V(1-29) 0.003300 4.7900 >10.00 1452 >3030 138 [Glu20; Ser28]JzTx-V(1-29) 0.002000 3.5800 >10.00 1790 >5000 138 [Glu20; Ser28]JzTx-V(1-29) 0.000400 2.9700 14.60 7425 36500 218 [Glu20; 1-Nal24; Tyr28]JzTx-V(1-29) 0.012000 5.2130 10.00 434 833 193 [Phe5; Glu20; Tyr28]JzTx-V(1-29) 0.004600* 1.0000 >1.00 217 217 232 [Glu20; Tyr28; 1-Nal29]JzTx-V(1-29) 0.004500* 1.6740 2.16 372 480 233 [Glu20; Tyr28; 2-Nal29]JzTx-V(1-29) 0.004600* 1.2190 1.99 265 433 238 [Glu20; Tyr28; Leu29]JzTx-V(1-29) 0.002600* 0.6260 7.33 241 2817 239 [Glu20; Tyr28; Nle29]JzTx-V(1-29) 0.006200* 0.7860 9.77 127 >1575 277 [Glu1, 20; Tyr28]JzTx-V(1-29) 0.005500* 0.9390 >10.00 171 >1818 192 [pI-Phe5; Glu20; Tyr28]JzTx-V(1-29) 0.002200* 0.1720 >1.00 78 >455 N-Terminal Analogs 425 Pra-[Nle6]JzTx-V 0.000037 0.0040 0.97 109 26092 425 Pra-[Nle6]JzTx-V 0.000763 425 Pra-[Nle6]JzTx-V(1-29) 0.002150 0.0025 0.70 1 327 369 Nva-[Nle6]JzTx-V(1-29) 0.000021 0.0116 0.49 552 23418 369 Nva-[Nle6]JzTx-V(1-29) 0.001184 361 Leu-[Nle6]JzTx-V(1-29) 0.000134 0 0 368 Abu-[Nle6]JzTx-V(1-29) 0.000143 0.0110 0.48 77 3332 373 D-Leu-[Nle6]JzTx-V(1-29) 0.000151 0.0287 0.41 190 2704 370 Nle-[Nle6]JzTx-V(1-29) 0.000223 0.0046 0.83 21 3729 357 Ala-[Nle6]JzTx-V(1-29) 0.000307 366 CyA-[Nle6]JzTx-V(1-29) 0.000307 375 Sar-[Nle6]JzTx-V(1-29) 0.000325 0.0061 0.83 19 2541 364 Trp-[Nle6]JzTx-V(1-29) 0.000334 374 D-Phe-[Nle6]JzTx-V(1-29) 0.000351 0.0068 0.62 19 1757 365 Tyr-[Nle6]JzTx-V(1-29) 0.000372 362 Pro-[Nle6]JzTx-V(1-29) 0.000372 359 Gly-[Nle6]JzTx-V(1-29) 0.000384 379 hPhe-[Nle6]JzTx-V(1-29) 0.000476 0.0048 0.44 10 916 367 AllyIG-[Nle6]JzTx-V(1-29) 0.000488 358 Phe-[Nle6]JzTx-V(1-29) 0.000493 360 Ile-[Nle6]JzTx-V(1-29) 0.000519 363 Val-[Nle6]JzTx-V(1-29) 0.000551 272 [Nle6]JzTx-V(1-29) 0.000586 377 hLeu-[Nle6]JzTx-V(1-29) 0.000676 0.0085 0.42 13 615 376 bAla-[Nle6]JzTx-V(1-29) 0.000951 0.0032 0.70 3 731 372 D-Ala-[Nle6]JzTx-V(1-29) 0.000957 0.0051 0.73 5 764 *= at high concentrations, compound would wash off slowly or not at all.

TABLE 12 Electrophysiology by PatchXpress ® (PX) of JzTx-V analogs for conjugation. PX PX PX SEQ hNav1.7 hNav1.4 hNav1.5 ID Tonic IC50 Tonic IC50 Tonic IC50 Nav1.4/ Nav1.5/ NO. Designation (μM) (μM) (μM) Nav1.7 Nav1.7 Pra-containing [Glu20, Trp29]JzTx-V analogs 298 Pra-[Phe6; Glu20; Trp29]JzTx-V(1-29) 0.014987 0.6611 0.78 44 52 299 Pra-[Leu6; Glu20; Trp29]JzTx-V(1-29) 0.000571 1.1824 1.33 2069 2332 300 Pra-[Nva6; Glu20; Trp29]JzTx-V(1-29) 0.000818 0.9675 5.30 1183 6483 290 [Nle6; Lys(Pra-NPEG11)14; Glu20; Trp29]JzTx-V(1-29) 0.520000 2.7289 6.10 5 12 291 [Nle6; Lys(Pra-NPEG3)14; Glu20; Trp29]JzTx-V(1-29) 0.030000 1.1302 3.01 38 100 292 [Nle6; Lys(Pra-NPEG11)17; Glu20; Trp29]JzTx-V(1-29) 0.900000 1.6280 3.12 2 3 293 [Nle6; Lys(Pra-NPEG3)17; Glu20; Trp29]JzTx-V(1-29) 0.570000 0.4531 0.58 1 1 437 Nva-[Nle6; Lys(Pra)14; Glu20, Trp29]JzTx-V(1-29) 0.009594 441 Nva-[Leu6; Lys(Pra)14; Glu20; Trp29]JzTx-V(1-29) 0.010355 AzK-containing [Glu20, Trp29]JzTx-V analogs 304 [AzK1; Nle6; Glu20; Trp29]JzTx-V(1-29) 0.003864 1.7362 2.56 449 662 305 [Nle6; AzK11; Glu20; Trp29]JzTx-V(1-29) 0.435437 0 0 306 [Nle6; AzK14; Glu20; Trp29]JzTx-V(1-29) 0.001153 0.6347 1.97 550 1712 307 [Nle6; AzK17; Glu20; Trp29]JzTx-V(1-29) 0.009085 0.3596 0.75 40 83 Aha-containing [Glu20, Trp29]JzTx-V analogs 308 Aha-[Nle6; Glu20; Trp29]JzTx-V(1-29) 0.001124 1.1997 3.77 1068 3351 309 [Aha1; Nle6; Glu20; Trp29]JzTx-V(1-29) 0.003207 0.7673 2.03 239 634 Pra-containing [Glu28]JzTx-V analogs 328 Pra-[Nle6; Glu28]JzTx-V(1-29) 0.000515 0.1302 3.02 253 5854 329 [Pra1; Nle6; Glu28]JzTx-V(1-29) 0.000269 0.1495 4.62 555 17167 330 [Nle6; Pra11; Glu28]JzTx-V(1-29) 0.000763 0.2216 5.98 291 7841 331 [Nle6; Pra14; Glu28]JzTx-V(1-29) 0.000493 0.1050 3.51 213 7119 332 [Nle6; Pra17; Glu28]JzTx-V(1-29) 0.003632 0.1252 3.08 34 849 392 CyA-[Nle6, Lys(Pra)14, Glu28]JzTx-V(1-29) >0.1 392 CyA-[Nle6, Lys(Pra)14, Glu28]JzTx-V(1-29) 0.000226 0.0861 381 392 CyA-[Nle6, Lys(Pra)14, Glu28]JzTx-V(1-29) 0.000299 392 CyA-[Nle6, Lys(Pra)14, Glu28]JzTx-V(1-29) 0.001402 0.1082 0.92 77 659 392 CyA-[Nle6, Lys(Pra)14, Glu28]JzTx-V(1-29) 0.002360 0.1095 1.45 46 615 392 CyA-[Nle6, Lys(Pra)14, Glu28]JzTx-V(1-29) 0.002573 0.1236 2.16 48 841 395 CyA-[Nle6, Pra17, Glu28]JzTx-V(1-29) 0.000144 0.0625 434 395 CyA-[Nle6, Pra17, Glu28]JzTx-V(1-29) 0.002786 0.2117 0.71 76 256 435 Nva-[Nle6; Lys(Pra)14; Glu28]JzTx-V(1-29) 0.002189 0.2174 99 439 Nva-[Leu6; Lys(Pra)14; Glu28]JzTx-V(1-29) 0.001038 0.2934 283 439 Nva-[Leu6; Lys(Pra)14; Glu28]JzTx-V(1-29) 0.001374 439 Nva-[Leu6; Lys(Pra)14; Glu28]JzTx-V(1-29) 0.000384 0.2997 781 439 Nva-[Leu6; Lys(Pra)14; Glu28]JzTx-V(1-29) 0.000612 442 Nva-[Leu6, Lys(Pra-NPEG3)14; Glu28]JzTx-V(1-29) 0.004616 0.4514 3.96 98 857 449 CyA-[Leu6, Lys(Pra)14, Glu28]JzTx-V(1-29) 0.001496 0.1656 1.55 111 1038 Pra-containing [Glu20]JzTx-V analogs 297 Pra-[Nle6; Glu20]JzTx-V(1-29) 0.001867 0.8040 1.20 431 642 343 [Pra1; Nle6; Glu20]JzTx-V(1-29) 0.002633 0.7902 2.66 300 1011 344 [Nle6; Pra11; Glu20]JzTx-V(1-29) 0.018359 4.2172 3.55 230 193 345 [Nle6; Pra14; Glu20]JzTx-V(1-29) 0.007162 1.6607 4.57 232 638 346 [Nle6; Pra17; Glu20]JzTx-V(1-29) 0.009953 0.2906 1.02 29 102 393 CyA-[Nle6, Lys(Pra)14, Glu20]JzTx-V(1-29) >0.1 >10 396 CyA-[Nle6, Pra17, Glu20]JzTx-V(1-29) 0.002837 0.2779 98 Pra-containing [Glu20, Tyr28]JzTx-V analogs 313 Pra-[Nle6; Glu20; Tyr28]JzTx-V(1-29) 0.000427 0.9659 4.37 2261 10226 315 [Nle6; Pra11; Glu20; Tyr28]JzTx-V(1-29) 0.001284 0.8251 2.46 643 1914 316 [Nle6; Pra14; Glu20; Tyr28]JzTx-V(1-29) 0.001759 0.7069 3.69 402 2099 317 [Nle6; Pra17; Glu20; Tyr28]JzTx-V(1-29) 0.003802 0.6137 3.52 161 927 394 CyA-[Nle6, Lys(Pra)14, Glu20, Tyr28]JzTx-V(1-29) 0.000050 0.9641 19130 397 CyA-[Nle6, Pra17, Glu20, Tyr28]JzTx-V(1-29) 0.087101 1.7601 20 436 Nva-[Nle6; Lys(Pra)14; Glu20; Tyr28]JzTx-V(1-29) 0.002961 440 Nva-[Leu6; Lys(Pra)14; Glu20; Tyr28]JzTx-V(1-29) 0.001953 Pra-containing JzTx-V analogs 283 [Nle6, Pra14]JzTx-V(1-29) 0.000300* 0.0050* 0.63 17 2090 380 CyA-[Nle6, Lys(Pra-NPEG3)14]JzTx-V(1-29) 0.000885 0 0 380 CyA-[Nle6, Lys(Pra-NPEG3)14]JzTx-V(1-29) 0.000845 385 CyA-[Nle6, Lys(Pra-NPEG3)17]JzTx-V(1-29) 0.003636 0 0 431 Nva-[Nle6, Lys(Pra)14]JzTx-V(1-29) 0.001621 0.0205 13 431 Nva-[Nle6, Lys(Pra)14]JzTx-V(1-29) 0.001629 432 Nva-[Nle6, Lys(Pra-NPEG3)14]JzTx-V(1-29) 0.001432 0.0165 12 432 Nva-[Nle6, Lys(Pra-NPEG3)14]JzTx-V(1-29) 0.001556 438 Nva-[Leu6, Lys(Pra)14]JzTx-V 0.002379 0.0161 7 438 Nva-[Leu6, Lys(Pra)14]JzTx-V 0.001567 *= at high concentrations, compound would wash off slowly or not at all.

TABLE 13 Electrophysiology by PatchXpress ® (PX) of JzTx-V peptide analogs with linkers. PX PX PX SEQ hNav1.7 hNav1.4 hNav1.5 ID Tonic IC50 Tonic IC50 Tonic IC50 Nav1.4/ Nav1.5/ NO. Designation (μM) (μM) (μM) Nav1.7 Nav1.7 247 Atz(NPEG10)-[Nle6]JzTx-V(1-29) 0.006000* 0.0080* 3.77 1 629 248 [Atz(NPEG10)1; Nle6]JzTx-V(1-29) 0.001000* 0.0150* 0.95 15 946 256 [Nle6; Atz(NPEG10)11]JzTx-V(1-29) 0.009300* 0.0270* 1.86* 3 200 270 [Nle6; Atz(NPEG10)29]JzTx-V(1-29) 0.022000 406 [Nle6; Atz(NPEG10)17; Glu28]JzTx-V(1-29) 0.005881 0.0659 11 407 [Atz(NPEG10)1; Nle6; Glu20]JzTx-V(1-29) 0.006480 0.5487 85 410 CyA-[Nle6, Lys(Atz(NPEG10)-NPEG3)14]JzTx-V(1-29) 0.006365 0.0166 3 433 Nva-[Nle6, Lys(Atz(NPEG10))14]JzTx-V(1-29) 0.004407 0.0148 1.27 6 288 434 Nva-[Nle6, Lys(Atz(NPEG10)-NPEG4)14]JzTx-V(1-29) 0.009670 0.0513 0.95 8 98 443 CyA-[Nle6, Atz(NPEG10)17, Glu28]JzTx-V(1-29) 0.005625 0.1724 1.33 31 236 444 CyA-[Nle6, Lys(Atz(NPEG10))14, Glu28]JzTx-V(1-29) 0.005258 0.3834 73 445 CyA-[Nle6, Lys(Atz(NPEG10))14, Glu20, Tyr28]JzTx-V(1-29) 0.007112 1.2747 179 446 Nva-[Leu6; Lys(Atz(NPEG10))14]JzTx-V(1-29) 0.011649 0.1275 2.41 11 207 447 Nva-[Leu6, Lys(Atz(NPEG10))14; Glu28]JzTx-V 0.009001 0.4131 4.70 46 522 448 Nva-[Nle6; Lys(Atz(NPEG10))14; Glu28]JzTx-V(1-29) 0.018442 0.4433 4.18 24 227 427 Atz(PEG11-benzylthioacetamide)-[Nle6]JzTx-V(1-29) 0.001400* 0.0130* 1.98* 9 1416 — Homodimeric Conjugate No. 2 (see, Example 5) 0.000200* 0.0010* 0.72* 5 3595 — Homodimeric Conjugate No. 2 (see, Example 5) 0.005920 0.0169 1.18 3 199 Immunoglobulin Peptide Conjugate 1 (see, Example 9, Table 0.002900 0.0024 19) *= at high concentrations, compound would wash off slowly or not at all.

TABLE 14 Manual Electrophysiology by Whole Cell Patch Clamp (WCPC) of JzTx-V and JzTx-V Analogs. SEQ Fully non-inactivated Partially inactivated ID Mean IC50 Mean IC50 NO. Designation (nM) 1.x/1.7 (nM) 1.x/1.7 n Channel type 2 JzTx-V(1-29) 0.1415 1 0.1615 1 2 hNav1.7 2 JzTx-V(1-29) 14 99 12.25 76 2 hNav1.3 2 JzTx-V(1-29) 10.6 75 9.35 58 2 hNav1.4 2 JzTx-V(1-29) 881.5 6230 426.5 2641 2 hNav1.5 2 JzTx-V(1-29) 810 5724 530 3282 2 hNav1.8 2 JzTx-V(1-29) 75 530 18 111 2 mTTX-S 2 JzTx-V(1-29) >>1000 >>1000 2 mTTX-R 112 [Glu20, Trp29]JzTx-V(1-29) 279 1213 2 mTTX-S (cultured DRG) 112 [Glu20, Trp29]JzTx-V(1-29) 211 917 2 mTTX-S (fresh DRG) 112 [Glu20, Trp29]JzTx-V(1-29) 0.23 1 2 hNav1.7 425 Pra-[Nle6]JzTx-V(1-29) 5.35 6335 2 mTTX-S 425 Pra-[Nle6]JzTx-V(1-29) 0.0004085 1 0.0008445 1 2 hNav1.7 392 CyA-[Nle6, Lys(Pra)14, Glu28]JzTx-V(1-29) 46.6 2 mTTX-S 395 CyA-[Nle6, Pra17, Glu28]JzTx-V(1-29) 15.9 2 mTTX-S

Example 4 Plasma Stability Studies

The stability of JzTx-V peptide analogs were studied in human, cynomolgus monkey (“cyno”), rat and mouse plasmas. Peptide stock solutions were made from JzTx-V peptide analog reference standards in 50/50 (v/v) methanol/water and stored at −20° C. 1 mg/mL peptide stock solutions were used to prepare 20 μg/mL peptide working solutions in HPLC grade water. The peptide working solutions were stored in a refrigerator at 2 to 8° C. prior to use.

Stability samples were prepared by adding 225 μl plasma into the vials containing 25 μl of 20 μg/mL peptide working solutions and were incubated at 37° C. The initial concentration was 2 μg/mL for each peptide in human, rat, or mouse plasma. 25 μl plasma samples at five time points (0, 2, 4, 8 and 24 hours) were aliquoted into the appropriate well of a 96-well plate, followed by the addition of 25 μl of internal standard solution (100 ng/mL, peptide analog made in 50/50 methanol/water) and 100 μL of 0.1% formic acid and the samples were vortex mixed. An Oasis HLB μElution 96-well solid phase extraction plate was used to extract JzTx-V peptide analog peptides from the pretreated plasma samples and the extracts were injected (10 μL) onto the LC-MS/MS system for analysis.

The LC-MS/MS consisted of an Acquity UPLC system (Waters, Milford, Mass.) coupled to a 5500 QTRAP mass spectrometer (AB Sciex, Toronto, Canada) with a Turbo IonSpray® ionization source. The analytical column was an Acquity UPLC BEH C₁₈ 2.1 mm×50 mm column. The mobile phases were 0.1% formic acid in acetonitrile/water (5/95, v/v, mobile phase A) and 0.1% formic acid in acetonitrile/water (95/5, v/v, mobile phase B). Data was collected and processed using AB Sciex Analyst® software (version 1.5).

The plasma stability of the tested peptides were derived from the peak area ratios corresponding to peptides and internal standard obtained from the LC-MS/MS analysis, all data were normalized to the value at 0-hr time point. Results are shown in Table 15, Table 16, Table 17, and Table 18, below. JzTx-V peptide analogs tested showed remarkable stability in human, cyno, mouse, and rat plasma, likely due to their compact, disulfide-stabilized structure.

TABLE 15 Stability of JzTx-V peptide analogs in human plasma. % Peptide Remaining Incubation [Glu20,Trp29]JzTx-V(1-29); [Glu20,Ser28]JzTx-V(1-29); Time (hr) SEQ ID No. 112 SEQ ID No. 138 0 100 100 2 95 86 4 84 82 6 75 72 8 71 68 24 48 49

TABLE 16 Stability of JzTx-V peptide analogs in cyno plasma. % Peptide Remaining Incubation [Glu20,Trp29]JzTx-V(1-29); [Glu20,Ser28]JzTx-V(1-29); Time (hr) SEQ ID No. 112 SEQ ID No. 138 0 100 100 2 93 78 4 91 75 6 90 69 8 91 62 24 89 59

TABLE 17 Stability of JzTx-V peptide analogs in mouse plasma. % Peptide Remaining Incubation [Glu20,Trp29]JzTx-V(1-29); [Glu20,Ser28]JzTx-V(1-29); Time (hr) SEQ ID No. 112 SEQ ID No. 138 0 100 100 2 88 64 4 82 61 6 85 55 8 85 51 24 77 50

TABLE 18 Stability of JzTx-V peptide analogs in rat plasma. % Peptide Remaining Incubation [Glu20,Trp29]JzTx-V(1-29); [Glu20,Ser28]JzTx-V(1-29); Time (hr) SEQ ID No. 112 SEQ ID No. 138 0 100 100 2 95 90 4 93 81 6 92 71 8 89 67 24 70 59

Example 5 PEGylated Conjugates of JzTx-V Peptide Analogs Studies

To identify sites within JzTx-V(1-29) (SEQ ID NO:2) that could be modified with a half-life extending moiety, a set of positional analogs was prepared containing norleucine at position 6 relative to SEQ ID NO:2 in place of the oxidizable methione and propargylglycine (Pra) at each non-cysteine position. This “Pra scan” was repeated with a [Nle6,Glu20]JzTx-V(1-29) scaffold. After folding, the alkyne-containing peptide was subjected to copper catalyzed 1,3-dipolar cycloaddition with a ˜500 Da MW azido PEG to obtain the site-specifically PEGylated peptides with a triazole linkage, thus converting the propargylglycine or Pra residue in the sequence to a 3-(1,2,3-triazol-4-yl)alanine or Atz residue. (See FIG. 76). Electrophysiological screening of this series of analogs (Table 9 and Table 13, above) identified several positions within JzTx-V, including the N-terminus and positions 1, 11, and 17 of SEQ ID NO:2, where a large chemical moiety could be introduced without significantly reducing potency at Na_(v)1.7. In general, these locations tend to be on the surface of JzTx-V, opposite or around the periphery of the hydrophobic face. Not all of the designed analogs in these series were successfully prepared via the high-throughput peptide synthesis approach. Additional positions were investigated and identified as potential conjugation sites, including positions 10, 12, 13, 14, and 20 relative to SEQ ID NO:2. Having identified these positions, peptide-linker constructs capable of conjugation to an engineered free cysteine residue within an IgG or Fc and homodimeric constructs of Atz-[Nle6]JzTx-V(1-29) (SEQ ID NO:571) were prepared (See, FIG. 81A) and tested (See, Table 9 and Table 13). Two of these homodimers, one with a reactive bromoacetamide functionality (see, Example 10). The bromoacetimide functionality was reacted with benzyl mercaptan to prevent deleterious reaction during assay analysis. Homodimeric conjugates were designated as follows (* =ethyl):

Bis-{Atz(PEG23*)-[Nle6]JzTx-V(1-29)}-54(2-bromoacetamido)methyl)isophthalamide (“Homodimeric Conjugate No. 1”) (See, FIG. 81A);

Bis-{Atz(PEG23*)-[Nle6]JzTx-V(1-29)}-542-(benzylthio)acetamido)methyl)isophthalamide (“Homodimeric Conjugate No. 2”) (See, FIG. 81A);

[Phe6,Atz(2 kDa EtO-PEG*-{[Phe6,Atz13*]GpTx-1(1-34)})13]GpTx-1(1-34) (“Homodimeric Conjugate No. 3”)(See, FIG. 75);

[Phe6,Atz(500 Da EtO-PEG*-{[Phe6,Atz13*]GpTx-1(1-34)})13]GpTx-1(1-34) (“Homodimeric Conjugate No. 4”);

[Ala5,Phe6,Atz(2 kDa EtO-PEG*-{[Ala5,Phe6,Atz13*,Leu26,Arg28]GpTx-1(1-34)})13,Leu26,Arg28]GpTx-1(1-34) (“Homodimeric Conjugate No. 5”).

Example 6 NMR Structure Determination of Pra-[Nle6]JzTx-V(1-29)

The structure of Pra-[Nle6]JzTx-V(1-29)(SEQ ID NO:425) was obtained by high resolution NMR spectroscopy in water, pH 4.5 and T=320 K. The data were collected on a Bruker Avance III 800 MHz spectrometer using 2D NOESY, TOCSY, and HMBC experiments. (See Wutchrich, NMR of Proteins and Nucleic Acids, John Wiley & Sons, Canada, (1986)). The N-terminus of the peptide appeared to be disordered at this temperature, as resonances could not be identified for the three most N-terminal residues. The structure was calculated from 283 NOE constraints, 4 CHI1 angle constraints for cysteine side-chains derived from PADLOC (See Poppe L.; Hui J. O.; Ligutti, J.; Murray, J. K.; Schnier, P. D; PADLOC: a powerful tool to assign disulfide bond connectivities in peptide and proteins by NMR spectroscopy, Analytical Chemistry 84(1): 262-266 (2011)), and 3 disulfide-bond constraints, using Cyana 2.1 software. Glycine was modeled as a substitution for the N-terminal propargylglycine to simplify the structural calculations. The final RMSD for the backbone atoms of residues 5-30 was 0.45±0.07 Å (0.74±0.12 Å for all heavy atoms) and had no NOE or angle constraint violations. (See FIG. 48 for the overlay of the 20 lowest energy conformations of the peptide backbone, FIG. 49 for the overlay of the heavy atoms from the 20 lowest energy conformations of the peptide, FIG. 50 for a ribbon representation of the lowest energy conformation of the peptide backbone, and FIG. 51 for the overlay of the ribbon representations of the 20 lowest energy conformation of the peptide backbone). The structure confirms the disulfide connectivity of the six cysteine residues as C₂-C₁₆, C₉-C₂₁, and C₁₅-C₂₅ or a C1-C4, C2-C5, C3-C6 pattern, confirming that Pra-[Nle6]JzTx-V(1-29)(SEQ ID NO:425) is a member of the inhibitory cystine knot (ICK) family of peptides.

The folded structure of Pra-[Nle6]JzTx-V(1-29)(SEQ ID N):425) is amphipathic in nature with a hydrophobic face on one side of the molecule. (See, FIG. 52). The hydrophobic face is ringed by a number of hydrophilic (mostly cationic) residues. The opposite face of the folded peptide is more neutral in character. The systematic analoging of JzTx-V, in particular the positional scanning with alanine, arginine and glutamic acid, identifies several residues as being critical for activity at Na_(v)1.7. (See, FIG. 53). These residues, namely Trp5, Met6, Trp7, Leu23, Trp24, and Ile34, relative to SEQ ID NO:2, are clustered on the one face of JzTx-V. The hydrophobic side chains of residues Leu23, Trp24, and Ile34 of SEQ ID NO:425 align on one face of the C-terminal strand, while Trp5 and Met6 are adjacent to that strand to form the hydrophobic face. Trp7 further expands that hydrophobic face. Since changes that alter the nature of this face disrupt activity against Na_(v)1.7, this may be the portion of the molecule that interacts with the VGSCs at the binding interface. It was also observed that the N-terminus of the folded JzTx-V peptide was positioned the hydrophobic C-terminal residue Ile29 relative to SEQ ID NO:2. Although a glycine residue was used in the structure calculation, it was apparent that extending the N-terminus of the peptide with a hydrophobic residue, such as propargylglycine in Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425), could position that residue in close proximity to the hydrophobic face of the molecule where it could contribute the binding interaction. This may help to explain the increased hNav1.7 potency of Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) and other N-terminally extended analogs. Substitution of a glutamic acid residue for either Arg20 or Ile28 resulted in increased selectivity against Nav1.4. (See Table 6, Table 11, and FIG. 54). Arg20 is quite distant from the hydrophobic face in the Pra-[Nle6]JzTx-V NMR structure. The guanadine of the Arg20 side chain is in close proximity to the carboxylic acid of Glu17, and these two functionalities may engage in a salt bridge that stabilizes the JzTx-V structure. Substitution of glutamic acid for arginine at position 20 would not only disrupt this possible salt bridge but create a repulsive electrostatic interaction that could alter the peptide conformation. It may be that the Glu20 substitution increases the Nav1.4 selectivity of JzTx-V more by influencing the conformation of the peptide than through a direct interaction with the channel. Conversely, Ile28 is located at the periphery of the hydrophobic face. Substitution of glutamic acid at position 28 also increases the Nav1.4 selectivity of JzTx-V, likely through a direct binding interaction with the channel. The NMR structure os Pra-[Nle6]JzTx-V shows that a number of the residues that can be modified without affecting potency and that have been explored as potential conjugation sites are on the face of the peptide opposite the hydrophobic face, i.e. positions 11, 14, and 17.

Example 7 Preliminary Pharmacokinetic Determination in Mice

Pharmacokinetic Studies.

A preliminary pharmacokinetic (PK) study was conducted with 7 week-old unmodified CD-1 mice from Taconic. [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) was dosed to 6 mice at 1 mg/kg subcutaneously. Blood samples were taken at 0.5, 1, 1.5, 2, 3, and 4 hours post-dose from 3 mice at each time point. For each sample 15 μL of blood was collected via the carotid artery catheter and mixed in 35 μL of 0.1 M citrate buffer. Samples were then frozen at −80° C. until analysis.

LC-MS/MS Analytical Procedure.

Peptide stock solutions (1 mg/mL) were made from peptide reference standards in 50/50 (v/v) methanol/water and stored at −20° C. 1 mg/mL peptide stock solutions were used to prepare 100 μg/mL peptide working solution in 50/50 (v/v) methanol/water. The peptide working solutions were stored in a refrigerator at 2 to 8° C.

Standard samples were prepared in citrate-buffered mouse blood (blood/0.1M citrate buffer, 30/70, v/v). Standards concentrations of 5, 10, 25, 50, 100, 250, 500 and 1000 ng/mL were prepared by serial dilution of a freshly prepared 5000 ng/mL solution in citrate-buffered mouse blood using the 100 μg/mL peptide working solution. 25 μl blood samples were aliquoted into the appropriate well of a 96-well plate, followed by the addition of 50 μl of internal standard solution (100 ng/mL, peptide analog made in 50/50 methanol/water) and 150 μL of 0.1M ZnSO₄ and the samples were vortex mixed for 5 min, then centrifuge for 10 min at 4000 rpm. Supernatant was then extracted using an Oasis HLB μElution 96-well solid phase extraction plate to extract peptides and the extracts were injected (10 μL) onto the LC-MS/MS system for analysis.

The LC-MS/MS consisted of an Acquity UPLC system (Waters, Milford, Mass.) coupled to a 5500 QTRAP mass spectrometer (AB Sciex, Toronto, Canada) with a Turbo IonSpray® ionization source. The analytical column was an Acquity UPLC BEH C₁₈ 2.1 mm×50 mm column. The mobile phases were 0.1% formic acid in acetonitrile/water (5/95, v/v, mobile phase A) and 0.1% formic acid in acetonitrile/water (95/5, v/v, mobile phase B). Data was collected and processed using AB Sciex Analyst® software (version 1.5).

The calibration curve was derived from the peak area ratios (peptide/internal standard) using 1/x² weighted linear least-squares regression of the area ratio versus the concentration of the corresponding peptide standard. The regression equation from the calibration standards was used to back calculate the measured concentration for each standard and blood samples.

Results.

In the pharmacokinetic study a 1 mg/kg subcutaneous (s.c.) dose of [Glu20,Trp29]JzTx-V(1-29)(SEQ ID NO:112) to mice was tolerated and showed measurable plasma concentrations for 4 h with an approximate in vivo half-life of 2.08 h. The dose yielded peptide concentrations in the plasma that were sustained at about 0.04 μM, 26-fold over the in vitro hNav1.7 IC₅₀ by PatchXpress® (PX), for 3 h, which was deemed suitable for further in vivo testing. (See, FIG. 55).

Example 8 In Vivo Pain Models

The compositions of the present invention can be tested in any relevant in vivo pain models. Examples include:

Tactile Allodynia—Von Frey Test.

Von Frey filaments are used to assess mechanical sensitivity in rodents. Mice are placed on a wire mesh floor, enclosed in an individual testing chamber and allowed to acclimate until calm. Calibrated filaments of various bending forces are then applied to the paw of a mouse to measure the response to a non-noxious tactile (e.g., touch) stimulus. The pattern of responses and non-responses to the series of filaments determines the animal's mechanical threshold. This threshold is used as the endpoint of the assay.

Rat Neuropathic Pain Model.

Male Sprague-Dawley rats (200 g) are anesthetized with isoflurane inhalant anesthesia and the left lumbar spinal nerves at the level of L5 and L6 are tightly ligated (4-0 silk suture) distal to the dorsal root ganglion and prior to entrance into the sciatic nerve, as first described by Kim and Chung (An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363, (1992)). The incisions are closed and the rats are allowed to recover. This procedure results in mechanical (tactile) allodynia in the left hind paw as assessed by recording the pressure at which the affected paw (ipsilateral to the site of nerve injury) is withdrawn from graded stimuli (von Frey filaments ranging from 4.0 to 148.1 mN) applied perpendicularly to the plantar surface of the paw (between the footpads) through wire-mesh observation cages. A paw withdrawal threshold (PWT) is determined by sequentially increasing and decreasing the stimulus strength and analyzing withdrawal data using a Dixon non-parametric test, as described by Chaplan, S. R., et al. (Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Meth, 53:55-63 (1994)).

Rat CFA Inflammatory Pain Model.

Male Sprague-Dawley rats (200 g) are injected in the left hindpaw with complete Freund's adjuvant (CFA). This procedure results in mechanical (tactile) and thermal allodynia in the left hind paw as assessed by recording the pressure at which the affected paw is withdrawn from graded stimuli (von Frey filaments ranging from 4.0 to 148.1 mN) applied perpendicularly to the plantar surface of the paw (between the footpads) through wire-mesh observation cages or by applying radiant heat. PWT is determined by sequentially increasing and decreasing the stimulus strength and analyzing withdrawal data using a Dixon non-parametric test, as described by Chaplan et al. (1994). Rats are included in the study only if they do not exhibit motor dysfunction (e.g., paw dragging or dropping) or broken skin and their PWT is below 39.2 mN (equivalent to 4.0 g). At appropriate times after CFA injection rats are treated with test peptides and/or test vehicle-conjugated peptides (usually a screening dose of 60 mg/kg) or control solution (PBS or other vehicle) once by s.c. injection and PWT is determined Average paw withdrawal threshold (PWT) was converted to percent of maximum possible effect (% MPE) using the following formula: % MPE=100* (PWT of treated rats—PWT of control rats)/(15-PWT of control rats). Thus, the cutoff value of 15 g (148.1 mN for mechanical allodynia) is equivalent to 100% of the MPE and the control response is equivalent to 0% MPE.

Preferred molecules of the present invention are expected to produce an antinociceptive effect with a PD with appropriate exposures compared to IC₅₀ on the target.

Mouse Formalin Pain Model Experimental Procedure.

Formalin injection into a rodent paw evokes a well-studied form of pain quantitated by the number of times the animal flinches its paw. The pain following formalin injection comes in two characteristic phases: a first phase lasts approximately ten minutes and likely corresponds to the immediate pain mediated by peripheral neurons. The second phase, beginning approximately ten minutes after formalin injection and lasting for another 30 to 40 minutes, corresponds to sensitization of neurons in the spinal cord and hyperactivity of peripheral pain-sensing neurons. Compounds represented in this application were tested to see if they reduce the number of flinches in phase II of the formalin response and so are potential analgesic drugs (Bregman H et al., “Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.” J Med Chem 54(13):4427-4445, 2011).

Male CD-1 mice (8-12 weeks of age, Harlan Laboratories, Frederick, Md.) were used for all in vivo efficacy experiments. Animal subjects had free access to food (Teklad Global Soy Protein-Free Extruded Rodent Diet 2020X) and water and were maintained on a 12-h light/dark cycle for the entire duration of the study. All animals were housed on standard solid-bottomed caging with corn cob bedding with 1 animal per cage. The animal colony was maintained at approximately 21° C. and 60% humidity. All experiments were conducted in accordance with the International Association for the Study of Pain guidelines.

On test day, during or before acclimation, the animals were dosed with either an investigational compound or vehicle. Following dose administration, all mice (n=12) were conditioned to behavioral analysis chambers (dimensions: 10 cm diameter, 14 cm tall cylinder with lid on top of elevated glass) for 5 minutes prior to the formalin injection. Video cameras were set underneath for recording the mouse behavior (5 minute acclimation and 40 minute test session). At test time, mice were lightly restrained in a cloth glove and injected with 20 μL of a 2% formalin solution into the dorsal surface of the left hind paw using an insulin syringe (U100, 0.3 cc, 28-30G) Immediately following the formalin injection, animals were returned to the chamber and observed for 40 minutes. Paw lifting/licking behavior was recorded in 5 minute intervals after which ipsilateral and contralateral paw widths were measured. After study completion animals were immediately euthanized.

In the first mouse formalin pain model study, [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) was dosed at 0.1, 0.3, and 1.0 mg/kg s.c. 1-hour pre-treatment with morphine at 3 mg/kg s.c. 30-min pre-treatment as the positive control. (See, FIG. 56). The peptide had no effect on time spent lifting and/or licking the affected paw in either the first or acute phase (0-5 minutes post-formalin injection) or during the second phase (5-40 minutes post-formalin injection) compared to vehicle (PBS). (See, FIG. 57 and FIG. 58). In this experiment the 3 mg/kg s.c. dose of morphine used as a positive control significantly reduced the pain response in the animals. The terminal plasma exposure (peptide plasma concentrations at 45 min post-formalin injection) for the peptide was 0.0278±0.0105, 0.121±0.0411, and 0.412±0.0858 μM for the 0.1, 0.3, or 1.0 mg/kg doses, respectively.

The mouse formalin pain model was repeated with a 1-hour pre-treatment dose of 5.0 mg/kg s.c. of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112). (See, FIG. 59). The peptide had no effect on the time spent lifting/licking the affected paw in either the first phase (0-5 minutes post formalin injection) or second phase (5-40 minutes post formalin injection) compared to the vehicle (PBS). (See, FIG. 60 and FIG. 61). The positive control, a 3 mg/kg s.c. dose of morphine, did significantly reduce the time spent lifting/licking the affected paw in the first and second phases. Terminal exposure (peptide plasma concentration at 45 min post formalin injection) was 2.63±0.777 μM for the 5.0 mg/kg dose. This peptide plasma concentration is only about 10-fold over the IC50 of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) for blocking the TTX-S current in mouse DRG neurons in the WCPC format. It is likely that the in vivo Nav1.7 target coverage was insufficient to produce efficacy in this pain model.

Mouse Complete Freund's Adjuvant (CFA)—Induced Thermal Hyperalgesia Experimental Procedure.

The CFA-induced inflammatory pain model is a widely used animal model to study inflammatory pain mechanisms. The classical symptoms of this model are swelling of the CFA-injected paw (edema), redness, allodynia and hyperalgesia. These symptoms develop within 2-3 hours of CFA injection and last more than seven days.

Male CD-1 mice (8-12 weeks of age, Harlan Laboratories, Frederick, Md.) were used for all in vivo efficacy experiments. Animal subjects had free access to food (Teklad Global Soy Protein-Free Extruded Rodent Diet 2020X) and water and were maintained on a 12-h light/dark cycle for the entire duration of the study. All animals were housed on standard solid-bottomed caging with corn cob bedding with 1 animal per cage. The animal colony was maintained at approximately 21° C. and 60% humidity. All experiments were conducted in accordance with the International Association for the Study of Pain guidelines.

At test time, mice (n=12) were lightly restrained in a cloth glove and injected with 20 μL of CFA (Sigma Aldrich) into the intraplantar surface of the left hind paw using an insulin syringe (U100, 0.3 cc, 28-30G). Thermal latency to the Hargreaves apparatus (San Diego Instruments) was recorded 24 hours post CFA injection and again following investigational compound or vehicle administration. Following the thermal test both ipsilateral and contralateral paw widths were measured. After study completion animals were immediately euthanized.

The mouse CFA thermal hyperalgesia pain model (24 h postdose) in male CD-1 mice was run with a 5.0 mg/kg s.c. dose of [Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112). After a lack of efficacy was observed at peptide doses ≦5 mg/kg in the formalin pain model, the peptide was tested in a second pain model. The peptide had no effect on thermal latency compared to vehicle (PBS). (See, FIG. 62). The positive control, a 30 mg/kg PO dose of mexilitine was sufficient to significantly reverse thermal hyperalgesia in the animals. The terminal plasma exposure (peptide plasma concentrations at 2 h post peptide injection) for the peptide was 1.75±0.536 μM. It is likely that the in vivo Nav1.7 target coverage was insufficient to produce efficacy in this pain model.

Mouse Open Field Analysis Experimental Protocol.

To verify that efficacy in the formalin model produced by a test compound is not due to sedation or damage to the animal, compounds were also tested for their effects on the overall movement of animals (open-field testing). Naïve animals are administered test compound and placed in a novel environment, and the movements the animal undergoes during exploration of the novel environment are automatically recorded. Reductions in movement of 50% or more mean that efficacy in the formalin test cannot be ascribed to true analgesia.

Male CD-1 mice (8-12 weeks of age, Harlan Laboratories, Frederick, Md.) were used for all in vivo efficacy experiments. Animal subjects had free access to food (Teklad Global Soy Protein-Free Extruded Rodent Diet 2020X) and water and were maintained on a 12-h light/dark cycle for the entire duration of the study. All animals were housed on standard solid-bottomed caging with corn cob bedding with 1 animal per cage. The animal colony was maintained at approximately 21° C. and 60% humidity. All experiments were conducted in accordance with the International Association for the Study of Pain guidelines.

On test day, animals were dosed with either an investigational compound or vehicle and given at least 30 minutes to acclimate to the testing room. Mice (N=10) were placed in a clean open field chamber (Kinder Scientific Photobeam Activity System) at the appropriate time after dose administration. The changes in overall animal movement were recorded on the system for 30 minutes under lights off conditions. The following parameters were evaluated: total basic movement, total rearing, total time rearing, and total fine movement.

Results of the Mouse Open Field Analysis.

[Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) at 0.1, 0.3, or 1.0 mg/kg s.c. doses with a 1-hour pre-treatment time had no effect on the total basic movement, total fine movement, total rearing, or total time rearing in CD-1 mice. None of these doses of peptide significantly decreased exploratory behavior in relation to the vehicle control. (See, FIG. 63 and FIG. 64). At a 5 mg/kg s.c. dose with a 1-hour pre-treatment, the peptide had no significant effect on the total basic movement of CD-1 mice relative to the vehicle. The peptide may have slightly reduced the total time rearing component of locomotor activity relative to the vehicle. (See, FIG. 65 and FIG. 66). Terminal exposures (peptide plasma concentrations at 2 h post-peptide injection) were 0.0248±0.00668, 0.121±0.0296, 0.419±0.226, and 4.73±0.584 μM for the 0.1, 0.3, 1.0, and 5.0 mg/kg s.c. doses, respectively. No observations were made at these doses and corresponding peptide plasma concentrations that would confound the experimental read out of the formalin or CFA pain models.

Rat Formalin Pain Model Experimental Procedure.

Formalin injection into a rodent paw evokes a well-studied form of pain quantitated by the number of times the animal flinches its paw. The pain following formalin injection comes in two characteristic phases: a first phase lasts approximately ten minutes and likely corresponds to the immediate pain mediated by peripheral neurons. The second phase, beginning approximately ten minutes after formalin injection and lasting for another 30 to 40 minutes, corresponds to sensitization of neurons in the spinal cord and hyperactivity of peripheral pain-sensing neurons. Compounds represented in this application were tested to see if they reduce the number of flinches in phase II of the formalin response and so are potential analgesic drugs (Bregman H et al., “Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.” J Med Chem 54(13):4427-4445, 2011).

Male Sprague-Dawley rats (10-12 weeks of age, Harlan Laboratories, Frederick, Md.) were used for all in vivo efficacy experiments. Animal subjects had free access to food (Teklad Global Soy Protein-Free Extruded Rodent Diet 2020X) and water and were maintained on a 12-h light/dark cycle for the entire duration of the study. All animals were housed on standard solid-bottomed caging with corn cob bedding in groups of 2 animals per cage. The animal colony was maintained at approximately 21° C. and 60% humidity. All experiments were conducted in accordance with the International Association for the Study of Pain guidelines.

On test day, during or before acclimation, the animals were dosed with either an investigational compound or vehicle. Following dose administration, all rats (n=8) were conditioned to behavioral analysis chambers (dimensions: 15 cm diameter, 30 cm tall cylinder) for 30 minutes prior to the formalin injection. At test time, rats were lightly restrained in a towel and injected with 50 μL of a 2.5% formalin solution into the dorsal surface of the left hind paw using an insulin syringe (U100, 0.3 cc, 28-30G). A soft metal band (10 mm wide 3×27 mm long, shaped into a C, and weighing 0.5 g) was placed on the left hind paw and glued onto the animal being tested Immediately following the formalin injection, animals were returned to the chamber on the automated flinch-detecting system (T. Yaksh, University of California at San Diego, La Jolla, Calif.). Each animal's flinch count value over an interval of time (1 min), for the duration of the study (40 min), forms the data set used in all subsequent analyses. These data are averaged in the phase 1 and phase 2 formalin intervals after which ipsilateral and contralateral paw widths were measured. After study completion animals were immediately euthanized.

Rat Formalin Model Results.

[Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) was tested in the formalin pain model in male Sprague-Dawley rats with a 1-hour pre-treatment dose of 5.0 mg/kg s.c. After a lack of efficacy was observed at peptide doses ≦5 mg/kg in mice, the formalin pain model was repeated at a 5 mg/kg dose in a second species, Sprague-Dawley rats. The peptide had no effect in the first or acute phase (0-5 minutes post formalin injection). The peptide did not decrease and may have actually increased the time spent lifting and/or licking the affected paw during the second phase (5-40 minutes post formalin injection, associated with spinal sensitization) compared to vehicle (PBS). (See, FIG. 67 and FIG. 68). The positive control, a 2 mg/kg s.c. dose of morphine was sufficient to significantly reduce pain response in the animals. The terminal plasma exposure (peptide plasma concentrations at 45 min post-formalin injection) for the peptide was 1.18±0.156 μM. It is likely that the in vivo Nav1.7 target coverage at this peptide plasma concentration was insufficient to produce efficacy in this pain model.

Rat Open Field Analysis Experimental Protocol.

To verify that efficacy in the formalin model produced by a test compound is not due to sedation or damage to the animal, compounds were also tested for their effects on the overall movement of animals (open-field testing). Naïve animals are administered test compound and placed in a novel environment, and the movements the animal undergoes during exploration of the novel environment are automatically recorded. Reductions in movement of 50% or more mean that efficacy in the formalin test cannot be ascribed to true analgesia.

Male Sprague-Dawley rats (10-12 weeks of age, Harlan Laboratories, Frederick, Md.) were used for all in vivo efficacy experiments. Animal subjects had free access to food (Teklad Global Soy Protein-Free Extruded Rodent Diet 2020X) and water and were maintained on a 12-h light/dark cycle for the entire duration of the study. All animals were housed on standard solid-bottomed caging with corn cob bedding in groups of 2 animals per cage. The animal colony was maintained at approximately 21° C. and 60% humidity. All experiments were conducted in accordance with the International Association for the Study of Pain guidelines.

On test day, animals were dosed with either an investigational compound or vehicle and given at least 30 minutes to acclimate to the testing room. Rats (N=8) were placed in a clean open field chamber (Photobeam Activity System, San Diego Instruments) at the appropriate time after dose administration. The changes in overall animal movement were recorded on the system for 30 minutes under lights off conditions. The following parameters were evaluated: total basic movement, total rearing, total time rearing, and total fine movement.

Rat Open Field Analysis Results.

[Glu20,Trp29]JzTx-V(1-29) (SEQ ID NO:112) at a 5.0 mg/kg s.c. dose with a 1-hour pre-treatment time had no significant effect on the total basic movement or total rearing components of locomotor activity in male Sprague-Dawley rats. The dose of peptide did not significantly decrease exploratory behavior in relation to the vehicle control. (See, FIG. 69 and FIG. 70). Terminal exposure (peptide plasma concentrations at 2 h post peptide injection) was 0.994±0.184 μM for the 5.0 mg/kg s.c. dose.

The foregoing example of in vivo pain models for the screen of therapeutic embodiments of the inventive molecules are non-limiting. The skilled practitioner is aware of other relevant pain models.

Example 9 Site Specific Peptide Conjugation

The following protocol was used to site-specifically conjugate a dimeric toxin peptide analog (see, Table 5 for toxin peptide analog amino acid sequences) to a human immunoglobulin at a linkage site on the heavy chain (C273 of SEQ ID NO:542).

Preparation of Peptide-Linker Construct.

Alkyne-containing peptide Pra-[Nle6]JzTx-V(1-29) (SEQ ID NO:425) was subjected to copper catalyzed 1,3-dipolar cycloaddition with a Bis-{azido-PEG23-ethyl}-5-((2-bromoacetamido)methyl)isophthalamide to obtain the site-specifically PEGylated peptide dimer with triazole linkages, thus converting a propargylglycine or Pra residue in each sequence to a 3-(1,2,3-triazol-4-yl)alanine or Atz residue to yield Atz-[Nle6]JzTx-V (SEQ ID NO:571 as set forth in Table 5). (See, FIG. 76 and FIG. 81A). Peptide containing propargylglycine (Pra) at the N-terminus (7.4 mM in 2.12 mL water), Bis-{azido-PEG23}-5-((2-bromoacetamido)methyl)isophthalamide (150 mM, 0.127 mL in water), tris((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amine (TBTA, 10 mM, 1.3 mL in DMSO), sodium ascorbate (50 mM, 5.1 mL in water), and copper (II) sulfate (35 mM, 0.8 mL in water) solutions were prepared fresh. Peptide and reagents were added in the following order to a 50 mL centrifuge tube to achieve the following final concentrations. Peptide stock solution (2.1 mL) was added for a final concentration of 3.7 mM, followed by addition of azido-PEG11-bromoacetamide (0.064 mL) for a final concentration of 2.25 mM. TBTA (0.191 mL) was added for a final concentration of 0.45 mM and mixed thoroughly. Sodium ascorbate (1.431 mL) was then added for a final concentration of 16.9 mM and mixed thoroughly. CuSO₄ (0.409 mL) was added for a final concentration of 3.4 mM. Additional peptide solution was added (0.4 mL of 7.4 mM stock) after 15 minutes. The solution was allowed to stand for 1 h at which time it was judged to be complete by LC-MS. The product mixture was purified by injecting onto a preparative HPLC column (Phenomenex Luna 5u C18(2) 100A AXIA, 250×30 mm) attached to a prep HPLC (Agilent), and the peptide was eluted with a 10-40% B gradient over 60 min, followed by a 10 min flush and a 10 min equilibration. The fractions were analyzed by LC-MS, pooled, and lyophilized to afford pure peptide-linker construct for conjugation to IgG or Fc domain.

Antibody Preparation/Reduction.

Anti-DNP mAb (E273C, hIgG1) (kappa/IgGlz) was concentrated to ˜5 mg/ml in reaction buffer (20 mM sodium phosphate pH 6.8, 2 mM EDTA).

The amino acid sequence of the human IgG heavy chain monomer that was used was the following (variable region is underlined; C273 linkage site is italicized and underlined):

SEQ ID NO.: 542 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVI WYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYNFN

The amino acid sequence of the human IgG kappa light chain monomer that was used was the following (variable region is underlined):

SEQ ID NO.: 543 DIQMTQSPSSVSASVGDRVTITCRASQGISRRLAWYQQKPGKAPKLLIYAA

The amino acid sequence of the human IgGlz Fc domain monomer that was used was the following (C52 linkage site is italicized and underlined):

SEQ ID NO.: 544 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDP C VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK//. Alternative preferred conjugation sites within the human IgG heavy chain monomer, besides E273C in the CH2 domain, are E89C in the VH domain and T360C in the CH3 domain and the analogous site in the IgGlz Fc domain. An alternative preferred conjugation site within the human IgG kappa light chain monomer is D70C in the VL domain.

TABLE 19 An immunoglobulin-JzTx-V peptide conjugate was made. (See FIG. 81B). The “bivalent” conjugate molecules actually had four toxin peptides (i.e., peptide dimer covalently conjugated via linker to each Fc domain monomer in the molecule) in the molecule. SEQ SEQ ID NOS of ID NO immunoglobulin of monomers in toxin Linker and residue position of conjugated Monovalent Designation peptide linkage on toxin peptide molecule or Bivalent Immunoglobulin- 571 Bis-{PEG23-ethyl}-5-((2- 542; 543; bivalent Peptide Conjugate 1 bromoacetamido)methyl)isophthalamide 542; 543 at N-terminus [See, FIG. 78B]

Reduction of engineered cysteines was done by incubating mAb with a 1:1 molar ratio of TCEP to cysteine (2:1 TECP to mAb) at room temperature for 30 minutes. TCEP was removed using a Zeba spin desalting column (≧7 kD Pierce) equilibrated with reaction buffer. Large scale preps were concentrated to appropriate volume prior to loading using amicon ultra (10,000-30,000MWCO) centrifugal concentrators.

Peptide Preparation.

Lyophilized dimeric peptide-linker containing a bromoacetamide functionality was resuspended in water at 20 mg/ml immediately prior to conjugation reaction.

Conjugation Reaction.

Peptide dimer and reduced mAb were mixed at a 2.5:1 molar ratio of peptide dimer to cysteine (5:1 peptide to mAb) in reaction buffer at mAb concentration of 10 mg/ml and incubated for 12-16 hours at 4° C. The engineered free cysteines in the immunoglobulin react with the bromoacetamide functionality in peptide-linker to form a site-specific immunoglobulin-peptide conjugate with a stable thioacetamide linkage. (See, FIG. 79, FIG. 81B and FIG. 81C). If one cysteine reacts, then the result is a monovalent immunoglobulin-peptide conjugate, and if both cysteines react, then the result is a bivalent immunoglobulin-peptide conjugate

Purification of Conjugates.

Following incubation, conjugation reaction was desalted to removed excess free peptide and loaded onto a HiTrap SP-HP column (GE Healthcare; 1 ml column for preps <10 mg, 5 ml column for preps >10 mg). Column was rinsed in 5 column volumes of 90% buffer A (10 mM sodium phosphate pH 6.5, 5% ethanol) 10% buffer B (10 mM sodium phosphate pH 6.5, 5% ethanol, 1M NaCl). Conjugate (see, Table 19) was eluted over a 20 column volume gradient from 10% buffer B to 70% buffer B. Unmodified mAb elutes first followed by monvalent imunoglobulin-peptide conjugate (1 peptide per mAb), followed by bivalent imunoglobulin-peptide conjugate (2 peptides per mAb). Higher order conjugates resulting from over reduction of the mAb elute later. (See, FIG. 92A-B). Following purification, conjugates were formulated into ASSU storage buffer (10 mM sodium acetate pH 5.0, 9% sucrose) and concentrated to 10 mg/ml to be stored at −80° C.

Analysis of Conjugate.

Conjugate was run on reducing SDS-PAGE to confirm conjugation to heavy chain (increase in size by ˜10 kD) and non-reducing SDS-PAGE to confirm internal disulfides remained intact. (See, FIG. 93).

Specific Reaction Results.

From 15 mg of Anti-DNP mAb (E273C, hIgG1; SEQ ID NO:542; SEQ ID NO:543; SEQ ID NO:542; SEQ ID NO:543) and 7 mg of peptide-linker contruct (“Homodimeric Peptide No. 1”, i.e., Bis-{Atz(PEG23*)-[Nle6]JzTx-V(1-29)}-5-((2-bromoacetamido)methyl)isophthalamide, see Example 5) were obtained 5 mg of bivalent conjugate (“Immunoglobulin Peptide Conjugate 1”, see Table 19). Sample was concentrated to 10 mg/mL in ASSU buffer and stored as aliquots at −80° C. Immunoglobulin Pepide Conjugate 1 was tested in the Nav1.7 and Nav1.4 PX assays and found to be potent against both channels with IC50 values of 0.2 nM for both targets. (See Table 13).

Example 10 Use of Multivalent Linkers to Prepare Toxin Peptide Analog Dimers

To increase the inventive toxin peptide analog's in vivo half-life, alter its distribution profile, and thus increase its in vivo Nav1.7 target coverage, we prepared IgG- and Fc-conjugates of Nav1.7 inhibitory peptides. (See, Murray et al., Potent and selective inhibitors of Nav1.3 and Nav1.7, WO 2012/125973 A2). However, the modest potency of these first peptide conjugates limited in vivo plasma concentrations to ˜1× the in vitro Nav1.7 IC50, a level of target coverage which was not been sufficient to achieve efficacy (data not shown).

In a parallel effort, dimerization was explored as a strategy to improve the potency of the Nav1.7 inhibitory peptides. Two peptide dimers with different linker lengths, 2000 and 500 Da polyethyleneglycol (PEG), were prepared and tested in the Nav1.7 PatchXpress® electrophysiology assays (Homodimeric Peptide No. 3 and Homodimeric Peptide No. 4). Although the IC₅₀ values of the two compounds were quite similar, the dimer with the longer linker was extremely slow to wash off of the target, if it ever did at all (see FIGS. 73-74). In Table 20 below, PEGylated versions of [Phe6,Atz13]GpTx-1(1-34) (DCLGFFRKCIPD[Atz]DKCCRPNLVCSRTHKWCKYVF-NH₂; SEQ ID NO:591) and [Ala5,Phe6,Atz13,Leu26,Arg28]GpTx-1 34 (DCLGAFRKCIPD[Atz]DKCCRPNLVCSRLHRWCKYVF-NH₂; SEQ ID NO:592) were used for comparison. This slower off-rate can be a very beneficial property for the inhibition of the target in vivo and demonstrates the importance of optimizing the linker length. These linkers were polydisperse bis-azido PEGs, and one alkyne-containing peptide was attached to each end via a copper-catalyzed 1,3-dipolar cycloaddition reaction to form a triazole (see, FIG. 75 and FIG. 76). However, these linkers did not contain an orthogonal chemical handle for conjugation of the peptide dimer to a protein.

Multivalent linkers with various monodisperse PEG lengths (n=3, 7, 11, 23, 35) that incorporate a haloacetamide (Br or I) functionality for reaction with the side chain thiol of an engineered cysteine within an Fc or IgG to form a stable thioether/thioacetamide linker were designed and prepared (see, FIG. 78 and FIG. 80). A series of monovalent and divalent peptides and a conjugate have been prepared from the potent Nav1.7 inhibitory peptide Pra-[Nle6]JzTx-V (SEQ ID NO:425). We modified Pra-[Nle6]JzTx-V (SEQ ID NO:425) with a PEG11 linker (Atz(PEG11-benzylthioacetamide)-[Nle6]JzTx-V(1-29); SEQ ID NO: 427) and prepared the dimer of Pra-[Nle6]JzTx-V (SEQ ID NO:425) with a multivalent linker (Homodimeric Conjugate No. 1 and Homodimeric Conjugate No. 2, see Example 5), and the Anti-DNP mAb (E273C, hIgG1; SEQ ID NO:542; SEQ ID NO:543; SEQ ID NO:542; SEQ ID NO:543) conjugate of the dimeric peptide (i.e, Bis-{Atz(PEG23*)-[Nle6]JzTx-V(1-29)}-5-((2-bromoacetamido)methyl)isophthalamide, see Example 5) to yield Immunoglobulin Peptide Conjugate 1 (see, Table 19). (Table 13 and FIG. 81A-C). These constructs showed an increase in potency upon dimerization, and the conjugate of the dimer shows a 10-fold increase in potency relative to the previous IgG-peptide conjugate. The linker structure in FIG. 78 demonstrated great utility for the preparation of multivalent conjugates comprising the inventive toxin peptide analogs.

TABLE 20 Nav1.7 PX analysis of Homodimeric GpTx-1 Peptide Analogs. Designation SEQ Nav1.7 (see, ID PX IC50 Wash Example 5) Peptide NO: Linker (μM) out Homodimeric [Phe6,Atz13]GpTx-1(1-34) 591 2000 Da PEG 0.013 No Peptide No. 3 Homodimeric [Phe6,Atz13]GpTx-1(1-34) 591  500 Da PEG 0.019 Yes Peptide No. 4 Homodimeric [Ala5,Phe6,Atz13,Leu26,Arg28]GpTx- 592 2000 Da PEG 0.091 Yes Peptide No. 5 1(1-34)

Experimental Methods.

The following series of reactions ((III)-(XI)) was conducted.

Benzene-1,3,5-tricarboxylic acid (50 g, 238 mmol) was dissolved in MeOH, and then conc. sulfuric acid (12.68 mL, 238 mmol) was slowly added. The solution became clear after 30 minutes of reflux and was left stirring at 72° C. for overnight. Solvent was removed under reduced pressure, the residue was dissolved in chloroform (2×800 mL) and washed with NaHCO3, then the organic solvent was removed in vacuo. (60 g, 100% yield).

The trimethyl benzene-1,3,5-tricarboxylate (62 g, 246 mmol) was dissolved in MeOH (800 mL), aq. sodium hydroxide (221 mL, 221 mmol)-(1N) was slowly added. The suspension was stirred vigorously and slowly dissolved during 8 hours. The reaction was left stirred at room temperature for 18 hours, then the solvent was removed in vacuo.

DCM (600 mL) was added to the solid and the organic phase was washed with sat. NaHCO₃ (3×500 mL) ˜3 layers in the separation funnel—solution was filtered and solid on the funnel was rinsed with DCM. The LC-MS of the crude confirmed that MW was of the desired product (MW:238; 48.8 g; yield 83%). The LC-MS analysis of material from the organic layer showed a mixture of the desired product as well as over-hydrolyzed product (MW: 224; 9g), and analysis of material from the aqueous layer showed start material.

3,5-bis(methoxycarbonyl)benzoic acid (10 g, 42.0 mmol) was dissolved in dry THF (80 mL). The flask was placed in ice-bath and bh3.thf (84 mL, 84 mmol) was added slowly (some bubbling occurred). The reaction mixture was left stirring at room temperature for 24 hours. After 14 hours reaction did not progress, another 3 eq. of bh3.thf (42.0 mL, 42.0 mmol) were slowly added and the reaction mixture was stirred at room temperature for hours. The reaction was completed (−95% by LC-MS).

The reaction mixture was quenched with MeOH (added slowly ˜80 mL) and left stirred for 1 hour at RT. The solvent was removed in vacuo. The product was re-dissolved in EtOAc (white solution ˜1000 mL) and the organic layer was washed with water (2×800 mL), sat. NaHCO₃ (800 mL) and brine (800 mL). The EtOAc was dried with MgSO₄, filtered and concentrated in vacuo (3.62 g; yield 38.5%).

The dimethyl 5-(chloromethyl)isophthalate (5.69 g, 23.45 mmol) was dissolved in acetone (90 mL) and water (30 mL). Sodium azide (9.15 g, 141 mmol) was added as a last reagent and the solution was refluxed for 14 hours. After 14 hours the reaction was completed by LC-MS monitoring.

The reaction mixture was cooled down to room temperature and then concentrated in vacuo, the residue was re-dissolved in CHCl₃ (250 mL) and the organic layer was washed with water (3×200 mL) and brine (200 mL). The organic layer was then dried over MgSO₄, filtered and concentrated in vacuo (5.34 g; yield 91%).

The dimethyl 5-(azidomethyl)isophthalate (1.5 g, 6.02 mmol) was dissolved in 40 mL of diethyl ether (40 mL). Tri-n-butylphosphine (1.654 mL, 6.62 mmol) was added slowly and the reaction mixture was stirred for 45 minutes at room temperature and then frozen to −50° C. The solution of di-tert-butyl dicarbonate (1.417 mL, 6.62 mmol) in ether (20 mL) was slowly added (−10 min) and the reaction mixture was stirred at −50° C. for 1 hour and then quenched with saturated NaHCO₃ (20 mL). The reaction mixture was then extracted with ether. Organic phase was dried with MgSO₄, filtered and concentrated in vacuo. Sample was dissolved in a mixture of DCM and MeOH, sillica gel was added, and it was concentrated in vacuo until dry. Automated normal phase purification was performed: 0-30 min. 0-30% of EtOAc in Hexanes. All fractions were collected and analyzed by LC-MS and TLC to identify desired product; concentrated in vacuo, used directly in the next step of the synthesis (760 mg; yield 75%).

A solution of dimethyl 5-(((tert-butoxycarbonyl)amino)methyl)isophthalate (830 mg, 2.57 mmol) in MeOH (40 ml) was treated with lithium hydroxide(984 mg, 41.1 mmol) previously dissolved with water (20 mL). The reaction mixture was stirred at 45° C. for 6 hours. After 6 hours the starting material was completely consumed. MeOH from the reaction solution was evaporated in vacuo and the aqueous layer was extracted with ether (50 mL). The aqueous layer was then acidified with an aqueous solution of HCl (2M) at 0° C. until pH 3-4 was reached and precipitation of the desired product occurred. Sample was filtered through a paper filter and washed twice with ether (10 mL). Sample was dried in air. (570 mg; yield 75%).

To a solution of 5-(((tert-butoxycarbonyl)amino)methyl)isophthalic acid (59.1 mg, 0.200 mmol) in dimethylformamide (DMF), 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 168 mg, 0.441 mmol) was added, the reaction mixture was stirred for 10 min. at room temperature, followed by Azido-dPEG11-amine (400 mg, 0.701 mmol) addition (20 minutes stirring) and N-ethyl-N-isopropylpropan-2-amine (0.116 ml, 0.701 mmol) addition. The reaction mixture was left at room temperature with stirring. The reaction was monitored on LC-MS, after 14 hours desired product was observed, nearly 95% by LC-MS. Sample was taken to purification directly: Gilson, Prep HPLC, 10 min. run time; 10-90% acetonitrile (ACN) in water, collect all, 254 nm); fractions were collected and concentrated in GeneVac overnight at 30° C. (158 mg; yield 56%).

To Reactant 1 (192.4 mg, 0.137 mmol) HCl in 1,4 Dioxane (3 mL) was added; the reaction mixture was stirred for 60 min. at room temperature. Sample was monitored on LC-MS and after 1 hour desired product was observed, nearly 98% by LC-MS. Sample was concentrated in vacuo and purified on Prep HPLC, 15 min. 10-90% ACN in water; 254 nm). Fractions were collected and dried in Genevac for 18 hours at 30° C. (127 mg; yield 71%).

To a solution of Reactant 2 (50 mg, 0.038 mmol) and dicyclohexylcarbodiimde (23.80 mg, 0.115 mmol) in dichloromethane was added bromoacetic acid (21.37 mg, 0.154 mmol). The reaction mixture was stirred for 2.5 hours, and sample mixture was concentrated in vacuo then redisolved in DMF/MeOH mixture (50:50 v/v). White material crushed out and it was filtered via 0.45 μm filter. The clear solution was injected directly to Prep HPLC Gilson (10-90% ACN in water in 10 min., collect all, 254 nm). The fractions were dried in GeneVac for 18 hours at 40° C., and the fractions were characterized by H-NMR and LC-MS (12.6 mg; yield 23%).

An analogous reaction scheme ((VII)-(XI)) was also employed with Azido-dPEG23-amine instead of Azido-dPEG11-amine to provide the divalent bifunctional linker that was used to prepare Homodimeric Conjugate No. 1 (see, Example 5) and then Immunoglobulin Peptide Conjugate 1 (see, Example 9).

ABBREVIATIONS

Abbreviations used throughout this specification are as defined below, unless otherwise defined in specific circumstances.

-   -   Ac acetyl (used to refer to acetylated residues)     -   AcBpa acetylated p-benzoyl-L-phenylalanine     -   ACN acetonitrile     -   AcOH acetic acid     -   ADCC antibody-dependent cellular cytotoxicity     -   Aib aminoisobutyric acid     -   bA beta-alanine     -   Bpa p-benzoyl-L-phenylalanine     -   BrAc bromoacetyl (BrCH₂C(O)     -   BSA Bovine serum albumin     -   Bzl Benzyl     -   Cap Caproic acid     -   CBC complete blood count     -   CNS central nervous system     -   COPD Chronic obstructive pulmonary disease     -   CTL Cytotoxic T lymphocytes     -   DCC Dicylcohexylcarbodiimide     -   DCM dichloromethane     -   Dde 1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethyl     -   DMF dimethylformamide     -   DOPC 1,2-Dioleoyl-sn-Glycero-3-phosphocholine     -   DOPE 1,2-Dioleoyl-sn-Glycero-3-phosphoethanolamine     -   DPPC 1,2-Dipalmitoyl-sn-Glycero-3-phosphocholine     -   DRG dorsal root ganglion     -   DSPC 1,2-Distearoyl-sn-Glycero-3-phosphocholine     -   DTT Dithiothreitol     -   EAE experimental autoimmune encephalomyelitis     -   ECL enhanced chemiluminescence     -   ESI-MS Electron spray ionization mass spectrometry     -   Et ethyl     -   FACS fluorescence-activated cell sorting     -   Fmoc fluorenylmethoxycarbonyl     -   H-NMR proton-nuclear magnetic resonance     -   HATU 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium         hexafluorophosphate     -   HOBt 1-Hydroxybenzotriazole     -   HPLC high performance liquid chromatography     -   HSL homoserine lactone     -   IB inclusion bodies     -   IWQ IonWorks® Quattro     -   KCa calcium-activated potassium channel (including IKCa, BKCa,         SKCa)     -   KLH Keyhole Limpet Hemocyanin     -   Kv voltage-gated potassium channel     -   Lau Laurie acid     -   LPS lipopolysaccharide     -   LC-MS liquid chromatography-mass spectrometry     -   LYMPH lymphocytes     -   MALDI-MS Matrix-assisted laser desorption ionization mass         spectrometry     -   Me methyl     -   MeO methoxy     -   MeOH methanol     -   MHC major histocompatibility complex     -   MMP matrix metalloproteinase     -   MW Molecular Weight     -   MWCO Molecular Weight Cut Off     -   1-Nap 1-napthylalanine     -   Nav, Nay voltage-gated sodium channel     -   NEUT neutrophils     -   Nle norleucine     -   NMP N-methyl-2-pyrrolidinone     -   NMR Nuclear Magnetic Resonance     -   OAc acetate     -   PAGE polyacrylamide gel electrophoresis     -   PBMC peripheral blood mononuclear cell     -   PBS Phosphate-buffered saline     -   Pbf 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl     -   PCR polymerase chain reaction     -   PD pharmacodynamic     -   Pec pipecolic acid     -   PEG Poly(ethylene glycol)     -   Pic picolinic acid     -   PK pharmacokinetic     -   PNS peripheral nervous system     -   PX PatchXpress®     -   pY phosphotyrosine     -   RBS ribosome binding site     -   RT room temperature (25° C.)     -   Sar sarcosine     -   SDS sodium dodecyl sulfate     -   STK serine-threonine kinases     -   t-Boc tert-Butoxycarbonyl     -   tBu tert-Butyl     -   TCR T cell receptor     -   TFA trifluoroacetic acid     -   TG trigeminal ganglion     -   THF thymic humoral factor     -   Trt trityl     -   TTX tetrodotoxin     -   WCPC whole cell patch clamp 

1. A composition of matter comprising an isolated polypeptide comprising the amino acid sequence of the formula: SEQ ID NO: 516 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰Leu²¹ X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹X_(aa) ³⁰X_(aa) ³¹ X_(aa) ³²X_(aa) ³³X_(aa) ³⁴//

or a pharmaceutically acceptable salt thereof, wherein: X_(aa) ¹X_(aa) ² is absent; or X_(aa) ¹ is any amino acid residue and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is absent and X_(aa) ² is any amino acid residue; or X_(aa) ¹ is absent and X_(aa) ² is absent; X_(aa) ³ is any amino acid residue; X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if X_(aa) ⁸ is SeCys; X_(aa) ⁵ is any neutral hydrophilic or basic amino acid residue; X_(aa) ⁶ is any basic amino acid residue; X_(aa) ⁷ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue; X_(aa) ⁸ is a Met, Nle, Nva, Leu, Ile, Val, or Phe residue; X_(aa) ⁹ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue; X_(aa) ¹⁰ is a basic or neutral hydrophilic amino acid residue, or an Ala residue; X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if X_(aa) ²³ is SeCys; X_(aa) ¹³ is any amino acid residue except a hydrophobic residue; X_(aa) ¹⁴ is a basic residue or an Ala residue; X_(aa) ¹⁶ is any amino acid residue; X_(aa) ¹⁷ is a Cys if X_(aa) ²⁷ is Cys; or X_(aa) ¹⁷ is a SeCys if X_(aa) ²⁷ is SeCys; X_(aa) ¹⁸ is a Cys or SeCys; X_(aa) ¹⁹ is any amino acid residue; X_(aa) ²⁰ is a Gly or Ala residue; X_(aa) ²² is an acidic, basic amino acid residue, or Ala residue; X_(aa) ²³ is a Cys or SeCys residue; X_(aa) ²⁴ is a basic amino acid or Ala residue; X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue; X_(aa) ²⁷ is a Cys or SeCys residue; X_(aa) ²⁸ is a basic amino acid residue; X_(aa) ²⁹ is a basic amino acid residue; X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue, if X_(aa) ²² is an acidic amino acid residue; or X_(aa) ³⁰ is an acidic amino acid residue, if X_(aa) ²² is a basic amino acid residue or an Ala residue; X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue; each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently absent or is independently a hydrophobic amino acid residue; and wherein: if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ¹¹ and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; if X_(aa) ¹⁷ and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; or if X_(aa) ¹⁷ and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and the carboxy-terminal residue is optionally amidated.
 2. The composition of matter of claim 1, wherein X_(aa) ²² is an acidic amino acid residue.
 3. The composition of matter of claim 2, wherein X_(aa) ²² is selected from Glu, Asp, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.
 4. The composition of matter of claim 3, wherein X_(aa) ²² is a Glu residue.
 5. The composition of matter of claim 2, wherein X_(aa) ³⁰ is an Ile, Trp, or Tyr residue.
 6. The composition of matter of claim 1, wherein X_(aa) ²² is a basic amino acid residue or an Ala residue.
 7. The composition of matter of claim 6, wherein X_(aa) ²² is selected from histidine, lysine, homolysine, ornithine, arginine, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, and homoarginine residues, and X_(aa) ³⁰ is selected from Glu, Asp, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.
 8. The composition of matter of claim 1, wherein X_(aa) ²² is an Arg residue or Ala residue, and X_(aa) ³⁰ is a Glu residue.
 9. The composition of matter of any of claim 6 or claim 7, wherein X_(aa) ³⁰ is selected from Glu, Asp, phosphoserine, phosphotyrosine, and gamma-carboxyglutamic acid residues.
 10. The composition of matter of claim 9, wherein X_(aa) ³⁰ is a Glu residue.
 11. The composition of matter of claim 1, wherein X_(aa) ³¹ is an Ile, Trp or Tyr residue.
 12. The composition of matter of claim 1, wherein X_(aa) ⁸ is an Nle or Leu residue.
 13. The composition of matter of claim 1, wherein the carboxy-terminal residue is amidated.
 14. The composition of matter of claim 1, wherein: (i) X_(aa) ¹ is a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue, and X_(aa) ² is any amino acid residue; or (ii)X_(aa) ¹ is absent and X_(aa) ² is a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, Atz, Ala, Phe, Ile, Leu, Met, Val, Trp, Tyr, proline, thiaproline, methionine, glycine, 1-Nal, 2-Nal, 1′NMe-Trp, cyclopentylglycine (Cpg), phenylglycine, N-methylleucine, N-methylphenylalanine, N-methylvaline, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-chloro-phenylalanine, 4-chloro-phenylalanine, 3,4-dichlorophenylalanine, 4-trifluoromethyl-phenylalanine, or 4-phenyl-phenylalanine (Bip) residue.
 15. The composition of matter of claim 1, comprising an amino acid sequence selected from SEQ ID NO:63, SEQ ID NO:69, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:131, SEQ ID NO:137, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:182, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:277, SEQ ID NO:279, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:394, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:406, SEQ ID NO:407, SEQ ID NO:408, SEQ ID NO:409, SEQ ID NO:411, SEQ ID NO:412, SEQ ID NO:413, SEQ ID NO:414, SEQ ID NO:415, SEQ ID NO:416, SEQ ID NO:417, SEQ ID NO:418, SEQ ID NO:419, SEQ ID NO:420, SEQ ID NO:421, SEQ ID NO:422, SEQ ID NO:426, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:439, SEQ ID NO:440, SEQ ID NO:441, SEQ ID NO:442, SEQ ID NO:443, SEQ ID NO:444, SEQ ID NO:445, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:449, SEQ ID NO:450, SEQ ID NO:451, SEQ ID NO:452, SEQ ID NO:455, SEQ ID NO:456, SEQ ID NO:457, SEQ ID NO:458, SEQ ID NO:459, SEQ ID NO:460, SEQ ID NO:461, SEQ ID NO:462, SEQ ID NO:463, SEQ ID NO:464, SEQ ID NO:465, SEQ ID NO:466, SEQ ID NO:467, SEQ ID NO:468, SEQ ID NO:469, SEQ ID NO:470, SEQ ID NO:471, SEQ ID NO:472, SEQ ID NO:473, SEQ ID NO:474, SEQ ID NO:475, SEQ ID NO:518, SEQ ID NO:520, SEQ ID NO:521, SEQ ID NO:523, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:546, SEQ ID NO:547, SEQ ID NO:548, SEQ ID NO:549, SEQ ID NO:550, SEQ ID NO:551, SEQ ID NO:552, SEQ ID NO:553, SEQ ID NO:554, SEQ ID NO:555, SEQ ID NO:556, SEQ ID NO:557, SEQ ID NO:558, SEQ ID NO:559, SEQ ID NO:560, SEQ ID NO:561, SEQ ID NO:562, SEQ ID NO:563, SEQ ID NO:565, SEQ ID NO:566, SEQ ID NO:568, SEQ ID NO:573, SEQ ID NO:574, SEQ ID NO:576, and SEQ ID NO:577.
 16. An isolated nucleic acid encoding any of SEQ ID NO:63, SEQ ID NO:69, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:131, SEQ ID NO:137, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:277, or SEQ ID NO:279, that does not include a non-canonical amino acid.
 17. An expression vector comprising the nucleic acid of claim
 16. 18. A recombinant host cell comprising the expression vector of claim
 17. 19. The composition of matter of any of claim 1, further comprising an optional linker moiety and a pharmaceutically acceptable, covalently linked half-life extending moiety.
 20. The composition of matter of claim 19, wherein the optional linker moiety is covalently linked at: (a) the N-terminal residue; (b) the C-terminal residue; or (c) X_(aa) ³, X_(aa) ¹³, X_(aa) ¹⁶, or X_(aa) ¹⁹.
 21. The composition of matter of claim 19, wherein the optional linker moiety is a multivalent linker.
 22. The composition of matter of claim 19, wherein the half-life extending moiety is polyethylene glycol of molecular weight of about 1000 Da to about 100000 Da, an IgG Fc domain, a transthyretin, or a human serum albumin.
 23. The composition of matter of claim 19, wherein the half-life extending moiety comprises a human immunoglobulin or a human immunoglobulin Fc domain, or both.
 24. The composition of matter of claim 23 having a configuration as set forth in any of FIG. 81A-C, FIG. 94A-N, FIG. 95, FIG. 96, FIG. 97, or FIG.
 98. 25. The composition of matter of claim 23, wherein the composition comprises a monovalent immunoglobulin-peptide or Fc-peptide conjugate.
 26. The composition of matter of claim 23, wherein the composition comprises a bivalent immunoglobulin-peptide or Fc-peptide conjugate.
 27. A pharmaceutical composition, comprising the composition of matter of claim 1, and a pharmaceutically acceptable carrier.
 28. A method of preventing pain, comprising administering a prophylactically effective amount of the composition of claim
 1. 29. A method of treating pain, comprising administering a therapeutically effective amount of the composition of claim
 1. 30. The method of claim 29, wherein the pain is chronic pain, acute pain, or persistent pain.
 31. The method of claim 30, wherein the chronic pain is associated with cancer, chemotherapy, osteoarthritis, fibromyalgia, primary erythromelalgia, post-herpetic neuralgia, painful diabetic neuropathy, idiopathic painful neuropathy, neuromas, paroxysmal extreme pain disorder, migraine, trigeminal neuralgia, orofacial pain, cluster headaches, complex regional pain syndrome (CRPS), failed back surgery syndrome, sciatica, interstitial cystitis, pelvic pain, lower back pain, inflammation-induced pain, or joint pain.
 32. The method of claim 30, wherein the acute or persistent pain is associated with trauma, burn, or surgery.
 33. A composition of matter comprising an isolated polypeptide comprising the amino acid sequence of the formula: SEQ ID NO: 517 X_(aa) ¹X_(aa) ²X_(aa) ³X_(aa) ⁴X_(aa) ⁵X_(aa) ⁶X_(aa) ⁷X_(aa) ⁸X_(aa) ⁹X_(aa) ¹⁰X_(aa) ¹¹ Asp¹²X_(aa) ¹³X_(aa) ¹⁴Arg¹⁵X_(aa) ¹⁶X_(aa) ¹⁷X_(aa) ¹⁸X_(aa) ¹⁹X_(aa) ²⁰ Leu²¹X_(aa) ²²X_(aa) ²³X_(aa) ²⁴Leu²⁵X_(aa) ²⁶X_(aa) ²⁷X_(aa) ²⁸X_(aa) ²⁹X_(aa) ³⁰ X_(aa) ³¹X_(aa) ³²X_(aa) ³³X_(aa) ³⁴//

or a pharmaceutically acceptable salt thereof, wherein: X_(aa) ¹ is absent; or X_(aa) ¹ is any amino acid residue; X_(aa) ² is any hydrophobic amino acid residue, or a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, or Atz residue; X_(aa) ³ is any amino acid residue; X_(aa) ⁴ is Cys, if X_(aa) ¹⁸ is Cys; or X_(aa) ⁴ is SeCys, if X_(aa) ¹⁸ is SeCys; X_(aa) ⁵ is any neutral hydrophilic or basic amino acid residue; X_(aa) ⁶ is any basic amino acid residue; X_(aa) ⁷ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue; X_(aa) ⁸ is a Leu or Nle residue; X_(aa) ⁹ is a Tip, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue; X_(aa) ¹⁰ is a basic or neutral hydrophilic amino acid residue, or an Ala residue; X_(aa) ¹¹ is Cys if X_(aa) ²³ is Cys; or X_(aa) ¹¹ is SeCys if X_(aa) ²³ is SeCys; X_(aa) ¹³ is any amino acid residue except a hydrophobic residue; X_(aa) ¹⁴ is a basic residue or an Ala residue; X_(aa) ¹⁶ is any amino acid residue; X_(aa) ¹⁷ is a Cys if X_(aa) ²⁷ is Cys; or X_(aa) ¹⁷ is a SeCys if X_(aa) ²⁷ is SeCys; X_(aa) ¹⁸ is a Cys or SeCys; X_(aa) ¹⁹ is any amino acid residue; X_(aa) ²⁰ is a Gly or Ala residue; X_(aa) ²² is a basic amino acid residue or Ala residue; X_(aa) ²³ is a Cys or SeCys residue; X_(aa) ²⁴ is a basic amino acid residue or Ala residue; X_(aa) ²⁶ is a Trp, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, or thioTrp residue; X_(aa) ²⁷ is a Cys or SeCys residue; X_(aa) ²⁸ is a basic amino acid residue; X_(aa) ²⁹ is a basic amino acid residue; X_(aa) ³⁰ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue; X_(aa) ³¹ is an Ile, Trp, Tyr, 5-bromoTrp, 6-bromoTrp, 5-chloroTrp, 6-chloroTrp, 1-Nal, 2-Nal, thioTrp, 1-Nal, or 2-Nal residue; each of X_(aa) ³², X_(aa) ³³, and X_(aa) ³⁴ is independently absent or is independently a hydrophobic amino acid residue; and wherein: if X_(aa) ⁴ and X_(aa) ¹⁸ are both Cys residues, there is a disulfide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; or if X_(aa) ⁴ and X_(aa) ¹⁸ are both SeCys residues, there is a diselenide bond between residue X_(aa) ⁴ and residue X_(aa) ¹⁸; if X_(aa) ¹¹ and X_(aa) ²³ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; or if X_(aa) ¹¹ and X_(aa) ²³ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹¹ and residue X_(aa) ²³; if X_(aa) ¹⁷ and X_(aa) ²⁷ are both Cys residues, there is a disulfide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; or if X_(aa) ¹⁷ and X_(aa) ²⁷ are both SeCys residues, there is a diselenide bond between residue X_(aa) ¹⁷ and residue X_(aa) ²⁷; the amino-terminal residue is optionally acetylated, biotinylated, or 4-pentynoylated, or PEGylated; and the carboxy-terminal residue is optionally amidated.
 34. The composition of matter of claim 33, wherein X_(aa) ² is a Pra, Aha, Abu, Nva, Nle, Sar, hLeu, hPhe, D-Leu, D-Phe, D-Ala, bAla, AllylG, CyA, Atz, Ala, Phe, Ile, Leu, Met, Val, Trp, Tyr, proline, thiaproline, methionine, glycine, 1-Nal, 2-Nal, 1′NMe-Trp, cyclopentylglycine (Cpg), phenylglycine, N-methylleucine, N-methylphenylalanine, N-methylvaline, cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-chloro-phenylalanine, 4-chloro-phenylalanine, 3,4-dichlorophenylalanine, 4-trifluoromethyl-phenylalanine, or 4-phenyl-phenylalanine (Bip) residue.
 35. The composition of matter of claim 33, wherein X_(aa) ³⁰ is an Ile, Trp, or Tyr residue.
 36. The composition of matter of claim 33, wherein the carboxy-terminal residue is amidated.
 37. The composition of matter of claim 33, comprising an amino acid sequence selected from SEQ ID NO:247, SEQ ID NO:296, SEQ ID NO:358, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:370, SEQ ID NO:372, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:391, SEQ ID NO:398, SEQ ID NO:399, SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:404, SEQ ID NO:405, SEQ ID NO:410, SEQ ID NO:423, SEQ ID NO:424, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:433, SEQ ID NO:434, SEQ ID NO:438, SEQ ID NO:446, SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:571, SEQ ID NO:579, SEQ ID NO:580, SEQ ID NO:581, SEQ ID NO:582, SEQ ID NO:583, SEQ ID NO:584, SEQ ID NO:585, SEQ ID NO:586, SEQ ID NO:587, and SEQ ID NO:588.
 38. The composition of matter of claim 33, further comprising an optional linker moiety and a pharmaceutically acceptable, covalently linked half-life extending moiety.
 39. The composition of matter of claim 38, wherein the optional linker moiety is covalently linked at: (a) the N-terminal residue; (b) the C-terminal residue; or (c) X_(aa) ³, X_(aa) ¹³, X_(aa) ¹⁶, or X_(aa) ¹⁹.
 40. The composition of matter of claim 38, wherein the optional linker moiety is a multivalent linker.
 41. The composition of matter of claim 38, wherein the half-life extending moiety is polyethylene glycol of molecular weight of about 1000 Da to about 100000 Da, an IgG Fc domain, a transthyretin, or a human serum albumin.
 42. The composition of matter of claim 38, wherein the half-life extending moiety comprises a human immunoglobulin or a human immunoglobulin Fc domain, or both.
 43. The composition of matter of claim 42 having a configuration as set forth in any of FIG. 81A-C, FIG. 94A-N, FIG. 95, FIG. 96, FIG. 97, or FIG.
 98. 44. The composition of matter of claim 42, wherein the composition comprises a monovalent immunoglobulin-peptide or Fc-peptide conjugate.
 45. The composition of matter of claim 42, wherein the composition comprises a bivalent immunoglobulin-peptide or Fc-peptide conjugate.
 46. A pharmaceutical composition, comprising the composition of matter of claim 33, and a pharmaceutically acceptable carrier.
 47. A method of preventing pain, comprising administering a prophylactically effective amount of the composition of claim
 33. 48. A method of treating pain, comprising administering a therapeutically effective amount of the composition of claim
 33. 49. The method of claim 48, wherein the pain is chronic pain, acute pain, or persistent pain.
 50. The method of claim 48, wherein the chronic pain is associated with cancer, chemotherapy, osteoarthritis, fibromyalgia, primary erythromelalgia, post-herpetic neuralgia, painful diabetic neuropathy, idiopathic painful neuropathy, neuromas, paroxysmal extreme pain disorder, migraine, trigeminal neuralgia, orofacial pain, cluster headaches, complex regional pain syndrome (CRPS), failed back surgery syndrome, sciatica, interstitial cystitis, pelvic pain, lower back pain, inflammation-induced pain, or joint pain.
 51. The method of claim 48, wherein the acute or persistent pain is associated with trauma, burn, or surgery. 